<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>About Us</td>
<td>04-08</td>
</tr>
<tr>
<td>Messages from Management</td>
<td>10-14</td>
</tr>
<tr>
<td>Chugai’s Value Creation</td>
<td>16-26</td>
</tr>
<tr>
<td>Highlights</td>
<td>28</td>
</tr>
<tr>
<td>Chugai’s Growth Strategies</td>
<td>37-52</td>
</tr>
<tr>
<td>Corporate Governance</td>
<td>56-68</td>
</tr>
<tr>
<td>Chugai in Action</td>
<td>72-96</td>
</tr>
<tr>
<td>Data Section</td>
<td>97-177</td>
</tr>
</tbody>
</table>

**About Us**
- 04 Mission Statement
- 06 Financial Performance and Chugai’s Strengths
- 08 The History of Chugai

**Messages from Management**
- 10 Message from the CEO
- 14 Message from the Deputy Chairman

**Chugai’s Value Creation**
- 16 Our Approach to Value Creation
- 18 Value Shared with Stakeholders
- 20 Will: What We Will Do
- 22 Must: What We Must Do
- 24 Can: What We Can Do
- 26 Process for Establishing Material Issues

**Highlights**
- 28 Financial and Pre-Financial Highlights

**Chugai’s Growth Strategies**
- 37 Previous Mid-Term Business Plans
- 38 Context of the Formulation of IBI 21
- 40 Overview of New Mid-Term Business Plan IBI 21
- 42 Strategy 1: Value Creation
- 44 Strategy 2: Value Delivery
- 46 Strategy 3: Promote Advances in PHC
- 48 Strategy 4: Strengthen Human Capital and Conduct Fundamental Structural Reform
- 50 Strategy 5: Strengthen Sustainable Platforms
- 52 Message from the CFO

**Corporate Governance**
- 56 Message from the Chairman
- 58 Messages from Directors
- 60 Corporate Governance
- 68 Board of Directors, Audit & Supervisory Board and Executive Committee Members

**Chugai in Action**
- 72 Overview of Activities in 2018
- 76 Research
- 79 Development
- 80 Pharmaceutical Technology and Production
- 81 Marketing
- 83 Medical Affairs
- 84 Drug Safety/Quality and Regulatory Compliance
- 86 Intellectual Property
- 87 Human Resources
- 90 Human Rights
- 91 Environment, Health and Safety
- 94 Social Contribution
- 96 Corporate Communications

**Data Section**
- 97 Basic Information
- 112 9-Year Financial Summary
- 114 Management’s Discussion and Analysis
- 121 Consolidated Financial Statements
- 172 Independent Auditor’s Report
- 173 Glossary
- 174 Network
- 176 Shareholder Information
- 177 Corporate Overview
We Engage in Dialogue for Creating Shared Value.

To fulfill its Mission of benefitting the medical community and human health around the world, Chugai has emphasized achieving sustainable growth by sharing value with its various stakeholders. That fundamental commitment has not changed since the Company was founded in response to the shortage of medicine after the Great Kanto Earthquake of 1923.

To apply this stance in a more concrete strategic form, we now advocate “Creating shared value” as a basic tenet of our management and strategies. In addition to updating our Envisioned Future, we specified material issues that Chugai should work on over the medium to long term, and formulated a new mid-term business plan to achieve those objectives.

The plan emphasize active engagement in dialogue with stakeholders, and this report is structured to promote such dialogue with our shareholders, investors and other stakeholders. We hope it will be useful in sharing value with you.

Chugai’s Sustainability and ESG

The material issues and strategies we have established form the basis of Chugai’s approach to the sustainability of creating shared value with its stakeholders.

To facilitate deeper understanding among readers, we are working to enhance information on environmental, social and governance (ESG) metrics for assessing corporate value that does not appear in the financial statements.

Measures for Further Evolution

External initiatives such as the U.N. Sustainable Development Goals (SDGs) are increasingly being used as key metrics in recent corporate management. Chugai’s mid- to long-term management policy shares common values with the SDGs, and our discussions on formulating the new mid-term business plan were based on the SDG targets. Meanwhile, to make clearer the value we share with our stakeholders and to contribute to development in cooperation with society, we have narrowed down the range of SDGs that Chugai will prioritize in order to apply these goals as more concrete strategic targets.
Editorial Policy

Chugai Pharmaceutical Co., Ltd. (“Chugai” or the “Company”) has adopted integrated reporting to communicate both the financial and pre-financial aspects of its corporate value by combining the traditional annual report with the print version of the corporate social responsibility (CSR) report.

Scope of This Report
This report presents information on Chugai Pharmaceutical Co., Ltd. and its consolidated subsidiaries. In some places, however, it gives data specifically pertaining to Chugai Pharmaceutical Co., Ltd.

Timeframe
The basic timeframe for this report is the financial reporting period of January to December 2018. However, in view of the importance of providing the latest information available, some information relating to activities that occurred in 2019 is included, mainly in research and clinical development data.

Information in This Report
This report presents information that Chugai believes to be important given its significance in building Chugai’s corporate value over the short, medium and long term, and its degree of impact on stakeholders.

Reference Guidelines
The content of this report is focused on value creation, using as reference The International Integrated Reporting Framework issued by the International Integrated Reporting Council (IIRC) and Guidance for Integrated Corporate Disclosure and Company-Investor Dialogue for Collaborative Value Creation compiled by the Ministry of Economy, Trade and Industry of Japan.

CSR information was prepared with reference to the Environmental Reporting Guidelines (Fiscal Year 2018 Edition) of the Ministry of the Environment of Japan, the G4 Sustainability Reporting Guidelines of the Global Reporting Initiative (GRI) (issued in 2013) and the Final Report on Recommendations of the Task Force on Climate-related Financial Disclosures (TFCD).

Forward-Looking Statements
This annual report includes forward-looking statements pertaining to the business and prospects of Chugai. These statements reflect the Company’s current analysis of existing information and trends. Actual results may differ from expectations due to risks and uncertainties that may affect the Company’s businesses.

Note
The information regarding pharmaceuticals (including products under development) is not intended for advertising, promotion or medical advice. All trademarks are the property of their respective holders.

Information on Chugai’s Sustainability Initiatives
Chugai discloses its initiatives in a variety of media, including this printed report and its website. Please refer to the website for further details on initiatives presented in this report.

https://www.chugai-pharm.co.jp/english/ csr

External Evaluation of Chugai’s ESG Initiatives

Chugai is included in all three ESG indices selected in 2017 by the Government Pension Investment Fund of Japan.

FTSE4Good
MCSI
MSCI
FTSE Blossom Japan

The inclusion of Chugai Pharmaceutical Co., Ltd. in any MSCI index, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement or promotion of Chugai Pharmaceutical Co., Ltd. by MSCI or any of its affiliates. The MSCI indices are the exclusive property of MSCI. MSCI and the MSCI index names and logos are trademarks or service marks of MSCI or its affiliates.
We pursue innovation for better healthcare.
Mission Statement

Dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world

1. Patient Centric
   Make each patient’s wellbeing our highest priority

2. Pioneering Spirit
   Pursue innovation by improving ourselves and thinking differently

3. Integrity
   Maintain the highest standards in all we do to create shared value with society

About Our Mission Statement
To share value and grow together with its various stakeholders, Chugai has set forth a Mission Statement consisting of its Mission, Core Values and Envisioned Future. This Mission Statement forms the basis of all of Chugai’s corporate activities.

We have established a new Envisioned Future, established material issues and formulated a new mid-term business plan and strategic agenda.

About Our Mission
Our Mission is the enduring, foremost concept behind Chugai’s corporate activities. It is the idea that all we do is “for the benefit of the medical community and human health around the world,” and is the continuation of our founding spirit, with which we sought to resolve medicine shortages following a natural disaster.
About Our Core Values
Formerly comprising seven items, our Core Values have been expressed in simpler terms reorganized for greater clarity. This has made them easier for employees to embody as shared values, and easier to understand. Contributing to the wellbeing of each patient, with their different disease conditions, circumstances and perspectives, underpins all our actions. It requires the ceaseless pursuit of innovation with a pioneering spirit. Moreover, the Core Values clearly state the importance of unwavering integrity to earn trust as a company that meets the expectations and requirements of society by working to solve social issues together with its stakeholders.

About Our Envisioned Future
Previously, we had set a goal of becoming a top pharmaceutical company by the latter half of the 2010s. Through continuous innovation, we have realized this goal, including the provision of value to patients and the establishment of our presence in the pharmaceutical industry. In light of the changing environment for medical treatment, we have committed ourselves to realizing an Envisioned Future as a “top innovator” that goes beyond the framework of the pharmaceutical business. Based on its alliance with Roche, Chugai will raise the quality of all its business activities by applying its unique strengths in science and technology as it works to solve social issues by achieving advanced and sustainable patient-centric healthcare.

Become a top innovator for advanced and sustainable patient-centric healthcare, powered by our unique strengths in science and technology and the alliance with Roche
Financial Performance

**¥579.8 billion**
Revenues (2018)
No. 6 among pharmaceutical companies in Japan
Due to exports of Chugai products and an increase in products in-licensed from Roche, among other factors, our revenues have grown substantially over the past 10 years, but we particularly emphasize profitability over the scale of sales. We are developing a business that specializes in the creation of innovative medicines, not blindly aiming for expansion.

**21.4%**
Ratio of operating profit to revenues (2018)
No. 2 among pharmaceutical companies in Japan
In working to increase Core EPS, the ratio of operating profit to revenues is an important indicator. We take pride in our very high ratio, with a ratio of operating expenses to revenues comparable to that of the world’s leading pharmaceutical companies. This is the result of the pursuit of greater profitability from an increase in products created in-house and greater productivity from our collaborative relationship with Roche, as well as our cost structure reforms going back more than 10 years.

**¥3.6 trillion**
Market capitalization (as of December 31, 2018)
No. 1 among pharmaceutical companies in Japan
Chugai’s market capitalization is about 10 times what it was prior to the strategic alliance with Roche and has roughly tripled over the past five years alone, ranking highest among Japanese pharmaceutical companies relative to sales (sixth in Japan). We will continue to emphasize dialogue with stakeholders as we accelerate value creation.

Chugai’s Five Strengths

**Continuous provision of innovative drugs**
59%
Proportion of sales from products that qualify for premium pricing (2018)

**48**
Pipeline projects
(as of January 31, 2019)
With projects developed in-house and in-licensed from Roche, Chugai has one of the richest development pipelines in Japan as well as the technologies and systems for efficient and stable production of the resulting new drugs. This underpins our continuous provision of innovative medicines. As a result, in Japan we have held the top market share in the oncology field for 11 consecutive years and have market-leading product lineups in the fields of bone and joint diseases and renal diseases.

**24.5%**
Share of sales in the Japanese therapeutic antibody market (2018)

**7**
Breakthrough therapy designations
(as of January 31, 2019)
Chugai has gained a reputation worldwide for its proprietary antibody engineering technologies as well as for its strong drug discovery capabilities backed by a research infrastructure in various modalities including small molecules. We also focus on technology research and genetic analysis for therapeutic antibodies as we strive for a deeper understanding of diseases and biology. We are the leading presence in the Japanese therapeutic antibody market.

---
1. Financial results: Chugai: Fiscal year ended December 31, 2018; Other companies in the same industry: Fiscal year ended December 31, 2018 or March 31, 2018
2. Note: “Pharmaceutical companies” covers the top 10 Japanese domestic manufacturers of pharmaceuticals in terms of sales:
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Otsuka Holdings Co., Ltd.
- Daiichi Sankyo Company, Limited
- Eisai Co., Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Sumitomo Dainippon Pharma Co., Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Kyowa Hakko Kirin Co., Ltd.
- Shionogi & Co., Ltd.

---
More than 50%  
Proportion of development projects based on PHC  
(as of January 31, 2019)

27  
Number of development projects based on PHC  
(as of January 31, 2019)

As a pioneer of PHC in Japan, Chugai has contributed to the progress of this approach to healthcare, in which treatment plans are prepared according to each patient’s genetic profile and other factors. Today, our efforts include providing PHC that uses genomic analysis technology and contributing to the progress of cancer genomic medicine to usher in the next generation of PHC, which offers more advanced treatments optimized for each patient.

Chugai has established a system for providing solutions that can be precisely adapted to diverse needs in different regions, backed by industry-leading safety management and a high level of expertise in each disease area. Our efforts to promote multidisciplinary team care and regional healthcare coordination include providing various kinds of information, holding study sessions and cooperating with the government in activities to raise awareness. These initiatives receive strong support from healthcare providers.

Chugai maintains its management independence under its strategic alliance with Roche, one of the world’s leading pharmaceutical companies. In addition to efficiently in-licensing the Roche Group’s pharmaceuticals for sale in Japan, we use the Roche Group’s powerful research infrastructure and its global development and sales platform to offer significant value to the rest of the world.

2. Copyright © 2019 IQVIA. Source: JPM 2018. Reprinted with permission. The scope of the market is defined by Chugai.
3. A system introduced in July 2012 by the U.S. Food and Drug Administration aimed at expediting the development and review of drugs for the treatment of severe or life-threatening diseases or symptoms
4. Copyright © 2019 anterio. Source: Rep-i 201808. Reprinted with permission. Based on a survey of overall assessments of companies by physicians, as defined by Chugai.
5. Based on an anterio market survey in 2018 for understanding safety information needs.
In 1925, concerned by the acute shortage of medicines following the Great Kantō Earthquake, Chugai’s founder Juzo Ueno established Chugai Shinyaku Shokai, Chugai’s predecessor. This founding spirit has been passed down through the years. Since its foundation, Chugai has continued to innovate its business structure based on the changing needs of patients, while repeatedly facing challenges including rebuilding in the aftermath of the Second World War.

In the 1960s, rapid change in the over-the-counter (OTC) drug market weakened Chugai’s performance. Subsequently, in light of changing healthcare conditions that required more advanced treatment, the Company restored its business by shifting its focus from OTC to prescription drugs. Meanwhile, Nippon Roche reinforced its research and production functions to generate outcomes including a major product in the oncology field.

Chugai decided that establishing biotechnology was essential to its future, and began investing resources in research and development of biopharmaceuticals in the 1980s. The Company also worked to establish technology for the mass production of biopharmaceuticals, and in the early 1990s it launched a biopharmaceutical product created through genetic engineering, laying the foundation for what would become one of its core strengths.

Factors including the launch in Japan of Herceptin, which Chugai in-licensed from Roche, led to a focus on the development of PHC. Recognizing that expanding the use of PHC was a priority issue in medical care, Chugai began providing support for relevant R&D as well as supplying healthcare providers with information and guidelines for its dissemination. In doing so, Chugai has made a substantial contribution as a pioneer of PHC.
Chugai's strategic alliance with Roche, one of the world's leading pharmaceutical companies, started in 2002. With this alliance, Chugai made a fresh start and created a unique business model in which each company benefited from the other’s strengths. Later, in anticipation of an increase in the number of projects in-licensed from Roche, Chugai reorganized its research centers and manufacturing plants and transformed its earnings structure.

Chugai has been committing management resources to the creation of innovative products in-house, backed in part by its strength in antibody engineering technologies and access to highly efficient research infrastructure through its strategic alliance with Roche. As a result, Chugai’s products have received seven breakthrough therapy designations from the FDA, proof of the high level of the Company’s drug discovery capabilities.

In 2009, to achieve even greater innovation, Chugai set the goal of becoming a top pharmaceutical company by the late 2010s. We also set targets for our position and presence in Japan and overseas as a trusted company that satisfies its stakeholders and lives up to their expectations. To achieve our goal and these targets, we continued to conduct business with a commitment to innovation.

In 2009, Chugai launched Actemra, the first therapeutic antibody created in Japan. Chugai also captured the top domestic market share in the field of oncology with a powerful product lineup. Since then, Chugai has maintained the top share in oncology and in the therapeutic antibody market.*

* Copyright © 2019 IQVIA. Source: JPM 2018. Reprinted with permission. The scope of the market is defined by Chugai.
Message from the CEO

With an unwavering focus on innovation, Chugai has finally achieved its longstanding management goal of becoming a top pharmaceutical company.

Starting in 2019, we will work toward becoming a “top innovator” for advanced and sustainable patient-centric healthcare based on creation of shared value with stakeholders.

The key to achieving that will remain the pursuit of innovation.

Chugai will further enhance its corporate value through steady and continuous innovation for the benefit of patients and the medical community.

Tatsuro Kosaka
Representative Director, President & CEO
What kind of company is Chugai? Please summarize the Company's growth and progress to date.

We are a company that pursues innovation for the benefit of patients and the medical community. As a result, we have also achieved our goal of becoming a top pharmaceutical company.

The key word for us has always been, and still is, innovation.

Chugai was founded in response to the shortage of medicine in the aftermath of the Great Kanto Earthquake of 1923. Since then, the Company has consistently conducted its business for the benefit of patients and human health. Chugai’s history is marked by ups and downs, but each time we have faced a significant change in the external environment or a management crisis, we have overcome it through innovation, and have continued to grow. The shift of our business from over-the-counter drugs to prescription drugs, our venture into and investment in biopharmaceutical research, and our strategic alliance with Roche, were all decisions Chugai made in order to continue to innovate for the benefit of patients and the medical community.

The “top pharmaceutical company” ideal we decided on in 2009 was a goal we sought to achieve by the late 2010s in order to position Chugai for further innovation. We set numerical and qualitative targets, and as a result of reforms in all our functions, we achieved our goal in 2018 (see page 12 for details). I view our position in the industry, successes in research and development, progress in globalization and other accomplishments as indicators of our evolution into a company that has earned the trust and confidence of stakeholders. In 2018, the final year of mid-term business plan IBI 18, accomplishments included the global growth of products from Chugai research, including Hemlibra, and the launch of Tecentriq in Japan, and we steadily advanced our priority agenda. Financially, we reported record profits, and as a result, our market capitalization was also in the top tier of Japanese pharmaceutical companies.

Our drug discovery capabilities, our unique business model and the growth of our human resources were the key factors. Moving forward, we will need to think about ways to contribute more broadly in such areas as the lifestyles of patients and medicine itself.

The key factor behind that achievement is our drug discovery capabilities. Innovative products from Chugai’s own research, including Actemra, Alecensa and Hemlibra, became growth drivers. Our development pipeline is also full of promising projects. Satalizumab (SA237), which has the potential to be our fourth global product, has received breakthrough therapy designation from the FDA, and is showing good results in clinical trials. Our unique business model based on our alliance with Roche enabled us to accelerate research and development and make it a foundation of our business. That model has led to significant achievements, as access to Roche’s network has made it possible for us to develop and market our products globally while in-licensing Roche’s major products, including Tecentriq, for sale in Japan. Above all, I am pleased that the growth of our human resources has become a driving force of our business growth. Our employees have continually taken on the challenge of meeting the rising expectations of patients and healthcare professionals. This in turn has made our employees more confident.
On the other hand, the healthcare and pharmaceutical industries foresee an environment of greater uncertainty and fierce competition. The problem of financing healthcare systems is becoming increasingly serious worldwide, while industry barriers are expected to disappear as a result of advances in life science and digital technologies, including artificial intelligence and IoT. Expectations for the healthcare and pharmaceutical industries will continue to rise, creating opportunities for Chugai, which has a leading presence in the industry, to contribute more broadly. While our core focus will continue to be pharmaceutical products for the benefit of patients (“the pill”), we also need to position Chugai for the future by expanding our field of vision to “around the pill” – i.e., initiatives to maximize the value of medicines – as well as services “beyond the pill” in medicine and healthcare, including the use of artificial intelligence and other disruptive innovations. An example is the genomic profiling tool of the FMI business,* which began in 2018. Use of this tool in diagnosis will promote the advancement of personalized healthcare, and by combining it with real-world data, we will further broaden the value we create.

* Development and commercialization of the products of Foundation Medicine Inc. in Japan

Results of Quantitative and Qualitative Goals for Becoming a Top Pharmaceutical Company

**Numerical target: Rank within the top 3 major Japanese pharmaceutical companies in the following categories**

- **Domestic sales share**
  - Ranked 5th
  - △

- **Consolidated operating profit margin**
  - 2nd
  - ○

- **Consolidated operating profit per employee**
  - 2nd
  - ○

- **Domestic sales per MR**
  - 1st
  - ○

**Numerical target: No. 1 domestic presence in strategic disease areas**

- **Oncology**
  - Market share: 1st
  - Stakeholder satisfaction: 1st
  - ○

- **Renal:**
  - 2nd/2nd
  - Bone & Joint: 2nd/2nd, RA (biologics): 2nd/1st

**Numerical target: No. 1 presence in hospital market based on medical care networks linking healthcare providers**

- **Share of hospital sales (<100 beds)**
  - Market share: 1st
  - Stakeholder satisfaction: 1st
  - ○

**Numerical target: Expansion of global presence**

- Increase overseas sales ratio
  - 2009: 10.4%
  - 2018: 24.2%

**Qualitative target: A company that satisfies all its stakeholders and receives their active support and trust**

- **Patients and Healthcare Professionals:** Play a part in improving treatment satisfaction and the contribution of drugs in cancer treatment in our capacity as a leading oncology company
  - ○

- **Shareholders and Investors:** Realize growth strategies based on innovation (Market capitalization: 31st in Japan overall, 1st in domestic pharmaceutical industry) (as of December 29, 2018)
  - ○

- **Roche:** Contribute to growth of Roche Group by out-licensing Actemra, Alecensa, and Hemlibra and realize revenue and profit growth by fully leveraging our alliance with Roche.
  - ○

**Goal: A company that works proactively on a global level**

- Continuous creation, development, and domestic and overseas launches of products with a competitive advantage in clinical results
  - ○

- Breakthrough therapy designations for 4 products (No. 1 in domestic pharm.)
  - ○

- Establish world-class manufacturing base (completion of HEM/ALC global inspections)
  - ○

- Contribution to the Roche Group’s results through product-appropriate fostering and sales
  - ○

- Maximize product value through simultaneous global development and filing
  - ○

- Achieve no. 1 customer satisfaction in strategic disease areas by establishing a system for providing new solutions
  - ○

**Leadership in pharmaceutical industry activities**

- Promote personalized healthcare in Japan
  - ○

- Raise employee awareness of being part of a top pharmaceutical company
  - ○

- Lead the field of drug safety by establishing a system to provide value-added safety information
  - ○

**Activities in which all employees have an awareness, sense of responsibility and pride as part of a top pharmaceutical company**

- Lead the industry as Japan’s foremost company in biopharmaceuticals
  - ○

- Become a world-class company in employee engagement
  - ○

- Facilitate human resource development that also creates win-win relationships at the individual level through collaboration with Roche
  - ○

We aim to become a top innovator for advanced and sustainable patient-centric healthcare based on the creation of shared value with stakeholders.

To show the direction of our value creation going forward, we decided to aim for “creating shared value” with stakeholders. We have long believed that the value of our medicines and solutions must lead to value for society. Our thinking is the same as that behind the U.N. Sustainable Development Goals (SDGs). For instance, with Hemlibra we help people with hemophilia A and their families. This drug not only improves the symptoms of the disease and quality of life, but is expected to dramatically change people’s lives. As we expand the scope of our contribution and our areas of value creation, I would like our employees to have a clear awareness of shared value. I think this could even be a driving force for innovation.

Based on this line of thinking, we have updated the Core Values and the Envisioned

**Question 3**

**What are your thoughts on Chugai’s value creation going forward?**

1. Copyright © 2019 IQVIA. Source: JPM 2018. Reprinted with permission. The scope of the market is defined by Chugai.
2. Calculated by Chugai, based on data from Fuji-Keizai Co., Ltd.
Future in our Mission Statement to clarify the path Chugai will take (see pages 4-5 for details on our Core Values and Envisioned Future). Now that we have achieved our goal of becoming a top pharmaceutical company, our next goal is to be a top innovator in the healthcare industry. In our difficult business environment, there is only one way for us to realize advanced and sustainable patient-centric healthcare, and that is to continuously pursue innovation.

Our image of a “top innovator” is that of a drug discovery startup that has the benefit of scale.

At the same time, through a wide-ranging assessment, we established the material issues we should work on in creating shared value. Sharing these issues both internally and externally will increase the momentum of our strategic initiatives and facilitate dialogue with stakeholders.

We formulated the new mid-term business plan IBI 21 for the three years from 2019 based on our view of the external environment and approach to value creation, which I mentioned earlier. It consists of strategies for continuously promoting innovation and sharing value with stakeholders, thereby increasing our own corporate value. The “IBI” in the name of the plan expresses our intention to achieve sustained business growth through innovation by further strengthening Chugai’s basic stance with regard to innovation: “Innovation Beyond Imagination.”

The plan consists of a two-part priority agenda – “Create global growth drivers and maximize value” and “Strengthen HR and infrastructure that support Chugai’s business” – and five strategies for accomplishing them. (See pages 38-51 for details on new mid-term business plan IBI 21.) We will focus even more on creating innovative drugs through advancement of new discovery technologies and modalities, and will enhance the value of solutions for addressing increasingly complex and diverse needs. We will also leverage the FMI business to promote the development of personalized healthcare.

To build a business foundation that will enable us to concentrate our resources on innovation, we will continue to strengthen talent development and improve our cost structure. At the same time, we will establish and strengthen platforms for the sustainability of both Chugai and society. There has been increasing emphasis on ESG issues recently, and I believe that bolstering initiatives for sustainability is what companies should aspire toward. We will concentrate on doing so while carefully examining issues.

Question 4

What are you aiming for in the new mid-term business plan?

Based on the five strategies of our priority agenda, we will continue to promote innovation and sharing value with stakeholders, thereby increasing our corporate value.

We formulated the new mid-term business plan IBI 21 for the three years from 2019 based on our view of the external environment and approach to value creation, which I mentioned earlier. It consists of strategies for continuously promoting innovation and sharing value with stakeholders, thereby increasing our own corporate value. The “IBI” in the name of the plan expresses our intention to achieve sustained business growth through innovation by further strengthening Chugai’s basic stance with regard to innovation: “Innovation Beyond Imagination.”

The plan consists of a two-part priority agenda – “Create global growth drivers and maximize value” and “Strengthen HR and infrastructure that support Chugai’s business” – and five strategies for accomplishing them. (See pages 38-51 for details on new mid-term business plan IBI 21.) We will focus even more on creating innovative drugs through advancement of new discovery technologies and modalities, and will enhance the value of solutions for addressing increasingly complex and diverse needs. We will also leverage the FMI business to promote the development of personalized healthcare.

To build a business foundation that will enable us to concentrate our resources on innovation, we will continue to strengthen talent development and improve our cost structure. At the same time, we will establish and strengthen platforms for the sustainability of both Chugai and society. There has been increasing emphasis on ESG issues recently, and I believe that bolstering initiatives for sustainability is what companies should aspire toward. We will concentrate on doing so while carefully examining issues.

Question 5

What will you need to do in order to carry out your strategies and enhance corporate value over the medium to long term?

The pursuit of innovation will continue to be the key. We will focus on three elements that give rise to innovation: science, technology and corporate culture.

The essential elements in carrying out our strategies – in other words, elements that give rise to innovation – are science, technology and corporate culture. While maintaining our uncompromising approach to science, which is the source of our value and the standard for determining our actions, we will accelerate open innovation with academia, startups, and companies in different industries. We plan to increase investment in this area. In addition, we will step up efforts for greater diversity and strengthen succession plans and talent management to shape our corporate culture for the continued pursuit of innovation.

Chugai has many employees who are mild-mannered yet passionately committed to improvement. The long-term perspective of Chugai’s founder is embedded in our corporate culture. It may be part of the reason why our employees persevere even after repeated setbacks, which has led to numerous research breakthroughs and new, unprecedented projects. If our employees can embrace new challenges supported by this culture and guided by a strong belief in sharing value with society, I am confident that we can create even greater value.

I plan to focus even more on engaging our shareholders and other stakeholders in active dialogue for sharing value. We remain committed to meeting your expectations.
Message from the Deputy Chairman

Motoo Ueno
Representative Director & Deputy Chairman
In charge of Sustainability Dept., Audit Dept.

Chugai will pursue innovation to create shared value with stakeholders. Adopting that approach throughout our business, we will continue our own evolution as a company.

Stakeholders with a Common Purpose

Human health and wellbeing is a shared goal among all of our stakeholder groups: patients, healthcare providers, business partners, and employees; the governments, health insurers and regulators that support healthcare systems; university and other research institutions, and companies in other industries; and patients’ families, communities, countries, industries and society as a whole. At Chugai, benefitting the medical community and human health around the world is the value we seek to deliver and subsequently expand through the pursuit of innovation.

That effort is focused on providing innovative pharmaceutical products, but it does not end there. We provide various kinds of information and promote coordination between healthcare facilities to enable the best treatment for each patient. We have also taken measures to improve screening rates and increase diagnostic accuracy, and cooperated with government entities and business partners in patient awareness campaigns. These and other activities, for which we have partnered with healthcare providers and local governments across Japan, have helped to eliminate regional disparities in standards of care, promote personalized healthcare and facilitate early detection and intervention in potential patients. As a result, the innovative Chugai products that play a part in patient-centric healthcare are widely used, and Chugai itself has grown.

However, maintaining sustainable growth in the current climate of uncertainty and rapid change will require us to further clarify our shared value with society and integrate it into concrete strategic activities. Accordingly, we set our redefined Envisioned Future as the foundation of creating shared value. The strategy we have formulated to realize that Envisioned Future is the new mid-term business plan IBI 21. I mentioned in Annual Report 2017 that we would draw up a value creation strategy that includes non-financial aspects by analyzing the social environment and identifying the value we can contribute. The strategy we developed from that process is synonymous with creating shared value, and I believe it will promote an even more active dialogue with stakeholders. In that regard, you can look forward to what comes next.

Strengthening the Principles and Platforms for Creating Shared Value

To move forward on creating shared value, we redefined the values shared by all our employees (Core Values) and updated the Chugai Business Conduct Guidelines as the Chugai Group Code of Conduct. These principles will guide us in precisely and quickly creating shared value based on changes in the external environment and stakeholder expectations. I will personally engage in dialogue with employees to ingrain the new code of conduct in our everyday operations as early as possible.

One of the strategies in IBI 21 is to strengthen sustainable platforms. For that, we analyzed and identified future issues for Chugai and defined priority areas for enhancement. We will take a more proactive approach to social issues such as climate change and environmental pollution. Moreover, we want to particularly emphasize human rights, health and productivity management, and compliance.

While respect for human rights was already part of our behavioral standards, and was emphasized in our operations, we felt doing more to ensure the protection of human rights throughout our supply chain was another key theme. Therefore, we recently issued a human rights declaration, and are working on a plan to steadily conduct due diligence in the supply chain.

In health and productivity management, a key theme is that the health of employees is connected to the health of the organization and improvement of productivity. This is an area where we believe Chugai should be in the forefront. We will raise the level of our health and productivity management by developing new metrics and accumulating case studies.
Compliance has always been important to Chugai, and that will not change. At Chugai, corporate ethics take priority over profit. Furthermore, we believe that in addition to abiding by laws and regulations, compliance is also about complying with the expectations and requests of stakeholders – in short, creating shared value. After restructuring our compliance system at the global level in 2017, we took further steps in 2018 that included the introduction of compliance planning and monitoring at each workplace. We will continue our rigorous efforts to ensure corporate, healthcare and regulatory compliance.

Innovation in Management

Having committed to a strategy of creating shared value, we will go beyond the innovation of products and services, and plan to focus more than ever on innovation and productivity improvement across the entire supply chain, as well as promoting the evolution of healthcare structures as a whole. Creating value by developing pharmaceuticals and providing solutions will remain our core business, but in the medium to long term, we can make a significant impact on healthcare overall by clarifying the value we deliver to patients and improving access to healthcare.

In the process of formulating our management strategy, we held discussions on the evolution of Chugai’s management. One topic of those discussions was participation in the Sustainable Development Goals (SDGs) adopted by the U.N. We fully endorse the underlying purpose and principles of the SDGs, and I believe that advancing the strategy we have formulated will advance the SDGs. Among the goals, “3. Good health and well-being” is aligned with Chugai’s Mission. Management is committed to fulfilling this goal, and will also actively work toward other objectives such as ensuring job satisfaction for employees, achieving technological innovation, and carrying out responsible manufacturing and marketing.

We will share value with our various stakeholders and grow together with them. To that end, Chugai will promote continuous innovation in management.

Chugai Group Code of Conduct

The Mission set forth in the Mission Statement of the Chugai Group is to “Dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world.”

We set Core Values as the most important standards of value judgment in realizing the Mission and will operate our business in accordance with them. Chugai Group will contribute to the realization of a sustainable society by solving social issues through creating innovation and efforts toward the global environment, human rights and others.

By acting as an appropriate business guide for every employee within the Chugai Group, the Chugai Group Code of Conduct aims to ensure that these business operations are implemented. Every member of the Chugai Group must act and judge in accordance with this code.

1. Responsibility to Patients
   We will make each patient’s wellbeing our highest priority, and provide innovative, high-quality products and services with superior safety and efficacy.

2. Pursuing Innovation
   With deep understanding and a broad perspective, we will focus our diverse talents on the continuous pursuit of innovation.

3. Acting with Integrity
   We will strictly adhere to all laws and regulations in every situation, and maintain the highest standards of integrity and ethicality.

4. Respect for Human Rights
   We will respect human rights in every aspect of our business activities.

5. Appropriate Partnerships
   We will maintain appropriate and transparent relations with all of our stakeholders through ongoing discussion. We will work together to realize mutual development and find solutions to social issues. We also expect our business partners to maintain the highest standards of integrity and ethicality.

6. Management of Corporate Assets
   We will achieve our management objectives through the optimal and appropriate management and use of corporate assets.

7. Disclosure of Information
   We will actively and fairly disclose corporate information.

8. Social Contribution
   As a good corporate citizen, we will actively promote our social contribution programs, and contribute to realizing a sustainable society.

9. Protection of the Global Environment
   We conduct our business activities in harmony with nature and the environment, and preserve our “one and only Earth” for future generations.

Chugai’s SDG Focus

Among the 17 SDGs, Chugai prioritizes Goal 3, which directly links to its Mission. The next four SDGs shown help to achieve Goal 3, and the final six undergird its business activities.
Our Approach to Value Creation

Mission Statement
—Innovation all for the patients—

Mission
Dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world

Core Values
Patient Centric/Pioneering Spirit/Integrity

Envisioned Future
Become a top innovator for advanced and sustainable patient-centric healthcare, powered by our unique strengths in science and technology and the alliance with Roche

Creation of shared value by Chugai and Society

Realize advanced and sustainable patient-centric healthcare

Focus on innovation
Creation of innovative drugs and services

Strategic alliance with Roche
Chugai’s unique science and technologies

Two Revenue Bases
Strategic Alliance with Roche

Products In-Licensed from Roche
Exclusive domestic sales of breakthrough therapies
Stable revenue base (Efficient product launches through collaboration with Roche)

Products from Chugai Research
Able to specialize in highly innovative drug discovery
Revenue base that drives growth (Out-licensing to Roche and global market development)

Chugai business model adopted
Chugai has adopted creating shared value with stakeholders as its basic policy.

The goal of this shared value is to bring about the realization of advanced and sustainable patient-centric healthcare. This goal is set forth in our Envisioned Future. While sharing value with our various stakeholders, we will also increase our corporate value by contributing to patients and to the creation of a framework for the next generation of healthcare. That is our approach for value creation.

In the emerging healthcare landscape, rapid advances in life science and digital technology will drive dramatic changes in social structures. Likewise, the healthcare issues that require solutions are expected to become more sophisticated, diverse and complex. Measures to curb drug costs will be tightened further due to financial strains on healthcare systems caused by the growth and aging of populations worldwide, and only solutions that offer true value will be pursued. This situation will make it increasingly difficult for pharmaceutical companies to maintain a sound earnings structure. Rather than being content with its growth thus far, Chugai is shifting to a business structure for concentrating its resources on value creation while making the resolution of social issues the linchpin of its operations.

The key to creating shared value is to focus on innovation. We will continuously generate innovation by fully leveraging our unique business model, which is based on the strategic alliance with Roche and our unique strength in science and technology.

In working to create shared value, Chugai recently specified 25 material issues in eight categories that should be given priority. They were identified through a multifaceted analysis of material issues that incorporated objective views from outside experts. We also set in-house performance indicators to measure our progress in addressing each issue. These material issues may be adjusted in response to changes in the external environment or the evolution of Chugai’s business activities, and we plan to update them periodically.

<table>
<thead>
<tr>
<th>25 Material Issues in 8 Categories</th>
<th>Material Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sustainable healthcare</td>
<td>• Creation of innovative drugs and services</td>
</tr>
<tr>
<td></td>
<td>• Provision of solutions for patients</td>
</tr>
<tr>
<td></td>
<td>• Fair marketing</td>
</tr>
<tr>
<td></td>
<td>• Fair pricing</td>
</tr>
<tr>
<td></td>
<td>• Adverse event management</td>
</tr>
<tr>
<td></td>
<td>• Quality assurance and stable supply of products</td>
</tr>
<tr>
<td>Corporate governance</td>
<td>• Corporate governance</td>
</tr>
<tr>
<td></td>
<td>• Risk management</td>
</tr>
<tr>
<td></td>
<td>• Disclosure and engagement</td>
</tr>
<tr>
<td>Ethics and compliance</td>
<td>• Compliance</td>
</tr>
<tr>
<td></td>
<td>• Code of conduct</td>
</tr>
<tr>
<td></td>
<td>• Fair transactions</td>
</tr>
<tr>
<td>Supply chain management</td>
<td>• Supply chain management</td>
</tr>
<tr>
<td>Human resources</td>
<td>• Employee job satisfaction</td>
</tr>
<tr>
<td></td>
<td>• Development of employee potential</td>
</tr>
<tr>
<td></td>
<td>• Diversity and inclusion</td>
</tr>
<tr>
<td></td>
<td>• Improvement of occupational health and safety</td>
</tr>
<tr>
<td>Human rights</td>
<td>• Human rights</td>
</tr>
<tr>
<td></td>
<td>• Safety of clinical trial subjects</td>
</tr>
<tr>
<td>Social contribution</td>
<td>• Social contribution activities</td>
</tr>
<tr>
<td></td>
<td>• Improvement of access to healthcare</td>
</tr>
<tr>
<td>Global environment</td>
<td>• Climate change countermeasures</td>
</tr>
<tr>
<td></td>
<td>• Use of renewable/recycled resources</td>
</tr>
<tr>
<td></td>
<td>• Protection of biodiversity</td>
</tr>
<tr>
<td></td>
<td>• Environmental management system</td>
</tr>
</tbody>
</table>
Value Shared with Stakeholders

In the context of patient-centric healthcare, we believe that Chugai should contribute to the actual structures and systems needed for realizing advanced, sustainable healthcare, while sharing value with its various stakeholder groups.

For patients, in addition to ensuring high drug efficacy and safety, we must enable them to receive care that matches their values and allows them to maintain their quality of life – in other words, to enable each individual patient to obtain true value. We also need to reduce the various burdens borne by patients’ families in connection with treatment and caregiving. For healthcare providers, value includes enabling proper disease control and expanding treatment options. As for insurers and regulators that build the medical insurance and authorization systems, they need to achieve appropriate levels of spending and sustainable healthcare financing so that patients and society can enjoy true value.

For government, enhancing regional healthcare in accordance with the delivery systems in each community where patients live is important. For countries, in addition to improving healthcare finances, development of healthcare as a growth industry is sure to have significant value. For the universities and research companies and institutions that collaborate with Chugai, as well as its partner companies, suppliers, pharmaceutical wholesalers and others, significant value will result from jointly promoting innovation and increasing added value toward the establishment of a framework for the next generation of healthcare. This will lead to sustainable growth for all, and shareholders who invest in the healthcare industry will also be able to share in the benefits of that added value.

Moreover, employees whose work is directly tied to the issue that society expects us to address – realization of advanced and sustainable patient-centric healthcare – will gain job satisfaction, a sense of fulfillment and opportunities to enhance their own abilities.

Chugai believes that sharing value with these various stakeholders beyond mere cooperation is the shortest path to realizing advanced, sustainable healthcare.

The chart to the right shows the material issues that we have identified as having particular importance in our creation of shared value with the stakeholders above.

---

**Relationship between Stakeholders and Material Issues**

- **Patients and families of patients**
  - Creation of innovative drugs and services
  - Provision of solutions for patients
  - Adverse event management
  - Quality assurance and stable supply of products
  - Safety of clinical trial subjects
  - Improvement of access to healthcare

- **Healthcare providers and medical institutions**
  - Creation of innovative drugs and services
  - Provision of solutions for patients
  - Fair marketing
  - Adverse event management
  - Quality assurance and stable supply of products

---
Shareholders and other investors, etc.
- Corporate governance
- Risk management
- Compliance
- Code of conduct
- Disclosure and dialogue

Employees
- Gain job satisfaction and sense of fulfillment
- Enhance abilities

Patients
- "Overall value"
  - Better drug efficacy and safety
  - Better QoL
  - Treatment choices that fit each patient

Countries
- Growth of the healthcare industry
- Improvement of fiscal balance

Communities
- Advanced and sustainable community-based care
- Improvement of local government finances

Healthcare providers and medical institutions
- Better disease control
- More treatment options

Medical device manufacturers and healthcare companies
- Collaborative solutions

Payers and regulators
- Fair pricing
- Creation of innovative drugs and services

Universities and research companies/institutions
- Creation of innovative drugs and services
- Provision of solutions for patients

Medical device manufacturers and healthcare companies
- Creation of innovative drugs and services
- Provision of solutions for patients
Chugai has continuously created innovative drugs and delivered them to patients around the world. As creation and development of new drugs becomes increasingly challenging, we intend to create value and deliver it more broadly.

Our value creation has two aspects. One is disease control. We believe that with scientific excellence and the potential of medicines, it is possible to realize medical care in which healthcare providers can control diseases and minimize the suffering of patients, even if they cannot eliminate the disease entirely. This will require the creation of pharmaceuticals that offer both greater efficacy and a high level of safety, and giving healthcare providers the tools to accurately grasp medical conditions.

The other aspect is going beyond treatment with existing pharmaceuticals to provide solutions that offer true value to patients. We believe that the next generation of healthcare will involve delivering overall value to patients by providing treatments that fit their situation and values, and which consider factors such as quality of life after administration of drugs and the psychological, physical and financial burdens. The key here will be proof of value. If we can scientifically measure and assess value for patients, and provide solutions that enhance that value, we can make a significant contribution to improving patients’ lives.

What We Will Do

**Bring true value to patients**
- Work toward treatment and disease control
- Contribute to the next generation of healthcare that delivers overall value to patients
Expanding Our Field of View from the Pill to around and beyond the Pill

In the next generation of healthcare that Chugai envisions, value creation entails providing solutions beyond the scope of products, and encompasses not just treatment, but the entire process from prevention and diagnosis to post-treatment.

Solutions to increase the value of drug therapy (“around the pill”) include diagnosis and post-treatment. Even now, diagnosis and treatment are seen as part of an integrated process in personalized healthcare, but with advances in genomic profiling and digital technology, preventive medicine will also play an important role. Furthermore, “beyond the pill” services may include providing solutions using different devices, and even information itself.

When considering cost effectiveness in terms of healthcare financing, it is necessary to take into account not just the price of the medicine itself, but also the therapeutic effect and impact on the patient’s lifestyle. The cost of a drug varies depending on the dosing frequency and dosing period, and other costs arise from managing adverse events after administration, traveling to and from the hospital, and so on. For instance, some drugs may cost less than others but require significant spending on adverse event management or limit the patient’s ability to work after treatment commences. In such cases, a more expensive drug often provides better overall value because the post-treatment financial burden is smaller. Going forward, it will be important to measure and prove the overall value of a drug, including patients’ ability to maintain employment and a normal lifestyle as well as quality of life.

Enhancing Overall Value for a Broad Range of Stakeholders
Must

What We Must Do

Fulfill our obligations as a top pharmaceutical company

• Build a sustainable healthcare framework
• Tirelessly pursue quality in every function

The problem of financing healthcare systems is becoming increasingly serious in many countries. Given the ongoing growth of populations and a rising proportion of seniors, who have relatively greater need for healthcare, providing healthcare sustainably is a critical issue going forward. Moreover, drug discovery is becoming more difficult, and the cost of creating new drugs is enormous. To ensure sustainable healthcare given limited resources, investment will be focused only on solutions that are truly valuable for patients. A framework for such healthcare must be built.

At the same time, on a global scale and from the perspective of social systems as a whole, companies are expected to contribute more broadly and at a more sophisticated level, both in terms of the issues they address and the roles they play. The SDGs adopted by the U.N. are an example of one such international initiative. Chugai supports the aims and philosophy of the SDGs in their entirety, and is working proactively toward their realization.

As a company that has established a solid presence in the industry through its growth and development, Chugai recognizes that it has an obligation to take greater initiative in resolving social issues. While playing a part in realizing sustainable healthcare, we will continue to raise the quality of our activities across all functions by pursuing innovation from the standpoint of increasing shared value with stakeholders. In this way, we will fulfill the role expected of us by society at a higher level.
We adopt a patient-centric approach to creating innovative drugs and providing solutions to cure and manage diseases. Through joint research and other initiatives, we are also working on treatments for neglected tropical diseases, including development of a new therapeutic antibody targeting the dengue virus.

We support and promote innovation in the field of healthcare by investing aggressively in research and development and by building open innovation networks through collaborative research with academia.

In the healthcare industry, we are working to ensure a stable supply and quality at a high level, including the accuracy of product quality and information. We are also promoting the reuse and sustainability of natural resources through efforts including environmental management and targeting water use throughout the value chain.

To help solve social issues, we are working in collaboration with research organizations, governments, non-governmental organizations and other specialized bodies. We also disclose information to our stakeholders and promote appropriate understanding of our corporate activities through dialogue.

In addition to recruiting talented and diverse people to support innovation, we provide rewarding environments where employees are able to develop their skills. We strive to optimize work environments and provide systems and conditions that promote job satisfaction and a sense of security among employees. We also expect our suppliers to consider EHS* issues in their business activities.

* Environment, health and safety
Can

Focus on science-based innovation
• Further innovate our unique strengths and technologies
• Take full advantage of cooperation with Roche

We have determined that the key to Chugai’s creation of shared value is to concentrate on innovation. Innovation is an important theme at any company, but we are proud that Chugai has maintained a commitment to science-based innovation ever since it was founded. Innovation is essential to creating breakthrough medicines, but drug discovery is not the only area where we innovate. We have been focusing our efforts on innovation with a scientific approach in all aspects of our business, including development, production, marketing, medical affairs, safety and quality assurance. One example is our use of precise area marketing based on a diverse range of information including real-world data. This approach helps us understand the characteristics of regional healthcare delivery systems and promote cooperation among healthcare providers. Innovating in various fields has allowed Chugai to establish its unique strengths, which are the source of its growth and development. By refining and reinforcing these strengths, we aim to bring about the realization of advanced and sustainable patient-centric healthcare.

Chugai’s concentration on innovation is enabled by its business model, which is based on partnership with Roche, and the efficient, resilient revenue bases that have been built through this model. We intend to make this business structure even stronger so that we can continue to steadily generate innovation.
Use of Chugai’s Unique Strengths and Further Progress

Chugai has unique strengths that give it a competitive advantage and have a considerable impact on the value it provides for patients. The diagram to the left shows how Chugai has redefined those strengths based on the direction of its value creation strategy, changes in the operating environment and other factors. Our business model, which combines scientific excellence with the strategic alliance with Roche, is the source of our value creation. Continuously providing innovative drugs that lead to further advancement of personalized healthcare, and providing healthcare services that maximize their value – these value creation activities are Chugai’s core strengths. We will continue to evolve these strengths by putting our strategies into action.

Optimal Use of Two Revenue Bases Allows Us to Concentrate on Innovation

Under the strategic alliance with Roche, Chugai efficiently in-licenses Roche’s innovative products and markets them on an exclusive basis in Japan. This stable revenue base allows us to concentrate investment on highly innovative proprietary technologies and drug discovery. In addition, out-licensing our in-house products to Roche gives us access to global markets, providing a revenue base that drives growth and generates profits that can be reinvested.

This business model also enables Roche to sell Chugai products – which have been created through highly innovative, specialized in-house research – in global markets. It is truly a win-win relationship. Based on this business model, we will further deepen our cooperation with Roche to drive continued innovation.
### Process for Establishing Material Issues

<table>
<thead>
<tr>
<th>STEP</th>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
</table>
| 1    | Analysis of mid- to long-term conditions and identification of risks and opportunities | • Healthcare industry outlook, and forecasts and assumptions of domains and participating companies  
• Identification of future risks and opportunities, and our relevant strengths and weaknesses |
| 2    | Discussion of management policies (Executive Committee) | • Decisions on management policies and business plan formulation process  
• Discussion on Mission Statement to express both Chugai’s growth and the development of society |
| 3    | Interviews of outside experts | • Advice of Chugai International Council (CIC) on mid- to long-term environmental changes and risks, strategic direction, and contributions Chugai can make  
• Advice from outside consultants on Chugai’s sustainability activities  
• Extraction of material issue categories based on expectations and requirements of society in accordance with the SDGs, GRI, SASB, etc.  
• Conducted gap analysis of current measures in terms of DJSI, MSCI and FTSE survey items |
| 4    | Gap analysis (requests from outside stakeholders, comparison with other companies) | • Drew up plan for solutions to social issues of stakeholders (value) and plan for material issues  
• Scope of outcome: “Move toward realization of advanced and sustainable patient-centric healthcare” |
| 5    | Analysis of social issues we want to solve (value) and material issues | • Review of plan for solutions to social issues (value) and plan for material issues, and consultations on wishes and views of divisions and supervising officers (Global Health Policy, Corporate Social Responsibility, Human Resources Management) |
| 6    | Consultation with internal divisions | • Based on the preceding steps, specified material issues on two axes: “stakeholder interest” and “Chugai’s impact on the economy, society and the environment”  
• Finalization after review by the Executive Committee, and approval by the Board of Directors |
| 7    | Specification of material issues (Outside directors, Executive Committee, Board of Directors) | |

In establishing material issues, we analyzed the future market environment, referred to the SDGs, GRI, SASB and other frameworks, and comprehensively identified the issues that society expects Chugai to address. We also scrutinized items for which Chugai is not sufficiently meeting expectations. We conducted an objective analysis that incorporated outside views, and narrowed the list of issues to those for realizing Chugai’s Envisioned Future. Based on that process, we specified 25 material issues in eight categories. (See table on page 17.)
Process for Establishing Material Issues

I think that Chugai’s process for establishing material issues was accurate because in the interest of thoroughness it incorporated gap analyses against an array of indices and objective third-party opinions. Above all, however, my evaluation of the process is positive because decisions are based on historical review and analysis of the medium-to-long-term environment, beginning with the Mission Statement renewal, and took into account consultations with each division and discussions among Chugai’s committees. As a result, the idea of sustainability has been embedded in the new mid-term business plan. As a member of the CSR Advisory Committee, I had the opportunity to offer opinions during the process. I believe that the interrelationships among issues have since been further clarified and made easier to understand.

I am confident in the effectiveness of Chugai’s material issues because in determining them Chugai has eschewed standard formulae and had the will to define issues, risks and opportunities in its own terms.

In the future, Chugai will of course have to take on issues based on its strategies, but dialogue with stakeholders remains important. By using annual reports based upon material issues as a common language in internal and external communications, these issues will become known throughout the Group. I have high expectations that Chugai will be able to craft its own unique approach to sustainability as a result.
Financial and Pre-Financial Highlights (IFRS)
Chugai Pharmaceutical Co., Ltd. and Consolidated Subsidiaries/ Years ended December 31

Financial Indicators (Core Basis)

- **Results**: Cost to sales ratio (%), Ratio of operating expenses to revenues (%)

<table>
<thead>
<tr>
<th>Year</th>
<th>Core Basis</th>
<th>Japanese GAAP</th>
<th>IFRS</th>
<th>Core Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>46.0</td>
<td>43.2</td>
<td>42.1</td>
<td>44.6</td>
</tr>
<tr>
<td>2016</td>
<td>39.8</td>
<td>40.2</td>
<td>37.2</td>
<td>37.2</td>
</tr>
<tr>
<td>2017</td>
<td>36.8</td>
<td>39.8</td>
<td>37.2</td>
<td>36.2</td>
</tr>
</tbody>
</table>

- **Sales (excluding Tamiflu)** (Billions of yen)

<table>
<thead>
<tr>
<th>Category</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overseas</td>
<td>342.9</td>
<td>357.4</td>
<td>354.7</td>
<td>363.2</td>
<td>390.2</td>
<td>423.8</td>
</tr>
<tr>
<td>Renal diseases</td>
<td>61.0</td>
<td>61.0</td>
<td>61.0</td>
<td>61.0</td>
<td>61.0</td>
<td>61.0</td>
</tr>
<tr>
<td>Bone and joint diseases</td>
<td>57.6</td>
<td>57.6</td>
<td>57.6</td>
<td>57.6</td>
<td>57.6</td>
<td>57.6</td>
</tr>
<tr>
<td>Oncology</td>
<td>123.7</td>
<td>141.2</td>
<td>141.8</td>
<td>156.1</td>
<td>172.4</td>
<td>188.9</td>
</tr>
</tbody>
</table>

- **Launch of main products in Japan**
  - Ediro
  - Mircera
  - Actemra (rheumatoid arthritis, E.U.)
  - Actemra (rheumatoid arthritis, U.S.)
  - Kadcyla
  - Alecensa
  - Perjeta

- **Approval of main products overseas**
  - Actemra (subcutaneous injection, U.S.)
  - Bonviva
  - Actemra (subcutaneous injection, E.U.)

- **Revenues and Operating Income** (Billions of yen)

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenues</th>
<th>Royalties and other operating income</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>498.8</td>
<td>534.2</td>
</tr>
<tr>
<td>2016</td>
<td>491.8</td>
<td>51.9</td>
</tr>
<tr>
<td>2017</td>
<td>579.8</td>
<td>64.5</td>
</tr>
<tr>
<td>2018</td>
<td>592.5</td>
<td>30.4</td>
</tr>
<tr>
<td>2019 (Forecast)</td>
<td>34.9</td>
<td></td>
</tr>
</tbody>
</table>

- **Operating Profit/ Ratio of Operating Profit to Revenues** (Billions of yen/ %)

<table>
<thead>
<tr>
<th>Year</th>
<th>Operating profit</th>
<th>Ratio of operating profit to revenues</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>90.7</td>
<td>18.2</td>
</tr>
<tr>
<td>2016</td>
<td>80.6</td>
<td>16.4</td>
</tr>
<tr>
<td>2017</td>
<td>103.2</td>
<td>19.3</td>
</tr>
<tr>
<td>2018</td>
<td>130.3</td>
<td>22.5</td>
</tr>
<tr>
<td>2019 (Forecast)</td>
<td>24.1</td>
<td></td>
</tr>
</tbody>
</table>

- **Net Income/Core EPS** (Billions of yen/Yen)

<table>
<thead>
<tr>
<th>Year</th>
<th>Net income</th>
<th>Core EPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>64.9</td>
<td>116.42</td>
</tr>
<tr>
<td>2016</td>
<td>54.8</td>
<td>102.50</td>
</tr>
<tr>
<td>2017</td>
<td>76.7</td>
<td>138.68</td>
</tr>
<tr>
<td>2018</td>
<td>97.3</td>
<td>176.42</td>
</tr>
<tr>
<td>2019 (Forecast)</td>
<td>198.00</td>
<td></td>
</tr>
</tbody>
</table>

- **Notes**
  1. Based on constant exchange rates for the three-year period

Revenues expanded substantially in 2018 due to exports of Chugai products and non-recurring income from the transfer of long-listed products and others. Royalties and other operating income (ROOI) is composed of recurring income, which has been increasing in conjunction with overseas sales of Actemra and other products, and non-recurring income, which changes from year to year and is the principal factor in the fluctuations in ROOI.

The ratio of operating profit to revenues is consistently high due to the low ratio of operating expenses to revenues. In 2018, the increase in ROOI and the lower cost to sales ratio contributed to the increase in the ratio of operating profit to revenues. In 2019, we expect record profit due to factors including ROOI growth from royalty income for Chugai product Hemlibra.

In new mid-term business plan BI 21, we set a high single-digit Core EPS compound annual growth rate (CAGR) as the quantitative outlook, and are using it as a key performance indicator shared both internally and externally.
Chugai has substantially improved its cost structure in view of the rising cost to sales ratio resulting from the increase in products in-licensed from Roche under the strategic alliance between the two companies. We have now secured high profitability by continuously achieving a ratio of operating expenses to revenues at a level that compares favorably with the world’s leading pharmaceutical companies.

Overseas sales were strong due to an increase in exports of Chugai products Actemra and Alecensa to Roche. In Japan, despite the impact of NHI drug price revisions and generic drugs on some mainstay products, Chugai products such as Alecensa and Actemra continued to drive growth.

About Core Basis Results

Chugai reports its results on a Core basis from 2013 in conjunction with its decision to adopt IFRS. Core basis results are the IFRS basis results adjusted by excluding non-Core items, and are consistent with the concept of Core basis results disclosed by Roche. Core basis results are used by Chugai as internal performance indicators for representing recurring profit trends both internally and externally, and as indices for establishing profit distributions such as returns to shareholders. No items have been excluded from the IFRS balance sheet and cash flows, as the Core basis results concept only applies to the income statement.
Chugai develops innovative medicines that allow it to differentiate itself from competitors by continuously establishing proprietary drug discovery technologies and applying them to development candidates while promoting research on commercialization for high quality and high added value. We will continue to generate research findings that may contribute to the overall advancement of healthcare by presenting those findings at scientific conferences and publishing them in academic papers.

2. Total of drug discovery and pharmaceutical technology

Although the percentage of product sales qualifying for premium pricing decreased substantially in 2018 due to the loss of premium pricing status for new drug creation and launches of generics, the number of new products and additional indications increased significantly. With our stable revenue base from the efficient in-licensing of Roche products for the Japanese market, we will continue to concentrate on the creation of innovative medicines.

Note: Products subject to special market-expansion repricing (2016, 2017: Avastin) are counted as products qualifying for premium pricing because they were assumed to meet the conditions for such pricing in the relevant fiscal years.

Energy consumption increased 10 percent year-on-year in 2018 due to the start of production at UK3. As Chugai expands its production system for new drugs, it is also working to reduce energy consumption as one of its tasks, based on its Core Values, “We care about the global environment.” (See pages 91-93 for details on environmental, health and safety initiatives.)

3. Benchmark year for mid-term environmental goals
4. Includes 40,000 GJ of overseas consumption
5. A new high-mix low-volume biological API manufacturing facility within the Ukima Plant (Kita-ku, Tokyo)
### Human Resource Management

#### Employees/Ratio of Female Employees

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of employees (Consolidated)</th>
<th>Number of employees (Non-consolidated)</th>
<th>Percentage of female employees (Non-consolidated)%</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>6,485</td>
<td>4,679</td>
<td>24.5</td>
</tr>
<tr>
<td>2010</td>
<td>6,709</td>
<td>4,764</td>
<td>25.0</td>
</tr>
<tr>
<td>2011</td>
<td>6,779</td>
<td>4,887</td>
<td>26.5</td>
</tr>
<tr>
<td>2012</td>
<td>6,836</td>
<td>4,910</td>
<td>27.3</td>
</tr>
<tr>
<td>2013</td>
<td>6,872</td>
<td>4,936</td>
<td>28.4</td>
</tr>
<tr>
<td>2014</td>
<td>7,023</td>
<td>4,932</td>
<td>26.2</td>
</tr>
<tr>
<td>2015</td>
<td>7,169</td>
<td>4,990</td>
<td>25.8</td>
</tr>
<tr>
<td>2016</td>
<td>7,245</td>
<td>5,036</td>
<td>24.5</td>
</tr>
<tr>
<td>2017</td>
<td>7,372</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>7,432</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Timeline:**
- **2012:** Creation and implementation of managerial talent development program
- **2013:** Introduction of talent management system
- **2015:** Promotion of measures to reduce excessive working hours
- **2017:** Promotion of work-life synergy
- **2018:** Diversity Office established

Chugai is working to enhance its management of human resources based on the belief that its people are the source of its contribution to patients in terms of providing greater value. We have implemented a talent management system to develop and retain leaders and core personnel, and also promote diversity and inclusion and work-life synergy so our diverse human resources can generate new value. The ratio of female employees is rising, and women have been steadily making inroads not only in our personnel systems but also in our initiatives.

#### Ratio of Female Managers (Non-consolidated)%

<table>
<thead>
<tr>
<th>Year</th>
<th>Percentage of Female Managers (Non-consolidated)%</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>9.7</td>
</tr>
<tr>
<td>2015</td>
<td>10.7</td>
</tr>
<tr>
<td>2016</td>
<td>11.3</td>
</tr>
<tr>
<td>2017</td>
<td>12.6</td>
</tr>
<tr>
<td>2018</td>
<td>13.3</td>
</tr>
</tbody>
</table>

#### Percentage of Male Employees Taking Childcare Leave (Non-consolidated)%

<table>
<thead>
<tr>
<th>Year</th>
<th>Percentage of Male Employees Taking Childcare Leave</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>52.0</td>
</tr>
<tr>
<td>2015</td>
<td>57.7</td>
</tr>
<tr>
<td>2016</td>
<td>28.9</td>
</tr>
<tr>
<td>2017</td>
<td>4.1</td>
</tr>
<tr>
<td>2018</td>
<td>16.9</td>
</tr>
</tbody>
</table>

#### Percentage of Employees Using the Telecommuting System (Non-consolidated)%

<table>
<thead>
<tr>
<th>Year</th>
<th>Percentage of Employees Using the Telecommuting System</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>18.1</td>
</tr>
<tr>
<td>2016</td>
<td>23.5</td>
</tr>
<tr>
<td>2017</td>
<td>29.7</td>
</tr>
<tr>
<td>2018</td>
<td>48.1</td>
</tr>
</tbody>
</table>

To promote the success of women in the workplace, we set a target ratio of female managers of 13 percent or higher by 2018, and focused on programs such as management candidate training to support the career development and professional growth of women. As a result, the percentage reached 13.3 percent as of December 31, 2018. However, this is still below global levels, so we plan to further accelerate our initiatives to develop female leaders.

Chugai implements various measures to promote work-life synergy and work arrangements that fit employee lifestyles, and to improve productivity. The number of male employees taking childcare leave is increasing. In addition to sending e-mails about taking childcare leave to men with newborn children and their supervisors, we have created a handbook for supervisors that contains examples of employees taking leave and guidance on key management points.

Since introducing the telecommuting system in 2012 for employees caring for young children and other family members, and for late-night teleconferencing with people overseas, we expanded the conditions for use of the system in 2015 to include productivity improvement, temporary injury and regular outpatient treatment. The number of users is on the rise. We will continue our efforts to raise awareness about the use of this system and continue to promote additional initiatives to achieve more flexible work styles.

6. Number of male employees taking childcare leave as a percentage of all male employees with newborn children

7. Percentage of eligible employees
### Review by Disease Area

#### Opportunities and Risks

#### Oncology

**Opportunities**
- Cancer is the largest area of unmet medical need (the leading cause of death in Japan).
- Personalized healthcare is expected to advance further due to factors including insurance coverage for cancer genomic profiling.
- Phase Three of the Basic Plan to Promote Cancer Control Programs is promoting delivery systems for cancer genomic medicine.

**Risks**
- Intensifying global competition for cancer immunotherapies including anti-PD-1/PD-L1 immune checkpoint inhibitors
- Return of premium for new drug creation for mainstay products
- Entry of large pharmaceutical companies into biosimilar markets

#### Bone and Joint Diseases/Autoimmune Diseases

**Opportunities**
- The emergence of biologics has dramatically improved the effectiveness of rheumatoid arthritis (RA) treatment, and the treatment goal is shifting to remission (a symptom-free state).
- The number of osteoporosis patients is increasing yearly as populations age.
- There are many potential osteoporosis patients because the treatment rate and adherence to treatment remain low.

**Risks**
- Intensifying global competition in the RA market
- Slower growth due to the maturing of Actemra in the medium to long term
- The emergence of biosimilars that compete with biologics

#### Renal Diseases

**Opportunities**
- Screening rates are increasing among potential patients and people who have not been screened due to enhanced measures to address chronic kidney disease (CKD) by the Ministry of Health, Labour and Welfare.
- Early intervention in potential patients is improving the treatment rate of renal anemia.
- Renal anemia is divided into the dialysis stage and the pre-dialysis stage, and the number of patients treated in the pre-dialysis stage is trending upward every year.

**Risks**
- Intensifying competition in the renal anemia market due to a reduction in fee points for dialysis as part of medical fee revisions

#### Other Diseases

**Opportunities**
- The burden on people with hemophilia A and caregivers due to the development of inhibitors and frequent administration is an issue.
- Neurology is an area of very high unmet medical need, with many pathologies and syndromes.
- Medical fee points have been increased to promote more kidney transplants, and treatment needs for kidney transplants in Japan are rising.
- In addition to skin deterioration, itching associated with atopic dermatitis reduces patients’ quality of life by disrupting sleep.

**Risks**
- Intensifying global competition due to the limited number of known molecular targets
- Possibility of few target patients despite high unmet medical need

#### Review of 2018 Performance

**In Japan, market penetration by new product Tecentriq was steady and sales of Alecensa, a product from Chugai research, were firm. However, sales decreased 0.1 percent year on year to ¥225.7 billion due to factors including the effect of NHI drug price revisions and lower sales of mainstay products Herceptin and Rituxan.**

Overall sales, including overseas sales, increased 5.7 percent to ¥266.7 billion supported by dramatic growth in Alecensa exports to Roche, which rose 107.9 percent to ¥28.9 billion, and other factors.

**In Japan, sales decreased 7.8 percent year on year to ¥100.5 billion. The increase was driven by the solid performance of mainstay products Actemra, a product from Chugai research for treatment of RA and other diseases; Ediroi, another product from Chugai research and the top brand in oral osteoporosis drugs; and Beniviva, which treats osteoporosis by inhibiting bone resorption.**

Overall sales, including overseas sales such as exports of Actemra, which is approved in more than 110 countries and is distributed through Roche, increased 17.4 percent to ¥181.0 billion.

**In Japan, sales decreased 7.8 percent year on year to ¥36.3 billion. Sales of Oxarol, an agent for secondary hyperparathyroidism, and Micera, a long-acting erythropoiesis stimulating agent, decreased in part because of the effect of NHI price revisions.**

**In Japan, market penetration was steady for Hemlibra, a treatment for hemophilia A launched in 2018, and CelCept, an immunosuppressant, maintained its share of the transplant segment and increased its share for lupus nephritis. However, sales decreased 10.4 percent year on year to ¥26.8 billion due to the transfer of long-listed products to Taiyo Pharma Co., Ltd. Sales of anti-influenza agent Tamiflu for ordinary use decreased 15.1 percent year on year to ¥10.1 billion, and sales for government stockpiles, etc. decreased 90.0 percent to ¥500 million.**

Overall sales in the other diseases category decreased 17.8 percent year on year to ¥43.8 billion.

---

1. Medical need that is not adequately met due to a lack of effective treatments
2. Successor products to biopharmaceuticals whose patent term has expired, made by manufacturers other than the manufacturer that developed the antecedent biopharmaceutical
3. Bone and joint diseases only
### Sales

#### Domestic market share in oncology: No. 1

<table>
<thead>
<tr>
<th>Product</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avastin</td>
<td>236.5</td>
<td>252.4</td>
<td>266.7</td>
</tr>
<tr>
<td>Herceptin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rituxan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alecensa (Domestic)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perjeta</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xeloda</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tecentriq</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kadcyla</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tarceva</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alecensa (Overseas)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrogen (Overseas)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Domestic market share in osteoporosis: No. 2

<table>
<thead>
<tr>
<th>Product</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actemra (Domestic)</td>
<td>146.5</td>
<td>154.2</td>
<td>181.0</td>
</tr>
<tr>
<td>Edirol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bonviva</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suvenyl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actemra (Overseas)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Domestic market share in RA: No. 2

<table>
<thead>
<tr>
<th>Product</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mircera</td>
<td>41.1</td>
<td>41.2</td>
<td>41.2</td>
</tr>
<tr>
<td>Oxarol</td>
<td>39.2</td>
<td>39.4</td>
<td>36.3</td>
</tr>
</tbody>
</table>

### Development Pipeline

( Including additional indications)

<table>
<thead>
<tr>
<th>Product</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tamiflu</td>
<td>48.5</td>
<td>53.2</td>
<td>43.8</td>
</tr>
<tr>
<td>CellCept</td>
<td>13.2</td>
<td>16.6</td>
<td></td>
</tr>
<tr>
<td>Hemlibra (Domestic)</td>
<td>9.0</td>
<td>3.0</td>
<td>2.3</td>
</tr>
<tr>
<td>Hemlibra (Overseas)</td>
<td>2.3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Note: Graph shows sales for bone and joint diseases only.

1. Products from Chugai research
## Development Pipeline (As of January 31, 2019)

### Oncology

<table>
<thead>
<tr>
<th>Development Code</th>
<th>Indication</th>
<th>Status</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Filed</th>
<th>Approved/Filing Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>RG7446</td>
<td>Non-small cell lung cancer (NSCLC) (2nd line)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>Jan. 2018</td>
<td></td>
</tr>
<tr>
<td>GA101 (RG7159)</td>
<td>Follicular lymphoma</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>Jul. 2018</td>
<td></td>
</tr>
<tr>
<td>RG1273*</td>
<td>Breast cancer (adjuvant)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>Oct. 2018</td>
<td></td>
</tr>
<tr>
<td>RG6268</td>
<td>Solid tumors [NTRK fusion-positive]</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>Dec. 2018</td>
<td></td>
</tr>
<tr>
<td>RG365*</td>
<td>Breast cancer (adjuvant)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>Jul. 2018</td>
<td></td>
</tr>
<tr>
<td>RG740</td>
<td>Prostate cancer</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021 or later)</td>
<td></td>
</tr>
<tr>
<td>RG756</td>
<td>Diffuse large B-cell lymphoma (DLBCL)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021 or later)</td>
<td></td>
</tr>
<tr>
<td>AF802 (RG7853)*</td>
<td>NSCLC (adjuvant)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021 or later)</td>
<td></td>
</tr>
<tr>
<td>GC33</td>
<td>Hepatocellular carcinoma</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021 or later)</td>
<td></td>
</tr>
<tr>
<td>CR12</td>
<td>Solid tumors</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021 or later)</td>
<td></td>
</tr>
<tr>
<td>ERY174</td>
<td>Solid tumors</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021 or later)</td>
<td></td>
</tr>
<tr>
<td>RG7423</td>
<td>Solid tumors</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021 or later)</td>
<td></td>
</tr>
<tr>
<td>RG7832</td>
<td>Solid tumors</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021 or later)</td>
<td></td>
</tr>
<tr>
<td>RG7828</td>
<td>Hematologic tumors</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021 or later)</td>
<td></td>
</tr>
</tbody>
</table>

### Bone and Joint Diseases

<table>
<thead>
<tr>
<th>Development Code</th>
<th>Indication</th>
<th>Status</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Filed</th>
<th>Approved/Filing Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED-71</td>
<td>Osteoporosis</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2018)</td>
</tr>
<tr>
<td>NRD101</td>
<td>Knee osteoarthritis/Shoulder periarthritis</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2019)</td>
</tr>
</tbody>
</table>

### Renal Diseases

<table>
<thead>
<tr>
<th>Development Code</th>
<th>Indication</th>
<th>Status</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Filed</th>
<th>Approved/Filing Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUS789</td>
<td>Hyperphosphatemia</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2020)</td>
</tr>
</tbody>
</table>

### Autoimmune Diseases

<table>
<thead>
<tr>
<th>Development Code</th>
<th>Indication</th>
<th>Status</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Filed</th>
<th>Approved/Filing Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRA* (RG1569)</td>
<td>Systemic sclerosis</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2019)</td>
</tr>
<tr>
<td>RG7845</td>
<td>Rheumatoid arthritis</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021)</td>
</tr>
</tbody>
</table>

### Neurology

<table>
<thead>
<tr>
<th>Development Code</th>
<th>Indication</th>
<th>Status</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Filed</th>
<th>Approved/Filing Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>RG1450</td>
<td>Alzheimer's disease</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021 or later)</td>
</tr>
<tr>
<td>RG7412</td>
<td>Alzheimer's disease</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021 or later)</td>
</tr>
<tr>
<td>SA237 (RG8168)</td>
<td>Neuronal nitric oxide spectrum disorder (NMOSD)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2019)</td>
</tr>
<tr>
<td>RG8264</td>
<td>Duchenne muscular dystrophy (DMD)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2020)</td>
</tr>
<tr>
<td>RG7916</td>
<td>Spinal muscular atrophy (SMA)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2020)</td>
</tr>
<tr>
<td>RG7935</td>
<td>Parkinson's disease</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021)</td>
</tr>
<tr>
<td>GYM323 (RG6237)</td>
<td>Neuromuscular disease</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2020)</td>
</tr>
<tr>
<td>RG7906</td>
<td>Psychiatric disorders</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2021)</td>
</tr>
</tbody>
</table>

### Other Diseases

<table>
<thead>
<tr>
<th>Development Code</th>
<th>Indication</th>
<th>Status</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Filed</th>
<th>Approved/Filing Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE910 (RG8013)</td>
<td>Hemophilia A (Inhibitor)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2018)</td>
</tr>
<tr>
<td>PC0371</td>
<td>Hemophilia B (Non-inhibitor)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2019)</td>
</tr>
<tr>
<td>CND31</td>
<td>Paroxysmal nocturnal hemoglobinuria (PNH)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2020)</td>
</tr>
<tr>
<td>AM109</td>
<td>Endometriosis</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(Multinational Study)</td>
<td>(2020)</td>
</tr>
</tbody>
</table>

### Highlights

- **Development Code**: Indicates the code assigned to the drug candidate.
- **Indication**: The condition or disease the drug is intended to treat.
- **Status**: The current status of the drug candidate.
- **Phase I, Phase II, Phase III**: The clinical development phases the drug candidate is in.
- **Filed**: The year the drug candidate was filed.
- **Approved/Filing Date**: The year the drug candidate was approved or filed.

---

*Designates change in status in 2018 and thereafter*  
PHC-based drug discovery

1. Multinational study managed by Chugai Pharmaceutical  
2. Development of atopic dermatitis was out-licensed to Galderma S.A. (Overseas)/Maruho Co., Ltd. (Japan)
<table>
<thead>
<tr>
<th>Generic Name/Product Name</th>
<th>Origin (Collaborator)</th>
<th>Mode of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>atezolizumab/Tecentriq</td>
<td>Roche</td>
<td>Engineered anti-PD1 monoclonal antibody (Injection)</td>
</tr>
<tr>
<td>obinutuzumab/Gazyva</td>
<td>Roche/Nippon (Shinpharma)</td>
<td>Glycoengineered type II anti-CD20 monoclonal antibody (Injection)</td>
</tr>
<tr>
<td>pertuzumab/Perjeta</td>
<td>Roche</td>
<td>HER2 dimerization inhibitory humanized monoclonal antibody (Injection)</td>
</tr>
<tr>
<td>entrectinib/Product name undetermined</td>
<td>Roche/Nerviano Medical Sciences</td>
<td>ROS1/TRK inhibitor (Oral)</td>
</tr>
<tr>
<td>bevacizumab/Avastin</td>
<td>Roche</td>
<td>Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody (Injection)</td>
</tr>
<tr>
<td>trastuzumab emtansine/Kadcyla</td>
<td>Roche</td>
<td>Anti-HER2 antibody-tubulin polymerization inhibitor conjugate (Injection)</td>
</tr>
<tr>
<td>ipatasertib/Product name undetermined</td>
<td>Roche/Amgen BiPharma</td>
<td>AKT inhibitor (Oral)</td>
</tr>
<tr>
<td>palifocizumab vedotinib/Product name undetermined</td>
<td>Roche</td>
<td>Anti-CU7/bi antibody-drug conjugate (Injection)</td>
</tr>
<tr>
<td>alemtuzumab/Herceptin/Perjeta</td>
<td>Roche</td>
<td>Anti-HER2 humanized monoclonal antibody/HER2 dimerization inhibitory humanized monoclonal antibody (Injection)</td>
</tr>
<tr>
<td>cobimetinib/Product name undetermined</td>
<td>In-house (Roche)</td>
<td>ALK inhibitor (Oral)</td>
</tr>
<tr>
<td>Generic and product names undetermined</td>
<td>In-house</td>
<td>Anti-Glypican-3 humanized monoclonal antibody (Injection)</td>
</tr>
<tr>
<td>Generic and product names undetermined</td>
<td>In-house</td>
<td>Raf and MEK dual inhibitor (Oral)</td>
</tr>
<tr>
<td>tocitinib/Product name undetermined</td>
<td>Roche/Exelixis</td>
<td>MEX inhibitor (Oral)</td>
</tr>
<tr>
<td>Generic and product names undetermined</td>
<td>In-house</td>
<td>Anti-S26b/C03 bispecific antibody (Injection)</td>
</tr>
<tr>
<td>mosunetuzumab/Product name undetermined</td>
<td>Roche</td>
<td>Anti-C02a/C03 bispecific antibody (Injection)</td>
</tr>
<tr>
<td>eldecalcitol/Edrocalcitol</td>
<td>In-house</td>
<td>Activated vitamin D3 agent (Oral)</td>
</tr>
<tr>
<td>purified sodium hyaluronate/Guvenyl</td>
<td>In-house</td>
<td>Sodium hyaluronate (Injection)</td>
</tr>
<tr>
<td>gantenerumab/Product name undetermined</td>
<td>In-house</td>
<td>— (Oral)</td>
</tr>
<tr>
<td>tocilizumab/Amitin (Oversea name: Actemra/RoActemra E.U.)</td>
<td>In-house (Roche)</td>
<td>Humamized anti-human IL-6 receptor monoclonal antibody (Injection)</td>
</tr>
<tr>
<td>fenebrutinib/Product name undetermined</td>
<td>Roche</td>
<td>BTK inhibitor (Oral)</td>
</tr>
<tr>
<td>gantenerumab/Product name undetermined</td>
<td>Roche/ImmuGene</td>
<td>Anti-amyloid-beta human monoclonal antibody (Injection)</td>
</tr>
<tr>
<td>cizumab/Product name undetermined</td>
<td>Roche/AC Immune</td>
<td>Anti-amyloid-beta humanized monoclonal antibody (Injection)</td>
</tr>
<tr>
<td>saralumab/Product name undetermined</td>
<td>Roche/Chugai/Institute for Molecular Biology</td>
<td>Anti-IL-6 receptor recycling antibody (Injection)</td>
</tr>
<tr>
<td>Generic and product names undetermined</td>
<td>Roche/Novartis</td>
<td>Anti-myostatin adnectin (Injection)</td>
</tr>
<tr>
<td>ruxolimus/Product name undetermined</td>
<td>Roche/PTC Therapeutics</td>
<td>SMN2 splicing modifier (Oral)</td>
</tr>
<tr>
<td>prasugrel/Product name undetermined</td>
<td>Roche/Prothena</td>
<td>Anti-o-synuclein monoclonal antibody (Injection)</td>
</tr>
<tr>
<td>Generic and product names undetermined</td>
<td>In-house (Roche)</td>
<td>— (Injection)</td>
</tr>
<tr>
<td>Generic and product names undetermined</td>
<td>In-house (Roche)</td>
<td>— (Oral)</td>
</tr>
<tr>
<td>emicizumab/Hemliba</td>
<td>In-house (Roche)</td>
<td>Anti-factor IXa/PI bispecific antibody (Injection)</td>
</tr>
<tr>
<td>fancimab/Product name undetermined</td>
<td>Roche</td>
<td>Anti-VEGF/Ang2/PI bispecific antibody (Injection)</td>
</tr>
<tr>
<td>nemolizumab/Product name undetermined</td>
<td>Inhouse</td>
<td>Anti-IL-31 receptor A humanized monoclonal antibody (Injection)</td>
</tr>
<tr>
<td>Generic and product names undetermined</td>
<td>In-house (Roche)</td>
<td>Anti-C5 recycling antibody (Injection)</td>
</tr>
<tr>
<td>Generic and product names undetermined</td>
<td>In-house (Roche)</td>
<td>PTH1 receptor agonist (Oral)</td>
</tr>
<tr>
<td>Generic and product names undetermined</td>
<td>In-house (Roche)</td>
<td>— (Injection)</td>
</tr>
</tbody>
</table>

Note: In principle, completion of first dose is regarded as the start of clinical studies in each phase.
Through innovation, we create shared value that leads to corporate growth.
Previous Mid-Term Business Plans

Chugai has established and implemented mid-term business plans with due consideration to changes in the external environment; the results of strategies, as well as the challenges encountered in their implementation; and the evolution of the Company’s strengths. The strategies in each mid-term business plan were evolutionary and linked, and while we addressed higher-level issues, we achieved steady results on all of them and demonstrated strong execution.

In the new mid-term business plan IBI 21, we will build on the value creation capabilities developed under our previous plans as we aim to create new value.

1. Diluted earnings per share attributable to Chugai shareholders on a core basis.
2. Compound annual growth rate
3. Based on average exchange rates for 2012
4. Based on average exchange rates for 2015
Context of the Formulation of IBI 21

Review of Previous Mid-Term Business Plan IBI 18

Business Performance during IBI 18

Financial targets

- Posted consecutive record revenues and operating profit
- Achieved industry-leading market capitalization

Priority agenda

Acquisition and implementation of competitiveness at a top global level

- Continuously generated new antibody projects and enhanced drug discovery platform for middle molecules
- Obtained early approval for Hemlibra
- Obtained approval for Tecentriq and simultaneously developed drugs for 19 indications
- Established system to manage FDA GMP* inspections
- Established framework to execute regional strategy through collaboration of three Chugai divisions (Marketing & Sales/Medical Affairs/Drug Safety)
- Made steady inroads towards accelerated growth based on Hemlibra and Tecentriq

Selection and concentration strategy for accelerated growth

In IBI 18, the previous mid-term business plan, Chugai focused on two priority agenda objectives: acquiring and implementing competitiveness at a top global level and pursuing a selection and concentration strategy for acceleration of growth. We worked to evolve quickly in every function, and achieved overwhelming success as a result.

In drug discovery, we successively generated a number of antibody projects and strengthened our technology platforms, including for middle molecule drugs. Development operations produced a steady stream of launches and new indications. We also improved our structure for providing healthcare solutions.

Financially, we achieved strong growth in sales and profits, and surpassed our guidance for Core EPS CAGR by a wide margin. Key factors driving these results included a substantial increase in exports of Chugai products, including Alecensa, to the Roche Group, better-than-expected sales of Tecentriq in Japan, and an increase in one-time income partly from the transfer of long-listed products.

Summary of IBI 18

Achieving record high profit, Chugai is enriching its platforms for further growth

<table>
<thead>
<tr>
<th>Financial targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Posted consecutive record revenues and operating profit</td>
</tr>
<tr>
<td>• Achieved industry-leading market capitalization</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Priority agenda</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acquisition and implementation of competitiveness at a top global level</td>
</tr>
<tr>
<td>• Continuously generated new antibody projects and enhanced drug discovery platform for middle molecules</td>
</tr>
<tr>
<td>• Obtained early approval for Hemlibra</td>
</tr>
<tr>
<td>• Obtained approval for Tecentriq and simultaneously developed drugs for 19 indications</td>
</tr>
<tr>
<td>• Established system to manage FDA GMP* inspections</td>
</tr>
<tr>
<td>• Established framework to execute regional strategy through collaboration of three Chugai divisions (Marketing &amp; Sales/Medical Affairs/Drug Safety)</td>
</tr>
<tr>
<td>• Made steady inroads towards accelerated growth based on Hemlibra and Tecentriq</td>
</tr>
</tbody>
</table>

---

* Good Manufacturing Practice: Standards for pharmaceutical production management and quality control

|= Achieved|
Chugai’s operating environment is expected to change more rapidly than ever. Several megatrends will have a significant impact, including remarkable advances in life science and digital technologies, fiscal pressure caused by demographic changes due to population growth and aging populations worldwide, and threats to the sustainability of the global environment and social systems, including healthcare systems. In response to this changing landscape, Chugai has identified the most important opportunities and risks and determined the approaches it should take in response.

Advances in life science technologies and digital technologies are expected to lead to the discovery of new disease mechanisms and entirely new approaches to drug discovery. With competition among companies for innovation likely to intensify further, Chugai will have to flexibly adopt various technologies to achieve more diverse and sophisticated value creation.

Demographic changes are fueling growing pressure to rein in healthcare costs. In the future, only those products and services proven to have true value for patients will be selected, which will further raise the stakes for success or failure among pharmaceutical companies. Chugai will need to focus on initiatives that bring substantial benefits for both patients and the sustainability of healthcare, as exemplified by personalized healthcare. In addition to healthcare, the sustainability of the environment and social systems are also global challenges, and it is already accepted that companies should participate in addressing such issues, as indicated by the adoption of the U.N. SDGs. Chugai is taking a holistic view of healthcare and will actively work to solve social issues in collaboration with governments, the rest of our industry, and other parties.
Overview of New Mid-Term Business Plan IBI 21

IBI 21

INNOVATION BEYOND IMAGINATION

Quantitative Outlook

Core EPS CAGR (2018-2021)

High single digit*

- We will make essential investment for future growth, while maintaining the momentum of growth achieved during IBI 18, and realize sustainable profit growth and expansion of corporate value.
- We will continue to target a Core EPS payout ratio of 50 percent on average.

* 3 years, based on constant exchange rate

New Mid-Term Business Plan: 5 Strategies

Create Global Growth Drivers and Maximize Value

Strategy 1: Value Creation
Realize innovative drug discovery to cure and manage diseases

Strategy 2: Value Delivery
Deliver patient-centric solution to maximize value of growth drivers

Strategy 3: Promote Advances in Personalized Healthcare (PHC)
Realize the further advancement of PHC and innovate R&D process by utilizing digital technology and data

Strengthen HR and Infrastructure That Support Chugai’s Business

Strategy 4: Strengthen Human Capital and Conduct Fundamental Structural Reform
Develop high-caliber HR talent that support innovation, and thoroughly reform costs, systems and processes

Strategy 5: Strengthen Sustainable Platforms
Simultaneously realize company growth and sustainable social development

The name of the new mid-term business plan, IBI 21, expresses our commitment to pursuing continuous innovation based on "Innovation Beyond Imagination (IBI)," and the challenges we will take on at a new stage with "21." Based on five strategies, we aim to accelerate the advancement of society and Chugai by generating innovation focused on novel drugs. In quantitative terms, we are targeting a Core EPS CAGR in the high single-digit range (assuming constant exchange rates) for the three years of the plan, and will allocate resources and make management decisions with emphasis on profitability and capital productivity, including evaluation based on capital costs. Our policy on shareholder returns is to continue to aim for a dividend payout ratio of 50 percent of Core EPS on average to provide stable dividends, taking into account the balance between shareholder returns and the internal reserves necessary for increasing corporate value.

Basic Principles of Increasing Corporate Value and Shareholder Returns
IBI 21 Growth Outlook

In addition to market penetration of growth drivers in Japan and overseas, the approval and launch of satralizumab will support further growth.

Market penetration
Revenue maximization

- Tecentriq/Hemlibra market penetration in Japan
- Alecensa/Hemlibra global expansion
- Promote FMI business
- Satralizumab launch (Japan/U.S./E.U.)

New drug approvals
Line extensions

- Satralizumab (Japan/U.S./E.U.)
- Key development products
- Additional indications for Tecentriq

Investment for future growth

- Nemolizumab, SKY59 global expansion
- Entry into new disease areas

- Nemolizumab (overseas)

Relationship of Strategies to Material Issues and SDGs

<table>
<thead>
<tr>
<th>Five Strategies</th>
<th>Material Issues</th>
<th>SDGs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strategy 1: Value Creation</td>
<td>• Creation of innovative drugs and services</td>
<td>- 3 GOOD HEALTH AND WELL-BEING</td>
</tr>
<tr>
<td></td>
<td>• Provision of solutions for patients</td>
<td>- 9 INDUSTRY, INNOVATION AND INFRASTRUCTURE</td>
</tr>
<tr>
<td></td>
<td>• Fair marketing</td>
<td>- 12 SUSTAINABLE CITY AND COMMUNITY</td>
</tr>
<tr>
<td></td>
<td>• Adverse event management</td>
<td>- 17 LEAVE NO ONE BEHIND</td>
</tr>
<tr>
<td>Strategy 2: Value Delivery</td>
<td>- 17 LEAVE NO ONE BEHIND</td>
<td></td>
</tr>
<tr>
<td>Strategy 3: Promote Advances in PHC</td>
<td>- 17 LEAVE NO ONE BEHIND</td>
<td></td>
</tr>
<tr>
<td>Strategy 4: Strengthen Human Capital and Conduct Fundamental Structural Reform</td>
<td>• Employee job satisfaction</td>
<td>- 5 DECENT WORK AND ECONOMIC GROWTH</td>
</tr>
<tr>
<td></td>
<td>• Development of employee potential</td>
<td>- 8 DECENT WORK AND ECONOMIC GROWTH</td>
</tr>
<tr>
<td></td>
<td>• Diversity and inclusion</td>
<td>- 9 INDUSTRY, INNOVATION AND INFRASTRUCTURE</td>
</tr>
<tr>
<td>Strategy 5: Strengthen Sustainable Platforms</td>
<td>• Quality assurance and stable supply of products</td>
<td>- 3 GOOD HEALTH AND WELL-BEING</td>
</tr>
<tr>
<td></td>
<td>• Disclosure and dialogue</td>
<td>- 9 INDUSTRY, INNOVATION AND INFRASTRUCTURE</td>
</tr>
<tr>
<td></td>
<td>• Improvement of healthcare access</td>
<td>- 12 SUSTAINABLE CITY AND COMMUNITY</td>
</tr>
<tr>
<td></td>
<td>• Climate change countermeasures</td>
<td>- 13 CLIMATE ACTION</td>
</tr>
<tr>
<td></td>
<td>• Use of renewable/recycled resources</td>
<td>- 15 LIFE ON LAND</td>
</tr>
<tr>
<td></td>
<td>• Protection of biodiversity</td>
<td>- 16 LIFE below MArINE AND INTEGRITY</td>
</tr>
<tr>
<td></td>
<td>• Environmental management system</td>
<td>- 17 LEAVE NO ONE BEHIND</td>
</tr>
<tr>
<td></td>
<td>• Supply chain management</td>
<td>- 17 LEAVE NO ONE BEHIND</td>
</tr>
<tr>
<td></td>
<td>• Human rights</td>
<td>- 17 LEAVE NO ONE BEHIND</td>
</tr>
<tr>
<td></td>
<td>• Social contribution activities</td>
<td>- 17 LEAVE NO ONE BEHIND</td>
</tr>
</tbody>
</table>
Realize innovative drug discovery to cure and manage diseases by integrating our core drug discovery technologies and biology, and by achieving rapid proof of concept (PoC).

**Strategic Points**

- Strengthen core drug discovery technologies
- Deepen understanding of pathology/Identify unique targets
- Achieve rapid early PoC/PoC¹
- Demonstrate value
- Bolster intellectual property (IP) strategy

---

¹ PoC is confirmation that the therapeutic effect conceived in the research stage is effective in humans. Early PoC means that in addition to safety, signs of efficacy or pharmacological effect have been confirmed in a limited number of cases.

² A drug that is highly novel and useful, and will significantly change the therapeutic system

³ A drug that offers clear advantages over other existing drugs in the same category, such as those with the same molecular target

⁴ Osaka University Immunology Frontier Research Center
Creation of Innovative Drugs

Continuous creation of innovative drugs is the core of Chugai’s identity, and the driver of its growth. In our drug discovery operations, we have created a succession of new drugs by prioritizing investment in cutting-edge antibody engineering technologies. In addition to therapeutic antibodies and small molecule drugs, we have selected middle molecule drugs as the domain for our next-generation core drug discovery technology, and established the requisite technological infrastructure. In IBI 21, we will attempt drug discovery at a whole new level, with the theme, “Realize innovative drug discovery to cure and manage diseases.”

At the same time, maintaining our technology-driven approach, we are aiming to achieve synergy by enhancing our understanding of biology. Our research thus far has shown the treatment limitations of drugs with only one mode of action, and that there are many diseases that have similar symptoms but completely different mechanisms. By gaining an even deeper understanding of biology, we can explore the potential for cure or full recovery from an earlier stage and identify original targets – it is here that Chugai’s advanced technologies will play an even bigger role. According to Dr. Hisafumi Okabe, Executive Vice President in charge of Research and Translational Research, “We are setting the goal of curing and completely managing diseases that have been difficult to treat. To achieve that, we will conduct research to gain a deeper understanding of biology, advance our technologies, and bring about process innovations to build a stronger modality platform.”

Maximizing Value

We will develop new drug candidates with world-class quality and speed. To that end, we will work to achieve PoC as quickly as possible by refining our development process, and will make full use of our translational research organization with bases in three regions – Japan, the United States and Europe – as well as Roche’s network. By doing so, we will continuously create innovative drugs with the potential to become next-generation growth drivers. At the same time, it is predicted that only those products and services that offer true value for patients will be selected. Therefore, in IBI 21, we will place emphasis on proving the value of the drugs we develop. That effort will involve establishing a system for collecting, analyzing and managing various data from the development stage to prove the value of our products for patients, including in areas such as quality of life and healthcare economics.

To deliver such innovative new drugs to patients as quickly as possible, Chugai will enhance its systems for accelerated development and product supply, with emphasis on the further evolution of manufacturing technologies to handle R&D projects for drugs with highly complex formulations, such as middle molecule drugs. Chugai will also continue striving to enhance quality control, quality assurance and regulatory functions in accordance with global standards.

Strengthening Our IP Strategy and Accelerating Open Innovation

In conducting discovery research and clinical development, one of our competitive strategies is the application of intellectual property rights, including technology patents, and we will work to strengthen this process. We will also generate new opportunities from outside the Chugai Group through joint research with IFReC and other research organizations in Japan and overseas, and the establishment of external networks, including investment in startups.
Maximize value of growth drivers (innovative drugs and services) through patient-centric consulting and enhanced digital solutions.

**Strategic Points**
- Maximize value of growth drivers
- Work to realize patient-centric healthcare
- Provide effective and efficient solutions

**Maximize value of growth drivers**

- Provide solutions through collaboration among a variety of specialists and integration of digital technology
- Deepen three-division collaboration and deliver sophisticated consulting
- Advancement of treatment support/solutions utilizing digital technology

**Additional value to realize personalization and differentiation**
- High-quality evidence including real-world evidence
- Real-time safety information

**Innovative drugs/services such as Hemlibra/Tecentriq**

Promote FMI business in Japan
Maximizing Value for Patients

Making a contribution to patients involves more than simply supplying medicines. To ensure that those medicines are used appropriately, it is also essential to accurately inform healthcare providers about their value and provide comprehensive safety information so that doctors and patients can feel confident in using them. At Chugai, the divisions in charge of these functions – Marketing & Sales, Medical Affairs and Drug Safety – collaborate with each other to provide sophisticated and diverse solutions.

In Japan, Chugai has built a solid presence in the fields of oncology, renal diseases, bone and joint diseases, and rheumatoid arthritis, among others, and holds a leading share in the hospital market. In IBI 21, we will develop solutions in these fields at a higher level to realize advanced and sustainable patient-centric healthcare, taking into consideration Chugai’s role and changes in society. “In the future, healthcare as a whole will be seen as an ecosystem in which various stakeholders converge as one community that shares the goal of maximizing value for patients,” says Dr. Osamu Okuda, Executive Vice President and Co-Head of the Project & Lifecycle Management Unit. “The quality of the solutions Chugai provides as part of that ecosystem will also have to evolve to deliver true value to patients.”

Advancing the Delivery of Effective and Efficient Solutions

Accordingly, in its value delivery strategy, Chugai will work to provide more sophisticated solutions through collaboration with various specialists and the integration of digital technology.

In medical affairs, in addition to continuing post-marketing clinical studies, we will generate high-quality evidence, including evidence derived from real-world data (RWD), to enhance the value of drugs for patients. In the field of drug safety, we will combine RWD from clinical settings with our existing post-marketing surveillance and safety information database tools to ensure the most up-to-date data and generate a visual image of safety evidence, enabling more effective solutions for healthcare providers. In marketing and sales, on the basis of these various forms of data, we have developed a database tool that is adaptable to local healthcare delivery systems, and we will use it to propose treatment plans optimized for each patient.

Along with these actions, we will develop the FMI business to promote cancer genomic medicine in Japan as an initiative for realizing advanced and sustainable patient-centric healthcare. See page 47 for details on the FMI business.

Acceleration of Growth Drivers

IBI 21, a plan designed to maximize the value of growth drivers by meeting the increasingly sophisticated and diverse needs of stakeholders in healthcare, includes measures for strengthening the incorporation of digital technology in response to technological advances. These efforts will focus specifically on new products and growth drivers including Tecentriq, Hemlibra and satralizumab (SA237). We are also looking to cooperate with Roche in the launch of Hemlibra and Edirol in China, which will further accelerate growth.

In the changing healthcare landscape, Chugai must create and deliver value at a higher level. We will grow by sharing value not only with patients, healthcare providers and medical institutions, but also with patients’ families, local communities and governments.

Osamu Okuda
Executive Vice President
In charge of Project & Lifecycle Management (Marketing), Foundation Medicine, Corporate Planning and Co-Head of Project & Lifecycle Management Unit

Today, tomorrow and onward, I want to deliver innovative drugs to more and more patients! Giving top priority to the wellbeing of each patient, I will help to create patient-centric healthcare by providing high-value-added information.

Maki Murata
Branch Manager, Atsugi Branch, Kanto-Minami Regional Management Office, Marketing & Sales Div.

Today, tomorrow and onward, I want to deliver innovative drugs to more and more patients! Giving top priority to the wellbeing of each patient, I will help to create patient-centric healthcare by providing high-value-added information.
Strategy 3 ➤ Promote Advances in PHC

Realize further advancements in personalized healthcare (PHC) and innovate R&D processes by utilizing digital technology and data.

**Strategic Points**
- Enable patient-centric PHC
- Establish a digital intelligence platform

---

**Further advance PHC and innovate R&D processes**

- **Collaboration with Roche**
  - Utilize Roche assets (e.g., Flatiron Health)

- **Promote advances in PHC to create value**
  - Advance in cancer genomic diagnostics (FMI) (e.g., accelerate developing liquid biopsy, etc.)
  - Develop high-quality medical database in collaboration with medical institutes
  - Generate insights by establishing data utilization structure and advanced data analysis

- **Intelligence**
  - Collect information incl. on science and digital technology
  - Confirm feasibility of digital devices

---

1. A company that provides oncology-specific electronic health record systems and has a comprehensive database developed in collaboration with medical institutions. It became a member of the Roche Group in 2018.
2. Unlike a conventional biopsy, which uses an endoscope and needle to take a tissue sample, liquid biopsy is a technology that uses blood or other body fluid samples to make a diagnosis and a prediction of therapeutic response.
Enabling Patient-Centric Personalized Healthcare

Personalized healthcare (PHC) offers value for patients, healthcare finances and society because treatments are given only to patients who will benefit from them. PHC is the main approach for realizing advanced and sustainable patient-centric healthcare. PHC has continued to advance in recent years, backed by dramatic progress in genomic medicine and data analysis technology. Chugai’s FMI business is part of that progress. Moreover, the evolution of digital devices and other developments have made it possible to obtain an immense amount of patient information in a timely manner, and to rapidly quantify a wide range of benefits for patients, including aspects such as quality of life in addition to the conventional yardsticks of drug efficacy and safety.

In that context, as a member of the Roche Group, a global leader in PHC, and as a pioneer of PHC in Japan, Chugai will focus on promoting the next stage of PHC to provide the best treatment for each patient. In close cooperation with government and academia, and in collaboration with the Roche Group, including Flatiron Health, Chugai will help establish a comprehensive database for healthcare providers. Speaking about this initiative, Dr. Yasushi Ito, Executive Vice President and Co-Head of the Project & Lifecycle Management Unit, says, “Through the promotion of advances in PHC we want to enable patients to live better-quality lives.”

Promoting Cancer Genomic Diagnostics (FMI Business)

To accelerate its contribution to PHC through cancer genomic medicine, in October 2018 Chugai established a specialized unit for FMI business that uses the technology of Roche Group member Foundation Medicine Inc. (FMI). “FoundationOne® CDx Cancer Genomic Profile (F1CDx),” for which we obtained regulatory approval in December 2018, is a system for comprehensive cancer-related genomic profiling using next-generation sequencing. The system detects alterations in 324 cancer-related genes in a single operation using DNA obtained from a solid tumor, which enables the dual functionality of comprehensive genomic profiling and companion diagnostics for anticancer drugs. Chugai will work toward advancements in PHC (strategy 3) by expanding use of this product and accelerating its development for liquid biopsy.

Establishing an Intelligence Platform Based on Digital Technology

To make effective use of the vast information in the database, it will be necessary to create a data utilization structure in cooperation with medical institutions and other outside organizations, as well as to utilize AI and acquire sophisticated data analysis technology. Chugai will collaborate with Preferred Networks, Inc., with which it entered into a comprehensive partnership in 2018, and plans to rapidly acquire capabilities by hiring and developing specialists and investing resources in technology upgrades.

Through initiatives utilizing these digital technologies and data, we will also work actively on innovation in research and development processes, including more efficient identification of drug discovery targets and target molecules and use of RWD to streamline the clinical development process.

Based on our long-standing commitment to properly delivering effective medicines to patients, and by combining various types of data, we will be able to quantify and prove the value of those medicines, and share that value with society. We are working to build a structure for collecting, analyzing and managing data within the company for that purpose.

Kosuke Iijima
Department Manager, Foundation Medicine Business Dept.

Yasushi Ito
Executive Vice President
In charge of Project & Lifecycle Management (R&D), Regulatory & Quality Management, Clinical Development, Drug Safety and Medical Affairs and Co-Head of Project & Lifecycle Management Unit

The FMI business provides cancer patients with access to appropriate treatments. By increasing the footprint of this service, we will be able to improve treatment outcomes, contribute to cancer genomic medicine, and bring about precision medicine.
Strategy 4 — Strengthen Human Capital and Conduct Fundamental Structural Reform

Recruit and develop diverse and high-caliber talent that supports innovation, and conduct fundamental structural reforms.

**Strategic Points**
- Develop and recruit talent from a mid- to long-term perspective
- Shift to a robust profit and cost structure

**Accelerate innovation by implementing strategies 1-3**

- **Recruit and develop talent**
  - Strengthen talent management system
  - Diversity & Inclusion
  - Reform remuneration system

- **Fundamental structural reform**
  - Structural reform by reviewing costs, systems and processes
  - Shift resources to facilitate innovation
Developing and Recruiting Talent from a Mid- to Long-Term Perspective

At Chugai, our people are an invaluable asset that drives the company’s growth and progress. Talent management is a key management theme for the pursuit of innovation.

In IBI 21, we are placing importance on recruiting, developing and assigning diverse, high-caliber human resources who will drive innovation and respond to the rapidly changing business environment as we implement strategies 1-3 described above. We will further strengthen human resource management with a medium- to long-term view. Shinya Unno, Executive Vice President in charge of Human Resources Management, explains Chugai’s upcoming human resource strategy: “For Chugai, where innovation is the key to value creation, it is important to be a great place to work, a place where every employee can work in good health, gain a sense of satisfaction, and continue to produce results. Our strategy will revolve around strengthening talent management, transforming our organizational culture, and accelerating diversity and inclusion.”

Specifically, we have revised human resource requirements, and will vigorously promote position management to assign the right leaders to the right positions, as well as talent management, including succession planning. In addition, we will recruit specialists who can play key roles in implementing strategies; shift to more flexible personnel and remuneration systems to support a corporate culture that embraces challenge; and further promote diversity and inclusion. Through these measures, we will foster an organizational culture that is conducive to innovation, and encourages the active participation of diverse employees.

In implementing the PDCA cycle in our human resource strategy, we will also change our approach to the employee surveys we have been conducting. In our formulation of IBI 21, we conducted a survey to identify human resource issues. The survey showed that our management system for implementing strategies and our level of employee engagement were at a high level compared to other global companies, but also that our work environments and organizational culture, though comparing favorably to our domestic competitors, still showed room for improvement at the global level. We will therefore focus on shifting to an organizational culture conducive to innovation throughout the company, and link that with implementation of IBI 21 to set detailed organizational reform tasks for each division and implement the PDCA cycle.

Transforming Our Profit Structure by Conducting Fundamental Structural Reform

Looking at carrying out the strategies of IBI 21 from a financial perspective, as financial pressure increasingly undermines the business environment for pharmaceutical companies, transforming cost structures will be critical to enable the concentration of resources on innovation. At Chugai, we have taken various measures that allow us to concentrate our finite resources on innovation, including productivity improvements aimed at reducing the expense ratio and the transfer of business rights of 13 long-term listed products in 2018, but we will make further improvements under IBI 21 to achieve greater profitability. We will reorganize systems, significantly reform our business processes and cost structures, and take firm steps to streamline operations, including the introduction of robotic process automation (RPA).* This will allow us to simultaneously achieve flexible investment in innovation and sustained profit growth. (See “Message from the CFO” on pages 52-55 for more details on Chugai’s structural reforms.)

* Automation of routine office work

I have been devising and promoting a Company-wide digital strategy, and supporting structural and process reforms. This will help us to optimize efficient resource allocation across Chugai in our pursuit of innovation, while establishing the internal platforms for continuing to provide patient-centric, innovative healthcare.
With the aim of improving corporate value continuously, we have specified six priority areas that support our challenge toward innovation, based on expectations and requests from society, Chugai’s impact on the economy, society and environment, and stakeholder interest.
Sustainable Platforms for Creating Shared Value

To achieve its Mission of benefiting the medical community and human health around the world, Chugai conducts its business in line with its Core Values1 and the Chugai Group Code of Conduct.1

Today, however, companies are being asked to take a more active role in solving social issues because of threats to the global environment and the sustainability of social systems. Accordingly, Chugai has specified material issues for value creation with the goal of creating shared value with stakeholders. These are the key issues we need to address in order to simultaneously achieve company growth and the sustainable development of society. We have established them as sustainable platforms to support innovation. (See “Process for Establishing Material Issues” on page 26 for more information.)

Material Issues in Six Categories

In IBI 21, we will work in the following six areas to enhance sustainable platforms.

1) In quality management, we will maintain and enhance our world-class level of quality, a key factor in the value of our products and services. In addition, we will foster and champion an organizational culture that is dedicated to the “quality” of value in every function.

2) In supply chain management, in addition to our ongoing efforts to ensure stable supplies and quality management, we will focus on supplier management in the areas of human rights and the environment. As there is room for improvement among suppliers overall in terms of human rights, we will conduct supplier due diligence in line with the human rights policy we announced in 2019.

3) Healthcare access is an area of particular emphasis in IBI 21. Up to now, we have contributed to global health through the GHIT Fund2 and Access Accelerated,3 but we intend to expand our activities. As Keiji Kono, Senior Vice President in charge of Global Health Policy, explains,

“Chugai’s innovative products have made a broad contribution to patients around the world in more 90 countries. However, access to healthcare coverage is a serious issue, particularly in low- and middle-income countries. Specific issues vary by country and region, so we will leverage Roche’s network and collaborate with international organizations, NGOs and other groups to develop activities that are precisely targeted to each issue.”

4) In social contribution, we will clarify the areas in which Chugai is active, and focus on activities suited to Chugai in order to contribute to medical care, welfare, social inclusion, support for the next generation, and communities.

5) For the global environment, we will actively contribute to measures to combat climate change, an issue of serious global concern, as well as increase the use of renewable and recycled resources and protect biodiversity. In addition, we will work to mitigate water risk and preserve water resources, which are especially critical to the pharmaceutical industry.

6) In stakeholder engagement, we believe that engaging with individual stakeholders more actively is a central part of our drive to create shared value. Other priorities will include strengthening disclosure and information dissemination, two-way communication, and creating new dialogue opportunities.

The Sustainability Dept. will spearhead activities to build a more inclusive society. This will entail developing Company-wide systems for resolving social issues, including those relating to the environment and human rights, in order to create value shared by Chugai and society, as stated in our Basic Policy.

1 . Both were revised in 2019.
2.  A public-private partnership to support research and development of pharmaceuticals, vaccines and diagnostics for serious infectious diseases in developing countries. It utilizes Japan’s medical technology, innovation and knowledge more directly. (https://www.ghitfund.org/)
3.  A global partnership launched by 22 major pharmaceutical companies that focuses on prevention and care of non-infectious diseases (http://www.accessaccelerated.org/)

Keiji Kono
Senior Vice President
In charge of External Affairs Dept.
and Global Health Policy

Shigehiro Yamada
General Manager,
Sustainability Dept.4

4. Name changed from Corporate Social Responsibility Department as of April 1, 2019
On a Strong Growth Track, But Level-Headed Analysis is Necessary

In the three years of our previous mid-term business plan IBI 18, Core EPS CAGR, our financial KPI, was 17.1 percent, well above our target of low single-digit growth (3 percent range based on constant exchange rates). Earnings were strong, with record-high revenues, operating profit and net income for two consecutive years. We saw steady increases in the ratio of operating profit to revenues (the operating margin) and return on equity (ROE), signifying substantial improvement in our profitability and capital productivity. This strong growth momentum also gave employee confidence a major boost.

However, we cannot allow ourselves to become complacent. Level-headed analysis is needed. The primary reason we exceeded our financial targets is the growth of Chugai products Actemra, Alecensa and Hemlibra. These global products became growth drivers that expanded our export business. We expect them to continue to drive earnings. On the other hand, our domestic revenues outperformed the plan partly because of the delay of drug price revisions in connection with the increase in the consumption tax rate that had been scheduled for 2017, as well as one-time income from the transfer of long-term listed products. These non-recurring factors must be discounted.

In our domestic business, which faces an increasingly challenging market environment, several issues have become apparent. In 2018, the premiums for new drug creation for Herceptin and Rituxan had to be returned, and biosimilars entered the market. As a result, revenue growth in

Message from the CFO

By pursuing a higher level of profitability and productivity, we will secure the financial resources for innovation and reinvest them in drug discovery that helps solve social issues.
Japan was negative as increased sales volume did not fully offset the effects of drug price reductions and other factors, and we project that sales will decrease again in 2019. Other mainstay products that have contributed to growth up to now are also expected to face similar circumstances over the next few years. We will have to confront the increasing and intensifying severity of the domestic environment, and are nearing a crucial stage.

Structural Reform and Business Process Improvements Remain Essential

Chugai’s business model based on the strategic alliance with Roche has two engines. One is the revenue base in which we supply breakthrough drugs discovered by Chugai to the world using the Roche Group’s infrastructure. The other is the revenue base in which we sell Roche products on an exclusive basis in Japan, along with Chugai products. We have swiftly increased the horsepower of the first engine. We need to preserve the horsepower of both engines evenly to maintain their driving force, which enables us to push forward with innovation.

After the strategic alliance agreement, Chugai reduced the number of operating bases and divested non-pharmaceutical businesses. Since then, we have continued to implement cost optimization initiatives, including business process reengineering (BPR) and productivity improvement. The sales growth of Chugai products,
particularly the expansion of exports to Roche, has boosted profitability, and Chugai’s ratio of operating profit to revenues is now higher than the domestic industry average. Nevertheless, in order to continuously create innovative new drugs and services, we must achieve a higher level of profitability and productivity so that we can continue to generate cash for investing in innovation.

Accordingly, one of the strategies of IBI 21 is fundamental structural reform aimed at maintaining and improving the profitability and productivity of our domestic business. To that end, we will stay ahead of trends in the market environment, and conduct a complete review of systems, organizations, processes and resource allocation. In addition, we will work to improve productivity and increase liquidity costs with measures such as business automation using RPA and other ICT systems, as well as improvement of operational efficiency through shared services and business process outsourcing, and improvement of workflow utilizing AI and data.

A Financial KPI Based on Our Business Model

In recent times, ROE has been emphasized in Japan from the standpoint of governance, but Chugai does not use ROE as a target KPI. A large portion of our business is biopharmaceuticals, which have a relatively lengthy manufacturing process, and we are required to hold adequate safety stock to fulfill our duty of providing reliable supply. For these reasons, there are certain limitations on increasing turnover. In addition, to maintain our independent management in our alliance with Roche, we must keep Roche’s equity share within a certain range, so it is difficult for us to reduce shareholders’ equity with share buybacks and treasury share cancellation. Therefore, of the three components for raising ROE – profit margins, turnover and financial leverage – increasing margins in our core business is our main approach. The best indicator of sustained growth in absolute terms from the viewpoint of shareholders is Core EPS CAGR. We publicly disclose our target for Core EPS CAGR as our financial commitment.

Of course, we place priority on cost of capital. In developing mid- to long-term business plans, we set out our strategy by clarifying the gap between our targets and current conditions considering the capital spread. In assessing the business feasibility of investments and development projects, the concept of cost of capital is also built into our internal management decision-making processes and mechanisms in ways such as discounting present value at the WACC. In addition, because of the need to consider both stock and flow, we began using ROIC as an internal KPI in 2019. Goals cascade from Company-wide targets to division targets, and we are shifting to measurement management that gives greater consideration to investment efficiency and cost of capital.

Focusing Resources on Investment in Innovation

In the creation of innovative drugs and services, it will be increasingly essential to achieve world-class quality. We have to prioritize investment allocation to ensure that funds do not run out. We will increase our investments in artificial intelligence, ICT and acquisition of real-world data. Investment in open innovation – alliances with academia and startups – will also be needed. Projects already under way include R&D using deep learning technology with Preferred Networks, Inc., and a data utilization project. Data utilization requires a considerable investment to build the infrastructure for integrating and coordinating internal and external data, and to acquire data analysis technology. We are also expanding our research in collaboration with Osaka University Immunology Frontier Research Center (IFReC), and we have decided to invest an additional SGD 282 million over the next five years in Chugai Pharmabody Research (CPR), our Singapore subsidiary that specializes in antibody research.

During IBI 18, we focused investment mainly on manufacturing facilities, but during IBI 21, we will ramp up investment in the area of drug discovery. Besides the investments I have already mentioned, a new synthetic research building is under construction in Osaka, a comprehensive R&D facility that will be the central hub for our research and development activities.

1. Weighted average cost of capital; the most common method of calculating cost of capital. The weighted average of the cost of borrowing money and the cost of raising funds through equity.
2. Return on invested capital; indicates how efficiently a company uses capital invested for business activities (invested capital) to generate profit.
construction at the Ukima Research Laboratories. Moreover, in 2019 we will construct a new research laboratory on a 170,000 m² site in Yokohama, Kanagawa Prefecture that we acquired at the end of 2018.

What makes these investments in intellectual capital for future value creation possible is the profit and cash inflow from our highly efficient and productive sales activities. In allocating that profit, we try to maintain a good balance between internal reserves that serve as investment resources and returns to shareholders. Our dividend policy is to deliver stable dividends with a target Core EPS payout ratio of 50 percent on average.

Deepening Dialogue with Society from the Perspective of Shared Value

Meeting the expectations of stakeholders by creating innovative pharmaceutical products and services is Chugai’s Mission. Our thoughts and actions for fulfilling our Mission, and the results of those actions, are the only straightforward approach: when Chugai’s financial value and social value rise, its corporate value – the sum of those two elements – increases. In that sense, the fact that Chugai’s market capitalization at the end of December 2018 was the highest among the leaders in the Japanese pharmaceutical industry is proof that our shareholders and other stakeholders understand and have positively evaluated our actions. This evaluation has reinforced our confidence and belief in the goals we are striving to achieve.

We will continue to strive for timely, appropriate information disclosure through various media, and will work to promote dialogue with stakeholders. In IBI 21, as reflected in our new slogan, “Creating shared value,” we will take a more active approach to providing information about the value we share with society, namely, the issues we plan to engage with and solve. To that end, we invite you to share your thoughts and comments with us. Thank you.

Current Status and Near-Term Plan of Major Investments

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ukima Plant:</td>
<td>Doubling of manufacturing capacity for investigational biologics (Simultaneous development of multiple projects)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2013-2015: ¥2.9 billion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Utsunomiya Plant:</td>
<td>Enhancement of high-mix low-volume production capability for pre-filled syringe form products (Installation of tray filler)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2013-2018: ¥6.0 billion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fujieda Plant:</td>
<td>Strengthening of solid formulation manufacturing facility, etc. (Achievement of quick launch and steady supply)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2015-2017: ¥6.0 billion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ukima Plant:</td>
<td>Enhancement of high-mix low-volume production of antibody API for initial commercial products (Expansion of production capability by construction of UK3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2015-2018: ¥37.2 billion (Plan)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CPR (Singapore):</td>
<td>Accelerate creation of clinical candidates utilizing proprietary antibody technologies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2012-2021: SGD 476 million (Plan), incl. capital investments of SGD 61 million (Plan)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yokohama site:</td>
<td>Establishment of new laboratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2016-2018: ¥43.4 billion (Plan)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive collaboration in research activities with IFReC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Details to be officially announced upon final decision</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ukima Research Laboratories:</td>
<td>Construction of a new synthetic research building for strengthening the process development function of small and middle molecule APIs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2018-2020: ¥4.5 billion (Plan)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Message from the CFO

CHUGAI PHARMACEUTICAL CO., LTD. Annual Report 2018
Message from the Chairman

At Chugai, our Mission is at the core of everything we do, and through our efforts to fulfill it, we will increase our corporate value.

Going forward, we will put more emphasis on ESG issues while evolving our governance system and taking steps to enhance our communication with stakeholders.

Osamu Nagayama
Representative Director & Chairman

Corporate Value and Governance

The importance of corporate governance has gained renewed attention in Japan in recent years. The Corporate Governance Code of the Tokyo Stock Exchange was revised, and among the issues currently being debated are the effectiveness of governance, the diversity of directors (including the percentage of outside directors on boards), clarification of criteria for CEO appointment and dismissal, and enhancement of succession plans.

In Chugai’s governance, it is crucial that we evolve and properly operate the governance system we have established. Our guiding principle in doing this is Chugai’s Mission, which defines the purpose of our business activities.

Chugai’s Mission is to “Dedicate itself to adding exceptional value through the creation of innovative medical products and services for the benefit of the medical community and human health around the world.” It is at the core of everything we do, and through our efforts to fulfill it we aim to increase our corporate value. That is Chugai’s fundamental management objective. Corporate value ultimately must stand up to economic and quantitative evaluation. That’s because, while corporate value incorporates various perspectives, since business activities are involved, providing returns to shareholders and other stakeholders is a critical responsibility.

Fulfilling Our Mission

Corporations exist side-by-side with various frameworks and relationships in society. In accomplishing their missions, they must abide by various regulations and fulfill responsibilities, and are required to follow certain rules while striving for economic efficiency in their business activities. Ensuring that they meet these requirements is the essence of governance. The Chugai Group Code of Conduct spells out the rules we must
follow, and is the evaluation standard for decisions in all our activities. Thorough compliance with the Code of Conduct supports Chugai.

So what is the key to fulfilling Chugai’s Mission? The answer is innovation. Expectations and the need for pharmaceuticals are increasing due to advances in life science and technological innovation. Developing new drugs requires substantial investment in research and development, and pharmaceutical companies are facing the universal challenge of how to continuously generate the capital necessary for strategic investment. However, the trend of drug price reductions as part of measures to curb social security costs is expected to continue, and only medicines that offer truly innovative value will be successful in the market. Only companies that can contribute to society’s development and meet medical and health needs through continuous innovation will be able to sustain growth.

Features of Chugai’s Governance

To support continuous innovation, Chugai began a strategic alliance with Roche in 2002 and built its current business model. This alliance, in which Chugai is a member of the Roche Group while maintaining autonomy and management independence, also lends significant distinctive features to our governance.

As long as we maintain our stock listing, it is important that we ensure fair treatment of all our shareholders. Basing our decision-making on the interests of Roche, the controlling shareholder of Chugai, would negate the purpose of the business model. Chugai must always consider the interests of minority shareholders to the maximum extent possible and pursue business activities that do not harm those interests.

For this reason, Chugai’s Board of Directors is divided equally into three types of directors: executive directors, non-executive directors from Roche, and independent outside directors. Each type consists of three people. I think this is a balanced composition that ensures fair treatment of minority shareholders while securing expertise and objectivity.

Another feature is that we have established the Chugai International Council (CIC), an advisory body composed of 10 experts and professionals from global business and the healthcare industry, to provide outside perspectives. The members of the CIC express their views and discuss matters such as Chugai’s future direction. I believe we benefit immensely from being able to obtain advice from broad, fresh perspectives.

Focal Points of Discussion in the Board of Directors

The Board of Directors supervises business execution aimed at achieving Chugai’s Mission through innovation. It deliberates and approves yearly plans and medium-to-long-term strategies, and monitors their progress. The board also receives timely reports in a number of important areas such as personnel systems and human resource development, and examines and discusses them. What we focus on here is whether activities in these areas have a scientific basis. We believe that it is Chugai’s duty to conduct not just research and development but all of its business operations based on science.

In addition to supervising business execution, the Board of Directors also focuses on discussing future trends in healthcare as a whole and technological innovation. Healthcare five to ten years in the future will certainly be different from how it is now. As new methods of treatment, drug discovery modalities, and groundbreaking life science technologies emerge, it will be important for the board to assess Chugai’s current technologies and consider the timeline for and extent to which it should prepare for future technological innovation.

Further Evolution of Governance

As I have already mentioned, there is no ideal form of governance. It must continuously evolve.

We have examined areas for improvement through evaluations of the effectiveness of the Board of Directors, and made improvements in the board’s operation. The results of evaluations during the past three years show that a certain level of effectiveness has been secured, but we need to do more.

In particular, we will emphasize the ESG perspective, expanding the scope of our contributions and supervising execution and making decisions from the standpoint of contributing to society as a whole. In our social action programs, for instance, we intend to take a more proactive approach rather than simply doing what society asks us to do.

Evolution is also needed in stakeholder engagement. For example, our dialogue with shareholders and investors has largely focused on topics such as business plans and their progress, but recently we have been receiving more requests for dialogue on governance, including supervision by the Board of Directors. We will respond to such changes appropriately in our efforts to engage stakeholders in an active dialogue.

Through its constant pursuit of innovation, Chugai will work to further increase its corporate value to fulfill its Mission. Thank you for your continued support.
Messages from Directors

Yoichiro Ichimaru
Independent Outside Director
Senior Advisor of Aioi Nissay Dowa Insurance Co., Ltd.

A Virtuous Cycle That Drives Growth and Development

In 2018, Chugai was able to realize the goal it established in 2009 of becoming a top pharmaceutical company. Looking at each of the targets, Chugai’s credibility and reputation in society have increased, including among healthcare providers and capital markets. Behind these successes is a business model based on the strategic alliance with Roche, and I believe that selection and concentration have been key to this alliance. Due to its collaboration with Roche, Chugai can select the regions and functions in which it concentrates management resources. This has led to a high level of results.

Another aspect where I feel Chugai excels is its use of diverse tools to effectively disseminate and share these results outside the Company. Chugai’s special features and the orientation of its value creation are conveyed in a very understandable fashion not just in this report, but also on the Company website and via other media. Consequently, Chugai is able to attract capable people from outside the Company and improve motivation within the Company, leading to even better results. I believe that this virtuous circle drives Chugai’s sustainable growth and development.

A Business Plan Imbued with Our Mission

The new mid-term business plan IBI 21 began in 2019. This plan reflects Chugai’s intention to provide true value for patients. In corporate management, it is extremely important to draw up long-term strategies without obscuring the company’s Mission, which expresses the purpose of its existence and what it intends to accomplish. It is likewise important to ensure that those strategies are adopted and implemented by everyone in the company. I worked for Toyota Motor Corporation for many years. To take an example from the automobile industry, which is at a turning point that only comes once every 100 years, a clear vision of wanting to provide freedom of movement for all is giving rise to innovative measures such as self-driving cars that will achieve new mobility for society. It is also bringing together diverse human resources and partner companies.

Without a doubt, the new mid-term business plan IBI 21 is imbued with Chugai’s long-term thinking, and I expect the Company to reach the even higher levels of innovation and ability that will be required to execute its strategies.

Evolution of Governance

I feel that Chugai’s governance system is a unique and effective framework from the viewpoint of fulfilling its Mission. Chugai has a large shareholder, Roche, whose long-term thinking is a perfect match. Consequently, Chugai can focus on sustainable growth without being limited by a short-term perspective. Moreover, by conducting independent management, Chugai can continue to produce results from its collaboration with Roche without losing its individuality. It is a win-win relationship that emphasizes diversity.

The Board of Directors consists of people from Chugai and Roche, as well as independent outside directors, such as me, with backgrounds in medicine, banking and manufacturing. I believe that lively discussions among directors with different experience and expertise are highly effective.

On the other hand, of course, there are also issues that still need to be addressed. I consider risk management particularly important. As society changes drastically and attention is focused on genomic medicine and other therapies, the risks Chugai faces will also change significantly. As it comes to grips with trends in other industries, the Company must envision and address new risks that affect the entire spectrum of the healthcare and pharmaceutical industries.

As an outside director, I still have much to learn about the pharmaceutical industry. In addition to gaining access to more substantive support so that I better understand the business, I will also study harder as I commit myself to Chugai’s management. Thank you for your continued support.
Just as important as our joint success today, is how we foster the collaboration going forward. Our achievements are rooted in a mutually beneficial business model. Although Roche is the majority shareholder, Chugai maintains its Japanese culture and identity and is managed autonomously, yet closely coordinated with Roche. It is our deep conviction that strong and self-reliant local management fosters an entrepreneurial spirit and drives innovation. On this basis our partnership has created a win-win situation. On the one hand, the Japanese management better understands business practices and the national environment, bringing Roche’s medicines more quickly to Japanese patients. On the other hand, Chugai is able to expand opportunities for innovative medicines through R&D synergies within the Group and gain access to the global market through Roche’s network, while still autonomously directing strategy and resources in drug discovery research. Thus, we mutually foster and benefit from our innovations.

Future Evolution of Chugai Management

Representing the interests of all shareholders, I and my colleagues of Chugai’s Board of Directors will continue to focus on our responsibilities as required by Japanese law, including the approval of senior management appointments and budgets for operations, research, development and capital expenditure.

There is a huge medical need and a growing demand for specific diagnostics and effective, better-tolerated therapies not only in Japan, Europe and the U.S. (due to rising life expectancy), but also increasingly in Asia, Latin America and Africa. Consequently, for Roche and Chugai there is still much work to do.

The foundation of our success is and will remain a clear focus on scientific innovation. Importantly, we have made great strides in advancing personalised healthcare, increasingly supported by real-world data and advanced analytics. Our success depends not only on working together within the Roche Group, but also on our access to external innovation, or in other words, to good ideas from the outside to further complement our capabilities.

Thus, we need to further focus on our strengths. In particular, I encourage Chugai management to concentrate their efforts on what they can do better than Roche and foster the collaborative spirit where there are joint opportunities. I am convinced that the companies that will succeed in the future are those that can differentiate themselves through such a strategic approach to innovation.

Importance of Improving Corporate Value

The Chugai-Roche strategic alliance has been a tremendous success story over the past 16 years. Together we are making a significant difference to patients in Japan and all over the world. Since 2003, Chugai has launched 14 Roche Group-originated products into the Japanese market, becoming the market leader in oncology. During this time, Chugai has also licensed nine compounds to Roche. Two terrific recent examples are Alecensa (reducing the risk of disease worsening or death by almost 80 percent in Asian patients with a specific lung cancer), which in 2018 was one of the key global growth drivers of our Pharma business, and Hemlibra (transforming medical practice in the treatment of haemophilia A), which is already indicated for most people with haemophilia A in the U.S. Another testament to the innovation power of the alliance is the fact that over the last six years, the Roche Group has received 25 breakthrough therapy designations from the U.S. Food and Drug Administration (FDA), with seven of them originating from Chugai. This high number, amongst the most in the industry, demonstrates how we are capitalizing on cutting-edge science for difficult-to-treat diseases such as haemophilia A, lung and breast cancer, and achieving great medical advances for millions of patients.

Management System of Chugai

Just as important as our joint success today, is how we foster the collaboration going forward. Our achievements are rooted in a mutually beneficial business model. Although Roche is the majority shareholder, Chugai maintains its Japanese culture and identity and is managed autonomously, yet closely coordinated with Roche. It is our deep conviction that strong and self-reliant local management fosters an entrepreneurial spirit and drives innovation. On this basis our partnership has created a win-win situation. On the one hand, the Japanese management better understands business practices and the national environment, bringing Roche’s medicines more quickly to Japanese patients. On the other hand, Chugai is able to expand opportunities for innovative medicines through R&D synergies within the Group and gain access to the global market through Roche’s network, while still autonomously directing strategy and resources in drug discovery research. Thus, we mutually foster and benefit from our innovations.
Corporate Governance

Chugai’s Corporate Governance

Chugai’s mission is to dedicate itself to adding exceptional value through the creation of innovative medical products and services for the benefit of the medical community and human health around the world.

To fulfill this mission, we have structured a unique business model, with a management emphasis on innovation. Under the strategic alliance with Roche, one of the world’s largest pharmaceutical manufacturers, Chugai is a member of the Roche Group, but at the same time maintains managerial autonomy and independence as a separate listed company. Chugai pursues management that fulfills the mandate of many stakeholders appropriately and fairly. Director composition and monitoring mechanisms are also based on this mindset.

In addition, corporate governance is an integral part of management at Chugai. We believe that both raising the effectiveness of corporate governance and creating systems and mechanisms for increasing corporate value are important. In other words, we realize that constantly implementing the PDCA cycle to continuously examine and improve corporate governance is essential. Making consistent efforts toward that objective is a major responsibility of management.

To fulfill our accountability to shareholders and other investors, Chugai’s corporate governance initiatives and policies are clearly stated in the Chugai Pharmaceutical Co., Ltd. Basic Corporate Governance Policy, which is disclosed on our website.

Responding to the Corporate Governance Code

We have verified and reviewed the status of compliance with each principle of the Corporate Governance Code of the Tokyo Stock Exchange in accordance with the

---

1. Chugai International Council (CIC): Chugai established the CIC as an advisory body composed of Japanese, American and European industry leaders and professionals in various sectors to respond accurately to changes in the global business environment and conduct business in an appropriate manner, and to provide advice to further enhance decision-making.

Internal Audit

Audit Department

Audit & Supervisory Board
Audit & Supervisory Board Members

Selection/Dismissal

Selection/Dismissal

Report

Report

Audit

Accounting Auditor

Internal Audits: The Audit Department, with a staff that includes certified internal auditors and certified fraud examiners, conducts audits of the status of business execution of the Chugai Group, including subsidiaries, from various standpoints, such as the effectiveness, efficiency and compliance of business activities; reports and makes recommendations to the Executive Committee; and reports to the Audit & Supervisory Board. In addition, Audit Department staff serve as Audit & Supervisory Board members at subsidiaries.

As an advisory body to the Board of Directors, the Compensation Committee deliberates on remuneration policy and the remuneration of individual directors. It consists of at least three outside committee members, including at least one outside director, appointed by the Board of Directors from among the nonexecutive directors including outside directors and persons with experience as non-executive directors.

Audit & Supervisory Board Member Audits: Chugai has an Audit & Supervisory Board, and audits of management decision-making and business execution are conducted independently from business operations by five Audit & Supervisory Board members, including three outside members.

Audit & Supervisory Board members express their opinions in real time from the standpoint of appropriate corporate governance in a variety of situations including at meetings of the Board of Directors, the Executive Committee (full-time Audit & Supervisory Board members only) and the Audit & Supervisory Board.

Principle 4-10-1: Establishment of Independent Advisory Committees

Independent outside directors do not make up the majority of Chugai’s Compensation Committee members. However, the committee comprises non-executive directors including one or more independent outside directors. Therefore, in consideration of the purpose of the Corporate Governance Code, Chugai believes that the current mechanism enables transparent and objective deliberation on compensation.

In addition, the Audit Department assesses whether effective internal controls are established and being implemented in accordance with internal control standards generally accepted as fair and appropriate in Japan to ensure the reliability of financial reporting based on the Financial Instruments and Exchange Act.

Accounting Audits: KPMG AZSA LLC handles accounting audits and internal control audits.

Cooperative Auditing: Audit & Supervisory Board members, the Audit Department and the Accounting Auditor cooperate closely by regularly exchanging information to improve the effectiveness of their respective audits. Audit & Supervisory Board members and the Accounting Auditor confirm each other’s audit plans and hold regular meetings to exchange opinions on matters including the results of quarterly audit reports. In addition, they work to strengthen governance at Group companies by coordinating with Audit & Supervisory Board members at subsidiaries on quarterly reports, fiscal year-end reports and other matters. The Office of Audit & Supervisory Board Members ensures the independence and enhances the auditing functions of Audit & Supervisory Board members.

The following two items are aligned with the concepts of the Corporate Governance Code. However, they are not applied at present or in all cases due to differences in specific structures, roles and for other reasons.

Principle 4-1-3: Appropriate Oversight of a Succession Plan for the CEO and Other Top Executives

Chugai revised the Chugai Pharmaceutical Co., Ltd. Basic Corporate Governance Policy. The Appointment Committee now deliberates on the succession plan for the CEO and other executive directors. The Appointment Committee provides the Board of Directors with policy, summary and progress reports to enable the Board to supervise successor candidate development that is conducted systematically with sufficient time and resources.

Principle 4-10-1: Establishment of Independent Advisory Committees

Independent outside directors do not make up the majority of Chugai’s Compensation Committee members. However, the committee comprises non-executive directors including one or more independent outside directors. Therefore, in consideration of the purpose of the Corporate Governance Code, Chugai believes that the current mechanism enables transparent and objective deliberation on compensation.

Revision of June 2018. Specifically, we clarified and announced policies for issues including the election and dismissal of executive directors, planning for and development of successors to the CEO and other top executives, verifying the suitability of holding and reducing cross-shareholdings, and the roles of corporate pension funds as asset owners. We also revised the Chugai Pharmaceutical Co., Ltd. Basic Corporate Governance Policy. In addition, our operating environment and strategy will continue to change quickly, so we plan to regularly verify these policies to support sustainable growth in the future.

The following two items are aligned with the concepts of the Corporate Governance Code. However, they are not applied at present or in all cases due to differences in specific structures, roles and for other reasons.

Principle 4-1-3: Appropriate Oversight of a Succession Plan for the CEO and Other Top Executives

Chugai revised the Chugai Pharmaceutical Co., Ltd. Basic Corporate Governance Policy. The Appointment Committee now deliberates on the succession plan for the CEO and other executive directors. The Appointment Committee provides the Board of Directors with policy, summary and progress reports to enable the Board to supervise successor candidate development that is conducted systematically with sufficient time and resources.

As an advisory body to the Board of Directors, the Compensation Committee deliberates on remuneration policy and the remuneration of individual directors. It consists of at least three outside committee members, including at least one outside director, appointed by the Board of Directors from among the nonexecutive directors including outside directors and persons with experience as non-executive directors.

Audit & Supervisory Board Member Audits: Chugai has an Audit & Supervisory Board, and audits of management decision-making and business execution are conducted independently from business operations by five Audit & Supervisory Board members, including three outside members.

Audit & Supervisory Board members express their opinions in real time from the standpoint of appropriate corporate governance in a variety of situations including at meetings of the Board of Directors, the Executive Committee (full-time Audit & Supervisory Board members only) and the Audit & Supervisory Board.

In addition, the Audit Department assesses whether effective internal controls are established and being implemented in accordance with internal control standards generally accepted as fair and appropriate in Japan to ensure the reliability of financial reporting based on the Financial Instruments and Exchange Act.

Accounting Audits: KPMG AZSA LLC handles accounting audits and internal control audits.

Cooperative Auditing: Audit & Supervisory Board members, the Audit Department and the Accounting Auditor cooperate closely by regularly exchanging information to improve the effectiveness of their respective audits. Audit & Supervisory Board members and the Accounting Auditor confirm each other’s audit plans and hold regular meetings to exchange opinions on matters including the results of quarterly audit reports. In addition, they work to strengthen governance at Group companies by coordinating with Audit & Supervisory Board members at subsidiaries on quarterly reports, fiscal year-end reports and other matters. The Office of Audit & Supervisory Board Members ensures the independence and enhances the auditing functions of Audit & Supervisory Board members.

As an advisory body to the Board of Directors, the Compensation Committee deliberates on remuneration policy and the remuneration of individual directors. It consists of at least three outside committee members, including at least one outside director, appointed by the Board of Directors from among the nonexecutive directors including outside directors and persons with experience as non-executive directors.

Audit & Supervisory Board Member Audits: Chugai has an Audit & Supervisory Board, and audits of management decision-making and business execution are conducted independently from business operations by five Audit & Supervisory Board members, including three outside members.

Audit & Supervisory Board members express their opinions in real time from the standpoint of appropriate corporate governance in a variety of situations including at meetings of the Board of Directors, the Executive Committee (full-time Audit & Supervisory Board members only) and the Audit & Supervisory Board.

In addition, the Audit Department assesses whether effective internal controls are established and being implemented in accordance with internal control standards generally accepted as fair and appropriate in Japan to ensure the reliability of financial reporting based on the Financial Instruments and Exchange Act.

Accounting Audits: KPMG AZSA LLC handles accounting audits and internal control audits.

Cooperative Auditing: Audit & Supervisory Board members, the Audit Department and the Accounting Auditor cooperate closely by regularly exchanging information to improve the effectiveness of their respective audits. Audit & Supervisory Board members and the Accounting Auditor confirm each other’s audit plans and hold regular meetings to exchange opinions on matters including the results of quarterly audit reports. In addition, they work to strengthen governance at Group companies by coordinating with Audit & Supervisory Board members at subsidiaries on quarterly reports, fiscal year-end reports and other matters. The Office of Audit & Supervisory Board Members ensures the independence and enhances the auditing functions of Audit & Supervisory Board members.
PDCA Cycle to Enhance Governance (Items Revised in 2018)

Based on the belief that constantly implementing the PDCA cycle to improve corporate governance is essential, Chugai emphasizes evaluation of the effectiveness of the Board of Directors and improvement activities based on evaluation results.

Chugai has been evaluating the effectiveness of the Board of Directors since 2015, and did so for the fourth time in 2018. We conduct a self-assessment survey in January every year for directors and Audit & Supervisory Board members who were in office during the applicable period, and discuss the results after receiving reports from the Secretariat for the Board of Directors. Based on the advice of external experts, the Secretariat for the Board of Directors prepares the survey, collects the directors’ responses and reports the results to the Board of Directors after having them aggregated, analyzed and evaluated by the external experts. A large number of responses for each item of the self-evaluation survey indicate achievement, and the percentage of responses indicating achievement has increased, confirming the overall effectiveness of the Board of Directors.

An analysis of results in 2017 indicated items that needed improvement, including consultation prior to discussion and enhanced explanation of complex agenda items. In response, in 2018 we were assiduous about deadlines for the submission of materials by divisions responsible for agenda items. We also confirmed complex agenda items with relevant divisions including governance and legal matters, and set required responses including additional information and advance explanation.

In 2019, we plan further improvements to the mechanism for evaluating the effectiveness of the Board of Directors. Formerly, attorneys conducted third-party evaluation and analysis based on the self-evaluations. We will consider having third parties other than attorneys evaluate effectiveness to add weight to the third-party perspective and increase objectivity.

Process for Evaluating Effectiveness of Board of Directors

<table>
<thead>
<tr>
<th>Self-evaluation survey of all directors and Audit &amp; Supervisory Board members (January)</th>
<th>Analysis and evaluation by external experts (March)</th>
<th>Board of Directors deliberates based on evaluation results (April)</th>
<th>Board of Directors identifies items for improvement and considers methods for improvement (April)</th>
</tr>
</thead>
</table>

Status of Improvements Identified through Evaluation of the Effectiveness of the Board of Directors

<table>
<thead>
<tr>
<th>Main Items for Improvement</th>
<th>Main New Initiatives Implemented after Analysis and Evaluation</th>
</tr>
</thead>
</table>
| 2016 | • Review structure of self-evaluation survey and answer options  
• As industriously provide materials for Board of Directors meetings at least four business days prior to the event  
• Enhance content of reports provided to Board of Directors and make materials easily understood |
| 2017 | • Change the procedure for providing materials to outside officers  
• Enhance topics for reports to the Board of Directors |
| 2018 | • Conduct prior and additional explanations on agenda items with complex content such as governance and legal matters |

Chugai’s Corporate Governance in 2018

<table>
<thead>
<tr>
<th>Organizational form</th>
<th>Company with an Audit &amp; Supervisory Board</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and execution</td>
<td>Separated</td>
</tr>
</tbody>
</table>
| Introduction of external perspectives | Implemented  
• 3 outside directors (of whom 3 are independent), 2 outside Audit & Supervisory Board members (of whom 2 are independent), and 3 other non-executive directors  
•  Appointment Committee and Compensation Committee as advisory bodies |
| Board of Directors | Composition |
|   | Number of meetings in 2018 |
| 2016 | 9 members (3 executive directors, 6 non-executive directors (of whom 3 are independent)) |
| 2017 | 9 |
| 2018 | 9 |
| Executive Committee | Composition |
|   | Number of meetings in 2018 |
| 2016 | 12 members (2 directors, 10 executive officers (excluding directors)) |
| 2017 | 35 |
| Appointment Committee | Chairperson  
Composition  
Number of meetings in 2018 |
| 2016 | Independent outside director  
4 members (1 director, 3 non-executive directors (of whom 2 are independent))  
2 |
| 2017 | 2 |
| Compensation Committee | Chairperson  
Composition  
Number of meetings in 2018 |
| 2016 | Non-executive director  
3 members (3 non-executive directors (of whom 1 is independent))  
2 |
| 2017 | 2 |
| Audit & Supervisory Board | Composition |
|   | Number of meetings in 2018 |
| 2016 | 4 members (2 full-time Audit & Supervisory Board members and 2 outside Audit & Supervisory Board members including 2 who are independent)  
11 (including 1 extraordinary meeting) |
| 2017 | 11 (including 1 extraordinary meeting) |
| Internal committees | Established IR Committee, Risk Management Committee, Corporate Social Responsibility Committee and Compliance Committee |
The Governance Structure That Supports Chugai’s Business Model

Separating management decision-making and business execution to expedite business execution and clarify executive responsibility is essential for promoting Chugai’s unique business model while ensuring its effectiveness. To that end, the Board of Directors is responsible for making decisions on management issues of primary importance, while other decisions on business execution are made at organizations such as the Executive Committee. The Chief Executive Officer (CEO) has ultimate responsibility for making decisions on Company-wide management strategies and important matters concerning business execution.

Principal Matters Deliberated by the Board of Directors

| Matters Concerning the General Meeting of Shareholders | • Calling of the General Meeting of Shareholders and determination of the agenda items  
• Approval of the Business Report, financial statements and other documents  
• Selection of director and Audit & Supervisory Board member candidates |
|---|---|
| Matters Concerning Directors and Audit & Supervisory Board Members | • Selection and dismissal of representative directors and executive directors  
• Directors’ remuneration and bonuses  
• Selection and dismissal of executive officers and advisors |
| Matters Concerning Stock | • Payment of interim dividend |
| Matters Concerning Management in General | • Formulation of plans and policies, and reports on their progress  
• Discussion of new business plans, alliances and other matters  
• Discussion of decision-making structure and organizations  
• Matters concerning finance and assets |
| Other Matters | • Approval and reporting of competing transactions  
• Approval and reporting of conflict of interest transactions  
• Implementation and reporting of evaluation of the effectiveness of the Board of Directors  
• Status of voting on proposals at the General Meeting of Shareholders  
• Verification of cross-shareholdings |

Composition of the Board of Directors

Chugai’s Board of Directors comprises three types of directors: executive directors, independent outside directors, and non-executive directors. The balance of experience among directors of each type enables effective corporate governance that ensures management autonomy as an independent publicly listed company within the Roche Group, and helps to increase corporate value.

Roles are as follows. Executive directors are responsible for business execution and supervision, report on and explain business execution matters and hold discussions on management. They execute the strategies decided in Board of Directors meetings. Currently, three executive directors are representative directors. Independent outside directors are appointed based on their knowledge and expertise as outside corporate executives or as medical, academic and other professionals. Their role is to provide advice concerning management, exercise supervisory functions and participate in discussions and decision-making at Board of Directors meetings from an objective, outside perspective. Other non-executive directors are principally appointed from the management team of the Roche Group. They provide an objective, expert perspective from a standpoint that is independent from business execution, offer recommendations and advice regarding strategies and management, and participate in discussions at Board of Directors meetings.

Composition of the Board of Directors

- Osamu Nagayama  
  Representative Director, Chairman
- Motoo Ueno  
  Representative Director, Deputy Chairman
- Tatsuro Kosaka  
  Representative Director, President & CEO
- Dr. Christoph Franz  
  Chairman of the Board of Directors of Roche Holding Ltd.
- William N. Anderson  
  CEO of Roche Pharmaceuticals
- Dr. James H. Sabry  
  Global Head of Roche Pharma Partnering

Composition of the Board of Directors

- Dr. Yasuo Ikeda  
  Outside Director  
  Vice-Chairman of the Board of Directors, Musashi Academy of the Nezu Foundation  
  Specially Appointed Professor of Waseda University, Professor Emeritus of Keio University
- Masayuki Oku  
  Outside Director  
  Outside Director of Komatsu Ltd.  
  Outside Director of Panasonic Corporation  
  Outside Corporate Auditor of Nankai Electric Railway Co., Ltd.  
  Non-Executive Director of The Bank of East Asia (China)
- Yoichiro Ichimaru  
  Outside Director  
  Senior Advisor of Aioi Nissay Dowa Insurance Co., Ltd.
Introduction of Outside Perspectives

To reflect diverse stakeholder viewpoints in business decisions, Chugai has actively taken measures to obtain outside perspectives, such as nominating outside directors and outside Audit & Supervisory Board members, enhancing support for outside officers, and establishing a council made up of domestic and overseas specialists.

Chugai International Council (CIC)

To respond accurately to changes in the global business environment and conduct international business in an appropriate manner, Chugai works to further enhance decision-making by operating the Chugai International Council (CIC), which is composed of Japanese and international professionals in various sectors. Of the current 10 council members, including the CIC Chair, one is a woman and one is Japanese.

Support System for Outside Directors and Outside Audit & Supervisory Board Members

Chugai appoints staff in the Secretarial Department to support the activities of outside directors. Managers including the General Manager of the Corporate Planning Department provide, as needed, reports on major changes in the operating environment and advance explanation of particular items to further enhance decision-making.

The Office of Audit & Supervisory Board Members is responsible for supporting the activities of Audit & Supervisory Board members in ways such as conveying internal information and providing materials for board meetings in advance.

In addition, Chugai invigorates the deliberations of the Board of Directors by preparing materials containing adequate information relevant to agenda items and distributing them to outside directors and outside Audit & Supervisory Board members well in advance of meetings. Chugai also provides additional information.

Chugai International Council (CIC) Composition

<table>
<thead>
<tr>
<th>CIC Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Henry L. Nordhoff (U.S.)</td>
</tr>
<tr>
<td>Former Chairman of the Board, Gen-Probe, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CIC Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Virginie Bottomley (U.K.)</td>
</tr>
<tr>
<td>Former Health Secretary of the U.K.</td>
</tr>
<tr>
<td>• William M. Burns (U.K.)</td>
</tr>
<tr>
<td>Former Chief Executive Officer of the Pharmaceuticals Division, F Hoffmann-La Roche Ltd</td>
</tr>
<tr>
<td>• Andrew von Eschenbach (U.S.)</td>
</tr>
<tr>
<td>Former Commissioner of the U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>• Victor Halberstadt (Netherlands)</td>
</tr>
<tr>
<td>Professor, Leiden University</td>
</tr>
<tr>
<td>• Andre Hoffmann (Switzerland)</td>
</tr>
<tr>
<td>Vice Chairman, Roche Holding Ltd.</td>
</tr>
<tr>
<td>• Franz B. Humer (Switzerland)</td>
</tr>
<tr>
<td>Former Chairman, Diageo plc</td>
</tr>
<tr>
<td>Former Chairman, Roche Holding Ltd.</td>
</tr>
<tr>
<td>• Robert A. Ingram (U.S.)</td>
</tr>
<tr>
<td>Former Vice Chairman of Pharmaceuticals, GlaxoSmithKline plc</td>
</tr>
<tr>
<td>• Arnold J. Levine (U.S.)</td>
</tr>
<tr>
<td>Professor Emeritus at the Institute for Advanced Study, Princeton University</td>
</tr>
<tr>
<td>Discoverer of the p53 cancer suppressor protein</td>
</tr>
<tr>
<td>• Sonosuke Kadonaga (Japan)</td>
</tr>
<tr>
<td>President, Intrinsics</td>
</tr>
</tbody>
</table>

Director Roles and Expertise in 2018

<table>
<thead>
<tr>
<th>Roles and Responsibilities</th>
<th>Name</th>
<th>Expertise</th>
<th>Board of Directors</th>
<th>Chugai Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Directors</td>
<td>Representative Director, Chairman</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Osamu Nagayama</td>
<td>Corporate management, Pharmaceuticals and healthcare</td>
<td>9 of 9</td>
<td>298,900 shares</td>
</tr>
<tr>
<td></td>
<td>Representative Director, Deputy Chairman, In charge of Corporate Social Responsibility Dept., Audit Dept.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Motoo Ueno</td>
<td>Corporate management, Pharmaceuticals and healthcare</td>
<td>9 of 9</td>
<td>788,300 shares</td>
</tr>
<tr>
<td></td>
<td>Tatsuro Kosaka</td>
<td>Corporate management, Pharmaceuticals and healthcare</td>
<td>9 of 9</td>
<td>34,700 shares</td>
</tr>
<tr>
<td>Independent Outside Directors</td>
<td>Director</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr. Yasuo Ikeda</td>
<td>Research, Medical science and healthcare</td>
<td>9 of 9</td>
<td>0 shares</td>
</tr>
<tr>
<td></td>
<td>Director</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Masayuki Oku</td>
<td>Corporate management, Global Group governance</td>
<td>9 of 9</td>
<td>0 shares</td>
</tr>
<tr>
<td></td>
<td>Director</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yoichiro Ichimaru</td>
<td>Corporate management, Global Group governance</td>
<td>9 of 9</td>
<td>0 shares</td>
</tr>
<tr>
<td>Non-Executive Directors</td>
<td>Director</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr. Christoph Franz</td>
<td>Corporate management, Global Group governance</td>
<td>8 of 9</td>
<td>0 shares</td>
</tr>
<tr>
<td></td>
<td>Director</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Daniel O’Day</td>
<td>Corporate management, Pharmaceuticals and healthcare</td>
<td>9 of 9</td>
<td>0 shares</td>
</tr>
<tr>
<td></td>
<td>Director</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr. Sophie Kornowski-Bonnet</td>
<td>Corporate management, Pharmaceuticals and healthcare</td>
<td>8 of 9</td>
<td>0 shares</td>
</tr>
</tbody>
</table>
required by outside directors and outside Audit & Supervisory Board members and takes advantage of opportunities to provide advance explanation.

The Relationship with Roche and Securing the Rights and Equality of Shareholders

Roche, the parent company of Chugai, holds 59.89 percent of Chugai’s outstanding shares based on the strategic alliance agreement between the two companies. Roche and Chugai have agreed to cooperate in maintaining the listing of Chugai’s common stock on the First Section of the Tokyo Stock Exchange.¹

The aim of this alliance is to establish a new business model that differs from conventional corporate acquisitions and joint ventures. Although Roche Holding Ltd. includes Chugai in its consolidated accounts, Chugai functions as an independent listed company and makes all of its own management decisions based on the principle of self-governance. Chugai believes that autonomy and diversity are key to generating innovation, that maintaining its independent management brings diversity to the Roche Group, and that the pharmaceuticals it creates as a result contribute to all stakeholders, including patients and minority shareholders. Chugai recognizes that the various benefits from being listed on the First Section of the Tokyo Stock Exchange – such as its solid credit rating, flexible fund procurement, name recognition and social presence – are supported by the understanding of minority shareholders, Roche and investors who are potential shareholders. That is why in its business dealings with the Roche Group, Chugai conducts all transactions fairly using third-party prices to protect the interests of minority shareholders.

As of March 28, 2019, three of Chugai’s nine directors are from the Roche Group. However, they do not comprise a majority of the Board of Directors, and thus Chugai considers its management independence to be secure. Chugai will continue to manage its business with autonomy and independence as a publicly listed company.

Chugai believes that securing substantially equal treatment of shareholders is very important. We therefore emphasize giving due consideration to minority and foreign shareholders and to maintaining an environment that allows them to exercise their rights.

Therefore, recognizing that business plans are a commitment to shareholders, Chugai promotes the disclosure of a variety of information and constructive dialogue with shareholders and investors. Directors and executive officers make every reasonable effort to meet requests for interviews from shareholders and investors.

2. The Tokyo Stock Exchange requires delisting if the ratio of tradable shares to listed shares is less than 5 percent.

Officer Remuneration That Emphasizes Linkage with Performance and Stock Price

Chugai’s fundamental policy for remuneration of directors and Audit & Supervisory Board members is to attract outstanding people and appropriately motivate them in order to continuously increase the Chugai Group’s corporate value. At the same time, remuneration levels and the remuneration system are designed to link compensation of officers with the Company’s performance and align their interests with those of shareholders.

In order to further clarify the link between remuneration and the Company’s business performance and shareholder value, and to raise directors’ ambition and motivate them to improve performance, remuneration of executive directors consists of bonuses paid according to performance in each fiscal year and restricted stock compensation linked to mid- and long-term performance (tenure-based and performance-based) as a long-term incentive to continuously increase corporate value, in addition to fixed regular compensation. These three components are paid by resolution of the Board of Directors based on the Company’s criteria within the limits on remuneration approved by the General Meeting of Shareholders. The Compensation Committee sets policies and deliberates details concerning remuneration of directors with specific titles to ensure the objectivity and transparency of the remuneration-setting process.

Remuneration of non-executive directors and Audit & Supervisory Board members (including outside members) consists solely of fixed regular compensation, and is paid by resolution of the Board of Directors for non-executive directors and through consultation with the Audit & Supervisory Board for Audit & Supervisory Board members. The amounts are set within the limits approved by the General Meeting of Shareholders.

A resolution was passed in the 98th Annual General Meeting of Shareholders held in March 2009 to abolish the retirement benefits system for directors. A resolution was passed in the 95th Annual General Meeting of Shareholders held in March 2006 to abolish the retirement benefits system for outside directors and Audit & Supervisory Board members (including outside members).

At the 100th Annual General Meeting of Shareholders held on March 23, 2017, a resolution was passed to newly introduce

Restrictions on Roche’s Shareholding

<table>
<thead>
<tr>
<th>Period</th>
<th>Maximum Shareholding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oct. 1, 2002 – Sep. 30, 2007</td>
<td>50.1%</td>
</tr>
<tr>
<td>Oct. 1, 2007 – Sep. 30, 2012</td>
<td>59.9%</td>
</tr>
<tr>
<td>Oct. 1, 2012 and thereafter</td>
<td>Cooperate in maintaining Chugai’s listing</td>
</tr>
</tbody>
</table>
System for Remuneration of Directors and Audit & Supervisory Board Members

<table>
<thead>
<tr>
<th>Type of Remuneration</th>
<th>Eligible Officers</th>
<th>Payment Criteria</th>
<th>Payment Method</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Executive Directors</td>
<td>Non-executive Directors (including Outside Directors)</td>
<td>Audit &amp; Supervisory Board Members</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed Regular Compensation</td>
<td>Regular Compensation</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Performance-based Remuneration</td>
<td>Bonuses</td>
<td>●</td>
<td>Paid according to performance in each fiscal year</td>
</tr>
<tr>
<td>Long-term Incentive (Stock-based Compensation)</td>
<td>Tenure-based Restricted Stock</td>
<td>●</td>
<td>Paid according to fixed length of service</td>
</tr>
<tr>
<td>Performance-based Restricted Stock</td>
<td>Performance-based Restricted Stock</td>
<td>●</td>
<td>Paid according to performance over fixed period in addition to above</td>
</tr>
</tbody>
</table>

Amount of Remuneration Paid to Directors and Audit & Supervisory Board Members (2018)

<table>
<thead>
<tr>
<th>Position</th>
<th>Total Remuneration, etc. (Millions of yen)</th>
<th>Total Amount by Type of Remuneration, etc. (Millions of yen)</th>
<th>Number of Eligible Officers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Regular Remuneration</td>
<td>Bonuses</td>
<td>Restricted Stock Compensation</td>
</tr>
<tr>
<td>Directors (Excluding Outside Directors)</td>
<td>533</td>
<td>261</td>
<td>123</td>
</tr>
<tr>
<td>Outside Directors</td>
<td>43</td>
<td>43</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>576</td>
<td>427</td>
<td>129</td>
</tr>
<tr>
<td>Audit &amp; Supervisory Board Members (Excluding Outside Audit &amp; Supervisory Board Members)</td>
<td>63</td>
<td>63</td>
<td>—</td>
</tr>
<tr>
<td>Outside Audit &amp; Supervisory Board Members</td>
<td>24</td>
<td>24</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>87</td>
<td>87</td>
<td>—</td>
</tr>
</tbody>
</table>

1. The table above includes one director who retired during the fiscal year under review. The amount of remuneration, etc. (regular remuneration and bonuses) paid to all directors was not more than ¥750 million per year as per the resolution passed in the 96th Annual General Meeting of Shareholders for the year ended December 31, 2006 held in March 2007.

2. Apart from this, the maximum amount of compensation paid to directors (excluding non-executive directors and excluding outside directors) in the form of restricted stock compensation (tenure-based and performance-based) was not more than ¥345 million per year as per the resolution passed at the 106th Annual General Meeting of Shareholders for the year ended December 31, 2016 held in March 2017.

3. The amount of remuneration for all Audit & Supervisory Board members was not more than ¥100 million per year as per the resolution passed at the 95th Annual General Meeting of Shareholders for the year ended December 31, 2005 held in March 2006.

4. The amounts of “restricted stock compensation (tenure-based and performance-based)” shown in the table above are the amounts that were posted as expenses for the fiscal year as each respective restricted stock compensation.

Accordingly, “number of eligible officers” includes one director who retired during the fiscal year under review and one director who retired during the previous fiscal year.

5. No new stock options have been granted in the fiscal year under review but the amount granted in the previous fiscal year that was posted as expenses in the current fiscal year is shown in Stock Options above.

6. A resolution was passed at the 98th Annual General Meeting of Shareholders for the year ended December 31, 2008 held in March 2009, to abolish the retirement benefits system for executive directors, and to pay retirement benefits corresponding to their residual term up to the abolishment of the system to each concerned director remaining in office after the closing of the 98th Annual General Meeting of Shareholders for the year ended December 31, 2008, at the respective time of their retirement.

7. Apart from the ¥234 million in provision for reserve for bonuses to directors noted in the Business Report for the previous fiscal year as bonuses for directors for the previous fiscal year, ¥136 million was paid to four directors (excluding non-executive directors and including outside directors) during the current fiscal year.

Amount of Remuneration Paid to Representative Directors (2018)

<table>
<thead>
<tr>
<th>Name</th>
<th>Total Consolidated Remuneration, etc. by Type (Millions of yen)</th>
<th>Total Consolidated Remuneration, etc. (Millions of yen)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Regular Remuneration</td>
<td>Bonuses</td>
</tr>
<tr>
<td>Osamu Nagayama</td>
<td>126</td>
<td>37</td>
</tr>
<tr>
<td>Motoo Ueno</td>
<td>58</td>
<td>26</td>
</tr>
<tr>
<td>Tatsuro Kosaka</td>
<td>68</td>
<td>60</td>
</tr>
</tbody>
</table>

1. Amounts are rounded to the nearest million yen.

2. Other than the representative directors in the table above, no director or Audit & Supervisory Board member received total remuneration of more than ¥100 million.
restricted stock in place of the current stock options for executive directors of the Company. The aggregate amount of such compensation shall not exceed ¥345 million on top of the aforementioned fixed regular compensation and bonuses. (For details of director remuneration, please refer to pages 43-44 of the “Notice of Convocation of the 108th Annual General Meeting of Shareholders for the Business Term Ended December 31, 2018.”)

Internal Control System and Risk Management

On May 18, 2006, the Company approved the Board of Directors’ resolutions concerning the Internal Control System as its basic policies in maintaining systems for ensuring appropriate business operations. On April 22, 2015, the Company revised the Board of Directors’ resolutions concerning the Internal Control System in response to the main revisions of the Partial Amendment to the Companies Act and the amended Ordinance for Enforcement of the Companies Act, namely “enhancement of systems for groups of enterprises,” “enhancement of audit systems,” and “obligation to disclose status of operations,” which came into effect in 2015. Since this revision, the status of implementation of the Internal Control System is regularly reported at Board of Directors meetings, and necessary revisions are made in a timely manner to maintain effective internal controls.

Chugai views risk management as a key issue pertaining to the Company’s core operations. Chugai has established Risk Management Regulations based on its Risk Management Policy to prevent the materialization of risks that could affect the Company’s business activities, as well as to ensure prompt and appropriate handling of problems that arise. We have also established Division Risk Management Committees and a Risk Management Committee under the Executive Committee. Division Risk Management Committees summarize and create risk maps of all the risks facing their divisions, make proactive efforts to prevent the materialization of such risks, and submit reports on the progress of those efforts to the Risk Management Committee. The Risk Management Committee identifies Group-wide risk issues that may have a material impact on management and submits a progress report to the Executive Committee concerning preventive measures. (See “Business Risks” on page 120 for details.)

Chugai and Compliance

Rooted in its belief that corporate ethics take priority over profit, Chugai places paramount importance on respect for life, and strives for fair and transparent corporate activities based on high ethical standards, along with sincere scientific initiatives.

As well as strictly complying with laws and regulations such as the Law for Ensuring the Quality, Efficacy and Safety of Drugs and Medical Devices and the voluntary Code of Practice for the industry established by the Japan Pharmaceutical Manufacturers Association (JPMA), Chugai proactively takes part in the activities of the Fair Trade Council of the Ethical Pharmaceutical Drugs Marketing Industry, the JPMA Code Compliance Committee and other organizations. In addition, by establishing its own two guidelines for transparency, Chugai works to ensure a high level of ethics, morality and transparency in its various business activities including collaboration with medical institutions and other parties and cooperation with patient groups. (For details about these transparency guidelines, see the Chugai website.*)

In light of increasing societal demands for greater compliance in the pharmaceutical industry, we have strengthened compliance measures Company-wide. In addition to working to enhance compliance education in each of our training programs, we conduct compliance risk management measures in each organizational unit. Moreover, every six months the Corporate Social Responsibility Department conducts monitoring surveys regarding compliance status. They are conducted for the entire organization, including subsidiaries and affiliated companies in Japan and overseas, and the results are reported to the Compliance Committee. Each organization appoints a Compliance Manager and Compliance Officer who work to ensure thorough legal compliance in the workplace and hold corporate ethics courses twice a year, among other programs.

The CCC Hotline and internal and external Harassment Hotlines have been established to receive employee inquiries and reports concerning laws, Company rules, the Chugai Group Code of Conduct and other related matters.

Enhancement of Global Compliance

In January 2017, the compliance oversight functions that were previously handled by multiple committees to comply with pharmaceutical regulations, general laws, industry standards, Company rules and healthcare compliance, were consolidated, and the Compliance Committee, a corporate management committee, was established to create an administrative system linked more directly to management.

The intention of this change is to facilitate proper and appropriate judgments and actions based on the societal norms and values required of pharmaceutical companies given the diversification of businesses and their employees due to the accelerating pace of globalization. It is also aimed at properly and appropriately responding to increasingly diverse and stringent regulatory regimes, including extraterritorial application of the laws of various countries, notably the antitrust and anti-bribery laws of the United States. Compliance oversight functions (Corporate Social Responsibility Department, Quality & Regulatory Compliance Unit) were established to monitor, lead and support the compliance of the Chugai Group as a whole, including overseas subsidiaries, creating a horizontal global compliance management framework.

* https://www.chugai-pharm.co.jp/english/csr/transparency/index.html
Board of Directors, Audit & Supervisory Board and Executive Committee Members (As of April 1, 2019)

Representative Directors

Osamu Nagayama
Representative Director, Chairman
Outside Director and Chairman of the Board of Directors of Sony Corporation

Executive Director
1978 Joined the Company
1985 Director, Deputy General Manager of Development Planning Div.
1987 Director, Senior Vice President
1989 Representative Director, Deputy President
1992 Representative Director, President & CEO
2010 Outside Director of Sony Corporation (to present)
2012 Representative Director, Chairman & CEO
2013 Chairman of the Board of Directors of Sony Corporation (to present)
2018 Representative Director, Chairman (to present)

Motoo Ueno
Representative Director, Deputy Chairman
In charge of Sustainability Dept., Audit Dept.

Executive Director
1984 Joined the Company
1991 General Manager of London Representative Office
1993 Director
1994 Director, General Manager of Medical Information Div.
1995 Director, General Manager of Clinical Research & Development Division
1996 Director, Deputy General Manager of Research and Development Division
1997 Director, Senior Vice President
1998 Senior Vice President
2000 Director, Senior Vice President
2002 Director, Deputy President
2003 Director, Deputy President, Vice President
2004 Representative Director, Deputy President
2006 Representative Director, President of Chugai Pharma Manufacturing Co., Ltd.
2012 Representative Director, Deputy Chairman (to present)

Tatsuro Kosaka
Representative Director, President & CEO
Outside Director of Asahi Group Holdings, Ltd.

Executive Director
1976 Joined the Company
1995 Deputy President of Chugai Pharma Europe Ltd. (U.K.)
2000 General Manager of Business Strategy Planning Office
2002 Vice President, General Manager of Corporate Planning Dept.
2004 Senior Vice President, General Manager of Corporate Planning Dept.
2005 Senior Vice President, Deputy Managing Director of Sales & Marketing Group
2008 Senior Vice President, Head of Strategic Marketing Unit
2009 Senior Vice President, Head of Lifecycle Management & Marketing Unit
2010 Director, Executive Vice President
2012 Representative Director, President & CEO
2016 Outside Director of Asahi Group Holdings, Ltd. (to present)
2018 Representative Director, President & CEO (to present)

Non-Executive Directors

Audit & Supervisory Board Members
Non-Executive Directors

1. Dr. Yasuo Ikeda
   Vice Chairman of the Board of Directors, Musashin Academy of the Neo Foundation
   Specially Appointed Professor of Waseda University
   Professor Emeritus of Keio University
   Outside Independent
   1979 Director of Keio University Hospital Blood Center
   1991 Professor of Internal Medicine, School of Medicine, Keio University
   2001 Director of Center for Integrated Medical Research of Keio University
   2005 Dean of School of Medicine, Keio University
   2009 Professor Emeritus of Keio University (to present)
   Professor of Department of Life Science and Medical School
   of Advanced Science and Engineering, Waseda University
   2010 Director of the Company (to present)
   2016 Vice-Chairman of the Board of Directors, Musashin Academy of the Neo Foundation (to present)
   2014 Specially Appointed Professor of Waseda University (to present)

2. Masayuki Oku
   Outside Director of Komatsu Ltd.
   Outside Director of Panasonic Corporation
   Outside Corporate Auditor of Nankai Electric Railway Co., Ltd.
   Non-Executive Director of The Bank of East Asia (China)
   Outside Independent
   1980 Joined The Sumitomo Bank, Ltd. ("SB")
   1994 Director of SB
   1998 Managing Director of SB
   1999 Managing Director and Managing Executive Officer of SB
   2001 Senior Managing Director and Senior Managing Executive Officer of SB
   2002 Senior Managing Director and Senior Managing Executive Officer of Sumitomo Mitsui Banking Corporation ("SMBC")
   2003 Deputy President and Executive Officer of SMIC
   2005 Chairman of SMFG
   2006 Independent
   2015 Director of the Company (to present)
   2017 Director of SMFG

Audit & Supervisory Board Members

7. Mamoru Togashi (Full-time)
   1982 Joined the Company
   2004 President, QIS Co., Ltd.
   2006 General Manager of Corporate Communications Department
   2009 General Manager of Human Resources Management Department
   2010 Vice President, General Manager of Human Resources Supervision Unit
   and General Manager of Human Resources Management Department
   2017 Audit & Supervisory Board Member (to present)

8. Atsushi Sato (Full-time)
   1989 Joined the Company
   2003 General Manager of Risk Management & Compliance Department
   2011 General Manager of Corporate Social Responsibility Department
   2015 General Manager of Corporate Social Responsibility Department
   2016 Associate Vice President, General Manager of Corporate Social Responsibility Department
   2018 Associate Vice President
   Audit & Supervisory Board Member (to present)

9. Hisashi Hara
   Advisor, The Law Office of Nagashima Ohno & Tsunematsu
   Outside Director of the Board of Nippon Paint Holdings Ltd.
   Outside Independent
   1975 Registered as an attorney-at-law (Dai-ichi Tokyo Bar Association)
   1983 Partner, Nagashima & Ohno
   1993 Partner, Nagashima & Ohno
   2008 Chairman, Nagashima Ohno & Tsunematsu
   2009 Administrative Council Member of the University of Tokyo
   2008 Auditor, JPMorgan Securities Japan Co., Ltd.
   2012 Outside Audit & Supervisory Board Member of the Company (to present)
   2013 General Representative of the Asia-Pacific region, The Law Office of Nagashima Ohno & Tsunematsu
   2018 Advisor, The Law Office of Nagashima Ohno & Tsunematsu
   Outside Director of the Board of Nippon Paint Holdings Co., Ltd. (to present)

10. William N. Anderson
    CEO of Roche Pharmaceuticals and Member of the Roche Corporate Executive Committee
    1997 Joined Biogen Idec
    1999 Managing Director, United Kingdom and Ireland of Biogen Idec
    2001 Vice President of Finance, Business Planning of Biogen Idec
    2004 Vice President and General Manager of Neurology Business Unit of Biogen Idec
    2006 Senior Vice President of Immunology & Ophthalmology Business Unit of Genentech
    2010 Senior Vice President of Biotechnology Business Unit of Genentech
    2013 Head of Global Product Strategy, Chief Marketing Officer of Roche
    2017 CEO of Genentech
    2019 CEO of Roche Pharmaceuticals and Member of the Roche Corporate Executive Committee (to present)
    Director of the Company (to present)

11. Dr. James H. Sabry
    Global Head of Roche Pharma Partnering and Member of the Roche Enhanced Corporate Executive Committee
    1992 Co-founder, President and CEO of Cytokinetics
    2008 President and CEO of Arite Therapeutics
    2010 Global Head and Vice President of Genentech Partnering
    2013 Global Head and Senior Vice President of Genentech Partnering
    2018 Global Head of Roche Pharma Partnering and Member of the Roche Enhanced Corporate Executive Committee (to present)
    Director of the Company (to present)

12. Dr. Yuko Maeda
    Director of CellBank Corp.
    Auditor (Part-time) for Japan Agency for Marine-Earth, Science and Technology
    1984 Joined Bridgestone Corporation
    1998 CFO of BTR Power Systems Japan
    2001 (Concurrent) Vice President of Tokyo University of Agriculture and Technology TEO Co., Ltd.
    2003 Director, Technology Transfer Center of Tokyo Medical and Dental University
    2009 Project Coordinator of Innovation Initiative Network Japan
    (Concurrent) Visiting Professor of Tokyo Medical and Dental University
    2011 (Concurrent) Specially Appointed Professor of Kyoto Prefectural University of Medicine
    2013 Executive Officer of Bridgestone Corporation
    2014 (Concurrent) Auditor for Marine-Earth Science and Technology (to present)
    2017 Director of CellBank Corp. (to present)
    2019 Outside Audit & Supervisory Board Member of the Company (to present)
Members of the Executive Committee and Enlarged Executive Committee Not on the Board of Directors (As of April 1, 2019)

1. Shinya Unno
   Executive Vice President
   In charge of Human Resources Management, Human Capital Development, Legal, General Affairs and Secretarial and General Manager of Human Resources Supervisory Div., in charge of General Affairs Dept. and Secretariat Dept.

2. Dr. Yasushi Ito
   Executive Vice President
   In charge of Project & Lifecycle Management (R&D), Regulatory & Quality Management, Clinical Development, Drug Safety and Medical Affairs and Co-Head of Project & Lifecycle Management Unit

3. Dr. Osamu Okuda
   Executive Vice President
   In charge of Project & Lifecycle Management (Marketing), Foundation Medicine, Corporate Planning and Co-Head of Project & Lifecycle Management Unit

4. Dr. Hisafumi Okabe
   Executive Vice President
   In charge of Research and Translational Research and General Manager of Translational Research Div.

5. Toshiaki Itagaki
   Executive Vice President & CIO
   In charge of Finance & Accounting, Corporate Communication, Information System and Purchasing and General Manager of Finance Supervisory Div., General Manager of Finance & Accounting Dept.

6. Dr. Yoshiaki Ohashi
   Executive Vice President
   In charge of Research and Translational Research and General Manager of Translational Research Div.

7. Keiiji Kono
   Senior Vice President
   In charge of Global Health Policy

8. Junichi Ebihara
   Senior Vice President
   General Manager of Legal Dept.

9. Dr. Hiroshi Murata
   Vice President
   General Manager of Pharmaceutical Technology Div.

10. Tsunanori Sato
    Vice President
    General Manager of Marketing & Sales Div.

* Executive Committee
** Enlarged Executive Committee
We are always innovating in every aspect of our business.
## Overview of Activities in 2018

<table>
<thead>
<tr>
<th>Category</th>
<th>Main initiatives</th>
<th>Connection with IBI strategies*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Research</td>
<td>• Continuously generating first-in-class¹ and best-in-class² drugs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Creating molecular targeted drugs that contribute to personalized healthcare (PHC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Strengthening innovative proprietary research technologies and creating innovative antibodies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Providing support and education for researchers from Asia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Maintaining high animal welfare standards in accordance with international guidelines</td>
<td></td>
</tr>
<tr>
<td>Development</td>
<td>• Improving clinical development of drugs to address unmet medical need</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identifying latent medical need³ and achieving early PoC⁴</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Increasing productivity and speed of global clinical development for early market launches</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Conducting simultaneous development and regulatory filing of drug therapies and diagnostics that contribute to PHC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Strengthening lifecycle management to maximize product value</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Obtaining early approval for projects in-licensed from Roche</td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Technology and Production</td>
<td>• Providing a stable supply of high-quality drugs and investigational drugs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Enhancing the system for faster global launches and simultaneous development of multiple products</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Achieving early PoC by raising the level of CMC⁵ development</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Raising the level of competitive advantages from late-stage development to initial commercial production (including investigation of next-generation industrial technologies)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Achieving world-class quality control, quality assurance and regulatory functions</td>
<td></td>
</tr>
<tr>
<td>Marketing</td>
<td>• Contributing to advances in medicine as Japan's leading therapeutic antibody company</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Promoting standards of care and proper use of medicines in oncology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Promoting PHC for optimal treatment options</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Supporting the resolution of medical issues in mainstay product areas and regions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Patient-centric consideration of therapeutic approach</td>
<td></td>
</tr>
<tr>
<td>Medical Affairs</td>
<td>• Building a consistent global medical affairs promotion system with proper independence of roles</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Strengthening systems for healthcare compliance and governance of contract-based post-marketing studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Conducting area-based evidence creation and promoting scientific communication activities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Introducing, expanding and upgrading global medical information functions</td>
<td></td>
</tr>
<tr>
<td>Drug Safety</td>
<td>• Strengthening pharmacovigilance system to meet the world's strictest standards and most comprehensive global regulations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Providing solutions to patients and healthcare providers using drug safety information</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Preparing and implementing risk management plans (RMPs)</td>
<td></td>
</tr>
<tr>
<td>Quality and Regulatory Compliance</td>
<td>• Enhancing production system for Actemra, Alecensa and Hemlibra, which are innovative products from Chugai research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Developing cross-organizational quality and regulatory compliance framework in order to strengthen quality control, quality assurance and regulatory intelligence functions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Strengthening compliance risk management throughout the product lifecycle and carrying out quality management that fosters a culture of quality</td>
<td></td>
</tr>
<tr>
<td>Intellectual Property</td>
<td>• Protecting and effectively using rights for broadly applicable innovative technologies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Filing high-quality patent applications and effectively allocating resources</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aggressively filing patent applications outside Japan with a view to global co-development</td>
<td></td>
</tr>
</tbody>
</table>

1. An original drug that is highly novel and useful, and will significantly change the therapeutic system
2. A drug that offers clear advantages over other existing drugs in the same category, such as those with the same molecular target
3. Medical need that is not adequately met due to a lack of effective treatments
4. PoC is confirmation that the therapeutic effect conceived in the research stage is effective in humans. Early PoC means that in addition to safety, signs of efficacy or pharmacological effect have been confirmed in a limited number of cases.
Main performance indicators in 2018

| 1. In-house products in development pipeline: 15 (as of January 31, 2019) |
| Academic papers and presentations at scientific conferences regarding Chugai’s innovative proprietary technologies: 53 (2014-2018) |
| Published academic papers regarding Chugai’s research findings: 90 (2014-2018) |
| R&D expenditures to revenues: 16.2% |

| 2. Share of sales in the Japanese therapeutic antibody market: 24.5% |
| Satisfaction ranking based on healthcare providers’ assessments (hospitals with 100 or more beds): 1st |
| Adequacy ranking for provision of safety information based on healthcare providers’ assessments (hospitals with 100 or more beds): 1st |
| Education for MRs with a high level of expertise |

| 3. Pipeline projects: 48 (as of January 31, 2019) |
| New products launched and new indications: 37 (as of January 31, 2019) |
| PHC-based development projects: 27 (as of January 31, 2019) |
| Projects in-licensed from Roche: 15 (2014-2018) |

| 4. Projects being co-developed with Roche Group: 37 (as of January 31, 2019) |

| 5. Invested in facilities for faster launches and simultaneous development of multiple antibodies and small molecule drugs (established new biological API manufacturing facility at Ukima Plant (UK3), enlarged solid formulation manufacturing facility at Fujieda Plant, etc.) |
| Received FDA pre-approval inspection and approval for Actemra (new manufacturing method) |
| Received pre-approval inspection and approval for Hemlibra in countries around the world |

| 6. Strengthened global supply chain management |
| Enhanced next-generation core technologies for API manufacture and formulation |
| Strengthened development ability by reducing costs from the early stage onward and planning and implementing a dosage form strategy |
| Established a system for quality control functions to enhance specialization and raise operational efficiency |

| 7. Share of sales in the Japanese oncology market: 17.9% |
| Inquiries to the Medical Information Department: 154 (as of January 31, 2019) |
| Number of joint preclinical studies: 11 |

| 8. Published research papers on Chugai’s preclinical studies: 11 |
| Presentations at scientific conferences: 5 overseas, 6 in Japan |
| Inquiries to the Medical Information Department: 56,120 (including telephone, e-mail, and fax inquiries) |

| 9. Cases for which drug safety information was collected from Japan and overseas according to global standards for clinical trials and post-marketing studies: 18,400 |
| Increased capacity for generating drug safety information using advanced technologies such as epidemiology and information technology, and enhanced the activities of Safety Experts, a new specialist position for handling drug safety information |

| 10. RMPs prepared and implemented for thorough risk management: 12 products |
| Papers and conference presentations on drug safety based on the results of post-marketing surveillance: 9 |

| 11. Developed quality and regulatory compliance framework for genomic mutation analysis program FoundationOne® CDx Cancer Genomic Profile and obtained regulatory approval |
| Prepared for inspection and obtained approval from FDA for Actemra (new production method), and Alecensa and Hemlibra (additional production sites) |

| 12. Formulated and circulated a global policy on counterfeit drugs, and raised awareness through activities in cooperation with Roche and at scientific conferences in Japan and overseas |
| Carried out awareness activities targeting all fundamental organizational units and introduced risk management methodologies at all companies in order to foster a “culture of quality” as recommended by the FDA |

| 13. Patents held (including pending applications): 4,647 |
| New patents granted worldwide: 213 |
| Market defense in lawsuits with manufacturers of similar products with the equivalent effect or developers and manufacturers of biosimilars |

| 14. Operated a system for monitoring other companies’ patents |
| Strengthened cooperation with the Research Division and Pharmaceutical Technology Division using IP liaisons as a hub |

---

5. Chemistry, Manufacturing and Controls: A concept that integrates API process research and pharmaceutical development research with quality evaluation research
7. Copyright © 2019 anterio. Source: Rep-i 201808. Reprinted with permission. Based on a survey of overall assessments of companies by physicians, as defined by Chugai.
8. Based on an anterio market survey in 2018 for understanding safety information needs
<table>
<thead>
<tr>
<th>Category</th>
<th>Examples of ESG initiatives in each division</th>
<th>E</th>
<th>S</th>
<th>G</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Research</strong></td>
<td>• Fostered employee awareness of energy saving through energy visualization</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Continued joint cleanup activities with a local high school for the Shinkawa River, which flows through the Kamakura Research Laboratories site</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Conducted activities at Kamakura Research Laboratories to raise awareness of the importance of cancer screening</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• As part of the Company's support for recovery from the Great East Japan Earthquake, held a charity sale at the Kamakura Research Laboratories of specialty products from the affected area</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Development</strong></td>
<td>• Fostered a corporate culture where employees can participate actively after returning from childcare or other leave</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Held cross-cultural training to cultivate leaders who can succeed globally</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Held study sessions with instructors from other industries to promote global success</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Held the Quality Forum to foster a corporate climate for becoming a top pharmaceutical company</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pharmaceutical Technology and Production</strong></td>
<td>• Reduced greenhouse gas emissions with the scheduled introduction of high-efficiency air conditioning</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Promoted reduction of energy consumption through an energy visualization task force</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Conducted firefighting activities in cooperation with local fire departments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Promoted “Techno” technology review activities to create new core competencies and strengthen basic technologies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Held U-MAST (at Utsunomiya Plant), UK-NEXT (at Ukima Plant) and F-OPEX (at Fujieda Plant) as initiatives to train young employees through proposal and improvement activities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Held interdivisional exchange meetings (Knowledge Cube for Marketing &amp; Sales, Medical Affairs and Pharmaceutical Technology divisions and BRIDGE for Research, Clinical Development, Translational Clinical Research and Pharmaceutical Technology divisions)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Marketing</strong></td>
<td>• Promoted proper use of medicines through support for improvements in the rate and accuracy of testing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Participated in Lung Cancer Awareness and attended to patient requests regarding drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Conducted support activities for working while undergoing breast cancer treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Promoted disease awareness through cooperation with businesses in other industries</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Held the Bone and Joint Forum 14 times as a measure against locomotive syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Disseminated information on a new issue related to cancer treatment (cancer patient dementia) through the Chugai website</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Medical Affairs</strong></td>
<td>• Conducted a training program from the standpoint of cultivating global medical human resources</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Measures to evaluate the effect of drugs on improving conditions for working during outpatient treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Drug Safety</strong></td>
<td>• Promoted paperless operations for stored materials and meeting materials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Provided the latest drug safety information through lectures and awareness-raising activities for the media</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Contributed to the enhancement of Japan’s epidemiological database</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Contributed to regulatory reforms and strengthening of drug safety monitoring systems in Japan and overseas through industry activities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Quality and Regulatory Compliance</strong></td>
<td>• Held information-exchange events for contract manufacturing organizations to share examples of Chugai best practices to ensure compliance with new regulations and regulatory trends</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Promoted reduction in paper consumption through the introduction of an electronic document archive system and digitalization of existing paper documents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Provided direct advice on amendments to the Law for Ensuring the Quality, Efficacy and Safety of Drugs and Medical Devices through industry activities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Promoted activities to foster a “culture of quality” as recommended by the FDA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Intellectual Property</strong></td>
<td>• Created and operated a paperless process for applications for public disclosure approval</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Established a separate organization specializing in intellectual property disputes (IP Liaison Group)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Chugai’s 2018 in Review

Products and Development Projects

<table>
<thead>
<tr>
<th>Month</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>Tecentriq intravenous infusion 1200mg obtained approval (unresectable, advanced or recurrent non-small cell lung cancer, Japan)</td>
</tr>
<tr>
<td>February</td>
<td>Hemlibra obtained approval (hemophilia A with inhibitors; E.U.)</td>
</tr>
<tr>
<td>March</td>
<td>Hemlibra obtained approval (hemophilia A with inhibitors; Japan)</td>
</tr>
<tr>
<td>April</td>
<td>Hemlibra received breakthrough therapy designation (hemophilia A without inhibitors; U.S.)</td>
</tr>
<tr>
<td>April</td>
<td>Tecentriq launched (Japan)</td>
</tr>
<tr>
<td>May</td>
<td>Alecensa obtained approval for additional indication (first line therapy for ALK-positive non-small cell lung cancer; Taiwan)</td>
</tr>
<tr>
<td>May</td>
<td>Hemlibra launched (Japan)</td>
</tr>
<tr>
<td>June</td>
<td>Hemlibra received priority review designation (hemophilia A without inhibitors; U.S.)</td>
</tr>
<tr>
<td>July</td>
<td>Gazyva intravenous infusion 1000 mg obtained approval (CD20-positive follicular lymphoma; Japan)</td>
</tr>
<tr>
<td>August</td>
<td>Gazyva launched (Japan)</td>
</tr>
<tr>
<td>September</td>
<td>Chugai and Eli Lilly and Company entered into a license agreement for GLP-1 receptor agonist OWL833</td>
</tr>
<tr>
<td>October</td>
<td>Hemlibra obtained approval for additional indication (hemophilia A without inhibitors; Japan)</td>
</tr>
<tr>
<td>October</td>
<td>Perjeta obtained approval for additional indication (neoadjuvant and adjuvant therapy for HER2-positive early breast cancer; Japan)</td>
</tr>
<tr>
<td>December</td>
<td>Hemlibra obtained approval (hemophilia A with inhibitors; Taiwan)</td>
</tr>
<tr>
<td>December</td>
<td>Satalizumab received breakthrough therapy designation (neuromyelitis optica and neuromyelitis optica spectrum disorder; U.S.)</td>
</tr>
<tr>
<td>December</td>
<td>Hemlibra obtained approval for additional indication (hemophilia A without inhibitors; Japan)</td>
</tr>
<tr>
<td>December</td>
<td>Tecentriq obtained approval for additional indication (unresectable, advanced or recurrent non-small cell lung cancer, Japan)</td>
</tr>
<tr>
<td>December</td>
<td>Chugai obtained approval for genomic mutation analysis program FoundationOne® CDx Cancer Genomic Profile (Japan’s first program with two functions of cancer genomic profiling and companion diagnostics, it enables oncology gene panel profiling)</td>
</tr>
</tbody>
</table>

Management

<table>
<thead>
<tr>
<th>Month</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>Transferred 13 long-listed products from Chugai to Taiyo Pharma</td>
</tr>
<tr>
<td>March</td>
<td>Appointed new CEO</td>
</tr>
<tr>
<td>March</td>
<td>Entered a license agreement with Roche to begin activities toward commercialization of the products of FMI in Japan</td>
</tr>
<tr>
<td>July</td>
<td>FMI business unit established</td>
</tr>
<tr>
<td>July</td>
<td>Extended Chugai Pharmabody Research operations for five years and committed to investment totaling 282 million SGD from 2022 through 2026</td>
</tr>
<tr>
<td>July</td>
<td>Decided to construct a new building for synthetic research at Ukima Research Laboratories to enhance process development for small and middle molecule APIs</td>
</tr>
<tr>
<td>July</td>
<td>Entered into comprehensive partnership agreement with Preferred Networks, Inc.</td>
</tr>
</tbody>
</table>

Stakeholders

<table>
<thead>
<tr>
<th>Month</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>March</td>
<td>Selected as a 2017 Tokyo Sports Promotion Model Company</td>
</tr>
<tr>
<td>March</td>
<td>Selected as a Nadeshiko Brand for the fourth consecutive year and recognized in the New Diversity Management Selection 100</td>
</tr>
<tr>
<td>August</td>
<td>Obtained Platinum Kurumin certification from the Minister of Health, Labour and Welfare as a company supporting childcare; the number of male employees taking childcare leave increased sevenfold in two years</td>
</tr>
<tr>
<td>September</td>
<td>Selected for the fourth time for Dow Jones Sustainability Asia Pacific Index</td>
</tr>
<tr>
<td>September</td>
<td>Donated para-transit vehicles to welfare services</td>
</tr>
<tr>
<td>October</td>
<td>First in the pharmaceutical industry to begin providing a treatment support app for immune checkpoint inhibitors using multidisciplinary SNS</td>
</tr>
<tr>
<td>October</td>
<td>Xeloda® adherence support app began contributing to improving communication between cancer patients and healthcare providers</td>
</tr>
<tr>
<td>December</td>
<td>Establishment of Gan with, an information website for cancer patients, their families and coworkers</td>
</tr>
</tbody>
</table>

Organizational Facts and Figures

- **Number of employees**: 5,037
- **Ratio of female employees**: 27.3%
- **Ratio of female managers**: 13.3%
- **Number of female officers**: 1

1. Number of female managers as a percentage of the total number of managers
2. Officers as per the Companies Act
3. Percentage of eligible employees who used the system
4. Percentage of employees who have had children

**Average tenure**
- Male: 18.4 years
- Female: 13.0 years

**Number of employees posted through the Roche Human Resource Exchange Program (2004-2018)**
- 174

**Percentage of employees using the telecommuting system**
- 34.5%

**Percentage of employees taking childcare leave**
- Male: 57.7%
- Female: 100.0%
Chugai in Action

Research

IBI 18 (2016–2018)
- Continuous new drug creation using proprietary antibody technologies
- Establishment of a technology platform for middle molecule drugs
- Strengthening of the research base for oncology/immunology using external network

IBI 21 (2019–2021)
- Construction of leading drug discovery technologies and continuous addition to pipeline
- Creation and promotion of innovative projects through the deepening of biological research into human diseases
- Expansion of opportunities to acquire new candidate compounds using external network

S (Strengths)
- Proprietary drug discovery technology, particularly in biotechnology (in-house products: 15), no. of academic papers and presentations at scientific conferences regarding Chugai’s innovative proprietary technologies: 53
- Efficient collaboration with the Roche Group, including infrastructure sharing (Ratio of research and development expenditures to revenues: 16.2%)

W (Weaknesses)
- Infrastructure for recruiting researchers is incomplete
- Lack of resources for biotechnology research

O (Opportunities)
- Progress in new modalities, including middle molecule drugs
- Mounting social expectations on drug discovery and healthcare as a growth industry

T (Threats)
- Increasing difficulty and escalating cost of new drug development worldwide, and intensifying competition
- Potential paradigm shift due to disruptive technologies, etc.

1. As of January 31, 2019   2. 2014-2018

Functions

Chugai began conducting research and development of biopharmaceuticals more than 30 years ago, and the former Nippon Roche had also established world-class technology for the discovery of chemically synthesized agents. Over the years, we have cultivated knowledge and gained experience through our own pioneering initiatives while also incorporating outside technologies. As a result, we have continuously evolved our capabilities, and have built a technology platform that we can flexibly and appropriately apply to drug discovery.

We are using this platform to generate a steady stream of innovative new drugs with first-in-class or best-in-class potential to address unmet medical need. In addition to developing antibody engineering technologies ahead of other companies, Chugai has industry-leading research and technological capabilities backed by small and middle molecule technologies, the world-class research infrastructure of the Roche Group and a powerful external network with academia and other parties. Through presentations of research findings at scientific conferences and other means, these strengths lead to benefits for the medical community around the world as we leverage them in the creation of in-house projects.

IBI 21 (2019–2021)
- Construction of leading drug discovery technologies and continuous addition to pipeline
- Creation and promotion of innovative projects through the deepening of biological research into human diseases
- Expansion of opportunities to acquire new candidate compounds using external network

Business Model

One of Chugai’s strategic advantages that enables it to continuously create innovative drugs is its ability to concentrate resources on innovative research. Efficient development in Japan of projects in-licensed from Roche provides a stable revenue base while we conduct global development of projects from our own research in collaboration with Roche. This enables us to concentrate personnel and funds on groundbreaking in-house projects, leading to the creation of a steady stream of innovative drugs. Another powerful advantage is our access to Roche’s global research infrastructure. The ability to share Roche’s global research resources and infrastructure, including a rich compound library for use in high-throughput screening, is a significant plus for Chugai in terms of cost, efficiency and other factors, and has dramatically increased our research productivity.

Process and Milestones of Drug Development

<table>
<thead>
<tr>
<th>Discovery Research</th>
<th>Development Research</th>
<th>Clinical Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idea/Concept</td>
<td>Lead optimization</td>
<td>Phase I</td>
</tr>
<tr>
<td>Target molecule</td>
<td>Lead identification</td>
<td>Clinical pharmacology</td>
</tr>
<tr>
<td>identification</td>
<td>(Compounds)</td>
<td>(Healthy volunteer/</td>
</tr>
<tr>
<td>Target evaluation</td>
<td>Protein structure</td>
<td>Patient)</td>
</tr>
<tr>
<td></td>
<td>optimization</td>
<td></td>
</tr>
<tr>
<td>(Biologics)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Establishing assay</td>
<td>Screening (in vitro)</td>
<td>Phase II Exploratory/</td>
</tr>
<tr>
<td>system/Target</td>
<td>(in vitro)</td>
<td>Confirmatory</td>
</tr>
<tr>
<td>evaluation</td>
<td>(Pilot toxicity)</td>
<td>(Patient)</td>
</tr>
<tr>
<td></td>
<td>Pharmacology/DMPP/</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmacokinetics/</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Efficacy/Dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Safety</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10–15 years</td>
<td></td>
</tr>
</tbody>
</table>
In addition, by concentrating on the creation of new therapeutic antibodies, Chugai Pharmabody Research (CPR), which we established in Singapore in 2012, is working to continuously create innovative therapeutic antibody drugs that apply our proprietary antibody engineering technologies and to accelerate the speed of drug discovery.

**Allocation of Resources**

In allocating research resources, we prioritize each project based on the following criteria:

1. The project's potential for development as a novel medicine that can be clearly differentiated
2. Whether it has a scientific basis for addressing unmet medical need
3. Whether it will enable personalized healthcare (PHC)

At decision points during research, we focus first and foremost on patient need in the belief that creating medicines truly needed by patients and healthcare providers will lead to Chugai’s medium-to-long-term growth.

**Bioethics and Animal Welfare**

To ensure that research using human-derived test material is carried out appropriately, Chugai has established Ethical Guidelines for Research That Uses Human-Derived Test Material and a Research Ethics Committee. More than half of the members of this committee are from outside the Company, enabling fair evaluations from a pluralistic frame of reference. Moreover, when handling laboratory animals used in research, Chugai acts in accordance with the Guidelines for the Care and Use of Laboratory Animals it has established to respect their lives from the standpoint of animal welfare, and to minimize their pain, keeping in mind the scientific conditions.

In 2018, we also held the Chugai 3Rs Day as part of our promotion of the principles of the 3Rs (Replacement, Reduction and Refinement) and animal welfare. Through such activities, we strive to raise awareness of animal welfare among all employees working in our laboratories.

**Main Initiatives and Progress**

**Creation of Innovative New Drugs**

In 2018, PHC-based projects represented 56 percent of our total pipeline, including projects in-licensed from Roche. Hemlibra received approval as a treatment for haemophilia A in the United States in November 2017, and in Europe and Japan in 2018. It is the first project applying our proprietary antibody technologies to be approved.

**Collaboration with Our External Network**

In April 2017, a collaborative lab began operating under our comprehensive agreement with Osaka University Immunology Frontier Research Center (IFReC) to conduct ongoing assessment and introduction of new candidate compounds from its cutting-edge immunology research.

**Progress of Development Projects**

<table>
<thead>
<tr>
<th>Breakdown</th>
<th>New Molecular Entities</th>
<th>Additional Indications</th>
<th>Additional Dosage and Administration/ Formulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved</td>
<td>13</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Filed</td>
<td>17</td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>Started phase III</td>
<td>10</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Started phase II</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Started phase I</td>
<td>6</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Development suspended</td>
<td>4</td>
<td>3</td>
<td>1</td>
</tr>
</tbody>
</table>

**Comparison of Drug Discovery Modalities**

<table>
<thead>
<tr>
<th>Small molecules</th>
<th>Middle molecules</th>
<th>Biologics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular weight</td>
<td>Below 500</td>
<td>500 - 2,000</td>
</tr>
<tr>
<td>Target specificity</td>
<td>Fair</td>
<td>High</td>
</tr>
<tr>
<td>Intracellular targets</td>
<td>Wide range</td>
<td>Numerous</td>
</tr>
<tr>
<td>PPI inhibition</td>
<td>Fair</td>
<td>Good</td>
</tr>
<tr>
<td>Administration route</td>
<td>Oral/Injection</td>
<td>Oral/Injection</td>
</tr>
<tr>
<td>Manufacturing method</td>
<td>Organic synthesis</td>
<td>Organic synthesis</td>
</tr>
</tbody>
</table>

*PPI: Protein Protein Interaction

Immunity is involved not only in diseases of the immune system itself, but also in cancer and various other diseases, and immune-mediated therapies are now becoming mainstream cancer treatments. Combining the global top-class research in immunology at IFReC and Chugai’s expertise in drug discovery research, accumulated through its proprietary technologies, is expected to result in the creation of innovative new drugs.

We are also looking to innovate the drug discovery process itself, including for next-generation personalized healthcare, by applying the highly advanced genomic analysis techniques and other capabilities of FMI, which joined the Roche Group in 2015.

**Research at Satellite Labs**

Research at satellite labs has also yielded solid results, leading to the successful establishment of stable cell lines of colon cancer stem cells in October 2012 and the identification of new drug targets at Forerunner Pharma Research Co., Ltd. CPR is making steady progress in the discovery of new therapeutic antibodies, with GYM329 entering clinical development in 2018 after SKY59. In addition, C&C Research Laboratories in South Korea is conducting small molecule drug discovery research, mainly in the fields of oncology and immunology.

**Evolution of Drug Discovery Modalities**

In the pharmaceutical industry, modality refers to the material classification of drugs such as therapeutic antibodies or therapeutic nucleic acids. Until around 1990, small...
molecule drugs were virtually the only modality available, but modality options are now increasing. Chugai is currently focusing on establishing middle molecules as a third modality in addition to biologics and small molecules, in which it is already strong. Middle molecules are a valuable method for molecules, in which it is already strong. Chugai is currently focusing on establishing middle molecules as a third modality in addition to biologics and small molecules, and we are proactively promoting the establishment of a hit/lead compound generation technology platform as we work toward the creation of development projects.

Enhancing our Intelligence Functions
Rapid scientific and technological advances, especially in life science and information and communications technology (ICT), are bringing dramatic changes to society and the pharmaceutical industry. Chugai’s Science and Technology Intelligence (STI) Department was established in April 2017 as an intelligence unit to consider Chugai’s response to emerging issues in the healthcare business.

Healthcare in the future is expected to center on PHC, which provides optimal solutions tailored to individual patients, and in addition to diagnosis and treatment, which are the focus of the current model, greater value will need to be provided in areas such as prevention and prognosis. Our goal is to contribute to higher-quality healthcare with solutions that lead to new value, and a critical part of that effort is formulating strategies for disruptive innovation, which will be essential for realizing such solutions.

STI’s mission is to find promising seeds for pursuing disruptive innovation, and to create strategies for bringing it about. In the three areas of life science, healthcare ICT, and data utilization, STI will perform radar, hub and intelligence functions in cooperation with internal cross-functional teams of experts. A number of projects have already begun.

In July 2018, Chugai entered into a comprehensive partnership agreement with Preferred Networks, Inc. (PFN), a global leader in AI technology. We aim to create innovative drugs and new value through the application of PFN’s cutting-edge deep learning technology and Chugai’s expertise, technologies and data.

3. Innovation that disrupts the order of existing business and causes drastic changes in the industry structure.

Chugai’s Proprietary Technologies
Drug discovery technologies, largely antibody engineering technologies, are Chugai’s core competence. We are focused on development of proprietary technologies that are necessary for addressing areas of unmet medical need. Their application leads to the generation of innovative and competitive medicines.

Chugai’s research and development operations have focused on the development of new antibody engineering technologies to create a series of technologies that overturned conventional wisdom about antibody engineering. Examples include the development of our Recycling Antibody®, Sweeping Antibody® and bispecific antibody technologies. In addition to antibody engineering and small molecules, we have selected drug discovery technologies for middle molecules as a candidate for our next-generation core technology. We intend to concentrate investments in this area to establish this new technology and quickly generate new projects.

Eight Technologies

<table>
<thead>
<tr>
<th>Antibody technology</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMART-Ig®</td>
<td>Creates the Recycling Antibody®, which has a longer duration of action than conventional antibodies because it can bind to an antigen multiple times.</td>
</tr>
<tr>
<td>SMART-Fc®</td>
<td>Creates the Sweeping Antibody®, which eliminates disease-causing antigens from plasma.</td>
</tr>
<tr>
<td>ART-Ig®/FAST-Ig®</td>
<td>Enable large-scale production of bispecific antibodies. Unlike conventional antibodies that bind only to a single antigen, bispecific antibodies bind to two different antigens, and are therefore expected to exhibit efficacy in a variety of ways.</td>
</tr>
<tr>
<td>ART-Fc®</td>
<td>Enhances the antibody-dependent cellular cytotoxicity (ADCC) activity using ART-Ig®. Induces enhanced ADCC activity compared with existing technologies. Potential applications in the oncology field.</td>
</tr>
<tr>
<td>TwoB-Ig®</td>
<td>Increases binding selectivity of the Fc region to inhibitory Fc receptor IIb. Potential applications in autoimmune diseases and other areas.</td>
</tr>
<tr>
<td>TRAB®</td>
<td>Activates T cells in an antigen-dependent manner to specifically kill cancer cells.</td>
</tr>
<tr>
<td>ACT-Ig®</td>
<td>Reduces clearance from plasma.</td>
</tr>
</tbody>
</table>

Bispecific Antibody

Effect of Recycling Antibody® against Soluble Antigen in Plasma

- Antibody can bind to the antigen only once
- Antigen persists as an antibody bound form, accumulating in plasma
- Antibody can bind to the antigen multiple times
- Prevents antigen accumulation by discarding the antigen within the cell
Development

**IBI 18 (2016–2018)**
- Maximization of the value of Roche products through simultaneous global development and regulatory filing
- Global development and early acquisition of PoC for Chugai products
- Implementation of an IDCP1 from the initial stage of development to maximize the value of each Chugai product

**IBI 21 (2019–2021)**
- Establishment of development methods for Chugai products with new modalities and mechanisms of action
- Further acceleration of development through use of data assets
- Maximization of product value based on VBHC2

---

### Functions

**Chugai has established a lifecycle management1 system for project-level integrated management of each of its functions, and cooperates with numerous medical institutions and clinical research centers. In this way, we work to implement clinical trials distinguished by exceptional speed, efficiency and scientific rigor.**

Specifically, in clinical development, we draw up clinical development plans based on the latest scientific findings and invite medical institutions to conduct clinical trials. In pharmaceutical technology and production, we examine commercial production that will turn candidate compounds into pharmaceutical products and manufacture investigational drugs for clinical trials. In drug safety, we ensure a high level of safety in clinical trials by gaining an understanding and beginning assessments of each drug's safety profile from the early stages.

Through our alliance with the Roche Group, we are implementing multiple global development projects (multinational studies) and strengthening the process that enables simultaneous development of drugs and companion diagnostics intended for personalized healthcare (PHC). Through these initiatives, we are creating best practices in development and filing for approval in Japan, which we believe contribute to the advancement of the industry.

### Enhancement of Functions and Organizational Change

*In October 2018, Chugai partially reorganized its Translational Clinical Research (TCR) Division. The aim of the change was to promote the development of in-house products that have passed from research to the early clinical development stage. From this perspective, we changed the name to the Translational Research (TR) Division, which functions as a bridge between preclinical and early clinical development. For overseas development of projects from in-house research, U.S. subsidiary Chugai Pharma USA and U.K. subsidiary Chugai Pharma Europe conduct high-quality clinical trials in close cooperation with medical institutions in the United States and Europe.*

We also accelerate global development by sharing knowledge and platforms for clinical development with the Roche Group. Moreover, we utilize Foundation Medicine Inc. (FMI)2 and others to generate evidence that will lead to PHC from the clinical development stage.

*In the Clinical Development Division, we have established the new Clinical Information & Intelligence Department to work as a hub for the collection, management, analysis and transmission of all clinical development data. The aim of the department is to strengthen data utilization and intelligence functions, which enable the planning of optimal clinical development strategies.*

### Main Initiatives and Progress

**A Well-Stocked Pipeline**

In 2018, all projects made steady progress. Chugai filed for regulatory approval for 5 projects, and obtained approval for 6 projects. Chugai’s pipeline grew even richer, with 6 new projects in-house or in-licensed (from Roche) advancing to the clinical phase.

**Speedy Global Development**

Chugai has been working to speed up global development by following a development model with a high probability of success and by making efforts to prove the value of in-house projects from the early stages of development. As a result, Alecensa took just seven years from concept to launch in Japan, and Hemlibra, for which we filed for approval simultaneously in Japan, the United States and Europe, obtained approval in less than five years, far ahead of our initial plan. Hemlibra is dramatically transforming treatment strategies for hemophilia and achieving unprecedented results. Moreover, now that nemolizumab (CIM331) has acquired PoC and satralizumab (SA237) has obtained positive results in global studies under Chugai’s management, we are taking on the new challenge of global filings for approval during 2019 in collaboration with Roche.
Pharmaceutical Technology and Production

**IBI 18 (2016–2018)**
- Raising the level of CMC development for early PoC acquisition
- Raising the level of competitive advantages from late-stage development to commercial production
- Achieving world-class quality control, quality assurance and regulatory functions

**IBI 21 (2019–2021)**
- Acquisition of PoC with world-class speed
- A production system with a strong competitive advantage in late-stage development
- Strengthening the commercial production system

### Functions

Our pharmaceutical technology and production functions play a wide range of roles in the pharmaceutical value chain – from turning drug candidates into products to stably supplying them. These candidates may be compounds created in our laboratories or projects in-licensed from Roche or elsewhere.

Product creation includes research on production methods for active pharmaceutical ingredients (APIs), formulation and packaging design, production of investigational APIs, and collection and analysis of production data. Among these activities, we have most recently been taking positive steps to build and patent new antibody bioreactors, and to prepare for development candidates that apply next-generation antibody technologies.

Through stable supply of our products, we maintain the trust of patients and healthcare providers – a duty central to Chugai’s existence as a pharmaceutical manufacturer. That is why we need to build and maintain a robust supply chain with production bases (including contract manufacturing organizations) in various regions around the world.

Chugai has competencies at Japan’s top level, including bioproduction technology and the ability to accommodate inspections. We will leverage our strengths as a member of the Roche Group to become a top innovator in our pharmaceutical technology and production operations.

### Main Initiatives and Progress

**Improving Flexibility and Speed**

In its pharmaceutical technology and production operations, Chugai is aiming for simultaneous development of multiple products for the quickest launches possible.

Specifically, at the Ukima Plant, we have achieved a significant increase in capacity utilization by employing plastic single-use bioreactors, and to prepare for development candidates that apply next-generation antibody technologies we have constructed UK3, a new antibody API facility capable of high-mix, low-volume production from late-stage to initial commercial products. At the Utsunomiya Plant, we have increased production flexibility by installing tray fillers that can handle filling of liquid medicines without making line changes or modifications, regardless of the syringe type.

**Evolving Supply Chain Management**

To minimize risks related to the supply and price of raw materials, we promote the globalization of our suppliers of raw materials and intermediate products in tandem with the globalization and establishment of two production bases for each finished product.

Our subsidiary Chugai Distribution Co., Ltd handles distribution of pharmaceuticals in Japan. The company’s computerized inventory management and inspection ensure stable and safe distribution, and the staff conducts ongoing process innovation in packaging.

**Thorough Quality Assurance**

Quality assurance functions have diversified in recent years in response to the increasing complexity of supplying products and accelerated development with the introduction of the fast-track review system to support the early launch of innovative new drugs.

In view of these trends, Chugai is working to further strengthen GMP* management oversight to promote more rigorous and high-level quality assurance. As part of these efforts, Chugai has created and operates a world-class system for pharmaceutical quality management.

### Biological API Production: Our Facility Portfolio

<table>
<thead>
<tr>
<th>Plant</th>
<th>Target/Production/Production of investigational APIs</th>
<th>Bioreactors</th>
<th>Features</th>
<th>Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Utsunomiya</td>
<td>Commercial production (Large-scale)</td>
<td>10,000 L x 8 (UT1, UT2: Stainless steel tanks)</td>
<td>Competitive low-cost production, Dedicated facilities</td>
<td>Actemra</td>
</tr>
<tr>
<td></td>
<td>Production of investigational APIs (Medium-scale)</td>
<td>6,000 L x 6 (UK3: Stainless steel tanks)</td>
<td>Emphasis on flexibility, Can handle high-mix, low-volume production</td>
<td>Future development projects</td>
</tr>
<tr>
<td></td>
<td>Production of investigational APIs (Small-scale)</td>
<td>2,000 L x 4 (UK1, UK2: Single-use plastic bags)</td>
<td>Improved capacity utilization through the application of single-use bioreactor technology</td>
<td>Future development projects</td>
</tr>
</tbody>
</table>

* Good Manufacturing Practice: Standards for pharmaceutical production management and quality control.
Marketing

IBI 18 (2016–2018)

- Realization of sales growth by concentrating on sales driver products and new products
- Providing advanced solutions through cross-functional collaboration with experts in different divisions
- Establishment of strategic and tactical system adapted to local area characteristics

IBI 21 (2019–2021)

- Maximization of the value of growth drivers (innovative drugs and services)
- Enhancement of consulting activities for innovative products to select the best treatment according to each patient’s condition
- Provision of solutions through cooperation with diverse specialized human resources and incorporation of digital technology

S (Strengths)

- Leading presence in specialty areas, such as biopharmaceuticals and personalized healthcare (PHC)
- A system for providing advanced solutions based on regional and customer characteristics, multidisciplinary team care and drug safety activities utilizing a database of adverse events, etc.

W (Weaknesses)

- Response to an increase in competing products and an increase in new entrants
- Response to the emergence of biosimilars and generic drugs

O (Opportunities)

- Further increase in unmet medical needs as a result of the aging population as well as incurable diseases and orphan drug designations
- Increase in therapeutic opportunities due to early detection and promotion of testing
- Progress in personalized and advanced healthcare, including genetic diagnosis

T (Threats)

- Progress in global control over drug costs, the shrinking domestic market amid drastic reform of NH insurance prices
- Loss of premium pricing status for new drug creation on mainstay products and the emergence of generic drugs
- Tighter regulations on promotional activities due to higher ethical and transparency standards

1. Successor products to biopharmaceuticals whose patent term has expired, made by manufacturers other than the manufacturer that developed the antecedent biopharmaceutical
2. Drugs approved after the expiry of the patents for original drugs with the same active ingredients and efficacy
3. Medical need that is not adequately met due to a lack of effective treatments

Functions

The need for new therapeutic agents to deal with cancers or rare or refractory diseases that lack effective treatments (unmet medical need) is high, and more sophisticated and individualized medical procedures such as cancer immunotherapy and genomic testing are attracting attention. Chugai is pursuing initiatives to meet unmet medical need based on its extensive lineup of first-in-class and best-in-class drugs and new diagnostic technologies.

As medicine becomes more sophisticated and individualized, healthcare providers will be expected to promptly provide high-quality information. Chugai takes three approaches to this process, which it refers to as “consulting.”

For patients
We conduct patient-centric consulting that gives the highest priority to patients, including proposing the optimal drug treatment according to each patient’s condition, providing relevant information on proper use and safety, and follow-up activities.

For regional healthcare
We aim to provide liaison services for regional healthcare with the aim of solving medical issues according to local area characteristics. We conduct consulting that improves patients’ access to treatment by supporting regional healthcare coordination among healthcare providers and medical institutions as well as collaboration among local governments, public entities, and other industries.

For stakeholders
Multidisciplinary team care has advanced in recent years, with various specialist healthcare providers working in collaboration to carry out treatment according to each patient’s condition. We conduct consulting to support our diverse stakeholders and multidisciplinary teams who follow up on treatment through proper management of adverse events.

Because consulting activities necessarily require extensive communication with relevant parties, our MRs play a key role. In addition to MRs, we also have a system for providing solutions that meet medical needs through participation in cross-functional teams by members of the Marketing & Sales, Medical Affairs and Drug Safety divisions, who have high-level expertise.

At the same time, we are innovating business processes using the latest digital technologies such as artificial intelligence and the Internet of Things to build a system that can provide more efficient and effective solutions based on higher-quality consulting.

As part of a multidisciplinary team, I am working toward treatments for bone diseases, which can be a factor causing a patient to require nursing care. Through collaboration with medical associations and local government, in 2019 we will create a framework that builds patient awareness and links it to examination and treatment. We then plan to expand this framework prefecture-wide to make Oita Prefecture a place where people have strong, resilient bones.

Yutaro Satake
Kumamoto and Oita Branch, Kyushu Regional Management Office, Marketing & Sales Div.
### Main Initiatives and Progress

#### Oncology

In 2018, sales in the oncology area in Japan decreased 0.1 percent year on year to ¥225.7 billion. The contribution from new products included ¥9.1 billion from rapid market penetration of Tecentriq, an anti-PD-L1 monoclonal antibody launched in April 2018 as a second-line treatment for non-small cell lung cancer (NSCLC) and ¥0.6 billion from Gazvya, a treatment for CD20-positive follicular lymphoma launched in August 2018, including sales due to a switchover from Rituxan. In addition, market uptake substantially exceeded expectations for Perjeta for the additional indication of HER2-positive early breast cancer, and sales increased ¥2.5 billion (18.4 percent) to ¥16.1 billion, contributing significantly to results.

In addition, amid the emergence of various new drugs in each area and their changing premium pricing status for new drug creation, drug prices resulting from the loss of the transplant segment in 2019 and expect for Oxirol decreased partly due to the impact of generics.

In 2019, we aim to maintain and improve the market presence of Mircera and Oxirol in the pre-dialysis and dialysis stages through ongoing provision of information and patient-centric activities rooted in our high level of expertise in the area of renal diseases.

#### Bone and Joint Diseases

In 2018, sales in the bone and joint diseases area in Japan increased ¥7.2 billion, or 7.7 percent, year on year to ¥100.5 billion. In addition to growth from uptake of Actemra as a first-line biologic for the treatment of rheumatoid arthritis (RA), sales growth continued for Edirox, which has been recognized as a base treatment for osteoporosis, and for Bonviva, which was launched in an oral formulation in April 2016 in addition to the intravenous formulation. Sales of Actemra outside Japan including exports to Roche increased ¥19.7 billion, or 32.3 percent, to ¥50.6 billion as firm global sales by Roche compensated for the negative effect of exchange rates.

In 2019, we expect continued firm sales of treatments in the bone and joint diseases area in Japan. Outside Japan, we expect growth in sales of Actemra, mainly due to further uptake of the subcutaneous formulation for RA and sales for giant cell arteritis, which became an additional indication in 2017.

#### Renal Diseases

Sales in the renal diseases area in Japan in 2018 decreased ¥3.0 billion, or 7.6 percent, year on year to ¥36.3 billion. Mircera, which only needs to be administered once every four weeks, has established a reputation in the pre-dialysis segment for convenience and long duration of action, and prescriptions are increasing. However, sales decreased slightly due to competition from biosimilars and other therapeutic agents in the dialysis field, in addition to the NHI drug price revision in April 2018. Sales of Oxirol decreased partly due to the impact of generics.

In 2019, we aim to maintain and improve the market presence of Mircera and Oxirol in the pre-dialysis and dialysis stages through ongoing provision of information and patient-centric activities rooted in our high level of expertise in the area of renal diseases.

#### Other Diseases

Hemlibra is a bispecific antibody created using Chugai’s innovative antibody engineering technologies. It obtained approval for routine prophylaxis in people with congenital hemophilia A with blood coagulation factor VIII inhibitors in March 2018, and received a drug price listing and was launched in May. Hemlibra’s product characteristics are different from those of conventional coagulation factor agents. We focused on providing information on clinical results demonstrating its high level of efficacy in reducing the frequency of bleeding episodes, and sales in Japan were ¥3.0 billion in 2018. In December 2018, Hemlibra also obtained approval for an additional indication for people with hemophilia A without factor VIII inhibitors, enabling administration regardless of the presence of such inhibitors. The approval also allowed dosing intervals of two weeks or four weeks in addition to once-weekly administration, enabling treatment options according to the needs of people with hemophilia A and their healthcare providers. In 2019, by focusing on collecting and providing safety information on people with hemophilia A with factor VIII inhibitors who are already using Hemlibra as well as activities to promote its proper use among people with hemophilia A and their healthcare providers.

### 2018 Product Sales by Therapeutic Area (Billions of yen)

#### Oncology

<table>
<thead>
<tr>
<th>Drug</th>
<th>Sales (Billion Yen)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avastin</td>
<td>95.6 (+2.7)</td>
</tr>
<tr>
<td>Herceptin</td>
<td>28.1 (-16.4)</td>
</tr>
<tr>
<td>Rituxan</td>
<td>21.3 (-36.2)</td>
</tr>
<tr>
<td>Actemra</td>
<td>38.3 (+15.4)</td>
</tr>
<tr>
<td>Perjeta</td>
<td>16.1 (+18.4)</td>
</tr>
<tr>
<td>Xeloda</td>
<td>12.5 (+2.5)</td>
</tr>
<tr>
<td>Tarofin</td>
<td>8.3 (+21.0)</td>
</tr>
<tr>
<td>Ketekysa</td>
<td>8.5 (+63.1)</td>
</tr>
<tr>
<td>Zeolbori</td>
<td>0.1 (0.0)</td>
</tr>
<tr>
<td>Others</td>
<td>4.8 (+0.0)</td>
</tr>
<tr>
<td>Overseas</td>
<td>28.9 (+112.2)</td>
</tr>
<tr>
<td>Domestic Total</td>
<td>225.7 (+0.1)</td>
</tr>
</tbody>
</table>

#### Bone and Joint Diseases

<table>
<thead>
<tr>
<th>Drug</th>
<th>Sales (Billion Yen)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actemra</td>
<td>10.7 (-36.7)</td>
</tr>
<tr>
<td>Edirox</td>
<td>9.0 (+1.1)</td>
</tr>
<tr>
<td>Others</td>
<td>3.0 (-)</td>
</tr>
<tr>
<td>Overseas</td>
<td>14.9 (-28)</td>
</tr>
<tr>
<td>Domestic Total</td>
<td>37.5 (-19.9)</td>
</tr>
</tbody>
</table>

#### Renal Diseases

<table>
<thead>
<tr>
<th>Drug</th>
<th>Sales (Billion Yen)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mincrea</td>
<td>23.1 (3.3)</td>
</tr>
<tr>
<td>Oxirol</td>
<td>7.3 (-11.1)</td>
</tr>
<tr>
<td>Others</td>
<td>5.9 (-18.1)</td>
</tr>
<tr>
<td>Overseas</td>
<td>58.5 (-30.7)</td>
</tr>
<tr>
<td>Domestic Total</td>
<td>36.3 (-7.6)</td>
</tr>
</tbody>
</table>

Note: Figures in parentheses are year-on-year percentage changes.
Medical Affairs

IBI 18 (2016–2018)
- Acceleration of evidence creation
- Promotion of medical affairs in Japan and overseas

IBI 21 (2019–2021)
- Contribution to healthcare through acceleration and advancement of evidence creation
- Promotion of innovative medical affairs through strengthening collaboration with all stakeholders and actively introducing new technologies

Functions
In addition to creating a steady flow of innovative drugs, Chugai recognizes the importance of ensuring that the value of its products is delivered accurately to patients, which will lead to better treatment. We have been focusing on creating evidence in support of this objective and supplying appropriate information to healthcare providers. We have also been working to establish a global support system for post-marketing studies. Our efforts have included being one of the first companies to operate a scheme for contract-based post-marketing studies to guarantee the independence and transparency of research, and establishing a research support structure that conforms to the GCP1 guidelines of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) to raise the quality and reliability of research.

In addition, we have been preparing an implementation and support system for post-marketing studies under the Clinical Trials Act that was promulgated in Japan in April 2018. We also started a new initiative in anticipation of the Next Generation Medical Infrastructure Act, which was promulgated in May 2018. In 2017, Chugai acquired third-party accreditation2 for its medical science liaison (MSL) certification program from the Japanese Association of Pharmaceutical Medicine, and we maintain global-level compliance standards, including transparency in funding and appropriate separation of marketing and medical affairs.3 At the same time, we are working to further enhance our internal systems to help raise the quality and scientific level of clinical and preclinical (basic) research and to deal with changes in our operating environment.

1. Good Clinical Practice: Standards for conducting pharmaceutical clinical trials
2. Composed of evaluation criteria (a total of 222 items in 42 categories) from the three perspectives of independence from promotional activities (compliance system), medical and scientific expertise, and the training system. In the accreditation examination, mail-in and on-site surveys of the evaluation criteria are conducted to evaluate whether the MSL certification program at the applicant company is being properly implemented.
3. Activities that contribute to healthcare from a scientific standpoint

Main Initiatives and Progress

Activities to Generate Evidence
We conduct and support contract-based post-marketing studies to create, communicate and disseminate evidence on efficacy and safety in the clinical setting and non-clinical studies (basic research) to shed light on the modes of action of drugs. Conducted in cooperation with medical institutions and healthcare providers, these studies are based on complete transparency.

Enhancing Intelligence Functions and Measures for PHC
In the future of healthcare, along with elucidation of the causes of diseases and pathological conditions, progress is expected in establishing preventive and treatment methods based on individual genetic, environmental and lifestyle differences. We will respond promptly to this changing environment by enhancing our intelligence functions, such as using ICT and other means to obtain medical information and gain insights from its analysis. At the same time, we intend to provide more suitable treatment methods through the generation of new evidence with higher scientific value and other activities that provide solutions. Through these measures, we will contribute to the development of patient-centric medical research and advanced healthcare.

Main Medical Affairs Activities

IBI 18 (2016–2018)
- Extensive track record in evidence creation
- Global collaboration with Roche and overseas subsidiaries
- Increase in opportunities to use internal and external databases following the promulgation of the Next Generation Medical Infrastructure Act
- Unmet medical need appearing with the advancement of medical care

IBI 21 (2019–2021)
- Systematic development of clinical research infrastructure
- Changes in the clinical research system in association with the promulgation of the Clinical Trials Act
- Potential paradigm shift due to disruptive technologies or other factors

Main Medical Affairs Activities

Drug Discovery & Early-Stage Development
- Conduct industry-initiated clinical studies
- Support investigator-initiated clinical studies
- Conduct preclinical research
- Conduct activities to provide appropriate information

Late-Stage Development
- Generate evidence
- Formulate medical plans

Post-Marketing
- Contribute to patient-centric healthcare

Main Initiatives and Progress

Activities to Generate Evidence
We conduct and support contract-based post-marketing studies to create, communicate and disseminate evidence on efficacy and safety in the clinical setting and non-clinical studies (basic research) to shed light on the modes of action of drugs. Conducted in cooperation with medical institutions and healthcare providers, these studies are based on complete transparency.

Enhancing Intelligence Functions and Measures for PHC
In the future of healthcare, along with elucidation of the causes of diseases and pathological conditions, progress is expected in establishing preventive and treatment methods based on individual genetic, environmental and lifestyle differences. We will respond promptly to this changing environment by enhancing our intelligence functions, such as using ICT and other means to obtain medical information and gain insights from its analysis. At the same time, we intend to provide more suitable treatment methods through the generation of new evidence with higher scientific value and other activities that provide solutions. Through these measures, we will contribute to the development of patient-centric medical research and advanced healthcare.
Drug Safety/Quality and Regulatory Compliance

**IBI 18 (2016–2018)**

**Drug Safety**
- Commitment to drug safety management for new products immediately after launch
- Delivery of drug safety solutions to healthcare providers through deployment of Safety Experts
- Creation of tools for providing drug safety information with high added value

**Quality and Regulatory Compliance**
- Restructuring of global compliance framework
- Realization of standardization and efficiency enhancements in global operations through IT systems
- Enhancement of quality assurance in the supply of products and investigational drugs

**IBI 21 (2019–2021)**

**Drug Safety**
- Maximization of the value of growth drivers through a commitment to promoting appropriate use
- Provision of new value based on insights garnered from customer needs
- Strengthening of systems for evaluating drug safety from the early stage of clinical trials

**Quality and Regulatory Compliance**
- Development of a system for quality and regulatory compliance for the gene mutation analysis program (F1CDx), regenerative medicine and other fields
- Establishment of quality and regulatory compliance and governance for data use in personalized healthcare
- Enhancement of global quality assurance standards and quality and regulatory compliance framework

**Drug Safety Functions**

In Japan and overseas, Chugai handles numerous biopharmaceuticals, molecular targeted therapies and other pharmaceuticals with innovative modes of action. To promote the appropriate use of these pharmaceuticals around the world and gain acceptance from patients and healthcare providers, Chugai establishes pharmacovigilance protocols with Roche and other partners and collects safety information on a global level. We consider expert safety evaluation and speedy decision-making to be essential for timely provision of safety information and implementation of measures to ensure safety. Consequently, Chugai has established an independent Drug Safety Division and a system directly linked to management. Through measures such as these, Chugai is building greater credibility, with the aim of providing truly valuable safety data and contributing to patients and healthcare worldwide.

**Quality and Regulatory Compliance Functions**

Protecting the rights of patients and clinical trial subjects and ensuring the reliability of data are serious responsibilities for the pharmaceutical industry. The Quality & Regulatory Compliance Unit is responsible for ascertaining trends in pharmaceutical regulations and ensuring the soundness of the quality management system spanning our business processes. It also ensures the reliability of data by confirming, improving and verifying the validity of these business processes through quality audits throughout the product lifecycle. In proactively leading cross-divisional activities for the purposes of introducing a global IT system and maintaining and improving quality, the unit aims to foster a self-sustaining quality mindset Company-wide and build a sturdier quality management system. Moreover, by engaging in dialogue with regulatory authorities through industry activities, it is also working to align regulations with society’s demands, in ways including revisions to the Law for Ensuring the Quality, Efficacy and Safety of Drugs and Medical Devices.

**Main Initiatives and Progress**

**Collecting and Managing Safety Information**

Post-marketing surveillance, which includes all-case registration surveillance, is conducted in (real world) clinical settings to collect safety information unobtainable in clinical trials. In post-marketing surveillance, data on safety are collected from medical institutions through electronic systems. Information on the results obtained from analysis of this data is provided to medical institutions and announced via scientific conferences, papers and other means.
Numerous anticancer agents, innovative new biopharmaceuticals and other drugs require wider-ranging and more rigorous management, such as thorough management of distribution and confirmation of conditions of use, in addition to all-case registration, in which all patients administered a product are registered. With its extensive experience in all-case registration surveillance and other areas, Chugai leads the industry in drug safety evaluation and safety measures. In accordance with the revised Ministerial Ordinance on Good Post-marketing Study Practice (Revised GDPSP Ordinance) that came into effect in April 2018, we are contributing to the implementation of epidemiological research, including a survey of post-marketing databases utilizing a network of domestic medical information databases.

Leading the Industry in Risk Management Plans
Chugai has been ahead of its competitors in drawing up and applying risk management plans (RMPs) to several of its products, and discloses them on its website. We consider RMPs to be part of our commitment to patients and healthcare providers. In applying RMPs, we believe we need to strengthen our ability to analyze data from an epidemiological standpoint. To achieve this, a specialized internal group in charge of epidemiology functions is cooperating with specialized companies and others to help upgrade Japan’s epidemiological database. We are also driving the industry in ways such as proactively working to formulate industry-wide recommendations and guidance for database research.

Enhancing Drug Safety Evaluations
Chugai is committed to highly transparent and speedy reporting and release of drug safety information. We collect a large volume of safety information from countries around the world and evaluate it from a medical standpoint. Using advanced information technology, we have established a system for recording the information in a database and conducting signal detection of adverse events using that database. Under this system, we are able to promptly consult with regulatory authorities in each country regarding safety measures. In addition to managing this large volume of safety information, we have in-house doctors with abundant clinical experience who also conduct expert safety evaluations.

Communications on Safety
Communications with customers include providing information on noteworthy adverse events to medical institutions and academic societies. We also distribute information leaflets for patients, post information on our website and present a variety of lectures. In particular, our ability to rapidly provide information according to patient characteristics using the post-marketing surveillance database tool (PMS DB tool) and safety information database tool (SAFETY DB tool) that we developed in 2016 has won praise from healthcare providers. With these tools, which include post-marketing surveillance and domestic post-marketing safety data, we can respond in a timely manner to urgent needs for safety information. In 2018, we broadened our contribution through the rollout of a clinical trial database tool for safety information on phase III multinational clinical trials so that healthcare providers can use new products with confidence immediately after their launch. Also, we have started using an app1 that supports adherence to medication in conjunction with a multidisciplinary social networking service (SNS). The app helps to alleviate the anxiety of patients undergoing treatment by facilitating smooth communication between patients and their healthcare providers. In addition, we have assigned Safety Experts as professional staff in each region to support risk communication geared to local area characteristics, and are strengthening safety-related consultation according to needs and building networks with local doctors and pharmacists.

2. A service developed by Chugai to support multidisciplinary team care in cancer treatment. The app is linked with MedicalCareSTATION, a completely private SNS developed exclusively for healthcare providers and operated by Embrace Co., Ltd., and promotes drug adherence and adverse event management.

I am working with in-house epidemiological specialists and colleagues from other departments to plan post-marketing database surveillance and drug use results surveys, so that we can provide patients with the information they truly need in a proper and timely manner, while responding to changes in the social environment.

Yuki Miyano
Real World Data Planning Group, Real World Data Science Dept.

New Efforts for Quality and Regulatory Compliance
• Ensuring quality and regulatory compliance in innovation and digital healthcare
• Comprehensively improving quality to achieve patient-centric medical care
• Fostering a culture of quality

In addition to the creation of new drugs, Chugai’s innovation will expand into medical devices, regenerative medicine and gene therapy. This innovation will include generating evidence in support of these areas, as well as to digital healthcare. Furthermore, as a leading innovator, we feel a heavy responsibility to create and champion related new quality assurance methods.

It is particularly important to realize patient-centric healthcare, and by refining our process for responding to patient requests we will improve our products and the quality and timeliness of the information we provide. It is our mission to comprehensively improve quality by proactively sharing experiences and knowledge regarding quality and regulatory compliance with stakeholders and affiliated companies involved in production, development and other processes, and thereby raise the competence of all parties.

To accomplish the above, fostering a culture of quality is essential. There are numerous procedures and rules in place at Chugai. However, given the successive appearance of new drug regulations, continuing to upgrade our systems for quality and regulatory compliance is vital. Particularly when we find faults in our rules, we must harness a Company-wide autonomous quality mindset that pushes forward with improvements and reforms. By infusing this attitude toward quality among employees, we will cultivate a culture of quality that further increases the trust we earn from all stakeholders.
Intellectual Property

IBI 18 (2016–2018)
- Realization of IP activities that help to acquire and demonstrate global top-class competitiveness
- Strengthening of rights formation functions globally
- Strengthening of strategic utilization of IP including in patent disputes

Continuation ➔ Evolution

IBI 21 (2019–2021)
- Creation of a database of Chugai’s competitors and use it to search out opportunities for utilizing the Company’s rights
- Utilization of antibody engineering technology patents through licensing and other means
- Formulation and execution of a scenario for combating biosimilars and generics

Implementation of Our IP Strategy

Chugai views its global intellectual property (IP) strategy as the foundation for creating innovative new drugs. By integrating it with our business and R&D strategies, we protect the competitive advantage of our products and ensure operational flexibility. We focus resources on and secure IP rights for high-priority R&D projects. At the same time, we actively work to secure rights outside Japan with a view to global co-development with the Roche Group. When we apply for patents for our business and R&D strategies, we protect innovative new drugs. By integrating it with the IP (IP) strategy as the foundation for creating intellectual property, we include filings for our inventions related to formulation, production method, diagnostic method and personalized healthcare in addition to those for the substance and use. We also work to establish rights globally for significant drug discovery technologies such as innovative antibody technologies, and use those rights in planning and executing our IP strategy. Moreover, we are building our own database for patents related to antibody engineering technologies, which are becoming increasingly complex and sophisticated, and are using this database to plan IP strategies, including monitoring trends at other companies.

Main Initiatives and Progress

Integration of IP and Research Strategies (Strategic Mix)
At Chugai, we view our antibody engineering technologies as a core drug discovery technology platform, and we are deploying research and development strategies both to cultivate basic technologies and to apply them to product development. Since 2018, we have been dispatching IP liaisons to the Fuji Gotemba Research Laboratories and Kamakura Research Laboratories to strengthen cooperation at the initial stage of research, and they are enhancing and promoting a strategic mix that builds a portfolio of our own technologies and development compounds in the white spaces (gaps) of technologies and rights. IP liaisons hold monthly meetings to review intellectual property with the Pharmaceutical Technology Division, which is also promoting the same strategic mix in manufacturing.

Current Patent Portfolio
Bone and joint diseases account for approximately 29% of patents by therapeutic area, oncology for approximately 27%, and other areas including chronic disorders, hematologic diseases, and drug discovery technology for approximately 44%. Supported by technological development, we have structured a well-balanced patent portfolio that reflects the diversity of products and development projects generated through Chugai’s own R&D. In addition, in 2018 Chugai acquired 213 patents in Japan, the United States, and major European countries, as well as other countries worldwide.

Creating Opportunities to Use the Company’s Rights and Establishing an IP Liaison Group
With the globalization of our product portfolio, the chance of conflicts arising over product-related IP is increasing. In addition, more sophisticated execution of strategies for utilizing lifecycle patents are required given the growing importance of generics, including biosimilars, in our IP strategy. Chugai will raise the sophistication of its strategies for using drug discovery technology patents by quickly identifying competitors that might use its proprietary drug discovery technologies and delineating drug discovery technology patent rights and their use. Moreover, we have established the IP Liaison Group as an implementation unit to resolve conflicts over IP rights, which are expected to increase in the future. Through these actions, we will continue to maximize the value of our business.

Number of Patents Held (Including Pending Applications) and New Patents Granted

<table>
<thead>
<tr>
<th>Year</th>
<th>Oncology</th>
<th>Bone and joint diseases</th>
<th>Others</th>
<th>New patents granted</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>194</td>
<td>164</td>
<td>176</td>
<td>1,267</td>
</tr>
<tr>
<td>2015</td>
<td>164</td>
<td>188</td>
<td>213</td>
<td>3,341</td>
</tr>
<tr>
<td>2016</td>
<td>176</td>
<td>188</td>
<td>213</td>
<td>4,030</td>
</tr>
<tr>
<td>2017</td>
<td>176</td>
<td>188</td>
<td>213</td>
<td>4,219</td>
</tr>
<tr>
<td>2018</td>
<td>188</td>
<td>188</td>
<td>213</td>
<td>4,647</td>
</tr>
</tbody>
</table>

* The ability to conduct business without the possibility of infringing the rights of others
Human Resources

Talent That Spearheads Innovation

Our people are our greatest asset in realizing management strategies and generating innovation, and we therefore position human resource management as a key management theme. Our Envisioned Future is to become a top innovator in the healthcare industry. Chugai will pursue this objective by building understanding and connection with the Mission Statement (corporate philosophy) among all employees. Furthermore, we will encourage employees to embody the Mission Statement while fulfilling their potential in accordance with their role.

Establishing an Organizational Culture That Generates Innovation

Chugai provides career development support over many years so that employees can excel in roles that reflect their expertise, ability and aptitude. Since 2012, we have instituted various measures and systems, including introducing a talent management system, promoting diversity and revising our personnel systems. As a result of these initiatives, we have secured leaders capable of driving sustainable growth, assigned roles and growth opportunities according to each individual’s ability and aptitude, and created an environment that supports the success of women.

At the same time, the speed of change in the business environment is escalating. Clarifying each employee’s approach and responsibilities to improve quality, speed and success rates in strategy execution will be essential to realizing our management strategies and establishing a competitive advantage. In addition to these issues, an important theme is to support our employees in proactively taking on challenges to generate innovation and new added value.

We have determined the following human resource management priorities as measures for these objectives and themes. With these measures, we aim to establish an organizational culture in which employees support each other to continuously generate innovation.

Changes to the All-Employee Survey

Chugai has regularly conducted its all-employee survey for instilling and promoting its identity as a top pharmaceutical company, initiatives to change organizational culture, and mid-term business plans. However, the high level of survey results in recent years made it difficult to set higher goals and to satisfactorily identify issues, and we were unable to use the results to compare Chugai with global companies and others. Therefore, in 2018 we transitioned to an employee survey that enables comparison against benchmarks.

Our objective for the new employee survey is to identify organizational change issues linked to the strategies of IBI 21. We will address the issues we identify with Group-wide and divisional PDCA cycles, while working to achieve our ideals.

Overview of Employee Survey (2018)

<table>
<thead>
<tr>
<th>Question categories</th>
<th>Participants</th>
<th>Respondents</th>
<th>Response rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Employee engagement</td>
<td>6,994 (6,498 in Japan, 496 overseas)</td>
<td>6,806 (6,321 in Japan, 485 overseas)</td>
<td>97.3%</td>
</tr>
</tbody>
</table>

Benchmark data

Average results from global companies, leading companies, pharmaceutical companies and Japanese companies

Survey Results (Overall Trends)

- In all question categories, Chugai scored above the average for Japanese companies. In Japan, Chugai is a leader in terms of employee awareness.
- Chugai is on par with global companies. Employee engagement is on par with top global companies.
- Issues for further improvement are the environment for utilizing employees, as well as the resources, framework for collaboration, and business processes and organizational structure that underlie that environment.
- The percentage of employees who gave employee engagement and working environment high marks is at the level of global companies.
1. Assignment of the right people to the right positions using position management and talent management and provision of growth opportunities

2. Promotion of talent management to quickly identify and develop leaders and highly competent specialists to accelerate strategy execution and innovation.

3. Promotion of diversity and inclusion (D&I) to accelerate the success of women.

In addition, we switched to a new employee survey in 2018 to set more ambitious targets and identify issues more accurately. Based on the results of this survey, we will conduct organizational reforms linked to IBI 21.

Main Initiatives and Progress

Competency-Based Development

Upgrading Standards and Platforms to a Global Level

In competency-based human resource development, a prerequisite for implementing talent management, we clarified the mindset and behavior that Chugai requires and are standardizing Group-wide competencies on which employees are evaluated. Under IBI 18, we identified the type of global-level employees we are looking for and articulated these competencies in our decision-making standards and behavioral standards. As a basis for developing human resources, we conduct workshops and training for the managers of individual organizations to encourage dialogue between supervisors and their staff based on these competencies.

In addition, in 2017, we revamped our backbone system for human resource management. The new system, called “CAPTAIN” (Chugai All Persons Talent Information system), is a multilingual, cloud-based global personnel system. The use of a common personnel database throughout the Chugai Group will enable managers to conduct unified talent management and real-time monitoring and analysis of organizational conditions, leading to faster, more effective enhancement of our human resource capabilities.

In new mid-term business plan IBI 21, in addition to talent management, we will conduct position management to ensure the right people are assigned to the right positions throughout the Group, and provide growth opportunities for employees who actively take on challenges. In line with changes to the business environment, we also need to update our requirements for the type of people we seek. In position management, we will clearly define the roles and duties required for realizing our strategies and visualize the corresponding human resource requirements. This will facilitate operation in concert with talent management and accelerate the realization of our strategies.

Talent Management

Structuring Human Resource Development Plans with the Strong Commitment of Management

Since 2012, Chugai has been introducing and promoting a talent management system for developing individuals based on visualization of human resources and their capabilities. Each department held discussions on medium-to-long-term human resource development policies and formulated individual development plans. At the same time, we have created a talent pool of future management candidates. In addition, we clarified our succession plan by selecting successor candidates for a total of 94 general manager and department manager positions in Japan. The Company-wide plan, which includes medium-to-long-term career paths for each candidate, is being formulated and implemented through discussions by executive management and department managers to accelerate training of successor candidates.

Under IBI 18, we expanded talent management to a global scale, creating a new system that has enabled Chugai to systematically and continuously recruit, develop and promote people who can perform internationally. For key positions in strategy execution, in addition to internal candidates, we also consider hiring from outside the Company, whether in Japan or overseas, and candidate selection is under the direct supervision of the president. In IBI 21, we will review our training system to improve our ability to acquire, develop and deploy world-class human resources with the aim of identifying and training them more quickly.

Establishment and Enhancement of the Foundations of Human Resource Management

Promoting Diversity & Inclusion and Work-Life Synergy to Improve Productivity

Chugai has positioned D&I as a priority issue for the establishment and enhancement of the foundations of human resource management. We believe that D&I, which leads to the creation of a diverse workforce that works together with enthusiasm, is essential in order for employees to generate new value – in other words, diversity is necessary for generating innovation. As such, in 2010 we launched a working team led by the president, and in 2012 we established a dedicated organization that has since been conducting initiatives to promote diversity.

To promote gender diversity, we are actively providing opportunities for women to succeed. We set a target for 2018 of a 13 percent or higher female manager ratio, and have focused on career planning and development measures for women. With a female manager ratio of 13.3 percent as of December 31, 2018, we have achieved that target and are working for further advances. To promote the success of older employees and foreign employees in Japan, we are building awareness of their potential through training and other programs and creating environments including workplace systems to help them play active roles. Also, amid demands for more active participation by diverse human resources, managers play a key part in promoting D&I. We will aim to enhance their practical workplace skills through training in diversity management awareness, skills and behavior modification.

Under IBI 18, we focused on leveraging D&I and presenting in-house case studies to encourage implementation by employees and vitalize the organization, thereby contributing to business success.

We also provide work arrangements and support systems so that all employees can benefit from work-life synergy that accommodates a variety of life events including but not limited to childbirth, child care
and nursing care. With respect to “work style reform,” which is currently a focal issue in Japan, studies and discussions between labor and management are under way with the goals of improving the work environment to enable employees to fully demonstrate their capabilities and promoting innovation by organically combining diverse knowledge.

Promoting D&I and work-life synergy is all about supporting the autonomy and growth of individuals to help realize an organization that generates innovation, which in turn contributes significantly to improving organizational productivity and increasing corporate value over the medium to long term.

IBI 21 sets forth a target outcome of innovation stories generated by leveraging the strengths of D&I, and we have created a roadmap for expedited realization of our strategies. Based on respect for different values and ideas, we are working to address the following three issues in order to foster an inclusive organizational culture in which diverse human resources can succeed and pursue innovation.

1. Fostering an organizational culture that generates innovation and is accepting of failure
2. Improving engagement of diverse talent
3. Proactively appointing and deploying women and people from different cultures and backgrounds to take on business challenges

We are targeting a 16 percent or higher female manager ratio by the end of 2021, and will continue to focus on career planning and development measures for women.

### D&I Roadmap for Promotion of IBI 21

<table>
<thead>
<tr>
<th>Year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fostering an organizational culture that generates innovation and is accepting of failure</strong></td>
<td>• Identify issues for fostering a culture that generates innovation&lt;br&gt; • Study measures and implement on a trial basis</td>
<td>• Review trials and fully introduce measures&lt;br&gt; • Identify and present innovation stories</td>
<td>• Reinforce behavior that generates innovation</td>
</tr>
<tr>
<td><strong>Improving engagement of diverse talent (improving engagement through work style reform)</strong></td>
<td>• Identify issues for improving engagement&lt;br&gt; • Study measures and implement on a trial basis</td>
<td>• Review trials and fully introduce measures</td>
<td>• Increase opportunities for employee growth and taking on challenges</td>
</tr>
<tr>
<td><strong>Work Style Reform</strong></td>
<td>• Study and implement measures for changing mindset and behaviors&lt;br&gt; • Identify issues for business process reform</td>
<td>• Implement measures for business process reform&lt;br&gt; • Promote work style reform by sharing best practices</td>
<td>• Work continuously to establish work style reform</td>
</tr>
<tr>
<td><strong>Proactively appointing and deploying women and people from different cultures and backgrounds to take on business challenges</strong></td>
<td>• Create a system of divisional commitment to the success of women&lt;br&gt; • Identify issues, and study and implement measures to encourage the promotion of women</td>
<td>• Enhance approach to managers and employees to encourage the promotion of women</td>
<td>• Further expand the number of female leader candidates</td>
</tr>
</tbody>
</table>

Employee Survey

- Reinforce behavior that generates innovation
- Increase opportunities for employee growth and taking on challenges
- Work continuously to establish work style reform
**Human Rights**

**Basic Approach**

Chugai believes that a culture of respect for human rights is a cornerstone for a company to be recognized as a member of society and to earn trust. Therefore, we declare our respect for human rights in the Chugai Business Conduct Guidelines (Chugai BCG), which are based on our shared Core Values. In respecting human rights, we aim to realize workplaces that prize diversity, where each person values his or her own feelings and accepts the values of others – allowing everyone to fully demonstrate his or her abilities, based on an organizational climate of appreciation for oneself and others. People in such a workplace can work creatively with enthusiasm and engagement, thus increasing their achievements. Moreover, we believe that the actions of individuals who raise their sensitivity to human rights and show respect for others in such a workplace can also help to eliminate social discrimination and infringements of human rights in society in general through corporate activities and their private lives.

Today, companies are expected not only to conduct in-house initiatives regarding human rights, which have been increasing in importance as a social issue, but also to conduct business activities that respect human rights throughout the entire supply chain. With our deep involvement in people’s lives and health as a member of the healthcare industry, we are promoting measures with a greater awareness of respect for human rights (see our website* for more details on our human rights policy).

* https://www.chugai-pharm.co.jp/english/csr/humanrights/

**Issues and Initiatives**

In previous initiatives toward respect of human rights, Chugai mainly focused on its employees in areas such as prohibition of workplace discrimination and harassment, respect for employee diversity, and safety and health. However, to conduct business activities in various regions of the world as a global company, we recognize that we need to address human rights issues throughout our entire supply chain, including labor-related rights at stakeholders involved in our business activities. Based on the United Nations’ Guiding Principles on Business and Human Rights, we began preparations for drawing up a policy on respect for human rights and for conducting human rights due diligence.

In September 2018, Chugai participated in the 2018 Business and Human Rights Conference in Tokyo sponsored by Caux Round Table Japan, and engaged in dialogue with individual experts from overseas, receiving opinions and advice on putting the U.N.’s guiding principles into practice, including the formulation of a human rights policy. Through discussions of the Chugai Group’s initiatives in the context of the principles, we received suggestions from these experts that will lead to more effective communication. They also expressed their expectations for us to incorporate and implement these principles in our business activities.

In addition, Chugai has established an Anti-Bribery Policy to help prevent bribery as part of the management of its corporate activities. In addition to setting standards for our own conduct, it prohibits our business partners from engaging in bribery of government officials, civil servants, corporate staff and other parties, whether corporations or individuals. We will continue our comprehensive efforts to prevent bribery.

We recognize Chugai’s responsibility for respecting the human rights of all people involved in its business activities, and will work to fulfill it by ensuring that we do not infringe on the human rights of these people, and by responding appropriately with corrective action in the event of an infringement.

**Initiatives to ensure respect for human rights must not be limited to employees, but should extend to all people affected by our business activities. We will convey the significance of such efforts through in-house training and foster understanding of their criticality among all links in our supply chain.**

**Emiko Mori**
Senior Specialist, Business Ethics Group, Sustainability Dept.
Environment, Health and Safety

Our Environmental, Health and Safety Functions

As a healthcare company, Chugai is engaged in many specialized scientific activities. One aspect of those activities involves handling antibodies and highly active pharmaceutical substances. Our responsibilities in environmental protection and health and safety are numerous, and we consider them an important foundation for all our business activities.

At the same time, the demands of society have grown more diverse and sophisticated. Integrated management of environment, health and safety is now required worldwide because of the close connection between “environmental protection” and “health and safety.” Accordingly, Chugai has developed an integrated management system for EHS and implements the plan – do – check – act (PDCA) cycle based on a consistent policy Company-wide, from top management to each facility.

We consider EHS management to extend throughout the value chain, from the procurement of raw materials to the manufacture of products and their supply to patients and healthcare providers. Going forward, we intend to broaden our activities to cover the overall value chain in closer cooperation with customers and suppliers, partners and industry organizations.

To utilize the PDCA cycle effectively, we introduced health and safety risk assessment in 2014 and EHS risk assessment in 2017 to remove EHS risks in the workplace. Since 2008, we have implemented an assessment system throughout the Chugai Group to reduce the risk of occupational injuries from exposure to all substances handled, not only restricted substances.

Main Initiatives and Progress

Promotion and Progress of Environmental Protection Activities

Chugai’s aims encompass not only its own sustainable development but also environmental protection in local communities and globally. We have set priority items to be addressed as well as medium-to-long-term targets.

Chugai designated climate change countermeasures, energy conservation,

Initiatives by Theme

<table>
<thead>
<tr>
<th>Theme</th>
<th>Details of Initiatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implementation of EHS risk assessment</td>
<td>Create work environments that are free from unacceptable EHS risks.</td>
</tr>
<tr>
<td>Workplace safety measures</td>
<td></td>
</tr>
<tr>
<td>Climate change countermeasures</td>
<td>Reduce greenhouse gas emissions by reducing energy consumption. Focus not only on reducing energy consumption at plants and laboratories, but also on promoting eco-friendly cars in the MR fleet and other Company-wide initiatives.</td>
</tr>
<tr>
<td>Energy conservation</td>
<td></td>
</tr>
<tr>
<td>Resource conservation</td>
<td>Achieve zero emissions of waste by improving recycling ratio and further reducing landfill waste. Promote awareness of effective use of water resources by monitoring water consumption and wastewater discharge.</td>
</tr>
<tr>
<td>Waste management</td>
<td></td>
</tr>
<tr>
<td>Biodiversity protection</td>
<td>Curb destruction of the ozone layer by eliminating usage of specific CFCs. Prevent emissions of pollutants into the environment by observing laws, regulations, agreements and other rules for air, water quality and soil. In particular, focus on controlling emissions into water with whole effluent toxicity (WET) tests and other methods to protect the water environment.</td>
</tr>
<tr>
<td>Prevention of environmental pollution</td>
<td></td>
</tr>
<tr>
<td>Improvement of environmental literacy</td>
<td>Circulate information on laws and regulations among related staff and raise awareness through ISO 14001 internal auditor training.</td>
</tr>
<tr>
<td>Chemical substance management</td>
<td>Advance the establishment of a system for proper management of chemical substances, and promote safety and the prevention of environmental pollution. Continue risk assessments to prevent exposure to substances handled.</td>
</tr>
<tr>
<td>Reduction of environmental risk</td>
<td>Ensure thorough compliance with environmental laws and regulations by conducting extensive environmental law checks through external consultants.</td>
</tr>
<tr>
<td>Employee health management</td>
<td>Maintain a support system based on cooperation with the health management organization and related departments. Improve health literacy as the basis for all health and safety activities, and enhance awareness through various media and opportunities.</td>
</tr>
<tr>
<td>Improvement of health literacy</td>
<td></td>
</tr>
<tr>
<td>Support for employees with cancer</td>
<td>Aim for early detection of cancer and provide enhanced support for continuing to work while undergoing cancer treatment.</td>
</tr>
<tr>
<td>Measures to prevent and treat lifestyle diseases among employees</td>
<td>Recommend check-ups for high-risk individuals and provide health guidance to those diagnosed to reduce leaves of absence, job departures and accidents caused by lifestyle diseases.</td>
</tr>
<tr>
<td>Measures for employees’ mental health</td>
<td>Conduct a return-to-work program for employees on leave due to mental health issues and use the results of stress checks to improve working environments in cooperation with related departments.</td>
</tr>
<tr>
<td>Measures to address employee presenteeism (working while sick)</td>
<td>Plan, implement and determine the effectiveness of measures based on health survey results.</td>
</tr>
</tbody>
</table>

IBI 18 (2016–2018)

Establishment of a promotion system for environment, health and safety (EHS)
Formulation and execution of single-year goals to achieve mid-term environmental goals
Formulation of priority items for health and productivity management, setting of targets and execution

IBI 21 (2019–2021)

Establishment of a global EHS promotion system
Achievement of mid-term environmental goals and formulation of new mid- and long-term environmental goals
Execution of priority items for health and productivity management and reassessment of evaluation indicators

Continuation → Evolution
resource conservation and waste management, biodiversity protection, prevention of environmental pollution and improvement of environmental literacy as its priority items. In 2010, we set four mid-term environmental goals focusing on management of energy consumption and waste from a medium-term perspective, with 2020 as the final year. We are implementing the PDCA cycle and conducting initiatives to meet these goals.

As measures to conserve energy, we are reducing energy consumption by introducing highly energy-efficient facilities, switching fuels, introducing eco-friendly cars, and conducting an energy conservation program in daily business activities while curbing greenhouse gas emissions, which is the key to combating climate change. To prevent environmental pollution, we are also working to reduce the use of CFCs and HCFCs to halt the destruction of the ozone layer, and to prevent the leakage of environmental pollutants.

Water is an important raw material in pharmaceutical manufacturing, and it is also a crucial global resource. Chugai therefore considers risks related to procurement and water damage to be water-related risks. Although Chugai’s procurement-related risks are low at present, it monitors the volume of water it uses and the wastewater it discharges each year, and is building awareness of the effective use of water resources. At the same time, Chugai conducts countermeasures for the risks to stable supply caused by water damage. In waste management, we aim to increase the waste recycling ratio and further reduce landfill waste to achieve zero emissions of waste, and our initiatives are yielding results.

Moreover, from the standpoint of protecting biodiversity, we began conducting WET tests in 2013 to ascertain the ecological impact of wastewater discharged from our facilities. In 2018, we conducted WET tests once at all plants and research laboratories, and confirmed that there were no problems.

1. We received independent verification of our 2018 greenhouse gas emissions associated with energy consumption, leakage of CFCs and HCFCs, use of aircraft for business travel, and industrial waste generated.
2. Whole effluent toxicity test: A method for comprehensive evaluation of the safety of wastewater and the aquatic environment by determining the impact on crustaceans (Daphnia), algae and fish (Oryzias latipes and others) immersed in diluted wastewater.

Promotion and Progress of Health and Safety Activities
Chugai engages in health and safety activities as one aspect of its health and productivity management, in the belief that sound employee physical and mental health and a satisfying and rewarding work environment where all employees can do their jobs with enthusiasm are the foundation for growth.

Climate Change Countermeasures
(2010 is the base year for per-employee energy consumption and CO2 emission mid-term environmental goals.)

Total and Per-Employee Energy Consumption
The Chugai Group’s energy consumption in 2018 increased 10% over the previous year. The main reason was the newly constructed UK3 manufacturing plant for handling high-mix, low-volume biological API production within the Ukima Research Laboratories in Kita-ku, Tokyo.

CO2 Emissions and CO2 Emissions per Employee
Total CO2 emissions increased 11% from 2017 to 111,348 tons. CO2 emissions per employee increased 1.4 times. The main reason was the newly constructed UK3 manufacturing plant for handling high-mix, low-volume biological API production within the Ukima Research Laboratories in Kita-ku, Tokyo.
To create such an environment, we established a Company-wide health and safety promotion framework in 2017, based on a policy of cooperating with the health insurance society and the labor union in simultaneous pursuit of both individual and organizational health. We also established six priority items: support for employees with cancer, measures to prevent and treat lifestyle diseases among employees, measures for employees’ mental health, measures to address employee presenteeism (working while sick), improvement of health literacy and workplace safety measures. We set mid-term health and safety goals for the underlined items and are conducting activities to achieve them. We are also working to improve organizational health using the results of an organizational analysis of stress checks in collaboration with relevant departments.

Of course, in addition to these preventive measures, we continue to conduct our existing programs to support employees during cancer treatment and after they return to work, as well as mental health awareness activities.

**GHG Emissions**

<table>
<thead>
<tr>
<th>Scope 1: 49,486 tons</th>
<th>Fugitive emissions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct emissions from fuel combustion: 49,240 tons</td>
<td>Ficarbon emitted, etc. from business activities</td>
</tr>
<tr>
<td>Plants: 31,017 tons</td>
<td>Head Office: 24 tons</td>
</tr>
<tr>
<td>Research labs: 13,996 tons</td>
<td>Distribution: 0 tons</td>
</tr>
<tr>
<td>Overseas: 0 tons</td>
<td>Japan: 248 tons</td>
</tr>
<tr>
<td>Plants: 26,030 tons</td>
<td>Overseas: 0 tons</td>
</tr>
<tr>
<td>Research labs: 13,996 tons</td>
<td></td>
</tr>
<tr>
<td>Overseas: 1,951 tons</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope 2: 62,108 tons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indirect emissions from the generation of purchased energy (electricity), heat</td>
</tr>
<tr>
<td>Plants: 31,842 tons</td>
</tr>
<tr>
<td>Research labs: 26,030 tons</td>
</tr>
<tr>
<td>Overseas: 1,951 tons</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scope 3: 4,583 tons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indirect emissions other than Scope 1 and 2</td>
</tr>
<tr>
<td>Plants: 31,842 tons</td>
</tr>
<tr>
<td>Research labs: 26,030 tons</td>
</tr>
<tr>
<td>Overseas: 1,951 tons</td>
</tr>
</tbody>
</table>

**Resource Saving and Waste Reduction**

**Industrial Waste**

The amount of industrial waste generated increased 13 tons from 2017 to 2,841 tons. Sludge increased due to higher production volume, but waste oil decreased substantially. The main reason for the decrease was that the Fujieda Plant, which had generated the largest amount of waste oil, was able to treat most of the waste oil as water by enhancing its wastewater treatment facilities.

To achieve our 2020 environmental goals, we have introduced a system for visualizing energy use, conducted data analysis, and created an energy conservation plan. In 2019, we will implement energy-saving measures according to plan, bringing us closer to achieving our environmental goals for 2020.

**Ratio of Eco-Friendly Cars**

As of December 31, 2018, Chugai had introduced a cumulative total of 1,415 hybrid and fuel-efficient vehicles in its MR fleet. The ratio of eco-friendly cars was 80 percent, remaining above the target of 60 percent.

**Resource Saving and Waste Reduction**

**Industrial Waste**

The amount of industrial waste generated increased 13 tons from 2017 to 2,841 tons. Sludge increased due to higher production volume, but waste oil decreased substantially. The main reason for the decrease was that the Fujieda Plant, which had generated the largest amount of waste oil, was able to treat most of the waste oil as water by enhancing its wastewater treatment facilities.
Social Contribution

Chugai’s Social Contribution Activities

As a responsible pharmaceutical company in healthcare, we work to raise awareness of diseases.

In the area of welfare, in conjunction with our business activities in the renal and bone and joint areas, we conduct ongoing donations of specially equipped para-transit vehicles as we understand the importance of transportation assistance services for people who require in-home nursing care. Regarding education, as a company that deals with leading-edge science we conduct activities to raise awareness of science and medicine among students, from elementary school children to university students, as well as among adults.

Moreover, we cooperate with local communities and engage in disaster preparedness education, mainly in areas where our research laboratories and plants are located. We also support para-sports to help create a society where everyone can participate in sports. Please see our website for more details on Chugai’s basic stance on social contribution.


Main Initiatives

Disease Awareness

Chugai participates in a variety of activities to support cancer patients and their families. One such activity is Relay For Life Japan, an awareness support campaign that forges ties in the fight against cancer. This event, a 24-hour walk-a-thon in which cancer patients, their families and supporters participate as relay teams, was held in 48 locations throughout Japan in 2018. Chugai employees have participated as volunteers in Relay For Life Japan since 2007. A total of 500 employees took part as “Team Chugai” at 27 locations in 2018.

This year, we conducted the awareness raising activity of screenings with the “Try! Scope,” which uses a fiberscope, and participants in various locations enjoyed the experience. As Team Chugai members provided explanations, participants experienced a simulated endoscopy, gaining an understanding of the importance of screening and early detection and treatment. We also promoted understanding of the importance of screening by using “Try! Scope” in health events hosted by local governments.

Initiatives for Generation AYA

Chugai launched the website AYA Life2 for young cancer patients in March 2017 and has been continuously updating the contents. The term “AYA” (an abbreviation of Adolescents and Young Adults) was relatively unknown in Japan at the time of the launch, but recognition has grown with the inclusion of “Generation AYA Cancer” in the Japanese government’s Third-Term Basic Plan to Promote Cancer Control Programs in March 2018. However, as the AYA generation ages, it will be dealing with a wide range of issues including higher education, employment and marriage. As a leader in the area of oncology, Chugai cooperates with academic and patient organizations to spread knowledge of generation AYA cancer patients’ individual concerns and social issues to create an environment where they can receive treatment with peace of mind.

Support for Para-Sports

Chugai co-sponsors the Japanese Para-Sports Association (JPSA) as an official partner, and cooperates in activities to help realize the JPSA’s philosophy of “creating a vital and inclusive society.” The main activities Chugai conducted in 2018 are as follows.

Dispatch of Volunteers to Competitive Sports Events

Chugai held the Chugai Pharmaceutical 2018 Wheelchair Softball Tournament in Tokyo as the title sponsor and provided support by sending 25 employee volunteers to assist with set-up, event management, English interpreting and other matters.

Raising Awareness of Para-Sports

- Co-sponsorship of a chair ski school for parents and children held by the Japan Chair Ski Association
- Support for a wheelchair tennis camp for children
- Operated a booth for experiencing wheelchair tennis and chair skiing at local community events and other venues
- Presentation of the para-sports-related webpages “Another Sport” and “ATHLETE MOTHERS” on the Chugai website (Japanese only)

Promotion of Measures against Locomotive Syndrome

Locomotive syndrome is a condition in which muscles, bones, joints, cartilage, intervertebral discs and other parts of the musculoskeletal system become impaired and motor function declines. The progression of the syndrome is highly likely to impede daily life. The Japanese Orthopaedic Association proposed it as a concept in 2007 and has been working to prevent the syndrome, establish measures for coping with it, and improve awareness. In cooperation with the prefectural chapters of the Japanese Clinical Orthopaedic Association, Chugai holds the Musculoskeletal Disorder/Bone and Joint Forum 10 or more times a year to deliver the latest information to healthcare providers. We will continue helping to promote healthy life expectancy through this activity.

Initiatives for Employees and Their Families

To deepen understanding of para-sports and people with disabilities, Chugai held a hands-on event for experiencing blind sports in cooperation with the Yokohama City Special Support School for the Visually Impaired. There were 18 participants from Chugai, including employees and their family members.
Disaster Relief
Support for Children in Stricken Areas
Chugai once again participated in the global charity event Roche Children’s Walk conducted by Roche to support children in need. In this annual initiative, Chugai matches the total amount of funds raised by its employees, with half of the total amount donated to Malawi and other countries and the remainder donated to an organization in an earthquake-affected area in Japan. In 2018, the recipient organization was the non-profit organization Chobora, a cooperative facility for disabled children and adults in Iwaki City, Fukushima Prefecture.

Charity Sale
As part of its support for recovery from the 2011 Great East Japan Earthquake and heavy rain in Western Japan in July 2018, Chugai held a charity sale at its Head Office and Kamakura Research Laboratories. As employees at each location handled the goods and conversed with the sales staff, they renewed their hopes and prayers for the restoration and recovery of the affected areas.

Para-Transit Vehicle Donation Program
Chugai’s program to donate specially equipped para-transit vehicles began in 1985 as part of activities to commemorate the Company’s 60th anniversary. The program marked its 34th year in 2018. A total of 253 vehicles have been donated to recipients in all of Japan’s 47 prefectures.

The para-transit vehicle donation program is conducted in cooperation with the Japan National Council of Social Welfare and Central Community Chest of Japan, and through it vehicles have been donated to recipients in all of Japan’s 47 prefectures.

Initiatives for Global Health
As international contributions in the area of global health, Chugai participates in the Global Health Innovative Technology Fund (GHIT Fund), which aims to conquer infectious diseases in developing countries, and Access Accelerated, which conducts measures for people in low and middle-income countries who are living with noncommunicable diseases (NCDs). Please see our website for more details on Chugai’s basic stance on global health initiatives.

GHIT Fund
Jointly established in April 2013 with funding from Japanese pharmaceutical companies, the Japanese government (the Ministry of Foreign Affairs and the Ministry of Health, Labour and Welfare), the Bill & Melinda Gates Foundation and the United Nations Development Programme, the GHIT Fund is Japan’s first public-private partnership to support and promote research and development of drugs, vaccines and diagnostics for infectious diseases in developing countries.

In December 2014, Chugai announced its participation in the GHIT Fund and contributed capital. It has also been promoting efforts using its innovative discovery technologies and research resources, including a program to develop drugs to prevent and treat dengue fever. As a partner in the GHIT Fund, Chugai expects that furthering the development of new medical technologies will go beyond fulfilling its basic social responsibility, leading to the promotion of health and sound economic growth in developing countries.

Access Accelerated
Access Accelerated was established in January 2017 by 22 global pharmaceutical companies including Chugai at the World Economic Forum Annual Meeting held in Davos, Switzerland. In partnership with the World Bank Group and the Union for International Cancer Control (UICC), Access Accelerated is working to achieve the U.N. Sustainable Development Goal 3 target of reducing premature deaths due to NCDs by one-third by 2030.

In addition to collaborative programs with other member companies, Chugai is conducting its own project to promote safer childbirth and maternity healthcare in Myanmar in partnership with AMDA-MINDS (AMDA-Multisectoral and Integrated Development Services). Through participation in Access Accelerated, Chugai will help to improve access to healthcare in low and middle-income countries.

Main Initiatives and Progress

- Conducted awareness-raising and support activities for para-sports (served as title sponsor of a sporting event, provided training facilities, and operated a booth for experiencing para-sports)
- Donation of para-transit vehicles to provide transportation for home welfare services: Total of 253 vehicles over 34 years (1 vehicle each to 5 organizations in 2018)
- Number of locations in which Chugai employees participated in the 24-hour charity event Relay For Life Japan: 27
- Biology lab classes for children at the Japan Science Foundation’s Science Museum: 130 participants in 12 labs
- Endowed courses at Waseda University: 2
- Number of employees who took volunteer leave: 45

We are supporting para-sports, healthcare, welfare and disaster relief efforts with the goal of creating a society in which everyone has the opportunity to flourish. We will continue to work on a broad range of issues based on social needs, contributing to the creation of a sustainable society in the process.

Megumi Sakai
Social Contribution Group, Sustainability Dept.
Corporate Communications

IBI 18 (2016–2018)

- Promotion of understanding of and trust in Chugai among stakeholders
- Establishment of a base for global public relations

IBI 21 (2019–2021)

- Maintenance of trust and high regard among stakeholders.
- Establishment of appropriate understanding and support from all stakeholders for new Mission Statement, management policy, and ESG activities

Functions

Chugai is strengthening communication activities for internal and external stakeholders with the aim of securing their support and trust and sustainably increasing corporate value. In addition to clearly, fairly and continuously transmitting information on activities related to the creation of shared value with society, as well as our business activities, we emphasize two-way communication.

As a result, Chugai is well regarded externally. Chugai was chosen for inclusion in all four ESG indices selected by the Japanese Government Pension Investment Fund (GPIF), and has been selected as a component of DJSI Asia Pacific for the fourth time. (See page 2 for more details on external evaluation of our ESG initiatives.)

Disclosure Policy

Under new mid-term business plan IBI 21, we have identified “strengthen sustainable platforms” as a Group-wide strategy. Accordingly, we will strive to further develop communications as we believe that enhancing the platforms through dialogue with stakeholders will support our quest for innovation. To this end, in April 2019 the IR Committee was reorganized as the Corporate Communications Committee and shifted its focus from considering information disclosure policies for capital market participants to considering corporate communication strategies encompassing a wider array of stakeholders.

The Corporate Communications Committee is a corporate management committee composed of the CFO and general managers of the Corporate Communications Department, the Corporate Planning Department, the Finance & Accounting Department, the Sustainability Department and the General Affairs Department. The committee holds regular meetings and is responsible for the establishment, revision and internal dissemination of the Disclosure Policy, and for the management and promotion of information accumulation, disclosure and related activities. Top management, including the CEO and key executive officers, has primary accountability for disclosure. In addition, the Corporate Communications Department takes the lead in coordinating with relevant departments, using various tools to communicate promptly and effectively.

Note: For further details on the Company’s policy for disclosure to shareholders, investors, securities analysts and other capital market participants, please refer to the Chugai website (https://www.chugai-pharm.co.jp/english/en/policy/disclosure.html).

Communication with Shareholders and Investors

Chugai’s policy for disclosing information to shareholders and investors is to make timely, appropriate and fair disclosure of information in accordance with the Financial Instruments and Exchange Act and relevant rules of the stock exchange on which Chugai’s shares are listed in order to receive fair valuation in capital markets. In addition, as a means to ensure transparency, we disclose information simultaneously in Japanese and English in principle, to allow easy access to disclosed information.

The 108th Annual General Meeting of Shareholders was held on March 28, 2019, and all agenda items were approved and passed by a majority. Moreover, in addition to quarterly investor presentations and conference calls to explain operations, we also conducted “R&D conference calls” to present and answer questions about information of great interest to investors. Furthermore, to improve communication with individual shareholders and investors, we hold production site tours and conduct investor presentations at securities company branches and via the Internet. Senior management also hosts visits by overseas institutional investors, and each year the president holds informal discussions with investors and analysts as an opportunity to speak directly in small groups.

Due to the introduction of the Principles for Responsible Institutional Investors (Japan’s Stewardship Code) and Japan’s Corporate Governance Code, greater dialogue between companies and shareholders is required. Chugai has proactively established forums for ongoing discussions between investors and the management team to ensure a fuller exchange of opinions. We will continue measures to enhance face-to-face IR with management.

Communicating Information to a Wide Range of Stakeholders

We emphasize proactive communication of information that is easy to understand in order to gain the support and trust of a wide range of stakeholders. Chugai takes an active approach to media relations through methods including press releases, various types of information meetings and informal discussions with management. We also use our website and a variety of other tools to promote understanding among the general public of the broad range of activities through which our businesses contribute to healthcare, the environment, human rights, society, human resource development and other areas. We plan to strengthen communication activities because we believe they help to enhance corporate value.

Main Initiatives and Progress

- Media and IR information events: 15
- Security analysts and institutional investors worldwide with whom individual meetings were held: 407
- Briefings for individual investors and shareholders: 8
- Attendees at the General Meeting of Shareholders: 414
- Second Prize, Nikkei Annual Report Award 2018
- 3rd place, Pharmaceuticals Category, 2018 Awards for Excellence in Corporate Disclosure, The Securities Analysts Association of Japan
- 2nd place, The 2018 All-Japan Executive Team Rankings, Institutional Investor magazine
- ESG website newly created
Basic Information

Overview of Domestic Pharmaceutical Market and NHI Drug Prices

Trends in National Medical Expenses
Without medical system reforms, Japan's national medical expenses will increase at a double the number of biosimilars by the end of September 2020. The government is also aiming to double the number of biosimilars by the end of September 2020.

Promotion of the Use of Generics
The Japanese government is promoting the use of generics with the primary objective of reducing the cost burden on patients and improving the finances of the health insurance system. Various measures have been carried out under the action program announced in October 2007 to promote the worry-free use of generics. In April 2013, the new "Roadmap to Further Promote the Use of Generics" was formulated. A Cabinet decision in June 2017 set the new goal of raising the volume market share of generics, which was 72.6 percent as of September 2018, to 80 percent by the end of September 2020. The government is also aiming to double the number of biosimilars by the end of March 2023.

1. Preliminary results of the Drug Price Survey

National Health Insurance (NHI) Drug Price Revision
The Ministry of Health, Labour and Welfare (MHLW) generally reviews drug reimbursement prices every two years and sets new standard prices (reimbursement prices) so that the official prices of pharmaceuticals prescribed under the health insurance system approximate their actual market price. MHLW does this by investigating the prices and volumes of all prescription drug transactions during a given period. In fiscal 2018 (the year ending March 2019), drug reimbursement prices are set to decline by 1.65 percent overall on a medical expense basis and 7.48 percent on a reimbursement price basis.

A special revision of NHI drug reimbursement prices will be implemented in conjunction with the increase in the consumption tax rate in October 2019. In its fiscal 2019 budget, the Japanese government has decided to reduce reimbursement prices by 0.51 percent on a government spending basis and -0.93 percent revision based on actual market prices and other factors.

Repricing Based on Market Expansion
Under this repricing rule introduced in 1994, drugs priced by the cost calculation method with annual sales exceeding ¥10.0 billion and more than 10 times the original forecast at the time of price revision, or with annual sales exceeding ¥15.0 billion and more than two times the original forecast, are subject to a price reduction of up to 25.0 percent. Drugs priced by methods other than the cost calculation method (including the similar efficacy comparison method) with annual sales exceeding ¥15.0 billion and more than two times the original forecast at the time of the price revision are subject to a price reduction of up to 15.0 percent.

Source: Chugai data

NHI Drug Price Revision Rate (%)

<table>
<thead>
<tr>
<th></th>
<th>2008</th>
<th>2010</th>
<th>2012</th>
<th>2014*</th>
<th>2016</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry Average</td>
<td>(5.2)</td>
<td>(6.5)</td>
<td>(6.25)</td>
<td>(2.65)</td>
<td>(7.8)</td>
<td>(7.48)</td>
</tr>
<tr>
<td>Chugai</td>
<td>(7.2)</td>
<td>(6.8)</td>
<td>(6.0)</td>
<td>0.8</td>
<td>(5.5)</td>
<td>(6.7)</td>
</tr>
</tbody>
</table>

*Includes provision for increase in consumption tax
the prices of drugs that have pharmacological action similar to a drug subject to this repricing rule are reduced by the same rate. In the NHI drug pricing system fundamental reforms of fiscal 2018, the NHI listing of new drugs that takes place four times a year will be used as an opportunity for repricing of drugs with annual sales exceeding ¥35.0 billion. The purpose of this change is to respond more quickly when sales expand rapidly due to an additional indication or other reasons.

Special Market-Expansion Repricing
In the reforms to the drug pricing system in fiscal 2016, an additional repricing rule for drugs with very high annual sales was introduced as a special measure from the standpoint of balancing reward for innovation with the sustainability of the National Health Insurance system. This rule lowers prices by up to 25.0 percent for drugs with annual sales of ¥100.0-150.0 billion and more than 1.5 times the original forecast, and lowers prices by up to 50.0 percent for drugs with annual sales exceeding ¥150.0 billion and more than 1.3 times the original forecast. In addition, the prices of drugs that have pharmacological action similar to a drug subject to the special repricing rule and were comparator drugs at the time of the NHI price listing are reduced by the same rate. In 2016, four active ingredients and six products, including Avastin, were subject to the additional repricing rule. In fiscal 2018, two active ingredients and four products were subject to the rule. In the NHI drug pricing system fundamental reforms of fiscal 2018, it was decided to use the NHI listing of new drugs that takes place four times a year as an opportunity for repricing under this scheme.

Premium to Promote the Development of New Drugs and Eliminate Off-Label Use
As part of the NHI drug pricing system reforms of fiscal 2010 (the year ended March 2011), a new pricing scheme was implemented on a trial basis to promote the creation of innovative medical products and solve the drug lag3 problem. In this scheme, at the time of the NHI drug price revisions, prices are maintained on drugs for which no generics are available (provided that they have been in the NHI price list for no more than 15 years), and which satisfy certain conditions.

This premium pricing for new drugs was continued on a trial basis in subsequent NHI drug pricing system reforms. However, in the NHI drug pricing system fundamental reforms of fiscal 2018, the decision was made to revise the requirements for companies and products and list them in the drug repricing rules.

Companies that do not respond appropriately to development requests from MHLW will continue to be excluded from eligibility for premium pricing. In addition, indicators have been set for (A) creation of innovative drugs, (B) drug lag countermeasures, and (C) development of novel drugs ahead of other countries, and the pricing premiums may vary according to the level of achievement or fulfillment of these indicators. Healthcare-related ventures are expected to play an important role in the creation of innovative

Response to Requests from the MHLW Review Committee on Unapproved Drugs and Indications with High Medical Needs
(As of February 1, 2019)

<table>
<thead>
<tr>
<th>Development request</th>
<th>Product</th>
<th>Indication</th>
<th>Development status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xeloda</td>
<td>Advanced or recurrent gastric cancer</td>
<td>Approved in February 2011</td>
<td></td>
</tr>
<tr>
<td>Tarceva</td>
<td>Advanced or recurrent pancreatic cancer</td>
<td>Approved in July 2011</td>
<td></td>
</tr>
<tr>
<td>Avastin</td>
<td>Advanced or recurrent breast cancer</td>
<td>Approved in September 2011</td>
<td></td>
</tr>
<tr>
<td>CellCept</td>
<td>Pediatric renal transplant</td>
<td>Approved in September 2011</td>
<td></td>
</tr>
<tr>
<td>Herceptin</td>
<td>Q3W dosage metastatic breast cancer overexpressing HER2</td>
<td>Approved in November 2011</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neoadjuvant breast cancer overexpressing HER2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kytril</td>
<td>Gastrointestinal symptoms associated with radiotherapy</td>
<td>Approved in December 2011</td>
<td></td>
</tr>
<tr>
<td>Pulmozyme</td>
<td>Improvement of pulmonary function in patients with cystic fibrosis</td>
<td>Approved in March 2012</td>
<td></td>
</tr>
<tr>
<td>Bactramin</td>
<td>Treatment and prevention of pneumocystis pneumonia</td>
<td>Approved in August 2012</td>
<td></td>
</tr>
<tr>
<td>Avastin</td>
<td>Ovarian cancer</td>
<td>Approved in November 2013</td>
<td></td>
</tr>
<tr>
<td>Copegus</td>
<td>Improvement of viraemia associated with genotype 3 chronic hepatitis C or compensated cirrhosis related to hepatitis C when administered in combination with sofosbuvir</td>
<td>Approved in March 2017</td>
<td></td>
</tr>
<tr>
<td>Xeloda</td>
<td>Adjuvant chemotherapy in rectal cancer</td>
<td>Approved in August 2016</td>
<td></td>
</tr>
<tr>
<td>Avastin</td>
<td>Additional Q2W dosage and administration for ovarian cancer</td>
<td>Submitted company opinion and waiting for evaluation by committee</td>
<td></td>
</tr>
<tr>
<td>Neutrogin</td>
<td>Combination therapy with chemotherapy including fludarabine for relapsed/refractory acute myeloid leukemia</td>
<td>Submitted company opinion and waiting for evaluation by committee</td>
<td></td>
</tr>
</tbody>
</table>

---

As of February 1, 2019
The aim of these investigations is to promote the development of those drugs in Japan.

In February 2010, MHLW established the Review Committee on Unapproved Drugs and Indications with High Medical Needs. This committee evaluates the medical necessity and the appropriateness of usage that are innovative or useful (limited to the top three first-in-class drugs within three years from listing).

In fiscal 2018, 314 active ingredients and 560 products qualified for premium pricing (publicly announced).

Among new drugs subject to premium pricing, including those for which generics (including biosimilars) have been launched or 15 years have elapsed since their drug price listing, the cumulative amount of premium pricing is deducted from the NHI drug price in the subsequent initial drug price revision. Furthermore, a reduction or other adjustment due to the actual market price of the new drug during the fiscal year is made to the NHI drug price less the cumulative amount.

Solving the Drug Lag Problem
In January 2005, MHLW established the Investigational Committee for Usage of Unapproved Drugs as one means of helping solve the drug lag problem. The committee is charged with investigating the clinical necessity and the appropriateness of usage of drugs already approved in Europe and the United States, but not yet approved in Japan.

In fiscal 2018, 314 active ingredients and 560 products qualified for premium pricing (publicly announced).

Among new drugs subject to premium pricing, including those for which generics (including biosimilars) have been launched or 15 years have elapsed since their drug price listing, the cumulative amount of premium pricing is deducted from the NHI drug price in the subsequent initial drug price revision. Furthermore, a reduction or other adjustment due to the actual market price of the new drug during the fiscal year is made to the NHI drug price less the cumulative amount.

Annual Drug Price Survey and Annual NHI Drug Price Revision
Due to the growing public financial burden of the current situation, in which drug prices are maintained for up to two years even if the market price declines, it was decided in the NHI drug pricing system fundamental reforms of fiscal 2018 that drug price surveys and drug price revisions will be carried out even in interyear when there would ordinarily be no price revisions. Fiscal 2018 and fiscal 2020 (the year ending March 2021) are price revision years even under the current system, and it is expected that a price revision will be implemented in conjunction with the consumption tax rate increase in October 2019. Therefore, the interyear price revision under the new rules will take place starting from fiscal 2021 (the year ending March 2022). The scope of items subject to interyear price revisions will be deliberated by the Central Social Insurance Medical Council (Chuikyo) and other organizations.

Creation of a System for Cost-Effectiveness Assessments
A system of price adjustments based on cost-effectiveness assessments has been approved by Chuikyo, and will be implemented starting in April 2019. The system primarily applies to products that meet the requirements of the selection criteria at the time of their NHI price listing. Cost-effectiveness assessments will be conducted for a certain period after the listing, and the price will be adjusted according to the results. The extent of the price adjustment is the portion corresponding to the amount of the corrective premium for usefulness applied at the time of the drug’s initial pricing (for products with a degree of disclosure under 50 percent, as calculated by the cost calculation method, the portion corresponding to operating profit is also subject to adjustment). Price adjustments will be made according to the incremental cost-effectiveness ratio (ICER). The corrective premium will be maintained if the ICER is less than ¥5 million (less than ¥7.5 million for anticancer agents), but will be reduced in stages by up to 90 percent if the ICER is ¥5 million or more. The price adjustment will be limited to 10-15 percent of the total drug price.

4. The ICER indicates the extent to which additional investment would be necessary to obtain the additional benefit from replacing existing drug (technology) B with new drug A.
Leading Cause of Death in Japan
Cancer has been the single most common cause of death in Japan since 1981. In 2017, 373,334 people died of cancer, accounting for 27.9 percent of all deaths in that year and the highest number since government surveys began in 1899.

Establishment of the Basic Act for Anticancer Measures and Improvement in the Healthcare Environment
The Cancer Control Act was enacted in June 2006 to establish a system so that patients can receive appropriate treatment based on scientific knowledge regardless of the region in which they reside and with respect paid to their wishes, as well as to implement the Basic Plan to Promote Cancer Control Programs (the “Basic Plan”). Since the enactment of the Cancer Control Act, significant results have been obtained, including establishment of designated cancer hospitals and a reduction of the cancer mortality rate and improvement of the five-year survival rate owing to advances in cancer treatment. The goal of reducing the age-adjusted cancer mortality by 20 percent over the 10-year period from fiscal 2007 was judged difficult to achieve, and therefore, in December 2015, the Plan for Acceleration of Cancer Control Programs was formulated. This plan specified concrete measures that should be implemented intensively in a short period of time.

In recent years, it has become apparent that new measures are necessary to fight rare cancers, difficult-to-treat cancers, childhood cancers, and cancers in adolescents and young adults (AYA) to promote new treatments such as genomic medicine; and to address societal problems including employment. The principles of the Cancer Control Act revised in 2016 require that the national goal of 30 percent reduction in cancer mortality rates and improvement of survival rates make effective use of healthcare and welfare resources and implement cancer control measures from the viewpoint of serving the public in order to achieve the stated goal of creating a society in which cancer patients can live with peace of mind and dignity. In the 3rd Basic Plan to Promote Cancer Control Programs released in March 2018, measures are being implemented based on three pillars – cancer prevention, cancer medical care and research, and coexistence with cancer – to educate the public, including patients, about cancer and help them to overcome it.

Changes in Treatment Methods
Cancer treatment is increasingly being based on a multidisciplinary approach that combines surgery, radiation therapy and chemotherapy. In particular, the field of anticancer agents is evolving, and highly innovative medicines such as molecular targeted drugs have been introduced. This has brought a dramatic improvement in treatment outcomes in colorectal, lung and breast cancer, gynecological cancers, kidney cancer, brain tumors, malignant melanoma, hematological malignancy and other forms of cancer.

Advances are being made in personalized healthcare, which involves testing patients with companion diagnostics when administering molecular targeted drugs to identify patients who are likely to benefit with minimal strain on the body and few side effects. In addition to enabling physicians to propose the optimal treatment tailored to each patient, this approach offers a number of other benefits. For example, it can reduce national healthcare expenditures by reducing the administration of drugs when their effect cannot be determined. When performing a diagnosis, there may be a number of different molecular targeted drugs available for the same disease, and there are some cases in which looking at the molecules expressed in the target tissues is insufficient for diagnosis; therefore, it is also becoming important to conduct exhaustive biomarker measurements such as multiplex testing and gene panel testing using next-generation sequencing. Moreover, the MHLW and pharmaceutical industry organizations have been setting up a framework to promote the realization of genomic medicine, starting with the Council to Promote the Realization of Genomic Medicine, which was established by the Japanese government in January 2015. The provision of optimal treatments based on each patient’s genetic profile is thus becoming a reality.

In addition, cancer immunotherapy, which takes advantage of the body’s own immune cells to fight cancer, is another important emerging field of treatment. Immune checkpoint inhibitors, one type of immunotherapy now in use, are a promising new direction in cancer treatment. Cancer has the ability to suppress immune functions to avoid attack from the immune system. By blocking the immune “brakes” (the binding of PD-1 to PD-L1) known as the immune checkpoint, immune cells can be awakened to attack cancer cells. In clinical trial results, immune checkpoint inhibitors have shown promise for long-term survival and cure, even in advanced cancer. Expectations are rising for their high therapeutic efficacy and potential for treating a wide range of cancers. On the other hand, some patients do not respond to cancer immunotherapy, so screening to select patients for whom this therapy is likely to be effective and combination therapy with existing anticancer agents are also being examined.

Avastin (RG435)
Anti-VEGF humanized monoclonal antibody (Generic name: bevacizumab)
Launch in Japan: June 2007

Basic Information
Avastin is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). It is the first therapeutic agent in the world that inhibits angiogenesis (the growth of the network of blood vessels that supply nutrients and oxygen to the cancer). Unlike conventional anticancer agents that act directly on cancer cells, Avastin acts on the cancer microenvironment. In Japan, Avastin was launched in 2007 for the treatment of unresectable advanced or recurrent colorectal cancer. In 2009, Chugai obtained approval for a new dosage and administration for colorectal cancer and the additional indication of unresectable advanced or recurrent non-squamous non-small cell lung cancer (NSCLC), followed in 2011 by inoperable or recurrent

Projected Cancer Incidence (2018)

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Incidence (Thousands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All cancers</td>
<td>1,014</td>
</tr>
<tr>
<td>Colon/rectum</td>
<td>152</td>
</tr>
<tr>
<td>Stomach</td>
<td>129</td>
</tr>
<tr>
<td>Lung</td>
<td>125</td>
</tr>
<tr>
<td>Breast (women)</td>
<td>78</td>
</tr>
<tr>
<td>Liver</td>
<td>40</td>
</tr>
<tr>
<td>Pancreas</td>
<td>87</td>
</tr>
<tr>
<td>Others</td>
<td>40</td>
</tr>
</tbody>
</table>

Source: National Cancer Center Cancer Information Service, “Cancer Registries/Statistics”

Note: Projections were performed with a model incorporating age, calendar year at diagnosis, and their interactions as independent variables, utilizing frequency of incidence of cancer by age bracket from Monitoring of Cancer Incidence in Japan (1975-2014 nationwide estimates) and cancer mortality figures from the Outline of Vital Statistics (1975-2016 estimates). The total may not add up because projections have been performed by cancer type and figures have been rounded.

breast cancer. Chugai also obtained approval for the additional indications of malignant glioma and ovarian cancer in 2013, and advanced or recurrent cervical cancer in May 2016.

Review of 2018 Performance
Sales of Avastin increased ¥2.5 billion, or 2.7 percent, year on year to ¥95.6 billion. Avastin has built a solid position in the treatment of colorectal cancer and lung cancer, but the competitive environment in the field of lung cancer has been changing due to the introduction of immune checkpoint inhibitors and other products. On the other hand, the use of Avastin for other indications, including breast cancer, has increased steadily. Phase III multinational studies in combination with Tecentriq in renal cell carcinoma and hepatocellular carcinoma patients are under way.

**Herceptin**

**Anti-HER2 humanized monoclonal antibody**
(Generic name: trastuzumab)
Launch in Japan: June 2001

**Basic Information**

Herceptin is a humanized monoclonal antibody that targets human epidermal growth factor receptor type 2 (HER2), which contributes to tumor cell growth. The earliest PHC-based anticancer agent, Herceptin has built a solid reputation as an essential treatment for HER2-positive breast cancer since its launch in 2001.

Overexpression of HER2 is found in about 20 percent of breast cancers. Such cancer is diagnosed as HER2-positive. HER2-positive breast cancer progresses rapidly, and has been associated with a poor prognosis. However, treatment outcomes have improved significantly with the emergence of Herceptin and other medicines that target HER2. In 2011, Herceptin obtained approval for the additional indication of advanced or recurrent gastric cancer overexpressing HER2, not amenable to curative resection, bringing personalized healthcare to the field of gastric cancer.

**Review of 2018 Performance**

Sales of Herceptin decreased ¥5.5 billion, or 16.4 percent, year on year to ¥28.1 billion. The decrease was mainly due to the substantial NIH drug price revision (~20.4 percent) that resulted from the return of the premium for new drug creation. Widely used in first-line treatment of HER2-positive advanced or recurrent breast cancer in combination with Perjeta, Herceptin is also used for more than 90 percent of lymph-node positive patients undergoing postoperative (adjuvant) chemotherapy for HER2-positive breast cancer. For gastric cancer, although Herceptin maintained its established position in first-line treatment, sales decreased slightly due to competition in second-line treatment.

2. A diagnostic test can determine if a patient's breast or gastric cancer cells have overexpression of a protein called HER2. Herceptin, Perjeta and Kadcyla target HER2 and are administered only to patients whose tumors are identified as HER2-positive.

**Perjeta (RG1273)**

HER2 dimerization inhibitory humanized monoclonal antibody
(Generic name: pertuzumab)
Launch in Japan: September 2013

**Basic Information**

Perjeta is a humanized monoclonal antibody and is the first molecular targeted therapy that inhibits the dimerization of HER2. The combination of Perjeta and Herceptin, which also targets HER2, provides a more comprehensive blockade of HER signaling pathways associated with the proliferation of tumor cells. Chugai launched Perjeta for the indication of HER2-positive inoperable or recurrent breast cancer in September 2013, after obtaining approval in June 2013. In 2018, Perjeta obtained approval for the additional indication of neoadjuvant and adjuvant therapy for HER2-positive breast cancer.

**Review of 2018 Performance**

Sales of Perjeta increased ¥2.5 billion, or 18.4 percent, year on year to ¥16.1 billion, exceeding projections. In the clinical practice guidelines for breast cancer, which were updated in July 2016, the combination therapy of Herceptin and Perjeta with docetaxel was the only therapy to receive a Grade A recommendation as a first-line therapy for HER2-positive metastatic or recurrent breast cancer, and uptake as a first-line treatment was steady. In addition, a phase III multinational study is underway for RG6264 (subcutaneous injection), a fixed-dose combination of Herceptin and Perjeta, for the potential treatment of HER2-positive breast cancer.

**Kadcyla (RG3502)**

Anti-HER2 antibody-tubulin polymerization inhibitor conjugate
(Generic name: trastuzumab emtansine)
Launch in Japan: April 2014

**Basic Information**

Kadcyla is an antibody-drug conjugate of the anti-HER2 humanized monoclonal antibody trastuzumab (product name: Herceptin) and the potent chemotherapeutic agent DM1, joined together with a stable linker. Chugai filed an application for approval for the treatment of HER2-positive inoperable or recurrent breast cancer in January 2013, obtained approval in September 2013 after priority review, and launched the product in April 2014.

**Review of 2018 Performance**

Sales of Kadcyla increased ¥0.5 billion, or 6.3 percent, year on year to ¥48.5 billion. Kadcyla is used as a second-line treatment in patients whose cancer worsened in first-line treatment with Herceptin and Perjeta plus a chemotherapeutic agent. In development, a phase III multinational study for the potential treatment of HER2-positive breast cancer (adjuvant) is under way.

**Rituxan**

Anti-CD20 monoclonal antibody
(Generic name: rituximab)
Launch in Japan: September 2001

**Basic Information**

Rituxan is a monoclonal antibody targeting the CD20 antigen found on the surface of lymphocytes. As a standard therapy for CD20-positive B-cell non-Hodgkin's lymphoma (hematological cancer), it has substantially improved clinical outcomes in combination with chemotherapy or in monotherapy. In Japan, Rituxan is marketed jointly by Chugai and Zenyaku Kogyo Co., Ltd. In recent years,
Extensive Contribution to Cancer Treatment (Breast Cancer)

- **Antimetabolites**
  - Xeloda
  - Neutrogin

**Xeloda**
Antimetabolite, 5-FU derivative
(Generic name: capecitabine)
Launch in Japan: June 2003

**Neutrogin**
Recombinant human granulocyte colony-stimulating factor (G-CSF)
(Generic name: lenograstim; overseas product name: Granocyte)
Launch in Japan: December 1991

**Molecular targeting therapy**
- Herceptin
- Perjeta
- Kadcyla
- Avastin

**Extensive Contribution to Cancer Treatment (Breast Cancer)**

### Treatment of breast cancer

- Early breast cancer
  - Neoadjuvant
  - Operation
  - Adjunct
- Advanced/metastatic breast cancer
  - Hormone therapy
  - Chemotherapy
- Supportive care

**Herceptin**
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
(Generic name: trastuzumab)
Launch in Japan: June 2001

**Perjeta**
Molecular targeting therapy
(Generic name: pertuzumab)
Launch in Japan: March 2018

**Kadcyla**
Molecular targeting therapy
(Generic name: ado-trastuzumab emtansine)
Launch in Japan: December 2020

**Avastin**
Molecular targeting therapy
(Generic name: bevacizumab)
Launch in Japan: May 2007

**Tarceva**
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
(Generic name: erlotinib)
Launch in Japan: December 2007

**Basic Information**
- **Alecsena**
  - ALK inhibitor
  - Launch in Japan: September 2014

**Antimetabolites**
Xeloda is a 5-fluorouracil (5-FU) anticancer agent developed at the research laboratories of Chugai's product name: Granocyte.

**Supportive care**
- Neutrogin

**Review of 2018 Performance**
Sales of Xeloda increased ¥0.3 billion, or 2.5 percent, year on year to ¥12.5 billion. Backed by Chugai's initiatives to promote adverse drug reaction management, Xeloda has obtained approval for the additional indication of pancreatic cancer not amenable to curative resection.
Gazyva (GA101/RG7159)
Glycoengineered type II anti-CD20 monoclonal antibody
(Generic name: obinutuzumab)
Launch in Japan: August 2018

Basic Information
Gazyva is a glycoengineered type II monoclonal antibody in-licensed from Roche that, like Rituxan, targets CD20. A study that directly compared its efficacy and safety with Rituxan, currently the most widely used monoclonal antibody, in patients in Japan and overseas (the GALLIUM study) was stopped early for benefit after positive results were reported. Gazyva obtained approval for the treatment of CD20-positive B-cell follicular lymphoma in July 2018, and was launched in August 2018. In November 2012, Chugai entered into an agreement with Nippon Shinyaku Co., Ltd. to co-develop and co-market this agent in Japan.

Review of 2018 Performance
Sales of Gazyva after its launch in August 2018 were ¥6.6 billion.

GC33 (RG7686) Development project
Anti-glypican-3 humanized monoclonal antibody
(Generic name: codrituzumab)
GC33, a humanized monoclonal antibody created by Chugai, targets glypican-3 (GPC3), which is specifically expressed in hepatocellular carcinoma. GC33 did not meet the primary endpoint in a phase II multinational monotherapy study started in March 2012. A phase I clinical study for the potential treatment of hepatocellular carcinoma in combination with Tecentriq has been under way since August 2016, and the study results were presented at the European Society of Medical Oncology (ESMO) 2018 Congress.

ERY974 Development project
Anti-glypican-3/CD3 bispecific antibody
ERY974 is the first T-cell redirecting antibody (TRAB) developed by Chugai. TRAB is a bispecific antibody that creates a short bridge between CD3 on T cells and tumor antigen on tumor cells to activate T cells in a tumor antigen-dependent manner, and is expected to demonstrate strong cytotoxicity against tumor cells. GPC3, a tumor antigen targeted by ERY974, is reported to be expressed in multiple types of tumor cells including hepatocellular carcinoma, gastric cancer and esophageal cancer. A phase I clinical study started overseas in August 2016.

RG7596 Development project
Anti-CD79b antibody-drug conjugate
(Generic name: polatuzumab vedotin)
RG7596 is an antibody-drug conjugate of an anti-CD79b monoclonal antibody and the microtubule inhibitor MMAE, joined together with a linker. In-licensed from Roche, the conjugate is designed to deliver MMAE directly into B cells via CD79b, which is expressed on B cells, so that the inhibitor can act. To demonstrate a cytostatic effect on tumor cells, a phase III multinational study for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) started in November 2017, and a phase II clinical study for the treatment of relapsed or refractory DLBCL started in Japan in October 2018.

CK127 Development project
Raf/MEK inhibitor
(CG127, Generic name: ipatasertib)
CK127 is a Raf and MEK dual inhibitor created by Chugai. Phase I clinical studies in Japan and overseas have been completed. Multiple investigator-initiated clinical studies (as monotherapy and in combination therapy) are ongoing in the United Kingdom and the United States, and study results were announced at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO). A presentation of summary results is planned at the International Congress on Targeted Anticancer Therapies (TAT) in 2019.

RG7421 Development project
MEK inhibitor
(Generic name: cobimetinib)
RG7421 is a MEK inhibitor in-licensed from Roche. Chugai started a phase I clinical study for the treatment of solid tumors in Japan in July 2017.

CEA-TCB (RG7802) Development project
Anti-CEA/CD3 bispecific antibody
(Generic name: cibisatamab)
CEA-TCB, a bispecific antibody in-licensed from Roche, is expected to activate T-cells and attack tumor cells by cross-linking CD3 on T-cells to carcinoembryonic antigen (CEA) on tumor cells. With a novel structure engineered to bind simultaneously with one arm to CD3 on T-cells and two arms to CEA on tumor cells, it exhibits higher tumor selectivity and stronger binding to CEA. CEA is reported to be overexpressed in a variety of cancers, including colorectal cancer.

CEA-TCB-mediated intra-tumor T-cell proliferation may yield efficacy in tumor types that are not responsive to current cancer immunotherapies because there are few T-cells in the tumor. In addition, combination immunotherapy of CEA-TCB with Tecentriq is expected to yield a potent antitumor effect
in various CEA-positive cancers by inducing further T-cell activation. Chugai started a phase I clinical study of CEA-TCB for the treatment of solid tumors in Japan in January 2018.

**CD20-TDB (RG7828)** Development project

Anti-CD20/CD3 bispecific antibody (Generic name: mosunetuzumab)

CD20-TDB is a bispecific antibody in-licensed from Roche. Similar to CEA-TCB, it is expected to activate T cells and attack tumor cells by cross-linking CD3 on T cells to CD20 on B cells. Chugai started a phase I clinical study for the treatment of hematologic tumors in Japan in March 2018.

**ROG6268 Development project**

ROS1/TRK inhibitor (Generic name: entrectinib)

RG6268, in-licensed from Roche, is an orally bioavailable CNS-active tyrosine kinase inhibitor that potently and selectively inhibits the ROS1 and TRK family, and also acts on brain metastases. Targeting NTRK fusion gene-positive solid tumors, RG6268 has been granted breakthrough therapy designation in the United States, PRLityMCedicines (PRIME) designation in the EU, and Sakigake designation in Japan. Chugai filed an application for approval for the treatment of NTRK fusion gene-positive solid tumors in December 2018.

**Bone and Joint Diseases/Autoimmune Diseases**

### Osteoporosis

Osteoporosis is a disease in which the bones become weak due to advanced age or other factors, increasing the risk of fractures. Osteoporosis patients may incur fractures through normal daily activities. Among these, compression fractures of the spine and femoral neck fractures can decrease quality of life by leaving patients bedridden and can also increase mortality risk. About 13 million people in Japan suffer from osteoporosis. However, the treatment rate stands at around only 20 percent of the estimated number of sufferers because there are usually no symptoms until a fracture occurs. The availability of superior new drugs that have higher efficacy, safety and convenience has brought promise for improvement in the quality of life of patients.

#### Treatment Methods

Osteoporosis drug therapies include active vitamin D derivatives, which improve bone metabolism, bisphosphonates, which are bone resorption inhibitors, an anti-RANKL antibody, selective estrogen receptor modulators (SERMs), and human parathyroid hormone (PTH), which is a bone formation agent.

#### Regulatory Trends

National prevention and treatment guidelines for osteoporosis were revised in October 2006. Subsequently, advances have been made in basic and clinical research into osteoporosis, evaluation of fracture risk and criteria for the initiation of drug treatment have been reviewed; and osteoporosis caused by lifestyle-related diseases has been addressed. In the interim, Edirol and other medicines have been approved for insurance coverage. Revisions issued in December 2011 added preventive and diagnostic items in light of the importance of early prevention to broaden the overall scope of osteoporosis treatment. Since then, the 2012 revised diagnostic criteria for primary osteoporosis and management and treatment guidelines for steroid-induced osteoporosis have been adopted. Bonviva IV Injection and other medicines have been launched and covered by insurance, and revised guidelines were issued in July 2016.

### Osteoporosis Market in Japan

(Billions of yen)

<table>
<thead>
<tr>
<th>Year</th>
<th>Selective estrogen receptor modulators (SERMs)</th>
<th>Bisphosphonates</th>
<th>Vitamin D</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>2010</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>2011</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>2012</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>2013</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>2014</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>2015</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>2016</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>2017</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>2018</td>
<td>200</td>
<td>200</td>
<td>200</td>
</tr>
</tbody>
</table>

Copyright © 2019 IQVIA. Reprinted with permission.

The scope of the market is defined by Chugai.

Recently, an osteoporosis liaison service (OLS) initiated by the Japan Osteoporosis Society was introduced for the purpose of preventing osteoporosis and inhibiting bone fractures by coordinating the efforts of various healthcare professionals, including doctors, nurses, pharmacists and physical therapists. Medical staff involved in liaison and possessing extensive knowledge related to osteoporosis are called osteoporosis managers. This education program has been ongoing since 2012, and more than 2,400 osteoporosis managers were active as of April 2018.

**Edirol**

Active vitamin D derivative (Generic name: eldecalcitol)

Launch in Japan: April 2011

**Basic Information**

Edirol, a vitamin D3 preparation born out of Chugai’s many years of research in vitamin D, is an agent that improves bone metabolism in addition to calcium metabolism. Chugai started sales of Edirol in April 2011 as the successor drug to Alfarol for the indication of osteoporosis. Under an agreement signed in May 2008, Edirol has been co-developed and is currently co-marketed with Taisho Pharmaceutical Co., Ltd. Clinical trials have confirmed that Edirol has a similar safety profile to alfalcacidol with a statistically significant greater effect in preventing fractures. In the 2015 osteoporosis prevention and treatment guidelines, Edirol received a Grade A recommendation, the only one for an active vitamin D3 preparation, for its effectiveness in increasing bone density and preventing vertebral fractures.

**Review of 2018 Performance**

Sales of Edirol increased ¥3.3 billion, or 11.1 percent, to ¥32.9 billion. It has become the most widely used active vitamin D3 preparation because of its superior efficacy in increasing bone mass and preventing fractures compared with existing products. Recognition and understanding of Edirol as a
Rheumatoid Arthritis Market in Japan

(Billions of yen)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Biologics</td>
<td>100</td>
<td>150</td>
<td>200</td>
<td>250</td>
<td>300</td>
<td>350</td>
<td>400</td>
<td>450</td>
<td>500</td>
<td>550</td>
</tr>
<tr>
<td>Nonsteroidal anti-inflammatory analgesics</td>
<td>50</td>
<td>75</td>
<td>100</td>
<td>125</td>
<td>150</td>
<td>175</td>
<td>200</td>
<td>225</td>
<td>250</td>
<td>275</td>
</tr>
<tr>
<td>Others</td>
<td>150</td>
<td>225</td>
<td>300</td>
<td>375</td>
<td>450</td>
<td>525</td>
<td>600</td>
<td>675</td>
<td>750</td>
<td>825</td>
</tr>
</tbody>
</table>

Changes in Rheumatoid Arthritis Drug Therapy

<table>
<thead>
<tr>
<th>Decade</th>
<th>1970s</th>
<th>1980s</th>
<th>1990s</th>
<th>2000s</th>
<th>2003 and after</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutic Aim</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain relief</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Halt progression of joint destruction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remission</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-inflammatory drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsteroidal anti-inflammatory analgesics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adrenocortical hormone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biological DMARDs (bDMARDs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Targeted synthetic DMARDs (tsDMARDs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

With the advent of biologics, the aim of therapy for rheumatoid arthritis has shifted to achieving and maintaining remission.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic disease characterized by painful inflammation and deformation of joints leading to dysfunction. Without appropriate treatment, the patient’s condition deteriorates over time. There are currently an estimated 700,000 to 800,000 patients in Japan suffering from RA, of whom some 330,000 are currently receiving drug treatment. The aging of the patient population has also become a problem in recent years. On the other hand, there are only about 8,000 patients in Japan with juvenile idiopathic arthritis (JIA), a form of RA suffered by children under 16 years of age.

Treatment Methods and Market Conditions

In drug therapy for RA, the introduction of biologics has made high remission rates a realistic treatment goal. Research in recent years suggests that the administration of biologics at the early onset stage is effective in inhibiting bone and joint damage. The global market for these agents is forecast to reach $56.7 billion* by 2024. The market continues to change, and the range of treatment options for RA is expanding. In 2013, biological DMARDs, a new class of oral drugs, were launched in the United States and Japan, and in 2014, a biosimilar was launched in Japan after previously being launched in Europe.

Systemic juvenile idiopathic arthritis (sJIA) accounts for 30 to 40 percent of all JIA cases, but steroids, the main treatment for sJIA, can cause growth impairment and other adverse reactions. Consequently, the approval and launch of Actemra in April 2008 provided a significant advance in therapy.

* Source: Evaluate Pharma

Regulatory Trends

In November 2018, MHLW released an update of the Report of the Rheumatism and Allergy Countermeasure Committee, which was previously issued in 2005 and 2011. To maximize long-term quality of life of RA patients through appropriate treatment that controls disease activity, and to provide comprehensive support in daily life at workplaces and schools, and for life events such as pregnancy and childbirth, the report calls for (1) enhancement of medical service systems; (2) improvement of the patient environment, including consultation opportunities and access to information, and (3) promotion of research and development and other activities. In Europe, revised treatment recommendations in 2013 added Actemra and Abatacept to the biologic drugs recommended in first-line therapy, which were previously limited to anti-TNF agents. In 2015, a proposed update of clinical practice guidelines was announced at the American College of Rheumatology, with biologics including Actemra added as first-line therapy along with anti-TNF agents. Moreover, the updated European League Against Rheumatism (EULAR) recommendations that were
Announced in June 2016, state the superiority of biologics in interleukin-6 (IL-6) inhibitor therapy in cases where MTX and other therapies cannot be used.

**Castlemann's Disease**

Castlemann's disease is a lymphoproliferative disease characterized by symptoms such as systemic lymphadenopathy, fever, and general fatigue, as well as various abnormal laboratory test values including anemia, hypergammaglobulinemia and hypoaalbuminemia. It has been confirmed that these manifestations result from the excessive production of IL-6, one of the cytokines that cause inflammation. Castlemann's disease is very rare, affecting approximately 1,500 people in Japan.

**Large-Vessel Vasculitis**

Large-vessel vasculitis belongs to a group of autoimmune diseases called vasculitis syndromes. It refers to vasculitis in the aorta and the major aortic branches to the limbs and head and neck, and includes Takayasu arteritis and giant cell arteritis (temporal arteritis).

Takayasu arteritis leads to inflammation of the aortic arch and its branch vessels. It affects women more than men, at a ratio of 9:1, and age of onset is between 20 and 50 years. It occurs most commonly in Asia, including Japan, and the Middle East. Initial symptoms are reduced head and cerebral blood flow-related conditions, primarily dizziness, lightheadedness and headaches, as well as neck pain, chest pain and vascular pain along the limb arteries.

Giant cell arteritis is a granulomatous vasculitis occurring primarily in the aorta and aortic branches, mainly the temporal arteries. It also affects women more than men, at a ratio of 1.6:1, and the age of onset is 55 years or older. It occurs most commonly in Western countries and is rare in Japan. Common initial symptoms include headache, systemic conditions such as fever, and loss of vision.

**Systemic Sclerosis**

Systemic sclerosis (SSc) is a rare, chronic disorder characterized by blood vessel abnormalities, as well as degenerative changes and scarring in the skin, joints and internal organs. The incidence rate of SSc is difficult to measure, but it is estimated to affect approximately 2.5 million people worldwide, and has the highest fatality rate of any rheumatic disease.

**Actemra (MRA/RG1569)**

Humanized anti-human IL-6 receptor monoclonal antibody
(Generic name: tocilizumab)
Launch in Japan: June 2005

**Basic Information**

Actemra, created by Chugai and the first therapeutic antibody originating in Japan, blocks the activity of IL-6, a type of cytokine. It was launched in Japan in June 2005 as a treatment for Castlemann's disease. In April 2008, Chugai obtained approval in Japan for the additional indications of RA, polyarticular juvenile idiopathic arthritis (pJIA) and sJIA. In May 2013, Chugai launched a new subcutaneous formulation that improves convenience for patients in addition to the existing drip infusion formulation. This subcutaneous formulation includes the first auto-injector in the Japanese RA market.

Actemra is marketed globally through Roche. In Europe, where the medicine is known as RoActemra, sales for the treatment of RA started in 2009. Chugai’s marketing subsidiary co-promotes RoActemra with Roche in the United Kingdom, France and Germany. In the United States, Actemra obtained approval in January 2010 for the treatment of adult patients with moderate to severe active RA who have had an inadequate response to one or more TNF antagonist therapies, and obtained approval in October 2012 as a first-line biologic treatment. In Taiwan and South Korea, where Chugai has marketing rights, Actemra obtained approval in July 2011 and April 2012, respectively. Following its launch in Japan, the subcutaneous formulation obtained approval in the United States in October 2013 and in Europe in April 2014, and has been launched in both markets. RoActemra was also approved for early RA in Europe in September 2014.

Furthermore, Actemra obtained approval for the additional indication of treatment of sJIA in the United States in April 2011 and in Europe in August 2011. Actemra also received breakthrough therapy designation from the U.S. FDA in 2016 as a treatment for giant cell arteritis. In Japan, it became possible in June 2017 to reduce the dose interval of Actemra from two weeks to one week in patients with an inadequate response to use of the subcutaneous formulation for RA. Actemra obtained approval in Japan for the additional indications of Takayasu arteritis and giant cell arteritis in August 2017.

**Review of 2018 Performance**

Sales of Actemra in Japan increased ¥5.1 billion, or 15.4 percent, to ¥38.2 billion. The increase continued to be driven by the strong growth of the subcutaneous formulation after Chugai obtained approval for an additional dosage and administration with a shorter dose interval of the subcutaneous formulation for RA, and for the additional indications of Takayasu arteritis and giant cell arteritis. Sales of the subcutaneous formulation accounted for more than 50 percent of the total.

Sales of Actemra outside Japan (including exports to Roche) increased ¥19.3 billion, or 32.5 percent, to ¥78.7 billion. Roche’s global sales increased 12.0 percent year on year with steady market penetration, including solid uptake of the subcutaneous formulation in all regions.

In development, Actemra obtained approval for the additional indication of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome in Europe in August 2018. In the United States, an autoinjector obtained approval as an additional formulation for the treatment of RA, giant cell arteritis, and sJIA and pJIA in November 2018.

**RG7845 Development project**

BTK Inhibitor
(Generic name: fenebrutinib)

RG7845 is an oral, small molecule Bruton's tyrosine kinase (BTK) inhibitor in-licensed from Roche. BTK, a non-receptor tyrosine kinase expressed in B cells and bone marrow, is involved in arthritis and joint destruction associated with RA. RG7845 is expected to improve RA symptoms because it selectively and reversibly binds to the BTK molecule, thereby having an inhibiting effect on its activity. A phase I clinical trial started in June 2017.

**Osteoarthritis**

The most common joint disease is osteoarthritis. It leads to degeneration of the cartilage in the joints and surrounding areas, causing joint pain and reduced mobility. The prevalence of this disease increases with age. Knee osteoarthritis is particularly common among women, and is reported to affect an estimated 30 percent of women in their fifties, 57 percent in their sixties, and 80 percent at 80 years of age or older.

Academic societies have been aggressively promoting research, diagnosis and treatment of osteoarthritis as an underlying cause of
“locomotive syndrome,” a term proposed in the field of orthopedics to designate the condition of individuals at high risk of suffering loss of motor function due to advanced age that leaves them requiring nursing care and bedridden.

The main drug therapies for osteoarthritis include non-steroidal anti-inflammatory analgesics, steroids and hyaluronic acid preparations, with intraarticular administration of hyaluronic acid preparations used as a treatment in the early and middle stages. Intraarticular administration of hyaluronic acid preparations has also demonstrated effectiveness in improving periarthritis of the shoulder and knee joint pain associated with rheumatoid arthritis.

### Renal Diseases

#### Renal Anemia

Complications of Renal Dysfunction

In dialysis patients and end-stage chronic kidney disease (CKD) patients, a key issue is treating the various complications of advanced renal dysfunction, such as renal anemia, secondary hyperparathyroidism, and abnormal calcium and phosphorus metabolism. Of these complications, renal anemia is one of the most frequent, occurring not only in renal disease patients undergoing dialysis but also in pre-dialysis CKD patients. Renal anemia is associated with reduced quality of life, and is also a factor in the progress of organ damage, including decreased cardiac function.

#### Number of Dialysis Patients in Japan

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of Patients (Thousands)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>310</td>
</tr>
<tr>
<td>2013</td>
<td>314</td>
</tr>
<tr>
<td>2014</td>
<td>320</td>
</tr>
<tr>
<td>2015</td>
<td>325</td>
</tr>
<tr>
<td>2016</td>
<td>330</td>
</tr>
<tr>
<td>2017</td>
<td>322</td>
</tr>
</tbody>
</table>

Source: Overview of Regular Dialysis Treatment in Japan (as of December 31, 2017) by Statistical Survey Committee, The Japanese Society for Dialysis Therapy


Erythropoiesis-Stimulating Agent (ESA)

Erythropoietin (EPO) is a hemopoietic factor produced mainly in the kidneys. It speeds up erythrocyte production using erythroid progenitor cells found in bone marrow. An erythropoiesis-stimulating agent (ESA) is effective in treating renal anemia caused primarily by the decline in EPO production due to CKD, and is thought to help improve quality of life. ESAs are currently used by approximately 80 percent of dialysis patients as well as by some pre-dialysis CKD patients with renal anemia. ESAs are thus an essential drug for the treatment of renal anemia.

### Flat-Sum Reimbursement System for ESAs

Since the 2006 revisions of medical fees, ESAs have been included in medical fee points for hemodialysis (artificial kidney). The integrated fee points are reviewed with each revision of medical fees, and were reduced in 2018, which has led to intensified price competition for ESAs in the dialysis market.

#### Review of 2018 Performance

Sales of Suvenyl decreased ¥1.0 billion, or 11.4 percent, to ¥7.8 billion, due to the impact from NHI drug price revisions and from competing products. In China, phase III clinical studies are under way for the potential treatment of knee osteoarthritis and shoulder periarthritis.

#### Basic Information

**Suvenyl**

Agent for joint function improvement  
(Generic name: sodium hyaluronate)  
Launch in Japan: August 2000

**Basic Information**

Suvenyl, a drug that improves joint function through injection into the joint cavity, is a high molecular weight sodium hyaluronate drug that alleviates knee osteoarthritis, shoulder periarthritis and knee joint pain caused by RA. With physical and chemical properties close to that of hyaluronic acid found in the body, Suvenyl has been recognized for its superior performance, including its anti-inflammatory and analgesic effects.

**Micrera**

Long-acting erythropoiesis-stimulating agent  
(Generic name: epoetin beta pegol)  
Launch in Japan: July 2011

**Basic Information**

Micrera is a drug that raises the stability of epoetin beta in the bloodstream through pegylation. It is a new type of renal anemia treatment with the longest serum half-life among ESAs, enabling stable and sustained control of hemoglobin. It stimulates erythropoiesis through a different interaction with the EPO receptor on burst-forming unit erythroid (BFU-E) cells in the bone marrow. Micrera was launched in Japan in July 2011 as a treatment for renal anemia. Outside Japan, Micrera obtained approval in Europe in 2007 and is currently sold in more than 100 countries, including the United States.

The serum half-life of Micrera is virtually the same for intravenous injection or subcutaneous administration, and the drug demonstrates efficacy in relieving the symptoms of anemia when administered at four-week intervals during the maintenance period. Consequently, it is expected to reduce the burden of hospital visits on patients with pre-dialysis CKD and to contribute to better treatment adherence. Furthermore, as a dialysis-related treatment, Micrera is expected to reduce the burden on medical staff and improve medical safety by dramatically reducing administration frequency. The product thus has the potential to expand the range of options for the treatment of renal anemia.

**Launch in Japan: July 2011**

**Modern Synthetic Hyaluronan**

Suvenyl, a drug that improves joint function through injection into the joint cavity, is a high molecular weight sodium hyaluronate drug that alleviates knee osteoarthritis, shoulder periarthritis and knee joint pain caused by RA. With physical and chemical properties close to that of hyaluronic acid found in the body, Suvenyl has been recognized for its superior performance, including its anti-inflammatory and analgesic effects.

**Basic Information**

**Launch in Japan: August 2000**

**Hydroxyethyl Starches**

with renal anemia. ESAs are thus an essential drug for the treatment of renal anemia.

**Basic Information**

Since the 2006 revisions of medical fees, ESAs have been included in medical fee points for hemodialysis (artificial kidney). The integrated fee points are reviewed with each revision of medical fees, and were reduced in 2018, which has led to intensified price competition for ESAs in the dialysis market.

**Flat-Sum Reimbursement System for ESAs**

Since the 2006 revisions of medical fees, ESAs have been included in medical fee points for hemodialysis (artificial kidney). The integrated fee points are reviewed with each revision of medical fees, and were reduced in 2018, which has led to intensified price competition for ESAs in the dialysis market.
**Alzheimer’s Disease**

Alzheimer’s disease (AD) is the most common form of dementia. Pathologically, it is a progressive neurodegenerative disease that causes neuron death in the brain and brain atrophy. It leads to a general and progressive loss of memory and other cognitive functions, which can interfere with daily life. While existing AD treatments have some effect in slowing disease progression by several months, they are unable to stop the neuron death, and a treatment for the underlying cause does not yet exist. Consequently, unmet medical need is high, and there is strong demand for a more effective drug.

**RG1450**

Anti-amyloid-beta human monoclonal antibody
(Generic name: gantenerumab)

RG1450 is an anti-amyloid-beta human monoclonal antibody in-licensed from Roche. The drug targets aggregate amyloid beta, with a high binding affinity to plaques in the brain. Phase III multinational studies of RG1450 as a potential treatment for AD began in June and July 2018.

**RG7412**

Anti-amyloid-beta humanized monoclonal antibody
(Generic name: crenezumab)

RG7412 is an anti-amyloid-beta humanized monoclonal antibody in-licensed from Roche. The drug targets all types of amyloid beta, with a high binding affinity to oligomers. It is expected to reduce cognitive deterioration by removing amyloid beta in the brain. A phase III multinational study of RG7412 as a potential treatment for AD is under way.

**Oxarol**

Agent for secondary hyperparathyroidism
(Generic name: maxacalcitol)
Launch in Japan: September 2000

Basic Information
Synthesized by Chugai, Oxarol is the first intravenous active vitamin D3 derivative agent in Japan. It treats secondary hyperparathyroidism, a result of conditions such as impaired vitamin D activation associated with renal dysfunction, by acting directly with high concentration on the parathyroid gland to control parathyroid hormone synthesis and secretion, and by acting to improve bone metabolism. With its short serum half-life, Oxarol shows efficacy and enables treatment in patients who previously could not be treated adequately with oral vitamin D3 derivatives due to the onset of hypercalcemia.

**EOS789**

Anti-IL-6 receptor humanized monoclonal antibody
(Generic name: satralizumab)

SA237, created by Chugai, is a next-generation therapeutic antibody that has shown success in blocking IL-6 receptors with a longer duration of action. Chugai created SA237 by applying its novel antibody technology (Recycling Antibody technology) that enables a single antibody molecule to block the target antigen repeatedly. As a result, a prolonged serum half-life has been demonstrated in clinical trials, and it is expected that a lower dosing frequency will be possible. Because IL-6 promotes the production of the anti-AQP4 antibodies that cause NMOSD, this drug is expected to improve (reduce recurrence of) the symptoms of these diseases as it inhibits the production of those antibodies by blocking the IL-6 signal. Two Chugai-sponsored phase III multinational studies in NMO and NMOSD patients achieved their primary endpoints. In addition to its designation as an orphan drug by the U.S. FDA, SA237 was also granted
orphan drug designation in Europe in 2016. Furthermore, in June 2016, Chugai concluded a license agreement that grants Roche exclusive rights for the development and marketing of SA237 worldwide, with the exception of Japan, South Korea and Taiwan. SA237 was granted breakthrough therapy designation by the FDA in December 2018 for the treatment of NMO and NMOSD.

### Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a fatal hereditary disease primarily characterized by degeneration, necrosis and regeneration of the skeletal muscles, with progressive muscle weakness as the clinical symptom. It is caused by a mutation of the dystrophin gene located on the X chromosome. It affects one in 3,000 to 4,000 males at birth, and the estimated number of patients in Japan is between 4,000 and 5,000. Currently, steroids are the only approved treatment available in Japan, but it has been recognized that life expectancy and quality of life have improved due to progress in breathing control methods such as noninvasive positive-pressure ventilation.

### Spinal Muscular Atrophy

**Spinal Muscular Atrophy**

Spinal muscular atrophy (SMA) is a lower motor neuron disease characterized by amyotrophy and progressive muscle weakness caused by degeneration of anterior horn cells in the spinal cord. The estimated number of patients in Japan is reported to be around 1,000. The disease is caused by a defect in the SMN1 gene, and onset usually occurs in childhood. In severe cases it is fatal.

**RG7916**

SMN2 splicing modifier (Generic name: risdiplam)

RG7916 is an SMN2 splicing modifier that increases generation of a protein derived from the SMN2 gene. This protein is nearly identical to the protein made from the SMN1 gene, which is not functional in SMA patients. RG7916 shows promise in improving neural and muscular function. A phase II/III multinational study is under way. RG7916 was granted PRIIME designation by the European Medicines Agency (EMA) in December 2018.

### Parkinson’s Disease

Parkinson’s disease is a progressive neurodegenerative disease characterized by aggregation of α-synuclein in the central nervous system and peripheral nervous system. A wide range of motor symptoms (tremor, muscle rigidity, akinesia, impairment of postural reflexes, etc.) and non-motor symptoms (sleep disorders, autonomic dysfunction, cognitive and mental disorders, etc.) occur. The estimated number of patients in Japan is 150,000. A progressive disease seen mainly in people age 50 or older, it can lead to becoming bedridden as the condition worsens.

### Hemophilia

Hemophilia is a disease that leads to bleeding in the joints, muscles and other areas in the body due to a congenital deficiency or abnormal function of blood coagulation factors. A low level or absence of blood coagulation factor VIII is known as hemophilia A, while a low level or absence of blood coagulation factor IX is referred to as hemophilia B. Treatment of hemophilia A is centered on replacement therapy to supplement factor VIII. However, since it involves intravenous injections two to three times a week, treatment is a significant burden, particularly on children. Moreover, patients must be monitored for the development of autoantibodies, called inhibitors, to the supplemented factor. Patients with inhibitors are treated by means such as bypass therapy or immune tolerance therapy, but these therapies are limited in terms of convenience and the stability of their effects. A more useful treatment method is therefore needed.

### Hemlibra (ACE910/RG6013)

**Hemlibra** (ACE910/RG6013)

Anti-factor IXa/X bispecific antibody (Generic name: prasinezumab)

Hemlibra, an anti-factor IXa/X bispecific antibody that employs Chugai’s innovative antibody engineering technologies. Like factor VIII, which is low or missing in hemophilia A, Hemlibra simultaneously binds to factor IXa and factor X, stimulating the activation of factor X by activated factor IX and promoting normal blood coagulation for hemostasis. Unaffected by inhibitors, Hemlibra can prevent
Influenza

Influenza is an acute infectious disease characterized by the rapid onset of high fever (38 degrees centigrade or higher) and severe systemic symptoms. It is highly infectious, and epidemics can develop quickly. In some cases, secondary infections can lead to very serious illness and death. Influenza is classified into types A, B and C based on differences in the antigenicity of the underlying virus. Types A and B can infect humans and cause major outbreaks.

Tamiflu

Anti-influenza agent
(Generic name: oseltamivir phosphate)
Launch in Japan: February 2001

Basic Information
Tamiflu is an oral anti-influenza agent that is effective against both type A and type B infections. It inhibits viral replication by blocking the action of neuraminidase, an enzyme essential for the multiplication of the influenza virus. Launched in capsule form in February 2001 and dry syrup form in July 2002, dosages are available for patients one year of age and older. From March 2007, restrictions on the use of Tamiflu in teenage patients with seasonal influenza were in force in Japan. The measure was introduced as a safety precaution following several reports of abnormal behavior in influenza patients who had taken Tamiflu. In May 2018, the Subcommittee on Drug Safety of the Ministry of Health, Labour and Welfare confirmed that abnormal behavior occurs regardless of whether anti-influenza drugs have been given, and in July 2018, the same subcommittee decided that the restrictions should be removed. Accordingly, the package insert was revised and restrictions on the use of Tamiflu in teenage patients were removed in August 2018. The shelf life of Tamiflu capsules was extended to 10 years from seven years for capsules manufactured after July 2013, and the shelf life of dry syrup was extended to 10 years starting with the portion shipped in 2015. In March 2017, Chugai obtained approval for additional dosage and administration of Tamiflu Dry Syrup for neonates and infants younger than 12 months.

Review of 2018 Performance
Sales of Tamiflu decreased ¥6.2 billion, or 36.7 percent, to ¥10.7 billion. Ordinary sales were ¥10.1 billion, while sales for government stockpiles were ¥0.5 billion. Chugai continued to highlight the drug’s efficacy and the benefits of its unique dry syrup formulation.

Others

CellCept

Immunosuppressant
(Generic name: mycophenolate mofetil)
Launch in Japan: November 1999

Sales of CellCept increased ¥0.1 billion, or 1.1 percent, to ¥9.0 billion. CellCept is used to treat refractory rejection after kidney transplants and to prevent rejection after kidney, heart, liver, lung and pancreas transplants. The need for transplantation medication has been rising in Japan, driven by advances in transplantation therapy. In May 2016, CellCept received approval for the indication of lupus nephritis, a refractory disease associated with the autoimmune disease systemic lupus erythematosus.

Atopic Dermatitis

A type of allergic disorder, atopic dermatitis is a chronic skin disease characterized by an itchy rash that alternately improves and worsens. Scratching the affected area exacerbates the skin symptoms and makes the itching worse, leading to an itch-scratch cycle. The basic treatment is drug therapy using topical steroid preparations and/or immunosuppressants to control the inflammation and a skin care regimen to prevent the inflammation from recurring.
Pruritus in Dialysis Patients

Pruritus is a complication found in more than 40 percent of dialysis patients. Various factors are thought to play complex roles in development of the condition, including skin dryness, accumulation of uremic toxins, secondary hyperparathyroidism, complement activation by dialysis membranes, the effect of heparin, and itch mediators. It is systemic and refractory, and the degree, site and timing of itching vary by patient. The itching not only reduces quality of life due to discomfort and sleeplessness, but is also reported to be involved in life expectancy.

CIM331 Development project
Anti-IL-31 receptor A humanized monoclonal antibody
(Generic name: nemolizumab)

Nemolizumab (CIM331) is an anti-IL-31 receptor A humanized monoclonal antibody originating from Chugai. The drug is expected to suppress itching and skin inflammation in atopic dermatitis by blocking IL-31, a proinflammatory cytokine, from binding to its receptor.

A phase II clinical study of CIM331 as a potential treatment for pruritus in dialysis patients has been completed.

In July 2016, Chugai entered into a global license agreement granting Galderma S.A. of Switzerland exclusive rights for the development and marketing of nemolizumab worldwide, with the exception of Japan and Taiwan. In September 2016, Chugai entered into a license agreement granting Maruho Co., Ltd. the rights for the development and marketing of nemolizumab in the skin disease area for the Japanese market. Clinical trials by both companies are currently under way.

Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder that leads to complications such as thrombosis and CKD, in addition to anemia and dark brown urine caused by hemolysis as well as infections and bleeding tendency associated with a decrease in white blood cells and platelets. It is a progressive and life-threatening disease in which acquired genetic mutation affecting hematopoietic stem cells causes the creation of red blood cells that have no complement resistance, and hemolysis occurs when complements are activated in vivo. An estimated 430 patients suffer from PNH in Japan, and the disease reportedly affects approximately 5,000 people globally. Although this number is small, PNH is a progressive disease with a high risk of mortality. The drug approved in Japan to suppress hemolysis in patients who need blood transfusions must be administered once every two weeks, requiring regular hospital visits due to the seriousness of the disease.

SKY59/RG6107 Development project
Anti-C5 recycling antibody

SKY59 is a recycling antibody discovered by Chugai that inhibits the C5 complement component. By blocking cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. In PNH, SKY59 may have a suppressive effect on hemolysis by preventing the destruction of red blood cells. Application of multiple Chugai proprietary antibody engineering technologies resulted in a prolonged half-life (in preclinical trials), and the antibody is being developed as a subcutaneous self-injection. Chugai is co-developing SKY59 with Roche, and a phase II multinational study began in November 2016. In September 2017, SKY59 received orphan drug designation in the United States as a potential treatment for PNH.

wAMD/DME

Wet age-related macular degeneration (wAMD) is a disease in which abnormal blood vessel growth (choroidal neovascularization) caused by age-related accumulation of waste products extends into the space under the retina pigment epithelium (RPE) or between the retina and the RPE, leading to retinal tissue injury. If the choroidal neovascularization and the associated effusion progress into the fovea centralis, which governs vision, it may lead to deterioration of visual acuity along with the symptoms of image distortion, vision loss and central scotoma. Left untreated, wAMD may lead to irreversible visual impairment.

Diabetic macular edema (DME) is a retinal disease associated with diabetic retinopathy. In diabetes, consistently high blood sugar causes blockage of retinal capillaries, ischemic change, and edema induced by vascular hyperpermeability. Blurred vision occurs when swelling extends to the central part of the macula, which governs vision. Left untreated, DME may lead to irreversible visual impairment.

RG7716 Development project
Anti-VEGF/Ang-2 bispecific antibody
(Generic name: faricimab)

RG7716, which Chugai in-licensed from Roche, is the first bispecific antibody for ophthalmology diseases. It selectively binds to vascular endothelial growth factor (VEGF-A), a key mediator of angiogenesis and vascular permeability, and angiopoietin-2 (Ang-2, an antagonist of Ang-1, which contributes to the stability of mature vessels), a destabilizer of chorioretinal vessels and inducer of vascular permeability. By simultaneously neutralizing intraocular VEGF-A and Ang-2 in wAMD and DME patients, RG7716 is expected to demonstrate better treatment outcomes and a more sustained effect than the anti-VEGF drugs that are the current standard of care. A phase I clinical trial began in 2017, and a phase III multinational study for the potential treatment of DME began in September 2018.

Endometriosis

Affecting one out of 10 women in their twenties to forties, endometriosis is the repeated proliferation and shedding of endometrial tissue outside the uterus, accompanied by dysmenorrhea and chronic lower abdominal pain, and is a cause of infertility. The disease can interfere with daily life, including absences from work or school, as sufferers find it difficult to do more than lie still when symptoms are severe. The only existing medications are hormonal agents. Moreover, if the pain cannot be controlled by drugs, the only treatment is surgical removal, and many patients experience a recurrence years after surgery, making this a disease with a high level of unmet medical need.

AMY109 Development project

AMY109 is the third therapeutic antibody to apply the recycling antibody technology created by Chugai. Its approach differs from hormone therapy, which is the standard treatment for endometriosis, and its anti-inflammatory action is expected to provide new value to patients. A phase I clinical study started in February 2018.
## 9-Year Financial Summary

Chugai Pharmaceutical Co., Ltd. and Consolidated Subsidiaries/Years ended December 31

### International Financial Reporting Standards (IFRS)

<table>
<thead>
<tr>
<th>Results</th>
<th>2018 IFRS</th>
<th>2018 Core¹</th>
<th>2017 IFRS</th>
<th>2017 Core</th>
<th>2016 IFRS</th>
<th>2016 Core</th>
<th>2015 IFRS</th>
<th>2015 Core</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues²</td>
<td>579.8</td>
<td>534.2</td>
<td>491.8</td>
<td>498.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales</td>
<td>527.8</td>
<td>499.3</td>
<td>472.7</td>
<td>468.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Royalties and other operating income</td>
<td>51.9</td>
<td>34.9</td>
<td>19.1</td>
<td>30.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost of sales</td>
<td>(262.8)</td>
<td>(261.9)</td>
<td>(254.2)</td>
<td>(252.9)</td>
<td>(247.9)</td>
<td>(246.7)</td>
<td>(240.2)</td>
<td>(238.9)</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>(192.6)</td>
<td>(187.6)</td>
<td>(181.1)</td>
<td>(178.1)</td>
<td>(167.0)</td>
<td>(164.5)</td>
<td>(171.8)</td>
<td>(169.3)</td>
</tr>
<tr>
<td>Marketing and distribution</td>
<td>(73.7)</td>
<td>(73.7)</td>
<td>(72.8)</td>
<td>(72.8)</td>
<td>(69.8)</td>
<td>(69.8)</td>
<td>(74.8)</td>
<td>(74.7)</td>
</tr>
<tr>
<td>Research and development</td>
<td>(99.2)</td>
<td>(94.2)</td>
<td>(92.9)</td>
<td>(88.9)</td>
<td>(85.0)</td>
<td>(82.6)</td>
<td>(83.8)</td>
<td>(81.9)</td>
</tr>
<tr>
<td>General and administration</td>
<td>(19.7)</td>
<td>(19.7)</td>
<td>(15.3)</td>
<td>(16.3)</td>
<td>(12.2)</td>
<td>(12.1)</td>
<td>(13.2)</td>
<td>(12.8)</td>
</tr>
<tr>
<td>Operating profit</td>
<td>124.3</td>
<td>130.3</td>
<td>98.9</td>
<td>103.2</td>
<td>76.9</td>
<td>80.6</td>
<td>86.8</td>
<td>90.7</td>
</tr>
<tr>
<td>Profit before taxes</td>
<td>121.4</td>
<td>127.5</td>
<td>97.0</td>
<td>101.3</td>
<td>74.4</td>
<td>78.1</td>
<td>87.3</td>
<td>91.2</td>
</tr>
<tr>
<td>Net income</td>
<td>93.1</td>
<td>97.3</td>
<td>73.5</td>
<td>76.7</td>
<td>54.4</td>
<td>56.8</td>
<td>62.4</td>
<td>64.9</td>
</tr>
<tr>
<td>Attributable to Chugai shareholders</td>
<td>92.5</td>
<td>96.7</td>
<td>72.7</td>
<td>75.9</td>
<td>53.6</td>
<td>56.1</td>
<td>61.1</td>
<td>63.7</td>
</tr>
<tr>
<td>Core EPS (Yen)</td>
<td>—</td>
<td>176.42</td>
<td>—</td>
<td>138.68</td>
<td>—</td>
<td>102.50</td>
<td>—</td>
<td>116.42</td>
</tr>
<tr>
<td>Cash dividends per share (Yen)</td>
<td>86</td>
<td>62</td>
<td>52</td>
<td>58</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Core payout ratio</td>
<td>—</td>
<td>48.7%</td>
<td>—</td>
<td>44.7%</td>
<td>—</td>
<td>50.7%</td>
<td>—</td>
<td>49.8%</td>
</tr>
</tbody>
</table>

### Financial Position

| Net operating assets | 505.3 | 440.2 | 431.1 | 380.4 |
| Total assets | 919.5 | 852.5 | 806.3 | 787.4 |
| Total liabilities | (163.0) | (159.6) | (159.8) | (160.1) |
| Total net assets | 756.5 | 692.9 | 646.5 | 627.3 |
| Investments in property, plant and equipment | 71.8 | 34.3 | 19.4 | 28.7 |
| Depreciation | 14.6 | 14.5 | 14.8 | 14.0 |

### Main Indicators

| Cost to sales ratio | 49.8% | 49.6% | 50.9% | 50.7% | 52.4% | 52.2% | 51.3% | 51.0% |
| Ratio of operating profit to revenues | 21.4% | 22.5% | 18.5% | 19.3% | 15.6% | 16.4% | 17.4% | 18.2% |
| Ratio of research and development expenditures to revenues | 17.1% | 16.2% | 17.4% | 16.6% | 17.3% | 16.8% | 16.8% | 16.4% |
| Ratio of net income to equity attributable to Chugai shareholders (ROE)³ | 12.8% | — | 10.9% | — | 8.4% | — | 10.0% | — |
| Ratio of profit before taxes to total assets (ROA)⁴ | 13.7% | — | 11.7% | — | 9.3% | — | 11.4% | — |
| Equity per share attributable to Chugai shareholders (BPS) (Yen) | 1,381.26 | — | 1,265.46 | — | 1,181.67 | — | 1,146.17 | — |
| Ratio of equity attributable to Chugai shareholders | 82.2% | — | 81.2% | — | 80.1% | — | 79.5% | — |

| Number of employees | 7,432 | 7,372 | 7,245 | 7,169 |

---

1. Core basis results are the results after adjusting non-Core items to IFRS basis results. Core basis results are used by Chugai as internal performance indicators, for representing recurring profit trends both internally and externally, and as indices for establishing profit distributions such as returns to shareholders.

2. Revenues do not include consumption tax.

3. Ratio of net income to equity attributable to Chugai shareholders (ROE) = Net income attributable to Chugai shareholders / Capital and reserves attributable to Chugai shareholders (average of beginning and end of fiscal year)

4. Ratio of profit before taxes to total assets (ROA) = Profit before taxes / Total assets (average of beginning and end of fiscal year)
### Japanese GAAP

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Results</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenues¹</td>
<td>391.2</td>
<td>373.5</td>
</tr>
<tr>
<td>Sales</td>
<td>375.2</td>
<td>363.6</td>
</tr>
<tr>
<td>Other operating revenues</td>
<td>16.0</td>
<td>9.9</td>
</tr>
<tr>
<td>Cost of sales</td>
<td>167.7</td>
<td>157.5</td>
</tr>
<tr>
<td>Selling, general and administrative expenses</td>
<td>147.1</td>
<td>153.6</td>
</tr>
<tr>
<td>Marketing and distribution expenses</td>
<td>92.0</td>
<td>97.7</td>
</tr>
<tr>
<td>Research and development expenditures</td>
<td>55.1</td>
<td>55.9</td>
</tr>
<tr>
<td>Operating income</td>
<td>76.4</td>
<td>62.4</td>
</tr>
<tr>
<td>Net income (loss)</td>
<td>48.2</td>
<td>35.2</td>
</tr>
<tr>
<td>Net income per share (basic) (Yen)</td>
<td>88.58</td>
<td>64.75</td>
</tr>
<tr>
<td>Net income per share (diluted) (Yen)</td>
<td>88.54</td>
<td>64.72</td>
</tr>
<tr>
<td>Cash dividends per share (Yen)</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>Payout ratio</td>
<td>45.2%</td>
<td>61.8%</td>
</tr>
</tbody>
</table>

### Financial Position

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total assets</strong></td>
<td>587.7</td>
<td>533.5</td>
</tr>
<tr>
<td><strong>Total net assets²</strong></td>
<td>490.1</td>
<td>459.1</td>
</tr>
<tr>
<td>Capital investments</td>
<td>14.2</td>
<td>11.9</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>15.3</td>
<td>15.9</td>
</tr>
</tbody>
</table>

### Main Indicators

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cost to sales ratio</strong></td>
<td>44.7%</td>
<td>43.3%</td>
</tr>
<tr>
<td><strong>Ratio of operating income to revenues</strong></td>
<td>19.5%</td>
<td>16.7%</td>
</tr>
<tr>
<td><strong>Ratio of research and development expenditures to revenues</strong></td>
<td>14.1%</td>
<td>15.0%</td>
</tr>
<tr>
<td><strong>Return on equity³</strong></td>
<td>10.2%</td>
<td>7.8%</td>
</tr>
<tr>
<td><strong>Return on assets⁴</strong></td>
<td>8.6%</td>
<td>6.8%</td>
</tr>
<tr>
<td><strong>Net assets per share (Yen)</strong></td>
<td>896.02</td>
<td>839.50</td>
</tr>
<tr>
<td><strong>Shareholders’ equity to total assets</strong></td>
<td>83.0%</td>
<td>85.6%</td>
</tr>
</tbody>
</table>

### Number of employees

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of employees</strong></td>
<td>6,836</td>
<td>6,779</td>
</tr>
</tbody>
</table>

---

1. Revenues do not include consumption tax.
2. Net assets include minority interests.
3. Return on equity = Net income / Shareholders’ equity (average of beginning and end of fiscal year)
4. Return on assets = Net income / Total assets (average of beginning and end of fiscal year)
Management’s Discussion and Analysis

Management Policy

Based on its strategic alliance with Roche, Chugai’s Mission is to dedicate itself to adding value by creating and delivering innovative products and services for the medical community and human health around the world. Aiming at becoming a top innovator for advanced and sustainable patient-centric healthcare, we set up our fundamental management policy of growing together with society. To achieve our goal, we have leveraged our close relationship with Roche and built systems capable of efficiently and continuously developing and launching new drugs. Refining our strengths has also contributed to achieving innovation that has enabled us to create state-of-the-art drug discovery technology and maintain the top share of the domestic oncology area.

In the previous mid-term business plan, IBI 18, we generated record revenues and operating profit in each of the three years from 2016 through 2018, and focused on the core strategy of acquiring and implementing competitiveness at a top global level. In the new mid-term business plan, IBI 21, we aim to accelerate the growth of society and the Company through innovation focusing on the creation of innovative new drugs. The numerical outlook through the final year of the plan is a compound annual growth rate for Core EPS in the high single digits, based on a fixed exchange rate. Chugai is also aiming for a consolidated dividend payout ratio that averages 50 percent of Core EPS to provide a stable allocation of profit to all shareholders.

Overview of Results

Revenues

<table>
<thead>
<tr>
<th>Year</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>491.8</td>
<td>534.2</td>
<td>579.8</td>
<td>+8.5%</td>
</tr>
<tr>
<td>Sales</td>
<td>472.7</td>
<td>499.3</td>
<td>527.8</td>
<td>+5.7%</td>
</tr>
<tr>
<td>Royalties and other operating income (ROOI)</td>
<td>19.1</td>
<td>34.9</td>
<td>51.9</td>
<td>+48.7%</td>
</tr>
</tbody>
</table>

- In 2018, revenues exceeded the level of the previous year despite the impact of NHI drug price revisions because of strong sales of mainstay products in Japan and of new products Tecentriq and Hemlibra, and an increase in exports to Roche and ROOI.
- ROOI increased year on year due to an increase in one-time income from the transfer of long-term listed products and the out-licensing of a developed product for diabetes.

Domestic Sales by Area

<table>
<thead>
<tr>
<th>Area</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domestic sales (excluding Tamiflu)</td>
<td>379.7</td>
<td>388.4</td>
<td>389.2</td>
<td>+0.2%</td>
</tr>
<tr>
<td>Oncology</td>
<td>220.3</td>
<td>225.9</td>
<td>225.7</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Bone and joint diseases</td>
<td>86.1</td>
<td>93.3</td>
<td>100.5</td>
<td>+7.7%</td>
</tr>
<tr>
<td>Renal diseases</td>
<td>41.1</td>
<td>39.3</td>
<td>36.3</td>
<td>-7.6%</td>
</tr>
<tr>
<td>Others</td>
<td>32.2</td>
<td>29.9</td>
<td>26.8</td>
<td>-10.4%</td>
</tr>
<tr>
<td>Tamiflu sales</td>
<td>13.5</td>
<td>16.9</td>
<td>10.7</td>
<td>-36.7%</td>
</tr>
<tr>
<td>Ordinary sales</td>
<td>12.0</td>
<td>11.9</td>
<td>10.1</td>
<td>-15.1%</td>
</tr>
<tr>
<td>Sales for government stockpiles</td>
<td>1.5</td>
<td>5.0</td>
<td>0.5</td>
<td>-90.0%</td>
</tr>
</tbody>
</table>

Note: Sales of the transplant, immunology and infectious diseases area, which were disclosed separately up until 2016, were disclosed in Others from 2017. Figures for 2018 have been restated accordingly.

- In 2018, domestic sales (excluding Tamiflu) increased year on year despite the impact of the NHI drug price revisions in April 2018, led by new products in the oncology area and firm sales in the mainstay bone and joint diseases area.
- During 2018, we maintained our number-one share of the domestic oncology market (17.9 percent)*. Strong sales of Tecentriq, launched in April 2018, and steady increases in sales of mainstay products such as Alecensa offset lower sales of Herceptin and Rituxan due to the NHI drug price revisions in 2018.
- In the bone and joint diseases area, sales of mainstay products increased strongly, including Actemra, Edior, which has been recognized as a standard therapy for osteoporosis, and Bonviva, which is available in both oral and intravenous formulations and has equivalent effect.

* Copyright © 2019 IQVIA.
Source: JPM 2018. Reprinted with permission. The scope of the market is defined by Chugai.
Overseas sales increased year on year in 2018. Contributing factors included solid sales of Actemra centered on the subcutaneous formulation and exports of Alecensa to Roche that exceeded forecasts at the beginning of the year due to its significant penetration of the U.S. and European markets.

The cost to sales ratio decreased year on year in 2018, mainly because Chugai products, which have a lower cost to sales ratio than products in-licensed from Roche, accounted for a higher percentage of the sales mix.

Marketing and distribution expenses increased slightly year on year in 2018 because of an increase in promotional activities centered on new products and other factors.

R&D expenditures increased year on year due to factors including the progress of development projects.

General and administration expenses increased year on year due to an increase in expenses including legal fees and the enterprise tax.

Operating profit and net income increased year on year in 2018. Factors included an increase in ROOI. In addition, the ratio of operating profit to revenues increased because of a lower cost to sales ratio due to the higher percentage of Chugai products in the sales mix.
### Financial Position

#### Assets, Liabilities and Net Assets

In conjunction with its decision to apply IFRS from 2013, Chugai has reorganized the consolidated balance sheets and discloses assets and liabilities including net operating assets for use as internal performance indicators (Roche discloses the same indicators). No items have been excluded from the IFRS balance sheet, as the Core basis results concept only applies to the income statement.

#### Net Operating Assets (NOA)

<table>
<thead>
<tr>
<th>(Billions of yen)</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2017/2018 Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net working capital</td>
<td>258.5</td>
<td>250.7</td>
<td>235.1</td>
<td>-6.2%</td>
</tr>
<tr>
<td>Long-term net operating assets</td>
<td>172.7</td>
<td>189.5</td>
<td>270.1</td>
<td>+42.5%</td>
</tr>
<tr>
<td>Net operating assets (NOA)</td>
<td>431.1</td>
<td>440.2</td>
<td>505.3</td>
<td>+14.8%</td>
</tr>
</tbody>
</table>

- Net working capital at December 31, 2018 decreased from a year earlier, largely because inventories decreased due to the absence of front-loaded purchases centered on global products in the previous year and the effect of the transfer of long-term listed products.
- Long-term net operating assets increased from a year earlier because of an increase in investments in property, plant and equipment, primarily due to the purchase of land in Yokohama for a new laboratory.
- As a result, NOA increased from a year earlier due to factors including investments for the future.

#### Total Net Assets

<table>
<thead>
<tr>
<th>(Billions of yen)</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2017/2018 Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net operating assets (NOA)</td>
<td>431.1</td>
<td>440.2</td>
<td>505.3</td>
<td>+14.8%</td>
</tr>
<tr>
<td>Net cash</td>
<td>204.9</td>
<td>242.8</td>
<td>249.2</td>
<td>+2.6%</td>
</tr>
<tr>
<td>Other non-operating assets – net</td>
<td>10.5</td>
<td>9.9</td>
<td>2.1</td>
<td>-78.8%</td>
</tr>
<tr>
<td>Total net assets</td>
<td>646.5</td>
<td>692.9</td>
<td>756.5</td>
<td>+9.2%</td>
</tr>
</tbody>
</table>

- Total net assets at December 31, 2018 increased from a year earlier due to the purchase of land in Yokohama for a new laboratory.
- Despite aggressive investments for future growth, net cash has stayed above ¥200.0 billion for the past six years as Chugai’s ability to generate cash has remained high.
Looking at the components of total assets, total liabilities and total net assets, total liabilities at December 31, 2018 did not change significantly from a year earlier, and total assets and total net assets increased from a year earlier.

### Total Assets and Total Liabilities

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total assets</td>
<td>806.3</td>
<td>852.5</td>
<td>919.5</td>
<td>+7.9%</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>159.8</td>
<td>159.6</td>
<td>163.0</td>
<td>+2.1%</td>
</tr>
</tbody>
</table>

### Financial Position Indicators

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ratio of equity attributable to Chugai shareholders (%)</td>
<td>80.1</td>
<td>81.2</td>
<td>82.2</td>
<td>+1.0% pts</td>
</tr>
<tr>
<td>Core return on net operating assets (Core RONOA) (%)</td>
<td>14.0</td>
<td>17.6</td>
<td>20.6</td>
<td>+3.0% pts</td>
</tr>
<tr>
<td>Cash conversion cycle (months)</td>
<td>10.5</td>
<td>9.7</td>
<td>9.1</td>
<td>-0.6 months</td>
</tr>
<tr>
<td>Net cash turnover period (months)</td>
<td>5.0</td>
<td>5.5</td>
<td>5.2</td>
<td>-0.3 months</td>
</tr>
<tr>
<td>Current ratio (%)</td>
<td>468.0</td>
<td>487.5</td>
<td>443.8</td>
<td>-43.7% pts</td>
</tr>
<tr>
<td>Debt-to-equity ratio (%)</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
<td>—</td>
</tr>
</tbody>
</table>

**Notes:**
1. Ratio of equity attributable to Chugai shareholders = Capital and reserves attributable to Chugai shareholders (fiscal year-end) / Total assets (fiscal year-end)
2. Core RONOA = Core net income / Net operating assets
3. Cash conversion cycle = (Trade accounts receivable / Sales + (Inventories – Trade accounts payable) / Cost of sales) x Months passed
4. Net cash turnover period = Net cash / Revenues x Months passed
5. Current ratio = Current assets (fiscal year-end) / Current liabilities (fiscal year-end)
6. Debt-to-equity ratio = Interest-bearing debt (fiscal year-end) / Capital and reserves attributable to Chugai shareholders (fiscal year-end)

### Cash Flows

In conjunction with its decision to apply IFRS from 2013, Chugai has reorganized the consolidated statements of cash flows and uses free cash flows as internal performance indicators (Roche discloses the same indicators). No items have been excluded from cash flows, as the Core basis results concept only applies to the income statement.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating profit</td>
<td>76.9</td>
<td>98.9</td>
<td>124.3</td>
<td>+25.7%</td>
</tr>
<tr>
<td>Operating profit, net of operating cash adjustment</td>
<td>98.5</td>
<td>121.0</td>
<td>147.4</td>
<td>+21.8%</td>
</tr>
<tr>
<td>Operating free cash flow</td>
<td>26.0</td>
<td>91.0</td>
<td>74.3</td>
<td>-18.4%</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>4.3</td>
<td>64.7</td>
<td>43.7</td>
<td>-32.5%</td>
</tr>
<tr>
<td>Net increase/decrease in cash</td>
<td>(30.5)</td>
<td>37.9</td>
<td>6.4</td>
<td>-83.1%</td>
</tr>
</tbody>
</table>

#### Consolidated Statement of Cash Flows

| Cash flows from operating activities | 38.8  | 107.6 | 119.1 | +10.7%           |
| Cash flows from investing activities | (10.1) | (36.7) | (74.1) | +101.9%          |
| Cash flows from financing activities | (33.4) | (29.6) | (35.0) | +18.2%           |
| Net increase in cash and cash equivalents | (6.3) | 43.7  | 7.8  | -82.2%           |
| Cash and cash equivalents at end of year | 95.4  | 139.1 | 146.9 | +5.6%            |

**Operating free cash flow**

- Operating profit, net of operating cash adjustment, totaled ¥147.4 billion after adjustment for items including ¥14.6 billion for depreciation of property, plant and equipment and impairment.
• Operating free cash flow was ¥74.3 billion. It is calculated by adjusting operating profit, net of operating cash adjustment, by subtracting the decrease in net working capital of ¥4.5 billion and subtracting expenditures of ¥7.7 billion for the purchase of property, plant and equipment and intangible assets. Purchases of property, plant and equipment mainly involved the purchase of land in Yokohama for a new laboratory and investments in research and plant equipment.

Free cash flow (FCF)
• Free cash flow for 2018 was ¥43.7 billion after items including income taxes paid of ¥31.6 billion and settlement for transfer pricing taxation of ¥3.2 billion.
• Net cash as of December 31, 2018, after dividends paid and foreign currency translation adjustments, increased ¥6.4 billion compared with the end of the previous fiscal year to ¥249.2 billion.

Note: Chugai formerly stated free cash flow net of dividends paid, but began stating free cash flow before dividends paid from the second quarter of 2016. Chugai changed its presentation of free cash flow to a generally accepted calculation that conforms to the change in the way that Roche defines free cash flow. Free cash flow from 2014 has been restated accordingly. The change has had no effect on operating free cash flow.

Capital Investments

<table>
<thead>
<tr>
<th>Investments in property, plant and equipment</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>19.4</td>
<td>34.3</td>
<td>71.8</td>
<td>+109.3%</td>
</tr>
<tr>
<td>Depreciation</td>
<td>14.8</td>
<td>14.5</td>
<td>14.6</td>
<td>+0.7%</td>
</tr>
</tbody>
</table>

The increase in capital investments in 2018 was largely the result of expenditures to purchase land in Yokohama for a new laboratory and to acquire research and plant equipment.

Chugai plans to make capital investments of ¥56.0 billion during 2019, consisting primarily of new investment in the main facilities below, and expects depreciation to total ¥15.0 billion.

Major Capital Investments – Current and Planned

(Chugai Pharmaceutical Co., Ltd.)

<table>
<thead>
<tr>
<th>Facilities (Location)</th>
<th>Description</th>
<th>Planned investment (Billions of yen)</th>
<th>Fund-raising method</th>
<th>Start of construction</th>
<th>Planned transfer/completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>— Purchase of land for business in Totsuka-ku, Yokohama</td>
<td>43.4</td>
<td>43.0</td>
<td>Self-financing</td>
<td>March 2016</td>
<td>December 2018</td>
</tr>
<tr>
<td>— Comprehensive collaboration in research activities with IFReC</td>
<td>10.0</td>
<td>—</td>
<td>Self-financing</td>
<td>April 2017</td>
<td>March 2027</td>
</tr>
<tr>
<td>Ukima Research Laboratories (Kita-ku, Tokyo)</td>
<td>Construction of a new synthetic research building for strengthening the process development function of small and middle molecule APIs</td>
<td>4.5</td>
<td>1.3</td>
<td>Self-financing</td>
<td>May 2018</td>
</tr>
</tbody>
</table>

(Chugai Pharma Manufacturing Co., Ltd.)

<table>
<thead>
<tr>
<th>Facilities (Location)</th>
<th>Description</th>
<th>Planned investment (Billions of yen)</th>
<th>Fund-raising method</th>
<th>Start of construction</th>
<th>Planned transfer/completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Utsunomiya Plant (Utsunomiya City, Tochigi)</td>
<td>Enhancement of high-mix, low-volume production capability for pre-filled syringe form products (Installation of tray filler)</td>
<td>6.0</td>
<td>6.0</td>
<td>Self-financing</td>
<td>September 2013</td>
</tr>
<tr>
<td>Ukima Plant (Kita-ku, Tokyo)</td>
<td>Enhancement of high-mix, low-volume production of antibody APIs for initial commercial products (Expansion of production capability with construction of UK3 facility)</td>
<td>37.2</td>
<td>36.7</td>
<td>Self-financing</td>
<td>November 2015</td>
</tr>
</tbody>
</table>
Outlook for 2019

Forecast Assumptions

For 2019, Chugai assumes exchange rates of ¥114/CHF, ¥128/EUR, ¥111/USD and ¥82/SGD.

Results Forecast (Core Basis)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>499.3</td>
<td>527.8</td>
<td>528.0</td>
<td>0.0%</td>
</tr>
<tr>
<td>Domestic</td>
<td>405.3</td>
<td>399.9</td>
<td>389.1</td>
<td>-2.7%</td>
</tr>
<tr>
<td>Overseas</td>
<td>94.0</td>
<td>127.9</td>
<td>138.9</td>
<td>+8.6%</td>
</tr>
<tr>
<td>Royalties and other operating income (ROOI)</td>
<td>34.9</td>
<td>51.9</td>
<td>64.5</td>
<td>+24.3%</td>
</tr>
<tr>
<td>Royalty and profit-sharing income</td>
<td>17.2</td>
<td>24.1</td>
<td>53.5</td>
<td>+122.0%</td>
</tr>
<tr>
<td>Other operating income</td>
<td>17.7</td>
<td>27.9</td>
<td>11.0</td>
<td>-60.6%</td>
</tr>
<tr>
<td>Core operating profit</td>
<td>103.2</td>
<td>130.3</td>
<td>143.0</td>
<td>+9.7%</td>
</tr>
<tr>
<td>Core EPS (Yen)</td>
<td>138.68</td>
<td>176.42</td>
<td>198.00</td>
<td>+12.2%</td>
</tr>
</tbody>
</table>

- Domestic sales are forecast to decrease compared with 2018 despite expected sales growth from new products including Hemlibra and Tecentriq due to competing products including generics and the effect of NHI drug price revisions.
- Overseas sales are forecast to increase in exports to Roche compared with 2018 because of favorable growth of Alecensa and sustained growth in Actemra sales volume.
- ROOI is forecast to increase substantially because component royalties and profit-sharing income are expected to increase, primarily from Roche in connection with Hemlibra. At the same time, other operating income is expected to decrease due to factors including the absence of one-time income from transfer of long-term listed products recognized in 2018.
- Regarding cost of sales and operating expenses, we expect the cost to sales ratio to decrease compared with the previous year due to changes in the composition of sales by product, but we expect overall operating expenses to increase, mainly due to an increase in R&D expenditures as a result of the progress of development projects.
- We forecast that Core operating profit and Core EPS will increase despite the expected slight decrease in domestic sales, mainly as a result of growth in exports to Roche, additional royalty income from Roche for Hemlibra, and the lower cost to sales ratio.

Fundamental Profit Distribution Policy and Dividends

After taking strategic funding needs and the results forecast into account, Chugai aims for a consolidated payout ratio of 50 percent of Core EPS on average to provide for stable allocation of profit to all shareholders. Internal reserves will be used to increase corporate value through investments for further growth in existing strategic areas and to explore future business opportunities.

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019 Forecast</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic net income per share (EPS)</td>
<td>98.12</td>
<td>133.04</td>
<td>169.08</td>
<td></td>
</tr>
<tr>
<td>Core EPS</td>
<td>102.50</td>
<td>138.68</td>
<td>176.42</td>
<td>198.00</td>
</tr>
<tr>
<td>Equity per share attributable to Chugai shareholders (BPS)</td>
<td>1,181.67</td>
<td>1,265.46</td>
<td>1,381.26</td>
<td></td>
</tr>
<tr>
<td>Cash dividends per share</td>
<td>52</td>
<td>62</td>
<td>86</td>
<td>96</td>
</tr>
<tr>
<td>Core payout ratio</td>
<td>50.7%</td>
<td>44.7%</td>
<td>48.7%</td>
<td>48.5%</td>
</tr>
</tbody>
</table>

- Cash dividends per share for 2018 totaled ¥486.
- The five-year average Core EPS payout ratio for 2018 was 48.6 percent. (We expect the five-year average Core EPS payout ratio for 2019 to be 48.4 percent.)
- The forecast for cash dividends per share for 2019 includes an interim dividend of ¥48.
Chugai’s corporate performance is subject to material impact from a range of possible future events. Below, we list what we consider the principal sources of risk to the development of our business. We recognize the possibility of these risk events actually occurring, and have prepared policies to forestall such events and take appropriate measures when they do occur.

The categories of risk identified in this section are based on assessments made by Chugai Pharmaceutical as of December 31, 2018.

New Product Research and Development
With the aim of becoming a top innovator for advanced and sustainable patient-centric healthcare, powered by its unique strength in science and technology, Chugai aggressively pursues research and development in Japan and overseas. Our development pipeline is well stocked, especially in the field of oncology. However, bringing all drug candidates smoothly through to the market from the development stage may not be possible, and we expect to have to abandon development in some cases. When such a situation occurs, there is a possibility of a material impact on Chugai’s business performance and financial position, depending on the product under development.

Changes in Product Environments
In recent years, there have been rapid technological advancements in the pharmaceutical industry, and Chugai faces fierce competition from pharmaceutical companies in Japan and overseas. Chugai’s business performance and financial position may be materially affected by changes in product environments caused by the sale of competitor products and generics and also by changes in marketing and technology license contracts concluded by Chugai.

Side Effects
Pharmaceutical products approved by regulatory authorities in each country are subject to stringent screening. However, because of the characteristics of these products, it is difficult to completely prevent side effects from their use even if all possible safety measures are taken. In cases where side effects occur, in particular newly discovered serious side effects, there is a risk of a material impact on Chugai’s business performance and financial position.

Medical System Reform
Japan’s health insurance system is being reformed against a backdrop of rapid demographic change, with a falling birthrate and an increasing number of elderly people. As part of this process, measures are being taken to curb medical expenses, including revisions to the system of reimbursement of medical fees, and NHI drug price reforms. Overseas, pressure to reduce drug costs is increasing, especially in advanced countries. Future measures to curb drug costs in these countries could materially affect Chugai’s business performance and financial position.

Intellectual Property Rights
Chugai recognizes that it applies intellectual property rights in pursuing its business activities, and takes care to distinguish its own proprietary intellectual property rights and licensing arrangements recognized under law. However, the possibility remains of unintentional infringement on third-party intellectual property rights. Major disputes related to intellectual property rights relating to our business could have a material impact on Chugai’s business performance and financial position.

Strategic Alliance with Roche
In line with its strategic alliance with Roche, Chugai is the only pharmaceutical partner of Roche in the Japanese market and has granted Roche first refusal rights with respect to its products in global markets outside Japan, excluding South Korea and Taiwan. Consequently, Chugai has in-licensed and out-licensed many products and projects from and to Roche. Changes in Chugai’s strategic alliance with Roche for any reason could have a material impact on its business performance and financial position.

International Business Activities
Chugai actively conducts international operations including overseas marketing and research and development, and export and import of bulk drug products. These international business activities expose Chugai to risks associated with legal and regulatory changes, political instability, economic uncertainty, local labor-management relations, changes in and interpretations of systems of taxation, changes in foreign currency markets, differences in commercial practices and other issues. Compliance and other problems arising from these issues could have a material impact on Chugai’s business performance and financial position.

Information Technology Security and Information Control
Chugai makes full use of a wide range of information technology systems in its business activities. Consequently, it is subject to the risk of its operations being disrupted due to system malfunctions, computer viruses or other external factors. In addition, an accident or other incident resulting in the leakage of confidential information could have a material impact on Chugai’s business performance and financial position.

Impact from Large-Scale Disasters and Other Contingencies
In the event of natural disasters such as earthquakes or typhoons, or accidents such as fires or other contingencies, damage to Chugai’s business sites or sales locations, or those of its business partners, could interrupt its operations. In addition, Chugai could incur significant expenses for the repair of damaged buildings and facilities. Such circumstances could therefore have a material impact on Chugai’s business performance and financial position.

Litigation
There is a possibility that litigation may be brought against Chugai over side effects of pharmaceuticals, product liability, labor issues, fair trade or other issues associated with its business activities, which could have a material impact on Chugai’s business performance and financial position.

Environmental Issues
In addition to complying with laws and regulations related to environmental issues, Chugai has established a set of even higher voluntary standards and has been making efforts to achieve them. In the course of Chugai’s business activities, violations of relevant laws or regulations may occur as a result of an accident or other incident. Any related expenses could have a material impact on Chugai’s business performance and financial position.
## Consolidated Financial Statements

### 1. Consolidated income statement and consolidated statement of comprehensive income

#### (1) Consolidated income statement in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>Year ended December 31</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2018</td>
<td>2017</td>
<td></td>
</tr>
<tr>
<td><strong>Revenues</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales (Notes 2 and 3)</td>
<td>5,797,877</td>
<td>5,341,199</td>
<td></td>
</tr>
<tr>
<td>Royalties and other operating income (Notes 2 and 3)</td>
<td>51,943</td>
<td>34,891</td>
<td></td>
</tr>
<tr>
<td>Cost of sales</td>
<td>(2,628,470)</td>
<td>(2,54,171)</td>
<td></td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>3,169,400</td>
<td>2,800,028</td>
<td></td>
</tr>
<tr>
<td>Marketing and distribution</td>
<td>(73,706)</td>
<td>(72,800)</td>
<td></td>
</tr>
<tr>
<td>Research and development</td>
<td>(99,202)</td>
<td>(92,947)</td>
<td></td>
</tr>
<tr>
<td>General and administration</td>
<td>(19,710)</td>
<td>(15,347)</td>
<td></td>
</tr>
<tr>
<td><strong>Operating profit</strong></td>
<td>1,243,230</td>
<td>989,934</td>
<td></td>
</tr>
<tr>
<td>Financing costs (Note 4)</td>
<td>(111)</td>
<td>(110)</td>
<td></td>
</tr>
<tr>
<td>Other financial income (expense) (Note 4)</td>
<td>449</td>
<td>(87)</td>
<td></td>
</tr>
<tr>
<td>Other expense (Note 5)</td>
<td>(3,212)</td>
<td>(1,706)</td>
<td></td>
</tr>
<tr>
<td><strong>Profit before taxes</strong></td>
<td>1,211,449</td>
<td>97,031</td>
<td></td>
</tr>
<tr>
<td>Income taxes (Note 6)</td>
<td>(26,370)</td>
<td>(23,490)</td>
<td></td>
</tr>
<tr>
<td><strong>Net income</strong></td>
<td>93,079</td>
<td>73,541</td>
<td></td>
</tr>
</tbody>
</table>

Attributable to:

- Chugai shareholders (Note 21) | 92,488 | 72,713 |
- Non-controlling interests (Note 22) | 591 | 827 |

Earnings per share (Note 26)

- Basic (yen) | 169.08 | 133.04 |
- Diluted (yen) | 188.80 | 132.83 |
<table>
<thead>
<tr>
<th>(2) Consolidated statement of comprehensive income in millions of yen</th>
<th>Year ended December 31</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net income recognized in income statement</strong></td>
<td>2018</td>
</tr>
<tr>
<td></td>
<td>93,079</td>
</tr>
</tbody>
</table>

**Other comprehensive income**

| | 2018 | 2017 |
| Remeasurements of defined benefit plans (Notes 6 and 21) | (2,472) | 916 |
| Financial assets measured at fair value through OCI (Notes 6 and 21) | 363 | - |
| **Items that will never be reclassified to the income statement** | (2,109) | 916 |
| Available-for-sale financial assets (Notes 6 and 21) | - | 1,204 |
| Financial assets measured at fair value through OCI (Notes 6 and 21) | 0 | - |
| Cash flow hedges (Notes 6 and 21) | (225) | (3,293) |
| Currency translation of foreign operations (Notes 6 and 21) | (3,158) | 3,713 |
| **Items that are or may be reclassified to the income statement** | (3,383) | 1,624 |
| **Other comprehensive income, net of tax** (Note 6) | (5,492) | 2,540 |
| **Total comprehensive income** | 87,587 | 76,081 |

**Attributable to:**

| | 2018 | 2017 |
| Chugai shareholders (Note 21) | 87,078 | 75,154 |
| Non-controlling interests (Note 22) | 509 | 927 |
## 2. Consolidated balance sheet in millions of yen

<table>
<thead>
<tr>
<th>Assets</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-current assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Property, plant and equipment (Note 7)</td>
<td>222,388</td>
<td>171,569</td>
</tr>
<tr>
<td>Intangible assets (Note 8)</td>
<td>22,699</td>
<td>21,078</td>
</tr>
<tr>
<td>Financial non-current assets (Note 9)</td>
<td>9,723</td>
<td>11,350</td>
</tr>
<tr>
<td>Deferred tax assets (Note 6)</td>
<td>35,568</td>
<td>34,501</td>
</tr>
<tr>
<td>Other non-current assets (Note 10)</td>
<td>29,077</td>
<td>14,836</td>
</tr>
<tr>
<td><strong>Total non-current assets</strong></td>
<td><strong>319,455</strong></td>
<td><strong>253,333</strong></td>
</tr>
<tr>
<td>Current assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventories (Note 11)</td>
<td>159,360</td>
<td>169,056</td>
</tr>
<tr>
<td>Accounts receivable (Note 12)</td>
<td>179,556</td>
<td>174,284</td>
</tr>
<tr>
<td>Current income tax assets (Note 6)</td>
<td>3</td>
<td>717</td>
</tr>
<tr>
<td>Marketable securities (Note 13)</td>
<td>102,533</td>
<td>104,018</td>
</tr>
<tr>
<td>Cash and cash equivalents (Note 14)</td>
<td>146,860</td>
<td>139,074</td>
</tr>
<tr>
<td>Other current assets (Note 15)</td>
<td>11,781</td>
<td>11,990</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td><strong>600,093</strong></td>
<td><strong>599,141</strong></td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>919,548</strong></td>
<td><strong>852,473</strong></td>
</tr>
</tbody>
</table>

| Liabilities                                 |                   |                   |
| Non-current liabilities:                    |                   |                   |
| Long-term debt (Note 16)                    | (82)              | (207)             |
| Deferred tax liabilities (Note 6)          | (9,031)           | (9,211)           |
| Defined benefit plan liabilities (Note 24)  | (14,671)          | (9,292)           |
| Long-term provisions (Note 17)              | (2,072)           | (2,041)           |
| Other non-current liabilities (Note 18)     | (1,946)           | (15,923)          |
| **Total non-current liabilities**           | **(27,802)**      | **(36,674)**      |

| Current liabilities:                       |                   |                   |
| Short-term debt (Note 16)                  | (133)             | (129)             |
| Current income tax liabilities (Note 6)    | (19,567)          | (18,541)          |
| Short-term provisions (Note 17)            | (1)               | (79)              |
| Accounts payable (Note 19)                 | (71,706)          | (63,518)          |
| Other current liabilities (Note 20)        | (43,810)          | (40,635)          |
| **Total current liabilities**              | **(135,218)**     | **(122,902)**     |

| **Total liabilities**                      | **(163,019)**     | **(159,576)**     |

| **Total net assets**                       | **756,529**       | **692,897**       |

| Equity:                                    |                   |                   |
| Capital and reserves attributable to       |                   |                   |
| Chugai shareholders (Note 21)              | 755,864           | 691,924           |
| Equity attributable to non-controlling     |                   |                   |
| interests (Note 22)                       | 864               | 973               |
| **Total equity**                           | **756,529**       | **692,897**       |
3. **Consolidated statement of cash flows** in millions of yen

<table>
<thead>
<tr>
<th>Year ended December 31</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash generated from operations (Note 27)</td>
<td>151,857</td>
<td>124,776</td>
</tr>
<tr>
<td>(Increase) decrease in working capital</td>
<td>4,486</td>
<td>14,465</td>
</tr>
<tr>
<td>Payments made for defined benefit plans</td>
<td>(2,652)</td>
<td>(2,483)</td>
</tr>
<tr>
<td>Utilization of provisions (Note 17)</td>
<td>(29)</td>
<td>(34)</td>
</tr>
<tr>
<td>Other operating cash flows</td>
<td>(3,022)</td>
<td>(6,447)</td>
</tr>
<tr>
<td><strong>Cash flows from operating activities, before income taxes paid</strong></td>
<td>150,639</td>
<td>130,278</td>
</tr>
<tr>
<td>Income taxes paid</td>
<td>(31,565)</td>
<td>(22,655)</td>
</tr>
<tr>
<td><strong>Total cash flows from operating activities</strong></td>
<td>119,074</td>
<td>107,623</td>
</tr>
<tr>
<td><strong>Cash flows from investing activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase of property, plant and equipment</td>
<td>(71,785)</td>
<td>(32,881)</td>
</tr>
<tr>
<td>Purchase of intangible assets</td>
<td>(5,886)</td>
<td>(11,645)</td>
</tr>
<tr>
<td>Disposal of property, plant and equipment</td>
<td>49</td>
<td>64</td>
</tr>
<tr>
<td>Disposal of intangible assets</td>
<td>-</td>
<td>452</td>
</tr>
<tr>
<td>Interest and dividends received (Note 17)</td>
<td>200</td>
<td>271</td>
</tr>
<tr>
<td>Purchases of marketable securities</td>
<td>(263,503)</td>
<td>(208,480)</td>
</tr>
<tr>
<td>Sales of marketable securities</td>
<td>264,711</td>
<td>215,510</td>
</tr>
<tr>
<td>Purchases of investment securities</td>
<td>(709)</td>
<td>-</td>
</tr>
<tr>
<td>Sales of investment securities</td>
<td>2,863</td>
<td>-</td>
</tr>
<tr>
<td>Other investing cash flows</td>
<td>(0)</td>
<td>(8)</td>
</tr>
<tr>
<td><strong>Total cash flows from investing activities</strong></td>
<td>(74,060)</td>
<td>(36,718)</td>
</tr>
<tr>
<td><strong>Cash flows from financing activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest paid</td>
<td>(5)</td>
<td>(5)</td>
</tr>
<tr>
<td>Dividends paid to Chugai shareholders</td>
<td>(35,010)</td>
<td>(30,054)</td>
</tr>
<tr>
<td>Dividends paid to non-controlling shareholders</td>
<td>(791)</td>
<td>(944)</td>
</tr>
<tr>
<td>Exercises as part of equity compensation plans (Note 25)</td>
<td>996</td>
<td>922</td>
</tr>
<tr>
<td>(Increase) decrease in own equity instruments</td>
<td>(19)</td>
<td>(20)</td>
</tr>
<tr>
<td>Other financing cash flows</td>
<td>(187)</td>
<td>538</td>
</tr>
<tr>
<td><strong>Total cash flows from financing activities</strong></td>
<td>(35,014)</td>
<td>(29,563)</td>
</tr>
<tr>
<td>Net effect of currency translation on cash and cash equivalents</td>
<td>(2,215)</td>
<td>2,363</td>
</tr>
<tr>
<td><strong>Increase (decrease) in cash and cash equivalents</strong></td>
<td>7,785</td>
<td>43,706</td>
</tr>
<tr>
<td>Cash and cash equivalents at January 1</td>
<td>139,074</td>
<td>95,368</td>
</tr>
<tr>
<td><strong>Cash and cash equivalents at December 31 (Note 14)</strong></td>
<td>146,860</td>
<td>139,074</td>
</tr>
</tbody>
</table>
4. Consolidated statement of changes in equity in millions of yen

<table>
<thead>
<tr>
<th>Year ended December 31, 2017</th>
<th>At January 1, 2017</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Share capital</td>
<td>Capital surplus</td>
<td>Retained</td>
<td>Other reserves</td>
<td>Subtotal</td>
<td>Non-controlling</td>
<td>Total equity</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,422</td>
<td>6,682</td>
<td>5,073</td>
<td>1,042</td>
<td>8,474</td>
<td>822</td>
<td>73,541</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net income</td>
<td>-</td>
<td>-</td>
<td>7,271</td>
<td>-</td>
<td>7,271</td>
<td>827</td>
<td>73,541</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Available-for-sale financial assets (Notes 6 and 21)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cash flow hedges (Notes 6 and 21)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Currency translation of foreign operations (Notes 6, 21 and 22)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Remeasurements of defined benefit plans (Notes 6 and 21)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total comprehensive income</td>
<td>-</td>
<td>-</td>
<td>73,630</td>
<td>1,524</td>
<td>75,154</td>
<td>927</td>
<td>76,081</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dividends (Notes 21 and 22)</td>
<td>-</td>
<td>-</td>
<td>(30,055)</td>
<td>(30,055)</td>
<td>(30,055)</td>
<td>(944)</td>
<td>(30,998)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equity compensation plans (Note 21)</td>
<td>3</td>
<td>102</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Own equity instruments (Note 21)</td>
<td>-</td>
<td>1,213</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>At December 31, 2017</td>
<td>72,967</td>
<td>63,500</td>
<td>507,399</td>
<td>1,642</td>
<td>645,508</td>
<td>989</td>
<td>646,497</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year ended December 31, 2018</th>
<th>At January 1, 2018</th>
<th>Impact of changes in accounting policies</th>
<th>At January 1, 2018 (revised)</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Share capital</td>
<td>Capital surplus</td>
<td>Retained earnings</td>
<td>Other reserves</td>
<td>Subtotal</td>
<td>Non-controlling</td>
<td>Total equity</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>73,000</td>
<td>65,033</td>
<td>618,091</td>
<td>1,270</td>
<td>755,864</td>
<td>664</td>
<td>756,529</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net income</td>
<td>-</td>
<td>-</td>
<td>90,016</td>
<td>2,938</td>
<td>87,078</td>
<td>509</td>
<td>87,587</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial assets measured at fair value through OCI (Notes 6 and 21)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>92,488</td>
<td>92,488</td>
<td>591</td>
<td>93,079</td>
<td></td>
</tr>
<tr>
<td>Cash flow hedges (Notes 6 and 21)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Currency translation of foreign operations (Notes 6, 21 and 22)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Remeasurements of defined benefit plans (Notes 6 and 21)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total comprehensive income</td>
<td>-</td>
<td>-</td>
<td>90,016</td>
<td>2,938</td>
<td>87,078</td>
<td>509</td>
<td>87,587</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dividends (Notes 21 and 22)</td>
<td>-</td>
<td>-</td>
<td>(35,003)</td>
<td>(35,003)</td>
<td>(35,003)</td>
<td>(817)</td>
<td>(35,820)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equity compensation plans (Note 21)</td>
<td>31</td>
<td>(97)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Own equity instruments (Note 21)</td>
<td>1,325</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Transfer from other reserves to retained earnings</td>
<td>-</td>
<td>-</td>
<td>1,498</td>
<td>(1,498)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>At December 31, 2018</td>
<td>73,000</td>
<td>66,043</td>
<td>618,091</td>
<td>1,270</td>
<td>755,864</td>
<td>664</td>
<td>756,529</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Notes to Consolidated Financial Statements

1. **General accounting principles and significant accounting policies**

(1) **Basis of preparation of the consolidated financial statements**
These financial statements are the annual consolidated financial statements of Roche Holding Ltd. ("Roche") which discloses its results in accordance with International Financial Reporting Standards ("IFRS"). The shareholding percentage of Roche Holding Ltd. in Chugai is 59.89% (61.25% of the total number of shares issued excluding own equity instruments). The Group became a principal member of the Roche Group after entering into a strategic alliance in October 2002.

The consolidated financial statements are presented in Japanese yen, which is Chugai’s functional currency and amounts are rounded to the nearest ¥1 million. As a result, the totals shown in the consolidated financial statements do not necessarily agree with the sum of the individual amounts. They have been prepared using the historical cost convention except for items that are required to be accounted for at fair value.

(2) **Key accounting judgments, estimates and assumptions**

The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts. Actual outcomes could differ from those management estimates. The estimates and underlying assumptions are reviewed on an ongoing basis and are based on historical experience and various other factors. Revisions to estimates are recognized in the period in which the estimate is revised. The following are considered to be the key accounting judgments, estimates and assumptions made and are believed to be appropriate based upon currently available information.

**Revenues.**

**Policy applicable from 1 January 2018**

Sales are recorded net of allowances for estimated rebates, cash discounts and estimates of product returns, all of which are established at the time of sale. The estimated rebates, chargebacks, cash discounts and estimates of product returns are recorded as current liabilities. The Group makes accruals for expected sales rebates, which are estimated based on analyses of existing contractual or legislatively-mandated obligations, historical trends and the Group’s experience. As these deductions are based on management estimates, they may be subject to change as better information becomes available. Such changes that arise could impact the accruals recognized in the balance sheet in future periods and consequently the level of sales recognized in the income statement in future periods.

Out-licensing agreements may be entered into with no further obligation or may include commitments to conduct research, late-stage development, regulatory approval, co-marketing or manufacturing. These may be settled by a combination of upfront payments, milestone payments, and reimbursements for services provided. Whether to consider these commitments as a single performance obligation or separate ones, or even being in scope of IFRS 15 ‘Revenues from Contracts with Customers’, is not straightforward and requires some judgement. Depending on the conclusion, this may result in all revenue being calculated at inception and either being recognized at once or spread over the term of a longer performance obligation.

As a practical expedient, the Group does not adjust the promised amount of consideration for the effects of a significant financing component, if the group expects, at contract inception, that the period between when the group transfers a promised good or service to a customer and when the customer pays for that good or service will be one year or less.
Policy applicable before 1 January 2018
Revenues are only recognized when, in management’s judgment, the significant risks and rewards of ownership have been transferred and when the Group does not retain continuing managerial involvement or effective control over the goods sold or when the obligation has been fulfilled. The Group is party to out-licensing agreements which involve upfront and milestone payments occurring over several years and which may also involve certain future obligations. Therefore, for some transactions this can result in cash receipts being initially recognized as deferred income and then released to income over subsequent periods on the basis of the performance of the conditions specified in the agreement.

The Group makes accruals for expected sales rebates, which are estimated based on analyses of existing contractual or legislatively-mandated obligations, historical trends and the Group’s experience.

As these deductions are based on management estimates, they may be subject to change as better information becomes available.

Such changes that arise could impact the accruals recognized in the balance sheet in future periods and consequently the level of sales recognized in the income statement in future periods.

Impairment. Intangible assets not yet available for use are reviewed annually for impairment. Property, plant and equipment and intangible assets in use are assessed for impairment when there is a triggering event that provides evidence that an asset may be impaired. To assess whether any impairment exists estimates of expected future cash flows are used. Actual outcomes could vary significantly from such estimates of discounted future cash flows. Factors such as changes in discount rates, the planned use of buildings, machinery or equipment, closure of facilities, the presence or absence of competition, technical obsolescence and lower than anticipated product sales could lead to shorter useful lives or impairment.

Post-employment benefits. The Group operates a number of defined benefit plans and the fair values of the recognized plan assets and liabilities are based upon statistical and actuarial calculations. The measurement of the net defined benefit obligation is particularly sensitive to changes in the discount rate and expected mortality. The actuarial assumptions used may differ materially from actual results due to changes in market and economic conditions, longer or shorter life spans of participants, and other changes in the factors being assessed. These differences could impact on the defined benefit plan assets or liabilities recognized in the balance sheet in future periods.

Legal. The Group provides for anticipated legal settlement costs when there is a probable outflow of resources that can be reliably estimated. Where no reliable estimate can be made, no provision is recorded and contingent liabilities are disclosed where material. The status of significant legal cases is disclosed in Additional Information. These estimates consider the specific circumstances of each legal case and relevant legal advice, and are inherently judgmental due to the highly complex nature of legal cases. The estimates could change substantially over time as new facts emerge and each legal case progresses.

Environmental. The Group provides for anticipated environmental remediation costs when there is a probable outflow of resources that can be reasonably estimated. Environmental provisions consist primarily of costs to fully clean and refurbish contaminated sites, including landfills, and to treat and contain contamination at certain other sites. These estimates are inherently judgmental due to uncertainties related to the detection of previously unknown contaminated sites, the method and extent of remediation, the percentage of the problematic materials attributable to the Group at the remediation sites, and the financial capabilities of the other potentially responsible parties. The estimates could change substantially over time as new facts emerge and each environmental remediation progresses.

Income taxes. Significant estimates are required to determine the current and deferred tax assets and liabilities. Some of these estimates are based on interpretations of existing tax laws or regulations. Where tax positions are uncertain, accruals are recorded within income tax liabilities for management’s best estimate of the ultimate liability that is expected to arise based on the specific circumstances and the Group’s historical experience. Factors that may have an impact on current and deferred taxes include changes in tax laws, regulations or rates, changing interpretations of existing tax laws or regulations, future levels of research and development spending and changes in pre-tax earnings.

Leases. The treatment of leasing transactions is mainly determined by whether the lease is considered to be an operating or finance lease. In making this assessment, management looks at the substance of the lease, as well as the legal form, and makes a judgment about whether substantially all of the risks and rewards of ownership are transferred. Arrangements which do not take the legal form of a lease but that nevertheless convey the right to use an asset are also covered by such assessments.
(3) Accounting policies

Consolidation policy

Subsidiaries are all companies over which the Group has control. Chugai controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Companies acquired during the year are consolidated from the date on which control is transferred to the Group, and subsidiaries to be divested are included up to the date on which control passes from the Group. Inter-company balances, transactions and resulting unrealized income are eliminated in full. Changes in ownership interests in subsidiaries are accounted for as equity transactions if they occur after control has already been obtained and if they do not result in a loss of control. Associates are companies over which the Group exercises, or has the power to exercise, significant influence, but which it does not control and they are accounted for using the equity method.

Foreign currency translation

Most foreign subsidiaries of the Group use their local currency as their functional currency. Certain foreign subsidiaries use other currencies (such as the euro) as their functional currency where this is the currency of the primary economic environment in which the entity operates. Local transactions in other currencies are initially reported using the exchange rate at the date of the transaction. Gains and losses from the settlement of such transactions and gains and losses on translation of monetary assets and liabilities denominated in other currencies are included in income, except when they are qualifying cash flow hedges. In such cases the gains and losses are deferred into other comprehensive income.

Upon consolidation, assets and liabilities of foreign subsidiaries using functional currencies other than Japanese yen are translated into Japanese yen using year-end rates of exchange. The income statement and statement of cash flows are translated at the average rates of exchange for the year. Translation differences due to the changes in exchange rates between the beginning and the end of the year and the difference between net income translated at the average and year-end exchange rates are taken directly to other comprehensive income.

Revenue

Policy applicable from 1 January 2018

Sales. Revenue from the sale of goods supplied is recorded as 'Sales'. Sales are recognized when a promise in a customer contract (performance obligation) has been satisfied by transferring control over the promised goods to the customer. Control over a promised good refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from, those goods. Control is usually transferred upon shipment or delivery to or upon receipt of goods by the customer, in accordance with the delivery and acceptance terms agreed with the customers.

The amount of sales to be recognized (transaction price) is based on the consideration the Group expects to receive in exchange for its goods, excluding amounts collected on behalf of third parties such as consumption tax or other taxes directly linked to sales. The Group recognises a deferred income (contract liability) if consideration has been received (or has become receivable) before the Group transfers the promised goods to the customer.

Royalty and other operating income. ‘Royalty and other operating income’ includes royalty income, income from out-licensing agreements and income from disposal of products and other items.

Revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property is recognized when the subsequent sale or usage occurs.

Income from out-licensing agreements typically arises from the receipt of upfront, milestone and other similar payments from third parties for granting a license to product or technology related intellectual property (IP). Out-licensing agreements may be entered into with no further obligation or may include commitments to conduct research, late-stage development, regulatory approval, co-marketing or manufacturing. Licenses granted are usually rights to use IP and generally unique. Therefore the basis of allocating revenue to performance obligations makes use of the residual approach. Upfront payments and other licensing fees are usually recognized upon granting the license unless some of the income shall be deferred for other performance obligations using the residual approach. Such deferred income is released and recognized as revenue when other performance obligations are satisfied. Milestone income is recognized at the point in time when it is highly probable that the respective milestone event criteria is achieved, and the risk of revenue reversal is considered remote.

Payments received for the disposal of product and similar rights are recognized as revenue upon transfer of control over such rights. To the extent that some of these payments relate to other performance obligations, a portion is deferred using the residual approach and recognized as revenue when performance obligations are satisfied.

Income from profit-sharing arrangements with collaboration partners is recognized as underlying sales and cost of sales are recorded by the collaboration partners.
Policy applicable before 1 January 2018

Sales represent amounts received and receivable for goods supplied to customers after deducting trade discounts, cash discounts and volume rebates, and exclude consumption taxes and other taxes directly linked to sales. Revenues from the sale of products are recognized upon transfer to the customer of significant risks and rewards. Trade discounts, cash discounts and volume rebates are recorded on an accrual basis consistent with the recognition of the related sales. Sales returns, charge-backs and other rebates are also deducted from sales and recorded as accrued liabilities or as a deduction from accounts receivable.

Royalties and other operating income are recorded as earned or as the services are performed. Single transactions are split into separately identifiable components to reflect the substance of the transaction, where necessary. Conversely, two or more transactions may be considered together for revenue recognition purposes, where the commercial effect cannot be understood without reference to the series of transactions as a whole.

Royalty income is recognized on an accrual basis in accordance with the substance of the respective licensing agreements. If the collectability of a royalty amount is not reasonably assured, those royalties are recognized as revenues when the cash is received. The Group receives upfront, milestone and other similar payments from third parties relating to the sale or licensing of products or technology. Revenues associated with performance milestones are recognized based on achievement of the deliverables as defined in the respective agreements. Upfront payments and license fees for which there are subsequent deliverables are initially reported as deferred income and are recognized in income as earned over the period of the development collaboration or the manufacturing obligation.

Cost of sales

Cost of sales includes the corresponding direct production costs and related production overheads of goods sold and services rendered. Royalties, alliance and collaboration expenses, including all collaboration profit-sharing arrangements are also reported as part of cost of sales. Start-up costs between validation and the achievement of normal production capacity are expensed as incurred.

Research and development

Internal research and development activities are expensed as incurred for the following:

• Internal research costs incurred for the purpose of gaining new scientific or technical knowledge and understanding.
• Internal development costs incurred for the application of research findings or other knowledge to plan and develop new products for commercial production. The development projects undertaken by the Group are subject to technical, regulatory and other uncertainties, such that, in the opinion of management, the criteria for capitalization as intangible assets are not met prior to obtaining marketing approval by the regulatory authorities in major markets.
• Post-marketing studies after regulatory approval, such as phase IV costs in the pharmaceuticals business, generally involve safety surveillance and on-going technical support of a drug after it receives marketing approval to be sold. They may be required by regulatory authorities or may be undertaken for safety or commercial reasons. The costs of such post-marketing studies are not capitalized as intangible assets, as in the opinion of management, they do not generate separately identifiable incremental future economic benefits that can be reliably measured.

Acquired in-process research and development resources obtained through in-licensing arrangements, business combinations or separate asset purchases are capitalized as intangible assets. The acquired asset must be controlled by the Group, be separately identifiable and expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for pharmaceutical products or compounds before regulatory marketing approval are recognized as intangible assets. Assets acquired through such arrangements are measured on the basis set out in the “Intangible assets” policy. Subsequent internal research and development costs incurred post-acquisition are treated in the same way as other internal research and development costs. If research and development are embedded in contracts for strategic alliances, the Group carefully assesses whether upfront or milestone payments constitute funding of research and development work or acquisition of an asset.

Employee benefits

Short-term employee benefits include wages, salaries, social security contributions, paid annual leave and sick leave, profit sharing and bonuses, and non-monetary benefits for current employees. The costs are recognized within the operating results when the employee has rendered the associated service. The Group recognizes a liability for profit sharing and bonuses where contractually obliged or where there is a past practice that has created a constructive obligation.

Termination benefits are payable when employment is terminated by the Group before the normal retirement date, or whenever an employee accepts voluntary redundancy in exchange for these benefits. Termination costs are recognized at
the earlier of when the Group can no longer withdraw the offer of the benefits or when the Group recognizes any related restructuring costs.

Post-employment benefits
For defined contribution plans, the Group contributions are recognized within the operating results when the employee has rendered the associated service.

For defined benefit plans the liability or asset recognized in the balance sheet is net amount of the present value of the defined benefit obligation and the fair value of the plan assets. All changes in the net defined benefit liability (asset) are recognized as they occur as follows:

Recognized in the income statement:
- Current service costs are charged to the appropriate income statement heading within the operating results.
- Past service costs, including curtailment gains or losses, are recognized immediately in general and administration within the operating results.
- Settlement gains or losses are recognized in general and administration within the operating results.
- Net interest on the net defined benefit liability (asset) is recognized in financing costs.

Recognized in other comprehensive income:
- Actuarial gains and losses arising from experience adjustments (the difference between previous assumptions and what has actually occurred) and changes in actuarial assumptions.
- The return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset).

Net interest on the net defined benefit liability (asset) comprises interest income on plan assets and interest costs on the defined benefit obligation. The net interest is calculated using the same discount rate that is used in calculating the defined benefit obligation, applied to the net defined benefit liability (asset) at the start of the period, taking account of any changes from contribution or benefit payments.

Pension assets and liabilities in different defined benefit plans are not offset unless the Group has a legally enforceable right to use the surplus in one plan to settle obligations in the other plan.

Equity compensation plans
The fair value of all equity compensation awards, including restricted stocks, granted to directors and certain employees is estimated at the grant date and recorded as an expense over the vesting period. The expense is charged to the appropriate income statement heading within the operating results. For equity-settled plans, an increase in equity is recorded for this expense and any subsequent cash flows from exercises of vested awards are recorded as changes in equity.

Property, plant and equipment
Property, plant and equipment are initially recorded at cost of purchase or construction, and include all costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. These include items such as costs of site preparation, installation and assembly costs and professional fees. The net costs of testing whether the asset is functioning properly, including validation costs, are also included in the initially recorded cost of construction. Property, plant and equipment are depreciated on a straight-line basis, except for land, which is not depreciated. The estimated useful lives of major classes of depreciable assets are as follows:

- Land improvements: 40 years
- Buildings: 10-50 years
- Machinery and equipment: 3-15 years

Where parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate components. The estimated useful lives of the assets are regularly reviewed, and, if necessary, the future depreciation charges are accelerated. Repairs and maintenance costs are expensed as incurred.

Leases
Where the Group is the lessee, finance leases exist when substantially all of the risks and rewards of ownership are transferred to the Group. Finance leases are capitalized at the start of the lease at fair value, or the present value of the minimum lease payments, if lower. The rental obligation, net of finance charges, is reported within debt. Finance lease assets are depreciated over the shorter of the lease term and its useful life. The interest element of the lease payment is charged against income over the lease term based on the effective interest rate method. Operating leases exist when substantially all of the risks and rewards of ownership are not transferred to the Group. Payments made under operating leases are charged against income on a straight-line basis over the period of the lease.
Intangible assets
Purchased patents, trademarks, licenses and other intangible assets are initially recorded at cost. Assets that have been acquired through a business combination are initially recorded at fair value. Once available for use, intangible assets are amortized on a straight-line basis over their useful lives. The estimated useful life is the lower of the legal duration and the economic useful life. The estimated useful lives of intangible assets are regularly reviewed. Estimated useful lives of major classes of amortizable intangible assets are as follows:

- Product intangibles in use: 10–17 years
- Marketing intangibles in use: 5 years
- Technology intangibles in use: 7–9 years

Impairment of property, plant and equipment and intangible assets
An impairment assessment is carried out at each reporting date when there is evidence that an item of property, plant and equipment or intangible asset in use may be impaired. In addition intangible assets that are not yet available for use are tested for impairment annually. When the recoverable amount of an asset, being the higher of its fair value less costs to sell and its value in use, is less than its carrying value, then the carrying value is reduced to its recoverable amount. This reduction is reported in the income statement as an impairment loss. Value in use is calculated using estimated cash flows. These are discounted using an appropriate long-term interest rate. When an impairment loss arises, the useful life of the asset is reviewed and, if necessary, the future depreciation/amortization charge is accelerated. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through the income statement as an impairment reversal.

Inventories
Inventories are stated at the lower of cost and net realisable value. The cost of finished goods, work in process and intermediates includes raw materials, direct labour and other directly attributable costs and overheads based upon the normal capacity of production facilities. Cost is determined using the weighted average method. Net realisable value is the estimated selling price less cost to completion and selling expenses.

Accounts receivable
Policy applicable from 1 January 2018
Accounts receivable are carried at the original invoice amount less allowances made for doubtful accounts, trade discounts, cash discounts, volume rebates and similar allowances. A receivable represents a right to consideration that is unconditional and excludes contract assets. The Group always measures an allowance for doubtful accounts that result from transactions that are within the scope of IFRS 15 equal to the credit losses expected over the lifetime of the trade receivables. These estimates are based on specific indicators, such as the ageing of customer balances, specific credit circumstances and the Group’s historical loss rates for each category of customers, and adjusted for forward looking macroeconomic data. While the Group measures an allowance for doubtful accounts that result from transactions that are not within the scope of IFRS 15 equal to 12-months expected credit losses, when the credit risk for these accounts has not increased significantly since initial recognition.

Expenses for doubtful trade receivables are recognized within marketing and distribution expenses. Trade discounts, cash discounts, volume rebates and similar allowances are recorded on an accrual basis consistent with the recognition of the related sales, using estimates based on existing contractual obligations, historical trends and the Group’s experience. Accounts receivable are written off (either partially or in full) when there is no reasonable expectation of recovery. Where receivables have been written off, the Group continues to engage in enforcement activities to attempt to recover the receivable due. Where recoveries are made, these are recognized in profit or loss.

Policy applicable before 1 January 2018
Accounts receivable are carried at the original invoice amount less allowances made for doubtful accounts, trade discounts, cash discounts, volume rebates and similar allowances. An allowance for doubtful accounts is recorded where there is objective evidence that the Group will not be able to collect all amounts due. These estimates are based on specific indicators, such as the ageing of customer balances, specific credit circumstances and the Group’s historical experience, taking also into account economic conditions.

Expenses for doubtful trade receivables are recognized within marketing and distribution expenses.

Trade discounts, cash discounts, volume rebates and similar allowances are recorded on an accrual basis consistent with the recognition of the related sales, using estimates based on existing contractual obligations, historical trends and the Group’s experience.
Cash and cash equivalents
Cash and cash equivalents include cash on hand and time, call and current balances with banks and similar institutions. Such balances are only reported as cash equivalents if they are readily convertible to known amounts of cash, are subject to insignificant risk of changes in their fair value and have a maturity of three months or less from the date of acquisition.

Provisions and contingencies
Provisions are recognized where a legal or constructive obligation has been incurred which will probably lead to an outflow of resources that can be reliably estimated. In particular, restructuring provisions are recognized when the Group has a detailed formal plan that has either commenced implementation or has been announced. Provisions are recorded for the estimated ultimate liability that is expected to arise and are discounted when the time value of money is material. A contingent liability is disclosed where the existence of the obligation will only be confirmed by future events or where the amount of the obligation cannot be measured with reasonable reliability. Contingent assets are not recognized, but are disclosed where an inflow of economic benefits is probable.

Fair values
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. It is determined by reference to quoted market prices or by the use of established valuation techniques such as option pricing models and the discounted cash flow method if quoted prices in an active market are not available.

Financial instruments
Policy applicable from 1 January 2018
The Group classifies its financial assets, with the exception of derivatives, in the following measurement categories: amortized cost; fair value through OCI; fair value through profit or loss.

The classification depends on the Group’s business model for managing the financial assets and the contractual terms of the cash flows. The Group reclassifies debt securities and financial assets measured at amortized cost when and only when its business model for managing those assets changes.

At initial recognition, the Group measures a financial asset at its fair value excluding trade receivables at transaction price if it does not contain a significant financing component. In the case of a financial asset not at fair value through profit or loss, transaction costs that are directly attributable to the acquisition of the financial asset are added to the fair value.

Financial assets measured at amortized cost: Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. A gain or loss on a debt security that is subsequently measured at amortized cost and is not part of a hedging relationship is recognized in profit or loss when the asset is derecognized or impaired. Interest income from these financial assets is included in other financial income using the effective interest rate method. Financial assets measured at amortized cost are mainly comprised of accounts receivable, cash and cash equivalents and time accounts over three months.

Financial assets measured at fair value through other comprehensive income (fair value through OCI): These are financial assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets’ cash flows represent solely payments of principal and interest. These assets are initially recorded and subsequently carried at fair value. Changes in the fair value are recorded in other comprehensive income, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses which are recognized in profit and loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss. Interest income from these financial assets is included in other financial income using the effective interest rate method. Financial assets measured at fair value through other comprehensive income are mainly comprised of money market instruments.

Equity instruments measured at fair value through other comprehensive income (fair value through OCI): These are equity instruments measured at fair value through OCI for which an irrevocable election at initial recognition has been made, to present subsequent changes in fair value in other comprehensive income. Dividends are recognized as other financial income in profit or loss. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss. When the instruments are derecognized, the cumulative amount of other comprehensive income is transferred to retained earnings.

The Group classifies its financial liabilities as measured at amortized cost, except for derivatives. Financial liabilities are initially recorded at fair value, less transaction costs and subsequently carried at amortized cost using the effective interest rate method. Financial liabilities are mainly comprised of trade payables.
Derivative financial instruments that are used to manage the exposures to foreign currency exchange rate fluctuations are initially recorded and subsequently carried at fair value. Apart from those derivatives designated as qualifying cash flow hedging instruments, all changes in fair value are recorded as other financial income (expense).

**Policy applicable before 1 January 2018**

Financial instruments are classified into the following categories:

**Available-for-sale.** These are non-derivative financial assets that are either designated as such or are not classified in any other financial asset category. Available-for-sale financial assets are initially recorded and subsequently carried at fair value. Changes in fair value are recorded in other comprehensive income, except for impairments, interest and foreign exchange components. When an investment is derecognized the cumulative gains and losses in equity are reclassified to other financial income (expense). Available-for-sale assets are mainly comprised of marketable securities and financial non-current assets.

**Fair value – hedging instruments.** These are derivative financial instruments that are used to manage the exposures to foreign currency risk. Derivative financial instruments are initially recorded and subsequently carried at fair value. Apart from those derivatives designated as qualifying cash flow hedging instruments, all changes in fair value are recorded as other financial income (expense).

**Fair value – designated.** These are non-derivative financial instruments that are designated as fair value through profit or loss on initial recognition. Designated fair value instruments are initially recorded and subsequently carried at fair value. Changes in fair value are recorded in the income statement. Designated fair value instruments mainly comprise of financial assets held for trading.

**Loans and receivables.** These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recorded at fair value and subsequently carried at amortized cost using the effective interest rate method, less any impairment losses. Loans and receivables are mainly comprised of accounts receivable, cash and cash equivalents and a part of financial non-current assets.

**Other financial liabilities.** These are non-derivative financial liabilities. Other financial liabilities are initially recorded at fair value and subsequently carried at amortized cost using the effective interest rate method. Other financial liabilities are mainly comprised of accounts payable and debt.

**Derecognition of financial instruments**

**Policy applicable from 1 January 2018**

A financial asset is derecognized when the contractual rights to the cash flows from the asset expire or when the Group transfers the rights to receive the contractual cash flows from the financial assets in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. A financial liability is derecognized when the contractual obligations are discharged, cancelled or expire.

**Policy applicable before 1 January 2018**

A financial asset is derecognized when the contractual cash flows from the asset expire or when the Group transfers the rights to receive the contractual cash flows from the financial assets in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. A financial liability is derecognized when the contractual obligations are discharged, cancelled or expire.

**Impairment of financial assets**

**Policy applicable from 1 January 2018**

The Group recognises loss allowances for expected credit losses (‘ECL’) for financial assets measured at amortized cost and debt securities measured at fair value through OCI.

The Group always measures loss allowance that result from transactions that are within the scope of IFRS 15 equal to the credit losses expected over the lifetime of the trade receivables.

The Group measures loss allowances at an amount equal to 12-month expected credit losses for its debt securities carried at fair value through OCI and at amortized cost when the credit risk for these accounts has not increased significantly since initial recognition at the reporting date. The Group considers a debt investment to have low credit risk when their credit risk rating is equivalent to the globally understood definition of ‘investment grade’. The Group considers this to be at least Baa3 from Moody’s and BBB-from S&P.
The Group measures the allowances for doubtful account at an amount equal to lifetime ECL for its debt investments at fair value through OCI and at amortized cost on which credit risk has increased significantly since their initial recognition. The Group assumes that the credit risk on a financial asset has increased significantly if it is more than 30 days past due.

The Group considers a financial asset to be in default when the counterparty is unlikely to pay its obligations to the Group in full. In assessing whether a counterparty is in default, the Group considers both qualitative and quantitative indicators that are based on data developed internally and for certain financial assets also obtained from external sources.

Financial assets are written off (either partially or in full) when there is no realistic prospect of recovery. This is generally the case when the Group determines that the customer does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that are written off are still subject to enforcement activities in order to comply with the Group’s policy for recovery of amounts due.

**Policy applicable before 1 January 2018**

Financial assets are individually assessed for possible impairment at each reporting date. An impairment charge is recorded where there is objective evidence of impairment, such as where the issuer is in bankruptcy, default or other significant financial difficulty. Available-for-sale equity securities that have a market value of more than 25% below their original cost, or have a market value below their original cost for a sustained six-month period will be considered as impaired.

For financial assets carried at amortized cost, any impairment charge is the difference between the carrying value and the recoverable amount, calculated using estimated future cash flows discounted using the original effective interest rate. For available-for-sale financial assets, any impairment charge is the amount currently carried in other comprehensive income for the difference between the original cost, net of any previous impairment, and the fair value.

An impairment loss is reversed if the reversal can be related objectively to an event occurring after the impairment loss was recognized. For equity securities held as available-for-sale, the reversal is recognized directly in other comprehensive income. For debt securities measured at amortized cost or available-for-sale, the reversal is recognized in other financial income (expense).

**Hedge accounting**

The Group uses derivatives to manage its exposures to foreign currency risk. The instruments used may include forwards contracts. The Group generally limits the use of hedge accounting to certain significant transactions. To qualify for hedge accounting the hedging relationship must meet several strict conditions on documentation, probability of occurrence, hedge effectiveness and reliability of measurement. While many of these transactions can be considered as hedges in economic terms, if the required conditions are not met, then the relationship does not qualify for hedge accounting. In this case the hedging instrument and the hedged item are reported independently as if there were no hedging relationship, which means that any derivatives are reported at fair value, with changes in fair value included in other financial income (expense).

Cash flow hedge. Is a hedge of the exposure to variability in cash flows that is attributable to a particular risk associated with a recognized asset or liability or a highly probable forecast transaction and could affect profit or loss. The hedging instrument is recorded at fair value. The effective portion of the hedge is included in other comprehensive income and any ineffective portion is reported in other financial income (expense). If the hedging relationship is the hedge of the foreign currency risk of a firm commitment or highly probable transaction, when that transaction results in the recognition of a non-financial item, the cumulative changes in the fair value of the hedging instrument that have been recorded in other comprehensive income are included in the initial carrying value of the non-financial item at the date of recognition, otherwise included in profit or loss when the hedged transaction affects net income.

For other hedged forecasted cash flows, the cumulative changes in the fair value of the hedging instrument that have been recorded in other comprehensive income, are included in other financial income (expense) when the forecasted transaction affects net income.

**Taxation**

Income taxes include all taxes based upon the taxable profits of the Group. Other taxes not based on income, such as property and capital taxes, are included in the appropriate heading within the operating results.

Liabilities for income taxes, which could arise on the remittance of retained earnings, principally relating to subsidiaries, are only recognized where it is probable that such earnings will be remitted in the foreseeable future. Where the amount of tax liabilities is uncertain, accruals are recorded within income tax liabilities for management’s best estimate of the ultimate liability that is expected to arise based on the specific circumstances and the Group’s historical experience.
Deferred tax assets and liabilities are recognized on temporary differences between the tax bases of assets and liabilities and their carrying values. Deferred tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the unused tax losses can be utilized.

Current and deferred tax assets and liabilities are offset when the income taxes are levied by the same taxation authority and when there is a legally enforceable right to offset them. Deferred taxes are determined based on the currently enacted tax rates applicable in each tax jurisdiction where the Group operates.

**Own equity instruments**

The Group’s holdings in its own equity instruments are recorded as a deduction from equity. The original purchase cost, consideration received for subsequent resale of these equity instruments and other movements are reported as changes in equity. The exercise of stock acquisition rights granted to directors and certain employees will result in the allotment from own equity instruments.

**(4) Significant accounting policies**

The Group applies the same significant accounting policies that are used for the previous fiscal year to the Consolidated Financial Statements, except for those stated in (5) Changes in accounting policies below.

**(5) Changes in accounting policies**

In 2018 the Group implemented the following new standards, including any consequential amendments to other standards, with a date of initial application of January 1, 2018.

- IFRS 9 ‘Financial Instruments’
- IFRS 15 ‘Revenue from Contracts with Customers’

The nature and the effects of the changes most relevant to the Group’s Consolidated Financial Statements are given below.

**IFRS 9 ‘Financial Instruments’**

Effective January 1, 2018 the Group has implemented IFRS 9 ‘Financial Instruments.’ The new standard replaces IAS 39 ‘Financial Instruments: Recognition and Measurement.’ The standard deals with the classification, recognition and measurement (including impairment) of financial instruments and also introduces a new hedge accounting model.

There is no material impact on the Group’s performance or financial position from the application of this standard.

**Classification and measurement of financial instruments.**

In accordance with the transitional provisions of IFRS 9, financial instruments are classified, on the basis of the facts and circumstances that exist at the date of initial application, as follows: Items such as equity securities and debt securities which were previously classified as available-for-sale under IAS 39, with the exception of time accounts over three months, are classified as financial assets measured at fair value through other comprehensive income (OCI), and time accounts over three months as amortized cost. Though the Group takes advantage of the exemption allowing it not to restate comparative information for prior periods with respect to classification and measurement changes, since there were no changes in the carrying amounts, no adjustments were made to retained earnings as of January 1, 2018.

Changes in the fair value of equity instruments designated as financial assets measured at fair value through other comprehensive income are recognized in other comprehensive income, and the cumulative amount of other comprehensive income is transferred to retained earnings when the instruments are derecognized.

**Impairment of financial assets.**

On January 1, 2018 the Group changed the methodology of assessing impairment of its financial assets from the incurred loss model (used in IAS 39) to the expected credit loss model (used in IFRS 9). The new impairment model is applied to financial assets measured at amortized cost and debt securities measured at fair value through OCI, but not equity securities. In accordance with the transitional provisions of IFRS 9, the Group has not restated prior periods but it has reassessed the impairment allowances under the expected credit loss model as of January 1, 2018.

**Hedge accounting.**

As the Group may continue to apply the hedge accounting requirements of IAS 39 instead of those in IFRS 9 at the initial application of IFRS 9, the Group has chosen to continue to apply the hedge accounting requirements of IAS 39.
IFRS 15 ‘Revenue from Contracts with Customers’
Effective January 1, 2018 the Group has implemented IFRS 15 ‘Revenue from contracts with customers.’ The new standard replaces IAS 18 ‘Revenue’ and IAS 11 ‘Construction Contracts.’ IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognized, and also contains new requirements related to presentation. The core principle in that framework is that revenue should be recognized dependent on the transfer of promised goods or services to the customer for an amount that reflects the consideration which should be received in exchange for those goods or services. The objective of the standard is to provide a five-step approach to revenue recognition that includes identifying contracts with customers, identifying performance obligations, determining transaction prices, allocating transaction prices to performance obligations, and recognizing revenue when or as performance obligations are satisfied. Judgement will need to be applied, including making estimates and assumptions, for multiple-element contracts in identifying performance obligations, in constraining estimates of variable consideration and in allocating the transaction price to each performance obligation. The new standard results in an increased volume of disclosure information in the Annual Financial Statements.

Changes introduced by the standard relevant to the Group.
The new standard provides new requirements and additional guidance that are relevant to the Group, notably on the following areas:

- Revenues from licenses of intellectual property, including sales-based royalties, on constraining estimates of variable consideration such as e.g. development milestones that may be regarded as a separate performance obligation involving variable consideration. There is no material impact from these changes.
- The new standard also clarifies how to allocate sales, including the treatment of discounts, to each element in multiple-elements contracts and when to recognize sales for each of those elements. It requires the use of estimates and assumptions and some judgement to apply this guidance in practice. There is no material impact from this guidance.
- Out-licensing contracts may be entered into with no further obligation or may include commitments to research, late-stage development, regulatory approval, co-marketing or manufacturing. These may be settled by a combination of up-front payments, milestone payments, and reimbursements for services provided. Whether to consider these commitments as a single performance obligation or separate ones is not straight-forward and requires some judgement. Depending on the conclusion, this may result in all revenue being calculated at inception and either being recognized at once or spread over the term of a longer performance obligation. With the application of this standard, upfront payment received, which was formerly recognized over time as deferred income, is recognized as one-time income on out-licensing.

Transition approach.
The Group recognizes the cumulative effect of applying the new standard at the date of initial application, with no restatement of the comparative periods presented. It records the cumulative effect, the amount of ¥10,606 million after tax effect, as an adjustment to the opening balance of retained earnings at the date of initial application. Except for this adjustment, there is no material impact on the Group’s performance or financial position from the application of this standard.

(6) Future new and revised standards
Of the new and revised standards that have been issued by the International Accounting Standards Board (IASB) by the date of approval of the Consolidated Financial Statements, the Group will implement the following from 2019.

Although there were other new establishments, minor revisions, etc. to the standards, the Group believes there is no material impact on the Group’s performance or financial position.

1) Standards that will be effective from January 1, 2019
IFRS 16 Leases
The main impact of the new standard will be to bring operating leases (lessee) on-balance sheet. In applying this standard, the Group will adopt a method that recognizes the cumulative effect at the date of initial application, which is permitted as a transitional measure.

The Group is assessing the potential impact, but currently anticipates that the new standard will result in the carrying value of leased assets being increased by approximately ¥15.0 billion, with lease liabilities increased by a similar amount at the date of implementation. The application of the new standard will result in part of what are currently reported as operating lease costs being recorded as interest expenses. Given the leases involved and the current low interest rate
environment, the Group does not currently expect this effect to be material. The new standard will also result in an increased volume of disclosure information in the Annual Financial Statements.

2) Standards that will be effective from January 1, 2020 and beyond
The Group is currently assessing the potential impacts of new standards and interpretations that will be effective from January 1, 2020 and beyond.
2. Operating segment information

The Group has a single business of pharmaceuticals and does not have multiple operating segments. The Group’s pharmaceuticals business consists of the research and development of new prescription medicines and the subsequent manufacturing, marketing and distribution activities. These functional activities are integrated and managed effectively.

Information on revenues by geographical area in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sales</td>
<td>Royalties and other</td>
<td>Sales</td>
<td>Royalties and other</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>operating income</td>
<td></td>
<td>operating income</td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>399,906</td>
<td>21,569</td>
<td>405,260</td>
<td>5,635</td>
<td></td>
</tr>
<tr>
<td>Overseas</td>
<td>127,939</td>
<td>30,374</td>
<td>94,028</td>
<td>29,256</td>
<td></td>
</tr>
<tr>
<td>of which Switzerland</td>
<td>109,938</td>
<td>24,250</td>
<td>76,359</td>
<td>28,957</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>527,844</td>
<td>51,943</td>
<td>499,308</td>
<td>34,891</td>
<td></td>
</tr>
</tbody>
</table>

Information on revenues by major customers in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Revenues</td>
<td>Revenues</td>
</tr>
<tr>
<td>F. Hoffmann-La Roche Ltd.</td>
<td>134,188</td>
<td>105,262</td>
</tr>
<tr>
<td>Alfresa Corporation</td>
<td>103,959</td>
<td>104,952</td>
</tr>
<tr>
<td>Mediceo Corporation</td>
<td>76,004</td>
<td>80,390</td>
</tr>
</tbody>
</table>

3. Revenue

Disaggregated revenue information in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sales</td>
<td>Revenue from contracts with customers</td>
<td>Revenue from other sources</td>
</tr>
<tr>
<td>Sales</td>
<td>525,643</td>
<td>2,202</td>
<td>527,844</td>
</tr>
<tr>
<td>Japan</td>
<td>399,906</td>
<td>-</td>
<td>399,906</td>
</tr>
<tr>
<td>Overseas</td>
<td>125,737</td>
<td>2,202</td>
<td>127,939</td>
</tr>
<tr>
<td>Royalties and other operating income</td>
<td>40,803</td>
<td>11,140</td>
<td>51,943</td>
</tr>
<tr>
<td>Royalty and profit-sharing income</td>
<td>12,942</td>
<td>11,140</td>
<td>24,082</td>
</tr>
<tr>
<td>Other operating income</td>
<td>27,861</td>
<td>-</td>
<td>27,861</td>
</tr>
</tbody>
</table>

For an explanation of the effects for the revenue from contracts with customers from the application of IFRS 15, please refer to "Changes in accounting policies" on Note 1 (4). The Group does not restate the information for the comparative periods, when IFRS 15 is first applied. The revenue from other sources primarily relates to collaboration income for which the counterparty is not considered a customer, such as income from profit-sharing arrangements and the gains or losses from hedge.
Contract balances in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>January 1, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receivables-contracts from customers</td>
<td>162,879</td>
<td>155,951</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>150,804</td>
<td>148,495</td>
</tr>
<tr>
<td>Other current receivable</td>
<td>12,075</td>
<td>7,456</td>
</tr>
<tr>
<td>Contract assets</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Contract liabilities</td>
<td>206</td>
<td>-</td>
</tr>
</tbody>
</table>

In 2018 there was revenue recognized of ¥17,364 million relating to performance obligations that were satisfied in previous periods, mainly due to royalty and milestone revenue.

Transaction price allocated to the remaining performance obligations

There is no material impact for transaction price allocated to the remaining obligations which has an original expected duration of more than one year as of December 31, 2018. As a practical expedient, the Group does not disclose the information for the remaining performance obligations. The performance obligation is part of a contract that has an original expected duration of one year or less.

There is no material amounts which do not include the transaction price in the consideration from the contracts with customers.

4. Financing costs and other financial income (expense)

Financing costs in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest expense</td>
<td>(5)</td>
<td>(5)</td>
</tr>
<tr>
<td>Net interest cost of defined benefit plans</td>
<td>(53)</td>
<td>(48)</td>
</tr>
<tr>
<td>Net other financing costs</td>
<td>(53)</td>
<td>(56)</td>
</tr>
<tr>
<td><strong>Total financing costs</strong></td>
<td>(111)</td>
<td>(110)</td>
</tr>
</tbody>
</table>

Other financial income (expense) in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dividend income from available-for-sale financial assets</td>
<td>-</td>
<td>183</td>
</tr>
<tr>
<td>Dividend income from equity instruments measured at fair value through OCI</td>
<td>115</td>
<td>-</td>
</tr>
<tr>
<td>Write-downs and impairments of equity instruments</td>
<td>-</td>
<td>(97)</td>
</tr>
<tr>
<td><strong>Net income from equity securities</strong></td>
<td>115</td>
<td>86</td>
</tr>
<tr>
<td>Interest income from available-for-sale financial assets</td>
<td>-</td>
<td>93</td>
</tr>
<tr>
<td>Interest income from debt securities measured at fair value through OCI</td>
<td>9</td>
<td>-</td>
</tr>
<tr>
<td>Interest income from financial assets measured at amortized cost</td>
<td>74</td>
<td>-</td>
</tr>
<tr>
<td><strong>Net interest income and income from debt securities</strong></td>
<td>83</td>
<td>93</td>
</tr>
<tr>
<td>Foreign exchange gains (losses)</td>
<td>680</td>
<td>140</td>
</tr>
<tr>
<td>Gains (losses) on foreign currency derivatives</td>
<td>(429)</td>
<td>(406)</td>
</tr>
<tr>
<td><strong>Net foreign exchange gains (losses)</strong></td>
<td>251</td>
<td>(266)</td>
</tr>
<tr>
<td><strong>Total other financial income (expense)</strong></td>
<td>449</td>
<td>(87)</td>
</tr>
</tbody>
</table>

5. Other expense

Chugai filed an Advance Pricing Arrangement covering certain transactions with F. Hoffmann-La Roche Ltd., to the Japanese and Swiss tax authorities. In the year ended December 31, 2017, Chugai received a notice of agreement from both tax authorities which includes the instruction that the taxable income of Chugai shall be decreased by a certain amount and that of Roche shall be increased by the same amount in each fiscal year from 2016 to 2020, and if necessary, additional adjustments to the accounts shall be made in 2021.

As a result of this agreement, Chugai will transfer a part of the deducted amount of corporate tax etc, to Roche as the estimated tax payable for Roche, in accordance with the license agreement between Chugai and Roche. In addition, it has posted ¥3,212 million of adjustment from transfer pricing taxation.
6. Income taxes

Income tax expenses in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current income taxes</td>
<td>(32,646)</td>
<td>(29,884)</td>
</tr>
<tr>
<td>Deferred taxes</td>
<td>4,276</td>
<td>6,394</td>
</tr>
<tr>
<td>Total income tax (expense)</td>
<td>(28,370)</td>
<td>(23,490)</td>
</tr>
</tbody>
</table>

Reconciliation of the Group’s effective tax rate

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weighted average expected tax rate</td>
<td>30.3%</td>
<td>30.3%</td>
</tr>
</tbody>
</table>

Tax effect of
- Non-taxable income/non-deductible expenses | 0.4%    | 0.5%    |
- Effect of changes in applicable tax rates on deferred tax balances | 0.0%   | 0%     |
- Research and development tax credits | (5.4)%  | (5.9)%  |
- Transfer pricing taxation related | (2.2)%  | (4.7)%  |
- Other differences | 0.4%   | 4.0%   |
| Group’s effective tax rate | 23.4%    | 24.2%    |

Tax effects of other comprehensive income in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remeasurements of defined benefit plans</td>
<td>(3,566)</td>
<td>1,094</td>
</tr>
<tr>
<td>Available-for-sale financial assets</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Financial assets measured at fair value through OCI</td>
<td>529</td>
<td>(166)</td>
</tr>
<tr>
<td>Cash flow hedges</td>
<td>(320)</td>
<td>95</td>
</tr>
<tr>
<td>Currency translation of foreign operations</td>
<td>(3,158)</td>
<td>(3,158)</td>
</tr>
<tr>
<td>Other comprehensive income</td>
<td>(6,516)</td>
<td>1,024</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-tax amount</td>
<td>1,094</td>
<td>1,313</td>
</tr>
<tr>
<td>Tax benefit</td>
<td>(2,472)</td>
<td>(396)</td>
</tr>
<tr>
<td>After-tax amount</td>
<td>(1,368)</td>
<td>916</td>
</tr>
<tr>
<td>Pre-tax amount</td>
<td>1,734</td>
<td>1,463</td>
</tr>
<tr>
<td>Tax benefit</td>
<td>(530)</td>
<td>(3,293)</td>
</tr>
<tr>
<td>After-tax amount</td>
<td>1,204</td>
<td>1,463</td>
</tr>
</tbody>
</table>

Income tax assets (liabilities) in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current income taxes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Assets</td>
<td>3</td>
<td>717</td>
</tr>
<tr>
<td>- Liabilities</td>
<td>(19,567)</td>
<td>(16,541)</td>
</tr>
<tr>
<td>Net current income tax assets (liabilities)</td>
<td>(19,564)</td>
<td>(17,824)</td>
</tr>
</tbody>
</table>

|                      |                   |                   |
| Deferred taxes       |                   |                   |
| - Assets             | 35,568            | 34,501            |
| - Liabilities        | (9,031)           | (9,211)           |
| Net deferred tax assets (liabilities) | 26,537 | 25,290 |
Current income taxes: movements in recognized net assets (liabilities) in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net current income tax assets (liabilities) at January 1</td>
<td>(17,824)</td>
<td>(16,532)</td>
</tr>
<tr>
<td>Income taxes paid</td>
<td>31,565</td>
<td>22,655</td>
</tr>
<tr>
<td>(Charged) credited to the income statement</td>
<td>(32,646)</td>
<td>(29,684)</td>
</tr>
<tr>
<td>Currency translation effects and other</td>
<td>(659)</td>
<td>(82)</td>
</tr>
<tr>
<td><strong>Net current income tax assets (liabilities) at December 31</strong></td>
<td>(19,564)</td>
<td>(17,824)</td>
</tr>
</tbody>
</table>

Deferred taxes: movements in recognized net assets (liabilities) in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>Property, plant and equipment</th>
<th>Intangible assets</th>
<th>Provisions</th>
<th>Employee benefits</th>
<th>Other temporary differences</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year ended December 31, 2017</strong></td>
<td>8,364</td>
<td>8,464</td>
<td>536</td>
<td>527</td>
<td>19,241</td>
<td>19,241</td>
</tr>
<tr>
<td>At January 1, 2017</td>
<td>(18,689)</td>
<td>(2,411)</td>
<td>69</td>
<td>5,568</td>
<td>33,790</td>
<td>18,328</td>
</tr>
<tr>
<td>(Charged) credited to the income statement</td>
<td>(306)</td>
<td>(745)</td>
<td>(31)</td>
<td>168</td>
<td>7,308</td>
<td>6,394</td>
</tr>
<tr>
<td>(Charged) credited to other comprehensive income</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(396)</td>
<td>933</td>
<td>537</td>
</tr>
<tr>
<td>Currency translation effects and other</td>
<td>(7)</td>
<td>2</td>
<td>4</td>
<td>6</td>
<td>27</td>
<td>31</td>
</tr>
<tr>
<td><strong>At December 31, 2017</strong></td>
<td>(19,002)</td>
<td>(3,155)</td>
<td>43</td>
<td>5,346</td>
<td>42,058</td>
<td>25,290</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Property, plant and equipment</th>
<th>Intangible assets</th>
<th>Provisions</th>
<th>Employee benefits</th>
<th>Other temporary differences</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year ended December 31, 2018</strong></td>
<td>8,364</td>
<td>8,464</td>
<td>536</td>
<td>527</td>
<td>19,241</td>
<td>19,241</td>
</tr>
<tr>
<td>At January 1, 2018</td>
<td>(19,002)</td>
<td>(3,155)</td>
<td>43</td>
<td>5,346</td>
<td>42,058</td>
<td>25,290</td>
</tr>
<tr>
<td>(Charged) credited to the income statement</td>
<td>(1,227)</td>
<td>32</td>
<td>2</td>
<td>251</td>
<td>5,216</td>
<td>4,276</td>
</tr>
<tr>
<td>(Charged) credited to other comprehensive income</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,094</td>
<td>595</td>
<td>1,690</td>
</tr>
<tr>
<td>(Charged) credited to Equity</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(4,677)</td>
<td>(4,677)</td>
</tr>
<tr>
<td>Currency translation effects and other</td>
<td>9</td>
<td>(1)</td>
<td>(3)</td>
<td>(4)</td>
<td>(42)</td>
<td>(41)</td>
</tr>
<tr>
<td><strong>At December 31, 2018</strong></td>
<td>(20,219)</td>
<td>(3,124)</td>
<td>42</td>
<td>6,689</td>
<td>43,149</td>
<td>26,537</td>
</tr>
</tbody>
</table>

Other temporary differences mainly relate to prepaid expenses, amortization of deferred assets and accrued expenses.

Deferred tax assets are not recognized for deductible temporary differences of ¥1,749 million (2017: ¥1,601 million). Deferred tax assets are recognized for tax losses carried forward only to the extent that realization of the related tax benefit is probable.

Unrecognized tax losses: expiry in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Over one year and less than five years</td>
<td>242</td>
<td>117</td>
</tr>
<tr>
<td>Over five years</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td><strong>Tax losses not recognized in deferred tax assets</strong></td>
<td>242</td>
<td>117</td>
</tr>
</tbody>
</table>

Deferred tax assets for unused tax credits are recognized only to the extent that realization of the related tax benefit is probable.

Unrecognized unused tax credits: expiry in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Over one year and less than five years</td>
<td>-</td>
<td>29</td>
</tr>
<tr>
<td>Over five years</td>
<td>111</td>
<td>114</td>
</tr>
<tr>
<td><strong>Unused tax credits not recognized in deferred tax assets</strong></td>
<td>111</td>
<td>143</td>
</tr>
</tbody>
</table>

Deferred tax liabilities have not been established for the withholding tax and other taxes that would be payable on the unremitting earnings of wholly owned foreign subsidiaries of the Group, where such amounts are currently regarded as permanently reinvested. The temporary differences relating to the unremitting earnings were ¥2,107 million (2017: ¥2,042 million).
7. Property, plant and equipment

Property, plant and equipment: movements in carrying value of assets in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>Land</th>
<th>Buildings and land improvements</th>
<th>Machinery and equipment</th>
<th>Construction in progress</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>At January 1, 2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>9,141</td>
<td>117,163</td>
<td>175,949</td>
<td>19,459</td>
<td>321,712</td>
</tr>
<tr>
<td>Accumulated depreciation and impairment</td>
<td>(28)</td>
<td>(56,470)</td>
<td>(106,133)</td>
<td>-</td>
<td>(164,631)</td>
</tr>
<tr>
<td>Net book value</td>
<td>9,112</td>
<td>58,693</td>
<td>68,817</td>
<td>19,459</td>
<td>157,081</td>
</tr>
<tr>
<td>Year ended December 31, 2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At January 1, 2017</td>
<td>9,112</td>
<td>58,693</td>
<td>68,817</td>
<td>19,459</td>
<td>157,081</td>
</tr>
<tr>
<td>Additions</td>
<td>-</td>
<td>1</td>
<td>368</td>
<td>33,916</td>
<td>34,285</td>
</tr>
<tr>
<td>Disposals</td>
<td>-</td>
<td>(115)</td>
<td>(230)</td>
<td>-</td>
<td>(345)</td>
</tr>
<tr>
<td>Transfers</td>
<td>-</td>
<td>3,523</td>
<td>17,761</td>
<td>(21,284)</td>
<td>-</td>
</tr>
<tr>
<td>Depreciation charge</td>
<td>-</td>
<td>(4,164)</td>
<td>(10,385)</td>
<td>-</td>
<td>(14,549)</td>
</tr>
<tr>
<td>Impairment charge</td>
<td>-</td>
<td>1</td>
<td>(5)</td>
<td>-</td>
<td>(4)</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>-</td>
<td>(5,034)</td>
<td>-</td>
<td>(5,034)</td>
</tr>
<tr>
<td>Currency translation effects</td>
<td>-</td>
<td>(2)</td>
<td>112</td>
<td>25</td>
<td>136</td>
</tr>
<tr>
<td>Net book value</td>
<td>9,112</td>
<td>57,937</td>
<td>72,404</td>
<td>32,116</td>
<td>171,569</td>
</tr>
<tr>
<td>Year ended December 31, 2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At January 1, 2018</td>
<td>9,112</td>
<td>57,937</td>
<td>72,404</td>
<td>32,116</td>
<td>171,569</td>
</tr>
<tr>
<td>Additions</td>
<td>-</td>
<td>13</td>
<td>633</td>
<td>71,197</td>
<td>71,843</td>
</tr>
<tr>
<td>Disposals</td>
<td>-</td>
<td>(94)</td>
<td>(299)</td>
<td>(394)</td>
<td></td>
</tr>
<tr>
<td>Transfers</td>
<td>43,040</td>
<td>16,506</td>
<td>38,938</td>
<td>(98,484)</td>
<td>-</td>
</tr>
<tr>
<td>Depreciation charge</td>
<td>-</td>
<td>(4,232)</td>
<td>(10,358)</td>
<td>-</td>
<td>(14,590)</td>
</tr>
<tr>
<td>Impairment charge</td>
<td>-</td>
<td>(59)</td>
<td>(59)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>-</td>
<td>(5,791)</td>
<td>-</td>
<td>(5,791)</td>
</tr>
<tr>
<td>Currency translation effects</td>
<td>-</td>
<td>(45)</td>
<td>(120)</td>
<td>(24)</td>
<td>(169)</td>
</tr>
<tr>
<td>Net book value</td>
<td>52,152</td>
<td>70,085</td>
<td>95,347</td>
<td>4,804</td>
<td>222,388</td>
</tr>
</tbody>
</table>

In 2018, no borrowing costs were capitalized as property, plant and equipment (2017: none).

Impairment charge

The carrying value was reduced to the recoverable amount in use as the recoverable amount of certain assets was less than the carrying value.

Classification of impairment of property, plant and equipment in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of sales</td>
<td>59</td>
<td>4</td>
</tr>
<tr>
<td>Marketing and distribution</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Research and development</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>General and administration</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total impairment charge</td>
<td>59</td>
<td>4</td>
</tr>
</tbody>
</table>
Finance leases
The capitalized cost of property, plant and equipment under finance leases was ¥701 million (2017: ¥759 million) and the net book value of these assets was ¥198 million (2017: ¥311 million). The carrying value of the leasing obligation was ¥214 million (2017: ¥336 million), which is reported as part of Debt (see Note 16).

Operating leases
Group companies are party to a number of operating leases, mainly for machinery and equipment, motor vehicles and property rentals. The arrangements do not impose any significant restrictions on the Group. Total operating lease rental expense was ¥7,184 million (2017: ¥7,013 million).

Operating leases: future minimum lease payments under non-cancellable leases in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within one year</td>
<td>5,177</td>
<td>4,656</td>
</tr>
<tr>
<td>Between one and five years</td>
<td>9,143</td>
<td>9,378</td>
</tr>
<tr>
<td>More than five years</td>
<td>46</td>
<td>46</td>
</tr>
<tr>
<td><strong>Total minimum payments</strong></td>
<td><strong>14,411</strong></td>
<td><strong>14,081</strong></td>
</tr>
</tbody>
</table>

Capital commitments
The Group has non-cancellable capital commitments for the purchase or construction of property, plant and equipment totaling ¥6,362 million (2017: ¥13,995 million).
8. Intangible assets

Intangible assets: movements in carrying value of assets in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>Product intangibles: in use</th>
<th>Product intangibles: not available for use</th>
<th>Marketing intangibles: in use</th>
<th>Technology intangibles: in use</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At January 1, 2017</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost</td>
<td>18,479</td>
<td>15,982</td>
<td>3,035</td>
<td>103</td>
<td>37,608</td>
</tr>
<tr>
<td>Accumulated amortization and impairment</td>
<td>(13,074)</td>
<td>(4,492)</td>
<td>(891)</td>
<td>(52)</td>
<td>(18,309)</td>
</tr>
<tr>
<td><strong>Net book value</strong></td>
<td>5,405</td>
<td>11,500</td>
<td>2,344</td>
<td>51</td>
<td>19,299</td>
</tr>
<tr>
<td><strong>Year ended December 31, 2017</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At January 1, 2017</td>
<td>5,405</td>
<td>11,500</td>
<td>2,344</td>
<td>51</td>
<td>19,299</td>
</tr>
<tr>
<td>Additions</td>
<td>25</td>
<td>6,581</td>
<td>1,348</td>
<td>-</td>
<td>7,953</td>
</tr>
<tr>
<td>Disposals</td>
<td>-</td>
<td>(452)</td>
<td>-</td>
<td>-</td>
<td>(452)</td>
</tr>
<tr>
<td>Transfers</td>
<td>1,100</td>
<td>(1,100)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Amortization charge</td>
<td>(1,243)</td>
<td>-</td>
<td>(525)</td>
<td>(17)</td>
<td>(1,765)</td>
</tr>
<tr>
<td>Impairment charge</td>
<td>-</td>
<td>(3,992)</td>
<td>(44)</td>
<td>-</td>
<td>(4,035)</td>
</tr>
<tr>
<td>Currency translation effects</td>
<td>25</td>
<td>72</td>
<td>-</td>
<td>-</td>
<td>97</td>
</tr>
<tr>
<td><strong>At December 31, 2017</strong></td>
<td>5,312</td>
<td>12,609</td>
<td>3,123</td>
<td>33</td>
<td>21,078</td>
</tr>
<tr>
<td>Cost</td>
<td>19,916</td>
<td>21,241</td>
<td>4,382</td>
<td>103</td>
<td>45,641</td>
</tr>
<tr>
<td>Accumulated amortization and impairment</td>
<td>(14,604)</td>
<td>(8,631)</td>
<td>(1,259)</td>
<td>(69)</td>
<td>(24,564)</td>
</tr>
<tr>
<td><strong>Net book value</strong></td>
<td>5,312</td>
<td>12,609</td>
<td>3,123</td>
<td>33</td>
<td>21,078</td>
</tr>
<tr>
<td><strong>Year ended December 31, 2018</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At January 1, 2018</td>
<td>5,312</td>
<td>12,609</td>
<td>3,123</td>
<td>33</td>
<td>21,078</td>
</tr>
<tr>
<td>Additions</td>
<td>148</td>
<td>5,178</td>
<td>2,577</td>
<td>564</td>
<td>8,468</td>
</tr>
<tr>
<td>Disposals</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Transfers</td>
<td>1,562</td>
<td>(1,562)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Amortization charge</td>
<td>(916)</td>
<td>-</td>
<td>(818)</td>
<td>(254)</td>
<td>(1,988)</td>
</tr>
<tr>
<td>Impairment charge</td>
<td>(76)</td>
<td>(4,765)</td>
<td>-</td>
<td>-</td>
<td>(4,844)</td>
</tr>
<tr>
<td>Currency translation effects</td>
<td>(13)</td>
<td>(2)</td>
<td>-</td>
<td>-</td>
<td>(15)</td>
</tr>
<tr>
<td><strong>At December 31, 2018</strong></td>
<td>6,015</td>
<td>11,457</td>
<td>4,883</td>
<td>344</td>
<td>22,099</td>
</tr>
<tr>
<td>Cost</td>
<td>21,409</td>
<td>20,862</td>
<td>6,887</td>
<td>687</td>
<td>40,625</td>
</tr>
<tr>
<td>Accumulated amortization and impairment</td>
<td>(15,394)</td>
<td>(9,205)</td>
<td>(2,904)</td>
<td>(323)</td>
<td>(20,927)</td>
</tr>
<tr>
<td><strong>Net book value</strong></td>
<td>6,015</td>
<td>11,457</td>
<td>4,883</td>
<td>344</td>
<td>22,099</td>
</tr>
</tbody>
</table>

**Significant intangible assets**
The product intangibles in use and not available for use are mainly acquired through in-licensing agreements of products with related parties. The remaining amortization periods for product intangibles in use are from 3 to 16 years.

**Impairment charge**
Impairment charge in each year was mainly related to the cessation of R&D projects and the uncertainty regarding expected profits.

**Classification of amortization and impairment expenses** in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>Amortization</th>
<th>Impairment</th>
<th>Amortization</th>
<th>Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2018</strong></td>
<td>1,014</td>
<td>-</td>
<td>1,327</td>
<td>-</td>
</tr>
<tr>
<td><strong>2017</strong></td>
<td>133</td>
<td>-</td>
<td>133</td>
<td>-</td>
</tr>
<tr>
<td>Marketing and distribution</td>
<td>428</td>
<td>4,844</td>
<td>93</td>
<td>4,035</td>
</tr>
<tr>
<td>Research and development</td>
<td>413</td>
<td>-</td>
<td>232</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>1,988</td>
<td>4,844</td>
<td>1,785</td>
<td>4,035</td>
</tr>
</tbody>
</table>
Internally generated intangible assets
The Group currently has no internally generated intangible assets from development as the criteria for the recognition as an asset are not met.

Intangible assets with indefinite useful lives
The Group currently has no intangible assets with indefinite useful lives.

Product intangibles not available for use
These mostly represent in-process research and development assets acquired either through in-licensing arrangements or separate purchases. Due to the inherent uncertainties in the research and development processes, intangible assets not available for use are particularly at risk of impairment if the project is not expected to result in a commercialized product.

Impairment of intangible assets
Impairment charges arise from changes in the estimates of the future cash flows expected to result from the use of the asset and its eventual disposal. Factors such as the presence or absence of competition, technical obsolescence or lower than anticipated sales for products with capitalized rights could result in shortened useful lives or impairment.

Potential commitments from alliance collaborations
The Group is party to in-licensing and similar arrangements with its alliance partners. These arrangements may require the Group to make certain milestone or other similar payments dependent upon the achievement of agreed objectives or performance targets as defined in the collaboration agreements.

The Group’s current estimate of future commitments for such payments is set out in the table below. These figures are undiscounted and are not risk adjusted, meaning that they include all such potential payments that can arise assuming all projects currently in development are successful. The timing is based on the Group’s current best estimate.

<table>
<thead>
<tr>
<th>Potential future collaboration payments at December 31, 2018 in millions of yen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within one year</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Between one and two years</td>
</tr>
<tr>
<td>Between two and three years</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

9. Financial non-current assets
Financial non-current assets in millions of yen

<table>
<thead>
<tr>
<th>Financial non-current assets</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Available-for-sale financial assets</td>
<td>-</td>
<td>11,350</td>
</tr>
<tr>
<td>Financial assets measured at fair value through OCI</td>
<td>9,723</td>
<td>-</td>
</tr>
<tr>
<td>Total financial non-current assets</td>
<td>9,723</td>
<td>11,350</td>
</tr>
</tbody>
</table>

Financial non-current assets are equity instruments held not for pure investment purposes, but for the Group’s business purposes to maintain and strengthen the relationship with business partners. Therefore, the Group has designated all equity instruments as measured at fair value through OCI (classified as available-for-sale in 2017).
10. Other non-current assets

**Other non-current assets** in millions of yen

<table>
<thead>
<tr>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-term prepaid expenses</td>
<td>23,654</td>
</tr>
<tr>
<td>Other assets</td>
<td>5,422</td>
</tr>
<tr>
<td><strong>Total other non-current assets</strong></td>
<td><strong>29,077</strong></td>
</tr>
</tbody>
</table>

Long-term prepaid expenses are mainly payments to related parties for start-up and validation costs at plants used for outsourcing to the related parties.

11. Inventories

**Inventories** in millions of yen

<table>
<thead>
<tr>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raw materials and supplies</td>
<td>42,199</td>
</tr>
<tr>
<td>Work in process</td>
<td>118</td>
</tr>
<tr>
<td>Intermediates</td>
<td>53,682</td>
</tr>
<tr>
<td>Finished goods</td>
<td>65,037</td>
</tr>
<tr>
<td>Provision for slow-moving and obsolete inventory</td>
<td>(1,076)</td>
</tr>
<tr>
<td><strong>Total inventories</strong></td>
<td><strong>159,360</strong></td>
</tr>
</tbody>
</table>

Inventories expensed through cost of sales totalled ¥245,919 million (2017: ¥241,487 million). Inventory write-downs during the year resulted in an expense of ¥1,051 million (2017: ¥630 million).

12. Accounts receivable

**Accounts receivable** in millions of yen

<table>
<thead>
<tr>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade receivables – third party</td>
<td>125,478</td>
</tr>
<tr>
<td>Trade receivables – related party</td>
<td>25,307</td>
</tr>
<tr>
<td>Notes receivables</td>
<td>19</td>
</tr>
<tr>
<td>Other receivables – third party (Contracts with customers)</td>
<td>1,105</td>
</tr>
<tr>
<td>Other receivables – related party (Contracts with customers)</td>
<td>10,970</td>
</tr>
<tr>
<td>Other receivables – third party</td>
<td>6,717</td>
</tr>
<tr>
<td>Other receivables – related party</td>
<td>9,967</td>
</tr>
<tr>
<td>Allowances for doubtful accounts</td>
<td>(7)</td>
</tr>
<tr>
<td><strong>Total accounts receivable</strong></td>
<td><strong>179,856</strong></td>
</tr>
</tbody>
</table>

13. Marketable securities

**Marketable securities** in millions of yen

<table>
<thead>
<tr>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Available-for-sale financial assets</td>
<td></td>
</tr>
<tr>
<td>Money market instruments and time accounts over three months</td>
<td>-</td>
</tr>
<tr>
<td>Debt securities</td>
<td>-</td>
</tr>
<tr>
<td>Financial assets measured at fair value through OCI</td>
<td></td>
</tr>
<tr>
<td>Money market instruments</td>
<td>94,000</td>
</tr>
<tr>
<td>Debt securities</td>
<td>8,001</td>
</tr>
<tr>
<td>Financial assets measured at amortized cost</td>
<td></td>
</tr>
<tr>
<td>Time accounts over three months</td>
<td>&lt;x2&gt;</td>
</tr>
<tr>
<td><strong>Total marketable securities</strong></td>
<td><strong>102,533</strong></td>
</tr>
</tbody>
</table>

Marketable securities are held for fund management purposes. Money market instruments are mainly certificates of deposit, cash in trust and commercial papers. Debt securities are mainly corporate bonds.
14. Cash and cash equivalents

<table>
<thead>
<tr>
<th>Cash and cash equivalents in millions of yen</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash - cash in hand and in current or call accounts</td>
<td>140,912</td>
<td>136,219</td>
</tr>
<tr>
<td>Cash equivalents - time accounts with a maturity of three months or less</td>
<td>5,948</td>
<td>2,855</td>
</tr>
<tr>
<td>Total cash and cash equivalents</td>
<td>146,860</td>
<td>139,074</td>
</tr>
</tbody>
</table>

15. Other current assets

<table>
<thead>
<tr>
<th>Other current assets in millions of yen</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derivative financial instruments</td>
<td>2,204</td>
<td>2,107</td>
</tr>
<tr>
<td>Total financial current assets</td>
<td>2,204</td>
<td>2,107</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>9,577</td>
<td>9,883</td>
</tr>
<tr>
<td>Total non-financial current assets</td>
<td>9,577</td>
<td>9,883</td>
</tr>
<tr>
<td>Total other current assets</td>
<td>11,781</td>
<td>11,990</td>
</tr>
</tbody>
</table>

16. Debt

<table>
<thead>
<tr>
<th>Debt: movements in carrying value of recognized liabilities in millions of yen</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>At January 1</td>
<td>336</td>
<td>645</td>
</tr>
<tr>
<td>Increase in debt</td>
<td>12</td>
<td>1</td>
</tr>
<tr>
<td>Decrease in debt</td>
<td>(134)</td>
<td>(310)</td>
</tr>
<tr>
<td>At December 31</td>
<td>214</td>
<td>336</td>
</tr>
<tr>
<td>Finance lease obligations</td>
<td>214</td>
<td>336</td>
</tr>
<tr>
<td>Total debt</td>
<td>214</td>
<td>336</td>
</tr>
<tr>
<td>Long-term debt</td>
<td>82</td>
<td>207</td>
</tr>
<tr>
<td>Short-term debt</td>
<td>133</td>
<td>129</td>
</tr>
<tr>
<td>Total debt</td>
<td>214</td>
<td>336</td>
</tr>
</tbody>
</table>
17. Provisions and contingent liabilities

Provisions: movements in recognized liabilities in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>Environmental provisions</th>
<th>Other provisions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year ended December 31, 2017</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At January 1, 2017</td>
<td>356</td>
<td>1,859</td>
<td>2,216</td>
</tr>
<tr>
<td>Additional provisions created</td>
<td>22</td>
<td>23</td>
<td>45</td>
</tr>
<tr>
<td>Unused amounts reversed</td>
<td>(33)</td>
<td>(77)</td>
<td>(110)</td>
</tr>
<tr>
<td>Utilized</td>
<td>(34)</td>
<td>-</td>
<td>(34)</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td><strong>At December 31, 2017</strong></td>
<td><strong>311</strong></td>
<td><strong>1,808</strong></td>
<td><strong>2,120</strong></td>
</tr>
<tr>
<td>Long-term provisions</td>
<td>283</td>
<td>1,758</td>
<td>2,041</td>
</tr>
<tr>
<td>Short-term provisions</td>
<td>29</td>
<td>51</td>
<td>79</td>
</tr>
<tr>
<td><strong>At December 31, 2017</strong></td>
<td><strong>311</strong></td>
<td><strong>1,808</strong></td>
<td><strong>2,120</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Environmental provisions</th>
<th>Other provisions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year ended December 31, 2018</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At January 1, 2018</td>
<td>311</td>
<td>1,808</td>
<td>2,120</td>
</tr>
<tr>
<td>Additional provisions created</td>
<td>-</td>
<td>36</td>
<td>36</td>
</tr>
<tr>
<td>Unused amounts reversed</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Utilized</td>
<td>(29)</td>
<td>(51)</td>
<td>(80)</td>
</tr>
<tr>
<td>Other</td>
<td>- (3)</td>
<td>-</td>
<td>(3)</td>
</tr>
<tr>
<td><strong>At December 31, 2018</strong></td>
<td><strong>282</strong></td>
<td><strong>1,791</strong></td>
<td><strong>2,073</strong></td>
</tr>
<tr>
<td>Long-term provisions</td>
<td>281</td>
<td>1,791</td>
<td>2,072</td>
</tr>
<tr>
<td>Short-term provisions</td>
<td>1</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td><strong>At December 31, 2018</strong></td>
<td><strong>282</strong></td>
<td><strong>1,791</strong></td>
<td><strong>2,073</strong></td>
</tr>
</tbody>
</table>

Expected outflow of resources

<table>
<thead>
<tr>
<th></th>
<th>Environmental provisions</th>
<th>Other provisions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Within one year</td>
<td>1</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Between one to two years</td>
<td>235</td>
<td>235</td>
<td>470</td>
</tr>
<tr>
<td>Between two to three years</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>More than three years</td>
<td>281</td>
<td>1,556</td>
<td>1,837</td>
</tr>
<tr>
<td><strong>At December 31, 2018</strong></td>
<td><strong>282</strong></td>
<td><strong>1,791</strong></td>
<td><strong>2,073</strong></td>
</tr>
</tbody>
</table>

Environmental provisions

Provisions for environmental matters include various separate environmental issues. By their nature the amounts and timings of any outflows are difficult to predict. Significant provisions are discounted where the time value of money is material.

Other provisions

Other provisions arise mainly from asset retirement obligations. The timings of cash outflows are by their nature uncertain. Significant provisions are discounted where the time value of money is material.

Contingent liabilities

The operations and earnings of the Group continue, from time to time and in varying degrees, to be affected by political, legislative, fiscal and regulatory developments, including those relating to environmental protection. The industries in which the Group operates are also subject to other risks of various kinds. The nature and frequency of these developments and events, not all of which are covered by insurance, as well as their effect on future operations and earnings, are not predictable.

The Group has entered into strategic alliances with various companies in order to gain access to potential new products or to utilize other companies to help develop the Group’s own potential new products. Potential future payments may become due to certain collaboration partners achieving certain milestones as defined in the collaboration agreements. The Group’s best estimates for future commitment payments are given in Note 8.
### 18. Other non-current liabilities

**Other non-current liabilities** in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deferred income</td>
<td>727</td>
<td>14,127</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>1,219</td>
<td>1,796</td>
</tr>
<tr>
<td><strong>Total other non-current liabilities</strong></td>
<td><strong>1,946</strong></td>
<td><strong>15,923</strong></td>
</tr>
</tbody>
</table>

### 19. Accounts payable

**Accounts payable** in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade payables – third party</td>
<td>5,991</td>
<td>9,761</td>
</tr>
<tr>
<td>Trade payables – related party</td>
<td>29,943</td>
<td>28,673</td>
</tr>
<tr>
<td>Other taxes payable</td>
<td>6,680</td>
<td>4,438</td>
</tr>
<tr>
<td>Accounts payable - purchase of property, plant and equipment</td>
<td>5,637</td>
<td>5,642</td>
</tr>
<tr>
<td>Other payables – third party</td>
<td>4,909</td>
<td>2,967</td>
</tr>
<tr>
<td>Other payables – related party</td>
<td>18,626</td>
<td>12,637</td>
</tr>
<tr>
<td><strong>Total accounts payable</strong></td>
<td><strong>71,706</strong></td>
<td><strong>63,518</strong></td>
</tr>
</tbody>
</table>

### 20. Other current liabilities

**Other current liabilities** in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deferred income</td>
<td>239</td>
<td>1,598</td>
</tr>
<tr>
<td>Accrued bonus and related items</td>
<td>14,024</td>
<td>12,480</td>
</tr>
<tr>
<td>Derivative financial instruments</td>
<td>2,096</td>
<td>1,652</td>
</tr>
<tr>
<td>Other accrued liabilities</td>
<td>27,451</td>
<td>24,905</td>
</tr>
<tr>
<td><strong>Total other current liabilities</strong></td>
<td><strong>43,810</strong></td>
<td><strong>40,635</strong></td>
</tr>
</tbody>
</table>
21. Equity attributable to Chugai shareholders

Changes in equity attributable to Chugai shareholders in millions of yen

<table>
<thead>
<tr>
<th>Year ended December 31, 2017</th>
<th>Share capital</th>
<th>Capital surplus</th>
<th>Retained earnings</th>
<th>Fair value reserve</th>
<th>Hedging reserve</th>
<th>Translation reserve</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>At January 1, 2017</td>
<td>72,967</td>
<td>63,500</td>
<td>507,399</td>
<td>4,864</td>
<td>3,574</td>
<td>(6,796)</td>
<td>645,508</td>
</tr>
</tbody>
</table>

Net income attributable to Chugai shareholders:
- Available-for-sale financial assets:
  - Fair value gains (losses) taken to equity: - 1,639
  - Transferred to income statement on sale or impairment: - 95
  - Income taxes: - (530)

Cash flow hedges:
- Effective portion of fair value gains (losses) taken to equity: - (1,415)
- Transferred to income statement: - (114)
- Transferred to initial carrying amount of hedged items: - (3,228)
- Income taxes: - (530)

Currency translation of foreign operations:
- Exchange differences: - 3,713
- Non-controlling interests: - (100)

Defined benefit plans:
- Remeasurement gains (losses): - 1,313
- Income taxes: - (386)

Other comprehensive income, net of tax:
- 916

Total comprehensive income:
- 73,630

Dividends:
- (30,055)

Equity compensation plans:
3 102

Own equity instruments:
- 1,213

At December 31, 2017:
72,970 64,815 550,974 6,068 281 (3,183) 691,924
### Changes in equity attributable to Chugai shareholders in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>Share capital</th>
<th>Capital surplus</th>
<th>Retained earnings</th>
<th>Fair value reserve</th>
<th>Hedging reserve</th>
<th>Translation reserve</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Year ended December 31, 2018</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At January 1, 2018</td>
<td>72,970</td>
<td>64,815</td>
<td>550,974</td>
<td>6,068</td>
<td>281</td>
<td>(3,183)</td>
<td>691,924</td>
</tr>
<tr>
<td>Impact of changes in accounting policies</td>
<td>-</td>
<td>-</td>
<td>10,006</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10,006</td>
</tr>
<tr>
<td>At January 1, 2018 (revised)</td>
<td>72,970</td>
<td>64,815</td>
<td>561,580</td>
<td>6,068</td>
<td>281</td>
<td>(3,183)</td>
<td>692,530</td>
</tr>
<tr>
<td>Net income attributable to Chugai shareholders</td>
<td>-</td>
<td>-</td>
<td>92,488</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>92,488</td>
</tr>
<tr>
<td>Financial assets measured at fair value through OCI</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>528</td>
<td>-</td>
<td>-</td>
<td>528</td>
</tr>
<tr>
<td>- Equity instruments measured at fair value through OCI</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>- Debt securities at fair value through OCI</td>
<td>-</td>
<td>-</td>
<td>(166)</td>
<td>-</td>
<td>-</td>
<td>(166)</td>
<td></td>
</tr>
<tr>
<td>- Income taxes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Cash flow hedges</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Effective portion of fair value gains (losses) taken to equity</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(441)</td>
<td>-</td>
<td>-</td>
<td>(441)</td>
</tr>
<tr>
<td>- Transferred to income statement</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>42</td>
<td>-</td>
<td>-</td>
<td>42</td>
</tr>
<tr>
<td>- Transferred to initial carrying amount of hedged items</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>77</td>
<td>-</td>
<td>-</td>
<td>77</td>
</tr>
<tr>
<td>- Income taxes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(166)</td>
<td>-</td>
<td>-</td>
<td>(166)</td>
</tr>
<tr>
<td>Currency translation of foreign operations</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(3,158)</td>
<td>(3,158)</td>
<td>(3,158)</td>
<td>(3,158)</td>
</tr>
<tr>
<td>Defined benefit plans</td>
<td></td>
<td></td>
<td></td>
<td>82</td>
<td>-</td>
<td>-</td>
<td>82</td>
</tr>
<tr>
<td>- Remeasurement gains (losses)</td>
<td>-</td>
<td>-</td>
<td>(3,566)</td>
<td>-</td>
<td>-</td>
<td>(3,566)</td>
<td></td>
</tr>
<tr>
<td>- Income taxes</td>
<td>-</td>
<td>-</td>
<td>1,094</td>
<td>-</td>
<td>-</td>
<td>1,094</td>
<td></td>
</tr>
<tr>
<td>Other comprehensive income, net of tax</td>
<td>-</td>
<td>-</td>
<td>(2,472)</td>
<td>363</td>
<td>(225)</td>
<td>(3,077)</td>
<td>(5,410)</td>
</tr>
<tr>
<td>Total comprehensive income</td>
<td>-</td>
<td>-</td>
<td>90,016</td>
<td>363</td>
<td>(225)</td>
<td>(3,077)</td>
<td>87,078</td>
</tr>
<tr>
<td>Dividends</td>
<td>-</td>
<td>-</td>
<td>(35,003)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(35,003)</td>
</tr>
<tr>
<td>Equity compensation plans</td>
<td>31</td>
<td>(97)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(66)</td>
</tr>
<tr>
<td>Own equity instruments</td>
<td>-</td>
<td>1,325</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1,325</td>
</tr>
<tr>
<td>Transfer from other reserves to retained earnings</td>
<td>-</td>
<td>-</td>
<td>1,498</td>
<td>(1,498)</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>At December 31, 2018</strong></td>
<td><strong>73,000</strong></td>
<td><strong>66,043</strong></td>
<td><strong>618,091</strong></td>
<td><strong>4,933</strong></td>
<td><strong>57</strong></td>
<td><strong>(6,260)</strong></td>
<td><strong>755,864</strong></td>
</tr>
</tbody>
</table>
Share capital (Number of shares)

<table>
<thead>
<tr>
<th>Authorized shares</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>799,805,050</td>
<td>799,805,050</td>
</tr>
</tbody>
</table>

Issued shares (Non-par value common stock)

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>559,685,889</td>
<td>559,685,889</td>
</tr>
</tbody>
</table>

Dividends

<table>
<thead>
<tr>
<th>Date of resolution</th>
<th>Type of shares</th>
<th>Total dividends (millions of yen)</th>
<th>Dividend per share (yen)</th>
<th>Record date</th>
<th>Effective date</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Resolution of the Annual General Meeting of shareholders)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Board resolution)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>March 22, 2018</td>
<td>Common stock</td>
<td>18,044</td>
<td>33</td>
<td>December 31, 2017</td>
<td>March 23, 2018</td>
</tr>
<tr>
<td>(Resolution of the Annual General Meeting of shareholders)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July 26, 2018</td>
<td>Common stock</td>
<td>16,960</td>
<td>31</td>
<td>June 30, 2018</td>
<td>August 31, 2018</td>
</tr>
<tr>
<td>(Board resolution)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>March 28, 2019</td>
<td>Common stock</td>
<td>3,566</td>
<td>4,594</td>
<td>December 31, 2018</td>
<td>March 29, 2019</td>
</tr>
<tr>
<td>(Resolution of the Annual General Meeting of shareholders)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Own equity instruments

<table>
<thead>
<tr>
<th></th>
<th>Number of shares</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2018</td>
</tr>
<tr>
<td>At January 1</td>
<td>12,909,947</td>
</tr>
<tr>
<td>Issue of common stocks</td>
<td>-</td>
</tr>
<tr>
<td>Exercises of equity compensation plans</td>
<td>(393,800)</td>
</tr>
<tr>
<td>Purchase/Disposal of own equity instruments</td>
<td>3,566</td>
</tr>
<tr>
<td>Retirement of own equity instruments</td>
<td>-</td>
</tr>
<tr>
<td>Grant of restricted stock</td>
<td>(60,300)</td>
</tr>
<tr>
<td>At December 31</td>
<td>12,459,413</td>
</tr>
<tr>
<td></td>
<td>29,190</td>
</tr>
</tbody>
</table>

Other reserves

Fair value reserve: The fair value reserve represents the cumulative net change in the fair value of financial assets measured at fair value through OCI (previously available-for-sale financial assets) until the asset is sold. Impaired or otherwise disposed of.

Hedging reserve: The hedging reserve represents the effective portion of the cumulative net change in the fair value of cash flow hedging instruments related to hedged transactions that have not yet occurred.

Translation reserve: The translation reserve represents the cumulative currency translation differences relating to the consolidation of foreign subsidiaries of the Group that use functional currencies other than the Japanese yen.
22. Non-controlling interests

Changes in equity attributable to non-controlling interests in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>At January 1</td>
<td>973</td>
<td>869</td>
</tr>
<tr>
<td>Net income attributable to non-controlling interests</td>
<td>591</td>
<td>827</td>
</tr>
<tr>
<td>Currency translation of foreign operations</td>
<td>(82)</td>
<td>100</td>
</tr>
<tr>
<td>Other comprehensive income, net of tax</td>
<td>(82)</td>
<td>100</td>
</tr>
<tr>
<td>Total comprehensive income</td>
<td>509</td>
<td>927</td>
</tr>
<tr>
<td>Dividends to non-controlling shareholders</td>
<td>(817)</td>
<td>(944)</td>
</tr>
<tr>
<td>At December 31</td>
<td>664</td>
<td>973</td>
</tr>
</tbody>
</table>

Non-controlling interests are attributable to the minority shareholders of Chugai sanofi-aventis S.N.C.

23. Employee benefits

Employee benefits expense in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wages and salaries</td>
<td>74,551</td>
<td>70,595</td>
</tr>
<tr>
<td>Social security costs</td>
<td>9,064</td>
<td>9,046</td>
</tr>
<tr>
<td>Defined contribution plans</td>
<td>973</td>
<td>1,029</td>
</tr>
<tr>
<td>Operating expenses for defined benefit plans</td>
<td>4,427</td>
<td>4,231</td>
</tr>
<tr>
<td>Equity compensation plans</td>
<td>286</td>
<td>415</td>
</tr>
<tr>
<td>Other employee benefits</td>
<td>4,205</td>
<td>4,143</td>
</tr>
<tr>
<td><strong>Employee benefits expense included in operating results</strong></td>
<td>¥3,535</td>
<td>¥9,459</td>
</tr>
<tr>
<td>Net interest cost of defined benefit plans</td>
<td>53</td>
<td>48</td>
</tr>
<tr>
<td><strong>Total employee benefits expense</strong></td>
<td>¥93,588</td>
<td>¥89,507</td>
</tr>
</tbody>
</table>

Other employee benefits consist mainly of welfare costs.

24. Post-employment benefits plans

Post-employment benefits plans are classified as “defined contribution plans” if the Group pays fixed contributions into third-party financial institutions and will have no further legal or constructive obligation to pay further contributions. All other plans are classified as “defined benefit plans”, even if Chugai’s potential obligation is relatively minor or has a relatively remote possibility of arising.

Employees are covered by defined contribution and defined benefit plans sponsored by Group companies, most of which are classified as defined benefit plans.

A resolution was passed in the 98th Annual General Meeting of shareholders held in March 2009 to abolish the retirement benefits system for directors. In addition, a resolution was passed in the 95th Annual General Meeting of shareholders held in March 2006 to abolish the retirement benefits system for outside directors and audit & supervisory board members (including outside audit & supervisory board members).

**Defined contribution plans**

Defined contribution plans are funded through payments by the Group to funds administered by third parties. The Group’s expenses for these plans were ¥973 million (2017: ¥1,029 million).

**Defined benefit plans**

The Group has defined benefit plans mainly comprising a corporate pension fund and a lump-sum retirement benefit plan. Under the corporate pension fund, employees can receive a lump-sum payment based on the number of accumulated points received during their years of service. Employees with over a certain period of service can receive part of or all of the payment as certain annuity or life annuity. Under the lump-sum retirement benefit plan, employees
can receive a lump-sum payment based on the number of accumulated points received during their years of service. A retirement benefit trust has been established for the lump-sum retirement benefit plan. Certain employees may be entitled to additional special retirement benefits apart from the defined benefit plans based on the conditions under which termination occurs.

The corporate pension fund and retirement benefit plan trust are independent of the Group and are funded only by payments from the Group.

A pension asset management strategy is developed to optimize expected returns and to manage risks through adopting investment strategies from a long-term perspective. For this purpose, the Group focusses on long-term objectives which are not influenced by fluctuations in short-term yields, and maintains a well-diversified portfolio.

The funding status is closely monitored at the corporate level and valuations at the balance sheet date are carried out annually.

The defined benefit obligation is calculated using the projected unit credit method. If potential assets arise since defined benefit plans are over-funded, the recognition of pension assets is limited to the present value of any economic benefits available from refunds from the plans or reductions in future contributions to the plan.

### Defined benefit plans: income statement in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current service cost</td>
<td>4,427</td>
<td>4,231</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>4,427</td>
<td>4,231</td>
</tr>
<tr>
<td>Net interest cost of defined benefit plans</td>
<td>53</td>
<td>48</td>
</tr>
<tr>
<td><strong>Total expense recognized in income statement</strong></td>
<td>4,479</td>
<td>4,279</td>
</tr>
</tbody>
</table>

### Defined benefit plans: funding status in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fair value of plan assets</td>
<td>76,157</td>
<td>78,516</td>
</tr>
<tr>
<td>Defined benefit obligation</td>
<td>(90,829)</td>
<td>(87,809)</td>
</tr>
<tr>
<td><strong>Over (under) funding</strong></td>
<td>(14,671)</td>
<td>(9,292)</td>
</tr>
<tr>
<td>Defined benefit plan assets</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Defined benefit plan liabilities</td>
<td>(14,671)</td>
<td>(9,292)</td>
</tr>
<tr>
<td><strong>Net recognized asset (liability)</strong></td>
<td>(14,671)</td>
<td>(9,292)</td>
</tr>
</tbody>
</table>

### Defined benefit plans: fair value of plan assets in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At January 1</strong></td>
<td>78,516</td>
<td>76,561</td>
</tr>
<tr>
<td>Interest income on plan assets</td>
<td>545</td>
<td>538</td>
</tr>
<tr>
<td>Remeasurements on plan assets</td>
<td>2,227</td>
<td>2,336</td>
</tr>
<tr>
<td>Currency translation effects</td>
<td>(8)</td>
<td>10</td>
</tr>
<tr>
<td>Employer contributions</td>
<td>2,442</td>
<td>2,243</td>
</tr>
<tr>
<td>Benefits paid – funded plans</td>
<td>(3,112)</td>
<td>(3,162)</td>
</tr>
<tr>
<td><strong>At December 31</strong></td>
<td>76,157</td>
<td>78,516</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composition of plan assets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Equity securities</td>
<td>10,640</td>
<td>13,426</td>
</tr>
<tr>
<td>- Debt securities</td>
<td>46,035</td>
<td>47,112</td>
</tr>
<tr>
<td>- Cash and cash equivalents</td>
<td>7,114</td>
<td>7,685</td>
</tr>
<tr>
<td>- Other investments</td>
<td>4,368</td>
<td>10,293</td>
</tr>
<tr>
<td><strong>Total plan assets</strong></td>
<td>76,157</td>
<td>78,516</td>
</tr>
</tbody>
</table>

Equity securities and debt securities have quoted market prices (Level 1 of fair value hierarchy)
Defined benefit plans: present value of defined benefit obligation in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>At January 1</td>
<td>87,809</td>
<td>85,341</td>
</tr>
<tr>
<td>Current service cost</td>
<td>4,427</td>
<td>4,231</td>
</tr>
<tr>
<td>Interest cost</td>
<td>597</td>
<td>586</td>
</tr>
<tr>
<td>Remeasurements – demographic assumption</td>
<td>991</td>
<td>513</td>
</tr>
<tr>
<td>Remeasurements – financial assumptions</td>
<td>153</td>
<td>70</td>
</tr>
<tr>
<td>Remeasurements – experience adjustments</td>
<td>197</td>
<td>434</td>
</tr>
<tr>
<td>Currency translation effects</td>
<td>(23)</td>
<td>30</td>
</tr>
<tr>
<td>Benefits paid – funded plans</td>
<td>(3,322)</td>
<td>(3,403)</td>
</tr>
<tr>
<td><strong>At December 31</strong></td>
<td><strong>90,829</strong></td>
<td><strong>87,809</strong></td>
</tr>
</tbody>
</table>

Duration in years

- 2018: 15
- 2017: 15.2

Actuarial assumptions

Actuarial assumptions are unbiased and mutually compatible estimates of variables that determine the ultimate cost of providing post-employment benefits. They are set on an annual basis by the responsible departments of the Group based on advice from actuaries. Actuarial assumptions consist of demographic assumptions on matters such as mortality and employee turnover, and financial assumptions on matters such as interest rates.

Demographic assumptions: Demographic assumptions relate to mortality and employee turnover rates. Mortality rates are based on the standard mortality rate stated in the Ordinance for Enforcement of the Defined-Benefit Corporate Pension Act. Rates of employee turnover are based on historical behavior within the Group companies.

Financial assumptions: Discount rates are determined mainly with reference to interest rates on high-quality corporate bonds and reflect the period over which the obligations are to be settled.

<table>
<thead>
<tr>
<th>Discount rates (%)</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.69</td>
<td>0.70</td>
</tr>
</tbody>
</table>

Defined benefit plans: sensitivity of defined benefit obligation to actuarial assumption in millions of yen

The impact resulting from changes of actuarial assumption on the defined benefit obligation is shown in the table below. It is based on the assumption that variables other than the stated assumption used for the calculation are held constant.

<table>
<thead>
<tr>
<th>Discount rates</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.25% increase</td>
</tr>
<tr>
<td></td>
<td>0.25% decrease</td>
</tr>
<tr>
<td>Life expectancy</td>
<td>1 year increase</td>
</tr>
</tbody>
</table>

Future cash flows

Based on the most recent actuarial valuations, the Group expects that employer contributions for defined benefit plans in 2019 will be approximately ¥2,443 million.
25. Equity compensation plans

The Group operates equity-settled equity compensation plans for directors and certain employees. IFRS 2 “Share-based Payment” requires that the value be estimated by fair value at grant date and recorded as an expense over the vesting period. Effective since 2017, for the purpose of further promoting shared value with shareholders and providing an incentive to sustainably increase the Group’s corporate value, strengthening linkage between their compensation and mid- to long-term business performance, a restricted stock compensation plan (the “Compensation Plan”) was introduced in place of the existing stock option compensation plans.

**Expenses for equity compensation plans in millions of yen**

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of sales</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Marketing and distribution</td>
<td>29</td>
<td>42</td>
</tr>
<tr>
<td>Research and development</td>
<td>60</td>
<td>70</td>
</tr>
<tr>
<td>General and administration</td>
<td>192</td>
<td>300</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>282</strong></td>
<td><strong>415</strong></td>
</tr>
</tbody>
</table>

**Equity-settled plans**

- Chugai common stock options
- Chugai stock options as stock-based compensation
- Tenure-based restricted stock
- Performance-based restricted stock

**Cash inflow from equity compensation plans in millions of yen**

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exercises of Chugai common stock options</td>
<td>896</td>
<td>922</td>
</tr>
<tr>
<td>Exercises of Chugai stock options as stock-based compensation</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

(1) Stock options

**Chugai common stock options**

The Group has issued stock acquisition rights to directors and certain employees as common stock options since 2003. Each right entitles the holder to purchase 100 Chugai shares at a specified exercise price. The rights are non-tradable and have an exercise period of around ten years after receiving the rights under the condition of approximately two years of continuous service of the holder after the grant date.

**Chugai common stock options – movement in number of rights outstanding**

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of rights</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weighted average exercise price (yen)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of rights</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weighted average exercise price (yen)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outstanding at January 1</td>
<td>11,727</td>
<td>15,966</td>
</tr>
<tr>
<td>Granted</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Forfeited</td>
<td>-</td>
<td>(40)</td>
</tr>
<tr>
<td>Exercised</td>
<td>(3,736)</td>
<td>(3,803)</td>
</tr>
<tr>
<td>Expired</td>
<td>-</td>
<td>(396)</td>
</tr>
<tr>
<td>Outstanding at December 31</td>
<td>7,991</td>
<td>11,727</td>
</tr>
<tr>
<td>- of which exercisable</td>
<td>7,991</td>
<td>9,013</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of rights</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weighted average exercise price (yen)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of rights</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weighted average exercise price (yen)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Chugai common stock options – terms of rights outstanding at December 31, 2018

<table>
<thead>
<tr>
<th>Year of grant</th>
<th>Rights outstanding</th>
<th>Rights exercisable</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number outstanding</td>
<td>Weighted average years remaining contractual life</td>
</tr>
<tr>
<td>2009</td>
<td>20</td>
<td>0.23</td>
</tr>
<tr>
<td>2010</td>
<td>29u</td>
<td>1.31</td>
</tr>
<tr>
<td>2011</td>
<td>213</td>
<td>2.40</td>
</tr>
<tr>
<td>2012</td>
<td>1,251</td>
<td>3.31</td>
</tr>
<tr>
<td>2013</td>
<td>1,108</td>
<td>4.32</td>
</tr>
<tr>
<td>2014</td>
<td>1,203</td>
<td>5.31</td>
</tr>
<tr>
<td>2015</td>
<td>2,075</td>
<td>6.31</td>
</tr>
<tr>
<td>2016</td>
<td>1,741</td>
<td>7.31</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>7,991</strong></td>
<td><strong>5.32</strong></td>
</tr>
</tbody>
</table>

Chugai stock options as stock-based compensation

The Group has issued stock acquisition rights to directors as stock options as stock-based compensation since 2009 in lieu of the retirement benefit system for directors which was abolished. Each right entitles the holder to purchase 100 Chugai shares at an exercise price of ¥100. The rights are non-tradable and have an exercise period of 30 years after receiving the rights, which may be vested upon the holder’s retirement as a director of Chugai.

Chugai stock options as stock-based compensation – movement in number of rights outstanding

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of rights</td>
<td>Weighted average exercise price (yen)</td>
</tr>
<tr>
<td>Outstanding at January 1</td>
<td>3,985</td>
<td>100</td>
</tr>
<tr>
<td>Granted</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Forfeited</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Exercised</td>
<td>(202)</td>
<td>100</td>
</tr>
<tr>
<td>Expired</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Outstanding at December 31</strong></td>
<td><strong>3,783</strong></td>
<td><strong>100</strong></td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Chugai stock options as stock-based compensation – terms of rights outstanding at December 31, 2018

<table>
<thead>
<tr>
<th>Year of grant</th>
<th>Rights outstanding</th>
<th>Rights exercisable</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number outstanding</td>
<td>Weighted average years remaining contractual life</td>
</tr>
<tr>
<td>2009</td>
<td>519</td>
<td>20.31</td>
</tr>
<tr>
<td>2010</td>
<td>579</td>
<td>21.31</td>
</tr>
<tr>
<td>2011</td>
<td>672</td>
<td>22.40</td>
</tr>
<tr>
<td>2012</td>
<td>659</td>
<td>23.31</td>
</tr>
<tr>
<td>2013</td>
<td>414</td>
<td>24.32</td>
</tr>
<tr>
<td>2014</td>
<td>383</td>
<td>25.31</td>
</tr>
<tr>
<td>2015</td>
<td>261</td>
<td>26.31</td>
</tr>
<tr>
<td>2016</td>
<td>296</td>
<td>27.31</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>3,783</strong></td>
<td><strong>23.27</strong></td>
</tr>
</tbody>
</table>

Exercise of stock acquisition rights

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of rights</td>
<td>Weighted average share price (yen)</td>
</tr>
<tr>
<td>Chugai common stock options</td>
<td><strong>3,736</strong></td>
<td><strong>6,158</strong></td>
</tr>
<tr>
<td>Chugai stock options as stock-based compensation</td>
<td><strong>202</strong></td>
<td><strong>5,380</strong></td>
</tr>
</tbody>
</table>
(2) Restricted stock compensation plan

Under the Compensation Plan, the restricted stocks to be provided consist of “tenure-based restricted stock” for Eligible Directors, as well as certain employees, which requires continuous service for a certain period for Chugai, and “performance-based restricted stock” for only Eligible Directors which requires the attainment of Chugai’s mid- to long-term business performance target in addition to the aforementioned continuous service. The Eligible Directors and employees, shall make in-kind contribution of all monetary compensation claims or monetary claims to be provided by Chugai according to the Compensation Plan, and shall, in return, receive shares of common stock of Chugai that will be issued or disposed of by Chugai.

For the disposal of shares of common stocks of Chugai under the Compensation Plan, Chugai and each Eligible Directors and employees, shall make an agreement on allotment of restricted stocks including that (1) The Eligible Directors and employees, shall not transfer, create a security interest on, or otherwise dispose of the allotted shares during a certain restriction period, and (2) Chugai shall take back all or part of the allotted shares without cost in case where certain events happen.

**Number of shares allotted and fair value at the grant date by year**

<table>
<thead>
<tr>
<th>Year</th>
<th>Tenure-based restricted stock</th>
<th>Performance-based restricted stock</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>Number of shares allotted</td>
<td>40,900 shares</td>
</tr>
<tr>
<td></td>
<td>fair value at the grant date</td>
<td>3,620 yen</td>
</tr>
<tr>
<td>2018</td>
<td>Number of shares allotted</td>
<td>40,600 shares</td>
</tr>
<tr>
<td></td>
<td>fair value at the grant date</td>
<td>5,400 yen</td>
</tr>
</tbody>
</table>

**Overview of the Compensation Plan**

<table>
<thead>
<tr>
<th>Evaluation method</th>
<th>Tenure-based restricted stock</th>
<th>Performance-based restricted stock</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allottees</td>
<td>Directors of Chugai</td>
<td>Directors of Chugai</td>
</tr>
<tr>
<td></td>
<td>Employees of Chugai</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Directors of Chugai's subsidiaries</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Employees of Chugai's subsidiaries</td>
<td></td>
</tr>
<tr>
<td>Settlement method</td>
<td>Equity settlement</td>
<td></td>
</tr>
<tr>
<td>Transfer restriction period</td>
<td>3 years</td>
<td></td>
</tr>
</tbody>
</table>

**Conditions for releasing transfer restriction**

On the condition that the Eligible Directors maintain their positions continuously during the transfer restriction period, Chugai shall release the transfer restriction for the number of allotted shares, which is calculated by multiplying the number of shares that the Eligible Directors obtain at the expiration of the transfer restriction period by the release rate that is determined by the growth rate on the three-year (the “Evaluation Period”) Total Shareholders Return (TSR) for a peer group as a performance goal decided by the Board of Directors in advance. The release rate is applied against the number of shares that is provided at the beginning of the restriction period by multiplying the maximum coefficient of 150%, ranging from 0% to 150% separately set by Chugai’s Board, and is set from 0% to 100%.

The TSR calculation formula is as follows:

\[
\text{TSR} = \frac{\text{increase in the stock price during the Evaluation Period}}{\text{Average closing price during the Evaluation Period}} - \text{Initial stock price (A)}
\]

A: Initial stock price (Average closing price for the three months prior to the start of the Evaluation Period)
B: Final stock price (Average closing price for the three months prior to the end of the Evaluation Period)
26. Earnings per share

Basic earnings per share

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income attributable to Chugai shareholders (millions of yen)</td>
<td>¥92,488</td>
<td>¥72,713</td>
</tr>
<tr>
<td>Weighted average number of common stock</td>
<td>559,685,889</td>
<td>559,685,889</td>
</tr>
<tr>
<td>Weighted average number of own equity instruments</td>
<td>(12,662,197)</td>
<td>(13,147,406)</td>
</tr>
<tr>
<td>Weighted average number of shares in issue</td>
<td>547,023,692</td>
<td>546,538,483</td>
</tr>
<tr>
<td>Basic earnings per share (yen)</td>
<td>168.08</td>
<td>133.04</td>
</tr>
</tbody>
</table>

Diluted earnings per share

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income attributable to Chugai shareholders (millions of yen)</td>
<td>¥92,488</td>
<td>¥72,713</td>
</tr>
<tr>
<td>Weighted average number of shares in issue</td>
<td>547,023,692</td>
<td>546,538,483</td>
</tr>
<tr>
<td>Adjustment for assumed exercise of equity compensation plans, where dilutive</td>
<td>(192,227)</td>
<td>(886,414)</td>
</tr>
<tr>
<td>Weighted average number of shares in issue used to calculate diluted earnings per share</td>
<td>547,915,919</td>
<td>547,424,897</td>
</tr>
<tr>
<td>Diluted earnings per share (yen)</td>
<td>168.80</td>
<td>132.83</td>
</tr>
</tbody>
</table>

There were no rights in equity compensation plans, which are anti-dilutive, and therefore excluded from the calculation of diluted earnings per share (2017: none).

27. Statement of cash flows

Cash flows from operating activities

Cash flows from operating activities arise from the Group’s primary activities including research and development, manufacturing and sales in the Pharmaceuticals business. These are calculated by the indirect method by adjusting the Group’s operating profit for any operating income and expenses that are not cash flows (for example depreciation, amortization and impairment) in order to derive the cash generated from operations. Operating cash flows also include income taxes paid on all activities.

Cash generated from operations in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net income</td>
<td>93,079</td>
<td>73,541</td>
</tr>
<tr>
<td>Financing costs</td>
<td>111</td>
<td>110</td>
</tr>
<tr>
<td>Other financial income (expense)</td>
<td>(440)</td>
<td>67</td>
</tr>
<tr>
<td>Other expense</td>
<td>3,212</td>
<td>1,706</td>
</tr>
<tr>
<td>Income taxes</td>
<td>28,370</td>
<td>23,490</td>
</tr>
<tr>
<td><strong>Operating profit</strong></td>
<td><strong>124,323</strong></td>
<td><strong>98,934</strong></td>
</tr>
<tr>
<td>Depreciation of property, plant and equipment</td>
<td>14,590</td>
<td>14,549</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>1,968</td>
<td>1,785</td>
</tr>
<tr>
<td>Impairment of property, plant and equipment</td>
<td>59</td>
<td>4</td>
</tr>
<tr>
<td>Impairment of intangible assets</td>
<td>4,844</td>
<td>4,035</td>
</tr>
<tr>
<td>Operating expense for defined benefit plans</td>
<td>4,427</td>
<td>4,231</td>
</tr>
<tr>
<td>Operating expense for equity-settled equity compensation plans</td>
<td>262</td>
<td>415</td>
</tr>
<tr>
<td>Net (income) expense for provisions</td>
<td>-</td>
<td>(11)</td>
</tr>
<tr>
<td>Inventories write-down</td>
<td>1,051</td>
<td>630</td>
</tr>
<tr>
<td>Other adjustments</td>
<td>294</td>
<td>205</td>
</tr>
<tr>
<td><strong>Cash generated from operations</strong></td>
<td><strong>151,857</strong></td>
<td><strong>124,776</strong></td>
</tr>
</tbody>
</table>
Cash flows from investing activities
Cash flows from investing activities are principally those arising from the Group’s investments in property, plant and equipment and intangible assets. Cash flows connected with the Group’s portfolio of marketable securities and other investments are also included, as are any interest and dividend payments received in respect of these securities and investments.

Interest and dividends received in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interest received</td>
<td>85</td>
<td>88</td>
</tr>
<tr>
<td>Dividends received</td>
<td>11b</td>
<td>11c</td>
</tr>
<tr>
<td>Total</td>
<td>200</td>
<td>271</td>
</tr>
</tbody>
</table>

Cash flows from financing activities
Cash flows from financing activities are primarily dividend payments to Chugai shareholders.

Significant non-cash transactions
There were no significant non-cash transactions (2017: none).

28. Risk management

(1) Financial risk management
The Group is exposed to various financial risks arising from its underlying operations and corporate finance activities. The Group’s financial risk exposures are predominantly related to changes in foreign exchange rates, interest rates and equity prices as well as the creditworthiness and the solvency of the Group’s counterparties.

Financial risk management within the Group is governed by policies approved by the board of directors of Chugai. These policies cover credit risk, liquidity risk and market risk. The policies provide guidance on risk limits, type of authorized financial instruments and monitoring procedures. Policy implementation and day-to-day risk management are carried out by the relevant functions and regular reporting on these risks is performed by the relevant finance & accounting and controlling functions within Chugai.

1) Credit risk
Accounts receivable are exposed to customer credit risk. The main accounts receivable are trade receivables. The management of trade receivables is focused on the assessment of country risk, setting of credit limits, ongoing credit evaluation and account monitoring procedures. As part of the credit risk management, sales administration departments regularly monitor the financial position of major customers by checking payment term and balances of trade receivables for each customer according to the accounting manuals to ensure early identification and mitigation of overdue balances and potential bad debts associated with the deterioration of customers’ financial position.

The objective of the management of trade receivables is to sustain the growth and profitability of the Group by optimizing asset utilization while maintaining risks at an acceptable level. The Group obtains credit insurance and similar enhancements when appropriate to protect the collection of trade receivables. No material collateral was held for trade receivables (2017: none).

Of the Group’s accounts receivable, trade receivables from third parties are mainly to Japanese customers, of which major customers account for 70% as of December 31, 2018.

Trade receivables: major customers in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfresa Corporation</td>
<td>32,483</td>
<td>31,492</td>
</tr>
<tr>
<td>Mediceo Corporation</td>
<td>22,585</td>
<td>24,656</td>
</tr>
<tr>
<td>Suzuken Co., Ltd.</td>
<td>19,998</td>
<td>22,192</td>
</tr>
<tr>
<td>Toho Pharmaceutical Co., Ltd.</td>
<td>13,171</td>
<td>13,592</td>
</tr>
<tr>
<td>Total</td>
<td>88,237</td>
<td>91,932</td>
</tr>
</tbody>
</table>
Customer credit risk exposure based on accounts receivable days overdue that are within the scope of IFRS15 in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>Current</th>
<th>Overdue 1-3 months</th>
<th>Overdue 4-12 months</th>
<th>Overdue more than 1 year</th>
<th>Credit Impaired</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>At December 31, 2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gross carrying amount</td>
<td>162,742</td>
<td>137</td>
<td>-</td>
<td>0</td>
<td>-</td>
<td>162,879</td>
</tr>
<tr>
<td>- Expected credit loss rate (%)</td>
<td>0</td>
<td>0</td>
<td>-</td>
<td>100</td>
<td>-</td>
<td>0</td>
</tr>
<tr>
<td>Allowance for doubtful accounts</td>
<td>(7)</td>
<td>(0)</td>
<td>-</td>
<td>(0)</td>
<td>-</td>
<td>(7)</td>
</tr>
</tbody>
</table>

The expected credit loss ('ECL') rate is based on the Group’s historical experience and the Group’s expectation of economic conditions over the period until receivables are expected to be paid.

Aging of accounts receivable that are not impaired in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neither overdue nor impaired</td>
<td>174,215</td>
</tr>
<tr>
<td>Overdue less than 1 month</td>
<td>64</td>
</tr>
<tr>
<td>Overdue 1-3 months</td>
<td>4</td>
</tr>
<tr>
<td>Overdue 4-6 months</td>
<td>1</td>
</tr>
<tr>
<td>Overdue 7-12 months</td>
<td>-</td>
</tr>
<tr>
<td>Overdue more than 1 year</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>174,284</td>
</tr>
</tbody>
</table>

Derivative transactions and money market instruments are restricted to financial institutions with high credit ratings in an effort to mitigate the counterparty risks.

The maximum exposure to credit risk resulting from financial activities, without taking into account any collateral held or other credit enhancements, is equal to the carrying value of the Group’s financial assets.

Financial assets with credit risks (excluding accounts receivables that result from transactions that are within the scope of IFRS 15)

Cash and cash equivalents are held with banks and financial institutions, which are predominantly rated investment grade, based on Moody’s and S&P Ratings. Cash and short-term time deposits are subject to rules which limit the Group’s exposure to individual financial institutions.

Investments in marketable securities (excluding equity securities) are entered into on the basis of guidelines with regard to liquidity, quality and maximum amount. As a general rule, the Group invests only in high-quality securities with adequate liquidity and with counterparties that have a credit rating of at least Baa3 from Moody’s and BBB– from S&P.

Credit risk on accounts receivables that result from transactions that are not within the scope of IFRS 15, are managed based on data obtained from external sources and historical experience.

The credit risk of the counterparties with external ratings below investment grade or non-rated is closely monitored and reviewed on an individual basis.

Rating analysis (excluding accounts receivables that result from transactions that are within the scope of IFRS 15) in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
</tr>
<tr>
<td>AAA~BBB- range</td>
<td>263,010</td>
</tr>
<tr>
<td>Total investment grade</td>
<td>263,010</td>
</tr>
<tr>
<td>Below BBB- range (below investment grade)</td>
<td>-</td>
</tr>
<tr>
<td>Unrated</td>
<td>3,067</td>
</tr>
<tr>
<td>Total gross carrying amounts</td>
<td>266,076</td>
</tr>
<tr>
<td>Loss allowance</td>
<td>-</td>
</tr>
</tbody>
</table>
Financial assets measured at amortized cost and those at fair value through OCI (excluding equity securities) are investment grade and therefore considered to be low risk, and thus the impairment allowance is determined at 12 months expected credit losses ('ECL') with a reference to external credit ratings of the counterparties. There were no financial assets for which the Group observed a significant increase in the credit risk which would require the application of the lifetime expected credit losses impairment model. There was no material impact resulting from the revised impairment approach under IFRS 9. In addition, there were no material movements in the loss allowance in 2018.

Impairment losses by asset class
The Group’s impairment loss on available-for-sale financial assets was ¥97 million in 2017.

2) Liquidity risk
Liquidity risk arises through a surplus of financial obligations over available financial assets due at any point in time. The Group’s approach to liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements at any point in time. The Group manages liquidity risks based on a cash management plan prepared and updated as appropriate by finance and accounting departments based on the reporting from each department.

Chugai is rated as highly creditable by more than one major credit rating agency. The ratings will permit efficient access to the international capital markets in the event of major financing requirements. Chugai has unused committed credit lines with various financial institutions totaling ¥40,000 million (2017: ¥40,000 million).

Contractual maturities of financial liabilities in millions of yen

<table>
<thead>
<tr>
<th>At December 31, 2018</th>
<th></th>
<th>0-3 months</th>
<th>4-6 months</th>
<th>7-12 months</th>
<th>Over 1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable</td>
<td>71,706</td>
<td>68,178</td>
<td>3,340</td>
<td>28</td>
<td>160</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>2,096</td>
<td>531</td>
<td>302</td>
<td>890</td>
<td>372</td>
</tr>
<tr>
<td>Total financial liabilities</td>
<td>73,802</td>
<td>68,709</td>
<td>3,642</td>
<td>919</td>
<td>532</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>At December 31, 2017</th>
<th></th>
<th>0-3 months</th>
<th>4-6 months</th>
<th>7-12 months</th>
<th>Over 1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable</td>
<td>63,518</td>
<td>61,447</td>
<td>2,029</td>
<td>43</td>
<td>-</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>1,652</td>
<td>625</td>
<td>324</td>
<td>478</td>
<td>225</td>
</tr>
<tr>
<td>Total financial liabilities</td>
<td>65,170</td>
<td>62,072</td>
<td>2,353</td>
<td>521</td>
<td>225</td>
</tr>
</tbody>
</table>

*Derivative financial instruments are held for risk management purposes and will not be canceled before the maturity date.

3) Market risk
Market risk arises from changing market prices, mainly due to foreign exchange rates and interest rates, of the Group’s financial assets or financial liabilities which affect the Group’s net income and equity.

Foreign exchange risk: Accounts receivable and accounts payable denominated in foreign currencies are exposed to foreign exchange risk. The objective of the Group’s foreign exchange risk management activities is to preserve the economic value of its current and future assets and to minimize the volatility of the Group’s financial result. The Group enters into derivative transactions such as foreign exchange forward contracts to reduce the risk of foreign currency exchange fluctuations related to both assets and liabilities denominated in foreign currencies. Some of these transactions qualify as cash flow hedges at the point that the forecast transaction is expected.

When making use of derivatives for hedging foreign exchange risk on assets and liabilities denominated in foreign currencies, Chugai conducts such operations in accordance with its internal regulations and monthly reports are prepared on the balance of such transactions, valuation gains and losses, and other related matters at fair value. Consolidated subsidiaries do not utilize derivative transactions.

Sensitivity analysis: Chugai has financial instruments denominated in currencies other than its functional currency. The table below shows the impact to profit before taxes resulting from a 1% decrease of the Swiss franc, euro and US dollar against the Japanese yen, which is Chugai’s functional currency. The effective portion of derivative financial instruments for which hedge accounting is applied is excluded from the calculation. All calculations are based on the assumption that exchange rates for other currencies are constant and there are no changes in other variables such as interest rates.
Foreign currency sensitivity analysis

<table>
<thead>
<tr>
<th>Currency</th>
<th>Exposure (m CHF)</th>
<th>Exposure (m YEN)</th>
<th>Impact (m YEN)</th>
<th>Exposure (m CHF)</th>
<th>Exposure (m YEN)</th>
<th>Impact (m YEN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHF</td>
<td></td>
<td></td>
<td></td>
<td>2018</td>
<td>2017</td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>324</td>
<td>36,278</td>
<td>(363)</td>
<td>227</td>
<td>26,165</td>
<td>(262)</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>(344)</td>
<td>(38,513)</td>
<td>385</td>
<td>(279)</td>
<td>(32,224)</td>
<td>322</td>
</tr>
<tr>
<td>Financial non-current assets</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>15</td>
<td>1,687</td>
<td>(17)</td>
<td>40</td>
<td>4,629</td>
<td>(46)</td>
</tr>
<tr>
<td>Notional amounts of derivative financial instruments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Effective portion of hedge</td>
<td>(5)</td>
<td>(637)</td>
<td>6</td>
<td>230</td>
<td>27,007</td>
<td>(270)</td>
</tr>
<tr>
<td>- Other than above</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>(10)</td>
<td>(1,204)</td>
<td>12</td>
<td>218</td>
<td>25,576</td>
<td>(256)</td>
</tr>
<tr>
<td>EUR</td>
<td></td>
<td></td>
<td></td>
<td>2018</td>
<td>2017</td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>2</td>
<td>265</td>
<td>(3)</td>
<td>14</td>
<td>1,385</td>
<td>(14)</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>(27)</td>
<td>(3,435)</td>
<td>34</td>
<td>(17)</td>
<td>(2,250)</td>
<td>23</td>
</tr>
<tr>
<td>Financial non-current assets</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Notional amounts of derivative financial instruments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Effective portion of hedge</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>- Other than above</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>(25)</td>
<td>(3,170)</td>
<td>32</td>
<td>(0)</td>
<td>(865)</td>
<td>9</td>
</tr>
<tr>
<td>USD</td>
<td></td>
<td></td>
<td></td>
<td>2018</td>
<td>2017</td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>35</td>
<td>3,850</td>
<td>(38)</td>
<td>32</td>
<td>3,636</td>
<td>(36)</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>(100)</td>
<td>(11,034)</td>
<td>110</td>
<td>(98)</td>
<td>(11,043)</td>
<td>110</td>
</tr>
<tr>
<td>Financial non-current assets</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Notional amounts of derivative financial instruments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Effective portion of hedge</td>
<td>(35)</td>
<td>36,061</td>
<td>(38)</td>
<td>240</td>
<td>26,139</td>
<td>(261)</td>
</tr>
<tr>
<td>- Other than above</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>267</td>
<td>28,877</td>
<td>(280)</td>
<td>174</td>
<td>18,732</td>
<td>(187)</td>
</tr>
</tbody>
</table>

(Note) Positive numbers are the amount of positive impact on profit before taxes resulting from a 1% decrease of each currency against the Japanese yen. The amounts above do not reflect the impact on Chugai's cash flows or forecast result.

The impact resulting from a 1% decrease of each currency against the Japanese yen on the financial instruments denominated in foreign currency is shown in the tables below.

**Interest rate risk:** The amounts of debt and loans were insignificant and therefore the Group is not exposed to material interest rate risk.
(2) Financial instruments

Carrying value and fair value of financial instruments

The Group’s financial instruments are mainly comprised of financial non-current assets, accounts receivable, marketable securities, cash and cash equivalents, derivative financial instruments included in other current assets, accounts payable, derivative financial instruments included in other current liabilities and debt. The carrying values of these financial instruments are equal to or reasonably approximate fair values.

Accounting classifications and fair values in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>Financial assets measured at fair value through OCI</th>
<th>Fair value through profit or loss (mandatorily)-other</th>
<th>Financial assets at amortized cost</th>
<th>Financial liabilities at amortized cost</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>At December 31, 2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current financial assets</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Equity instrument</td>
<td>9,723</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9,723</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>-</td>
<td>-</td>
<td>179,556</td>
<td>-</td>
<td>179,556</td>
</tr>
<tr>
<td>Marketable securities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Debt instrument</td>
<td>8,001</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>8,001</td>
</tr>
<tr>
<td>- Money market instruments</td>
<td>94,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>94,000</td>
</tr>
<tr>
<td>- Time accounts over 3 months</td>
<td>-</td>
<td>-</td>
<td>532</td>
<td>-</td>
<td>532</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>-</td>
<td>-</td>
<td>146,860</td>
<td>-</td>
<td>146,860</td>
</tr>
<tr>
<td>Other current assets</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Derivative financial instruments</td>
<td>-</td>
<td>2,096</td>
<td>-</td>
<td>-</td>
<td>2,096</td>
</tr>
<tr>
<td>Total financial assets</td>
<td>111,724</td>
<td>2,096</td>
<td>326,948</td>
<td>-</td>
<td>440,876</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>71,706</td>
<td>71,706</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Derivative financial instruments</td>
<td>-</td>
<td>2,096</td>
<td>-</td>
<td>-</td>
<td>2,096</td>
</tr>
<tr>
<td>Total financial liabilities</td>
<td>-</td>
<td>2,096</td>
<td>-</td>
<td>71,706</td>
<td>73,801</td>
</tr>
</tbody>
</table>

Fair value hierarchy

The table below analyses financial instruments carried at fair value, by valuation method. The different levels have been defined as follows:

- Level 1 – quoted prices (unadjusted) in active markets for identical assets and liabilities.
- Level 2 – observable inputs directly or indirectly other than quoted prices in active markets for identical assets and liabilities.
- Level 3 – fair value determined using valuation method which includes unobservable inputs.
### Fair value hierarchy of financial instruments in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At December 31, 2018</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marketable securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Money market instruments</td>
<td>-</td>
<td>94,000</td>
<td>-</td>
<td>94,000</td>
</tr>
<tr>
<td>- Debt securities</td>
<td>8,001</td>
<td>-</td>
<td>-</td>
<td>8,001</td>
</tr>
<tr>
<td>Other current assets</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Derivative financial instruments</td>
<td>-</td>
<td>2,204</td>
<td>-</td>
<td>2,204</td>
</tr>
<tr>
<td>Financial non-current assets</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Equity instruments measured at fair value through OCI</td>
<td>7230</td>
<td>-</td>
<td>2,394</td>
<td>9,723</td>
</tr>
<tr>
<td><strong>Financial assets recognized at fair value</strong></td>
<td>15,331</td>
<td>96,204</td>
<td>2,394</td>
<td>113,928</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derivative financial instruments</td>
<td></td>
<td>(2,096)</td>
<td>-</td>
<td>(2,096)</td>
</tr>
<tr>
<td><strong>Financial liabilities recognized at fair value</strong></td>
<td>-</td>
<td>(2,096)</td>
<td>-</td>
<td>(2,096)</td>
</tr>
<tr>
<td><strong>At December 31, 2017</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marketable securities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Money market instruments and time accounts over 3 months</td>
<td>-</td>
<td>99,018</td>
<td>-</td>
<td>99,018</td>
</tr>
<tr>
<td>Debt securities</td>
<td>5,000</td>
<td>-</td>
<td>-</td>
<td>5,000</td>
</tr>
<tr>
<td>Other current assets</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Derivative financial instruments</td>
<td></td>
<td>2,107</td>
<td>-</td>
<td>2,107</td>
</tr>
<tr>
<td>Financial non-current assets</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Available-for-sale financial assets</td>
<td>9,734</td>
<td>-</td>
<td>1,616</td>
<td>11,350</td>
</tr>
<tr>
<td><strong>Financial assets recognized at fair value</strong></td>
<td>14,735</td>
<td>101,125</td>
<td>1,616</td>
<td>117,476</td>
</tr>
<tr>
<td>Other current liabilities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Derivative financial instruments</td>
<td></td>
<td>(1,652)</td>
<td>-</td>
<td>(1,652)</td>
</tr>
<tr>
<td><strong>Financial liabilities recognized at fair value</strong></td>
<td>-</td>
<td>(1,652)</td>
<td>-</td>
<td>(1,652)</td>
</tr>
</tbody>
</table>

The fair value hierarchy has been adjusted to reflect the presentational changes required as a result from implementing IFRS 9 Financial Instruments. Time accounts over three months are accounted for at amortized cost under IFRS 9 and as a result are no longer included in the fair value hierarchy analysis for 2018 (they were accounted for as available-for-sale under IAS 39 and therefore were included in the fair value hierarchy in 2017).

Level 1 financial assets consist of corporate bonds and quoted shares. Level 2 financial assets consist primarily of certificates of deposit, cash in trust, commercial paper and derivative financial instruments.

Fair values Level 2 financial assets are determined as follows:
- Marketable securities and derivative financial instruments are based on valuation models that use observable market data for interest rates, yield curves, foreign exchange rates and implied volatilities for similar instruments at the measurement date.

The Group recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period during which the transfer has occurred. There were no significant transfers between Level 1 and Level 2 and vice versa.

Level 3 financial assets consist of unquoted shares. Valuation is based on valuation method which includes unobservable inputs.
Reconciliation of financial instruments classified into level 3 in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>Fair value through other comprehensive income</th>
<th>Fair value through income statement</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>At January 1, 2017</td>
<td>1,552</td>
<td>1,552</td>
<td></td>
</tr>
<tr>
<td>Gains or losses</td>
<td>64</td>
<td>-</td>
<td>64</td>
</tr>
<tr>
<td>Purchases</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Disposals</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Transfers</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Currency translation effects</td>
<td>(1)</td>
<td>-</td>
<td>(1)</td>
</tr>
<tr>
<td><strong>At December 31, 2017</strong></td>
<td><strong>1,616</strong></td>
<td>-</td>
<td><strong>1,616</strong></td>
</tr>
<tr>
<td>At January 1, 2018</td>
<td>1,616</td>
<td>-</td>
<td>1,616</td>
</tr>
<tr>
<td>Gains or losses</td>
<td>72</td>
<td>-</td>
<td>72</td>
</tr>
<tr>
<td>Purchases</td>
<td>706</td>
<td>-</td>
<td>706</td>
</tr>
<tr>
<td>Disposals</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Transfers</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Currency translation effects</td>
<td>(1)</td>
<td>-</td>
<td>(1)</td>
</tr>
<tr>
<td><strong>At December 31, 2018</strong></td>
<td><strong>2,394</strong></td>
<td>-</td>
<td><strong>2,394</strong></td>
</tr>
</tbody>
</table>

(3) Derivative financial instruments

**Derivative financial instruments** in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forward exchange contracts</td>
<td>2,204</td>
<td>2,107</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,204</strong></td>
<td><strong>2,107</strong></td>
</tr>
<tr>
<td>Liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forward exchange contracts</td>
<td>(2,096)</td>
<td>(1,652)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>(2,096)</strong></td>
<td><strong>(1,652)</strong></td>
</tr>
</tbody>
</table>

Hedge accounting

Hedge effectiveness is determined at the inception of the hedge relationship, and through periodic prospective effectiveness assessments at each reporting date to ensure that an economic relationship exists between the hedged item and hedging instrument. The Group performs a qualitative assessment of the hedge effectiveness, and the Group concludes that risks being hedged for the hedged items and the hedging instruments are sufficiently aligned.

The Group manages foreign exchange rate fluctuation risks by applying cash flow hedge, and an ineffective portion may occur when the volume of hedged items is lower than the hedged amount. The ineffective portion of the hedge accounting is recognized in the income statement and included in other financial income (expense). It is measured using the hypothetical derivative method for cash flow hedges. In 2018 there were no actual ineffectiveness being reported for any hedge accounting relationships, or hedging relationships for which hedge accounting is no longer applied (2017: None).

The table below shows fair values and nominal amounts of derivative financial instruments, including a range of the timing of the nominal amounts of the hedging instruments, which are designated as hedging instruments in a cash flow hedge. At 31 December 2018 the Group has the following cash flow hedges which are designated in a qualifying hedge relationship.

**Cash flow hedges**

<table>
<thead>
<tr>
<th>Risk hedged:</th>
<th>Nominal amount</th>
<th>Fair value in million Yen</th>
<th>Maturity range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreign exchange rate fluctuations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Forward exchange contracts</td>
<td>CHF 2,108 million</td>
<td>1,893</td>
<td>(1,863)</td>
</tr>
<tr>
<td></td>
<td>USD 333 million</td>
<td>311</td>
<td>(233)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,204</strong></td>
<td></td>
<td>(2,096)</td>
</tr>
</tbody>
</table>
The Group is exposed to foreign exchange risk from transactions for inventories and others in foreign currencies with foreign related parties. The Group has entered into foreign exchange forward contracts to hedge a part of foreign exchange risk. Such instruments are recorded as fair value assets of ¥109 million (2017: fair value assets of ¥456 million).

**Reconciliation of hedging reserves in equity** in millions of yen

<table>
<thead>
<tr>
<th>Forward exchange contracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>At January 1, 2018</td>
</tr>
<tr>
<td>Effective portion of fair value gains</td>
</tr>
<tr>
<td>(losses) taken to equity</td>
</tr>
<tr>
<td>Transferred to income statement</td>
</tr>
<tr>
<td>Transferred to initial carrying amount of hedged items</td>
</tr>
<tr>
<td>Income taxes</td>
</tr>
<tr>
<td><strong>At December 31, 2018</strong></td>
</tr>
</tbody>
</table>

The present value of expected cash flows from qualifying cash flow hedges is shown in the table below.

**Present value of expected cash flows of qualifying cash flow hedges** in millions of yen

<table>
<thead>
<tr>
<th>Year ended December 31, 2018</th>
<th>Total</th>
<th>0-6 months</th>
<th>7-12 months</th>
<th>Over 1 Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash inflows</td>
<td>¥275,004</td>
<td>102,316</td>
<td>119,583</td>
<td>53,105</td>
</tr>
<tr>
<td>Cash outflows</td>
<td>(274,895)</td>
<td>(102,221)</td>
<td>(119,610)</td>
<td>(53,065)</td>
</tr>
<tr>
<td><strong>Total cash inflow (outflow)</strong></td>
<td><strong>109</strong></td>
<td><strong>95</strong></td>
<td><strong>(27)</strong></td>
<td><strong>41</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year ended December 31, 2017</th>
<th>Total</th>
<th>0-6 months</th>
<th>7-12 months</th>
<th>Over 1 Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash inflows</td>
<td>224,308</td>
<td>107,794</td>
<td>96,290</td>
<td>38,224</td>
</tr>
<tr>
<td>Cash outflows</td>
<td>(241,852)</td>
<td>(107,570)</td>
<td>(96,042)</td>
<td>(38,239)</td>
</tr>
<tr>
<td><strong>Total cash inflow (outflow)</strong></td>
<td><strong>(456)</strong></td>
<td><strong>223</strong></td>
<td><strong>248</strong></td>
<td><strong>(15)</strong></td>
</tr>
</tbody>
</table>

(4) Capital management

The Group defines the capital that it manages as the Group’s total capitalization, being the sum of debt plus equity including non-controlling interests. The Group’s objectives when managing capital are:

- To safeguard the Group’s ability to continue as a going concern, so that it can continue to provide benefits for patients and returns to investors.
- To provide an adequate return to investors based on the level of risk undertaken.
- To have available the necessary financial resources to allow the Group to invest in areas that may deliver future benefits for patients and returns to investors.
- To maintain sufficient financial resources to mitigate against risks and unforeseen events.

Capitalization is monitored and reported to the Chief Financial Officer as part of the Group’s regular internal management reporting.

The Group is not subject to regulatory capital adequacy requirements.

**Capital** in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital and reserves attributable to Chugai shareholders</td>
<td>755,864</td>
<td>691,924</td>
</tr>
<tr>
<td>Equity attributable to non-controlling interests</td>
<td>664</td>
<td>973</td>
</tr>
<tr>
<td>Total equity</td>
<td>756,529</td>
<td>692,897</td>
</tr>
<tr>
<td>Total debt</td>
<td>214</td>
<td>336</td>
</tr>
<tr>
<td><strong>Capitalization</strong></td>
<td><strong>756,743</strong></td>
<td><strong>693,233</strong></td>
</tr>
</tbody>
</table>
29. Related parties

(1) Controlling shareholder
Effective October 1, 2002, Roche and Chugai completed an alliance to create a leading research-driven Japanese pharmaceutical company, which was formed by the merger of Chugai and Roche’s Japanese pharmaceuticals subsidiary, Nippon Roche. Through the merger, Chugai became a member of the Roche Group as the surviving company.

Chugai has entered into certain agreements with Roche, which are discussed below:

**Basic Alliance Agreement:** As part of the Basic Alliance Agreement signed in December 2001, Roche and Chugai entered into certain arrangements covering the future operation and governance of Chugai. Amongst other matters these cover the following areas:
- The structuring of the alliance.
- Roche’s rights as a shareholder.
- Roche’s rights to nominate members of Chugai’s Board of Directors.
- Certain limitations to Roche’s ability to buy or sell Chugai’s common stock.

Chugai issues additional shares of common stock in connection with its convertible debt and equity compensation plans, and may issue additional shares for other purposes, which affects Roche’s percentage ownership interest. The Basic Alliance Agreement provides, amongst other matters, that Chugai will guarantee Roche’s right to maintain its shareholding percentage in Chugai at not less than 50.1%.

**Licensing Agreements:** Under the Japan Umbrella Rights Agreement signed in December 2001, Chugai has exclusive rights to market Roche’s pharmaceutical products in Japan. Chugai also has right of first refusal on the development and marketing in Japan of all development compounds advanced by Roche.

The Rest of the World Umbrella Rights Agreement (excluding Japan and South Korea) signed in May 2002 was revised and the Amended and Restated Rest of the World Umbrella Rights Agreement (excluding Japan, South Korea and Taiwan) was signed in August 2014. Under this Agreement, Roche has the right of first refusal on the development and marketing of Chugai’s development compounds in markets outside Japan, excluding South Korea and Taiwan.

Further to these agreements, Roche and Chugai have signed a series of separate agreements for certain specific products. Depending on the specific circumstances and the terms of the agreement, this may result in payments on an arm’s length basis between Roche and Chugai, for any or all of the following matters:
- Upfront payments, if a right of first refusal to license a product is exercised.
- Milestone payments, dependent upon the achievement of agreed performance targets.
- Royalties on future product sales.

These specific product agreements may also cover the manufacture and supply etc. of the respective products to meet the other party’s clinical and/or commercial requirements on an arm’s length basis.

**Research Collaboration Agreements:** Roche and Chugai have entered into research collaboration agreements in the areas of small-molecule synthetic drug research and biotechnology-based drug discovery.

**Dividends:** The dividends distributed to Roche by Chugai in respect to its holdings of Chugai shares totalled ¥21,454 million (2017: ¥18,437 million).

(2) Material transactions and balances with related parties

**Transactions with F. Hoffmann-La Roche** in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>109,938</td>
<td>76,369</td>
</tr>
<tr>
<td>Purchases of inventory and other materials</td>
<td>125,657</td>
<td>124,792</td>
</tr>
</tbody>
</table>

**Balances with F. Hoffmann-La Roche** in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade accounts receivable</td>
<td>25,307</td>
<td>18,593</td>
</tr>
<tr>
<td>Trade accounts payable</td>
<td>(29,567)</td>
<td>(24,805)</td>
</tr>
</tbody>
</table>
(3) Remuneration of key management personnel

Remuneration of members of the board and audit & supervisory board members in millions of yen

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Board of Directors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Regular remuneration</td>
<td>304</td>
<td>333</td>
</tr>
<tr>
<td>- Bonuses</td>
<td>120</td>
<td>234</td>
</tr>
<tr>
<td>Tenure-based restricted stock compensation plan</td>
<td>57</td>
<td>92</td>
</tr>
<tr>
<td>- Performance-based restricted stock compensation plan</td>
<td>72</td>
<td>35</td>
</tr>
<tr>
<td>- Chugai common stock options</td>
<td>21</td>
<td>83</td>
</tr>
<tr>
<td>Chugai stock options as stock-based compensation</td>
<td>-</td>
<td>34</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>573</td>
<td>811</td>
</tr>
<tr>
<td><strong>Audit &amp; supervisory board members</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular remuneration</td>
<td>67</td>
<td>65</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>67</td>
<td>85</td>
</tr>
</tbody>
</table>

Effective from the previous fiscal year, for the purpose of further promoting shared value with shareholders and providing an incentive to sustainably increase the Group’s corporate value, strengthening linkage between their compensation and mid- to long-term business performance, a restricted stock compensation plan was introduced in place of the existing stock option compensation plans.
30. Subsidiaries

<table>
<thead>
<tr>
<th>Subsidiaries</th>
<th>Country of incorporation</th>
<th>Equity interest %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consolidated subsidiaries</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chugai Research Institute for Medical Science, Inc.</td>
<td>Japan</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Clinical Research Center Co., Ltd.</td>
<td>Japan</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Business Support Co., Ltd.</td>
<td>Japan</td>
<td>100</td>
</tr>
<tr>
<td>Medical Culture, Inc.</td>
<td>Japan</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Distribution Co., Ltd.</td>
<td>Japan</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Pharma Manufacturing Co., Ltd.</td>
<td>Japan</td>
<td>100</td>
</tr>
<tr>
<td>Forerunner Pharma Research Co., Ltd.</td>
<td>Japan</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Pharma USA, Inc.</td>
<td>United States</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Pharma Europe Ltd.</td>
<td>United Kingdom</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Pharma U.K. Ltd.</td>
<td>United Kingdom</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Pharma France S.A.S.</td>
<td>France</td>
<td>100</td>
</tr>
<tr>
<td>Chugai sanofi-aventis S.N.C.</td>
<td>France</td>
<td>55</td>
</tr>
<tr>
<td>Chugai Pharma Taiwan Ltd.</td>
<td>Taiwan</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Pharma Science (Beijing) Co., Ltd.</td>
<td>China</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Pharma China Co., Ltd.</td>
<td>China</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Pharma Technology Taizhou Co., Ltd.</td>
<td>China</td>
<td>100</td>
</tr>
<tr>
<td>Chugai Pharmabody Research Pte. Ltd.</td>
<td>Singapore</td>
<td>100</td>
</tr>
</tbody>
</table>

(Note) Chugai sanofi-aventis S.N.C. became a wholly-owned subsidiary of Chugai Pharma Europe Ltd., through the additional acquisition of its shares in January 2019, and changed its name to Chugai Pharma Europe Logistics S.A.S. In addition, Chugai Pharma Germany GmbH was established as a subsidiary of Chugai Pharma Europe Ltd. in February 2019.

31. Subsequent events

There were no material subsequent events.
Additional information

This Additional information is provided for the information of readers and does not form part of the consolidated financial statements.

1. Significant legal cases

At December 31, 2018, the Group is involved in the following significant legal cases for which the outcome cannot be determined at this time, but for which the Group assesses that the possibility of any settlement to be remote:

(1) Arbitration in United Kingdom regarding Actemra
In May 2017 Medical Research Council and LifeArc (formerly Medical Research Council Technology) (‘Claimants’) requested arbitration against Chugai Pharmaceutical Co., Ltd. with an arbitrator being appointed on 9 August 2017. In April 2018 United Kingdom Research and Innovation (‘UKRI’) was established and became the successor in title to the Medical Research Council, and the current claimants in the arbitration are LifeArc and UKRI. Sums are sought from Chugai for alleged breach of obligations under a collaboration agreement dated 15 August 1990 in connection with the development of the humanized anti-human IL-6 receptor monoclonal antibody, Actemra. It is claimed that Chugai is obliged to pay royalties to the Claimants pursuant to the collaboration agreement.

(2) Patent infringement lawsuit regarding emicizumab in Japan
Baxalta (Baxalta Incorporated and Baxalta GmbH) filed a lawsuit against Chugai at the Tokyo District Court on 6 May 2016 requesting an injunction against the manufacture, usage, transfer, exportation and offer of any transfer regarding emicizumab alleging emicizumab is infringing its Japanese patent (patent number 4313531). With regard to this action, Tokyo District Court rendered a decision in favor of Chugai’s claim. Given this ruling, Baxalta appealed to the Intellectual Property High Court on 29 June 2018.

(3) Patent infringement lawsuit regarding emicizumab in the United States
Baxalta (Baxalta Incorporated and Baxalta GmbH) filed a lawsuit against Chugai and Genentech Inc., at the United States District Court for the District of Delaware on 4 May 2017 requesting relief including an injunction against manufacturing, using, offering to sell, or selling of emicizumab within the United States, or importing emicizumab into the United States. Baxalta filed a stipulation of dismissal with prejudice regarding Baxalta’s claims against Chugai with the Court on 13 September 2018, and the Court issued an Order Dismissing Chugai from this lawsuit on 19 September 2018.

(4) Patent infringement lawsuit against Alexion in the United States
Chugai alleges that the anti-C5 antibody ALXN1210 (ravulizumab) product, an investigational drug developed by Alexion Pharmaceuticals, Inc., infringes one of its U.S. patents (U.S. Patent No. 9,890,377) relating to its proprietary antibody engineering technology. Thus, Chugai filed a patent infringement lawsuit against Alexion at the United States District Court for the District of Delaware on 15 November 2018 requesting a judgment that the ALXN1210 product infringes Chugai’s U.S. patent and injunctive relief precluding manufacturing and selling of the ALXN1210 product within the United States.

(5) Patent infringement lawsuit against Alexion in Japan
Chugai alleges that the anti-C5 antibody ALXN1210 (ravulizumab) product, an investigational drug developed by Alexion Pharma Godo Kaisha (Japan Regional Headquarters), infringes some of its Japan patents (Patent No. 4954326 and No. 6417431) relating to its proprietary antibody engineering technology. Thus, Chugai filed a patent infringement lawsuit against Alexion at the Tokyo District Court on 5 December 2018 requesting a judgment that the ALXN1210 product infringes Chugai’s Japan patent and injunctive relief precluding manufacturing and selling of the ALXN1210 product in Japan.
Independent Auditor's Report

To the Board of Directors of Chugai Pharmaceutical Co., Ltd.:

We have audited the accompanying consolidated financial statements of Chugai Pharmaceutical Co., Ltd. and its consolidated subsidiaries, which comprise the consolidated balance sheet as at December 31, 2018, and the consolidated income statement, statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes, comprising a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in Japan. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the entity’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, while the objective of the financial statement audit is not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Chugai Pharmaceutical Co., Ltd. and its consolidated subsidiaries as at December 31, 2018, and their financial performance and cash flows for the year then ended in accordance with International Financial Reporting Standards.

KPMG AZSA LLC

March 28, 2019
Tokyo, Japan
### Glossary

#### Terms Related to Chugai’s Business

**Unmet medical need**  
Medical need that is not adequately met due to a lack of effective treatments.

**First-in-class**  
An original drug that is highly novel and useful, and will significantly change the therapeutic system.

**Best-in-class**  
A drug that offers clear advantages over other existing drugs in the same category, such as those with the same molecular target.

**Development pipeline**  
At pharmaceutical companies, refers to drug candidates that are being developed.

**Proof of Concept (PoC)/Early PoC**  
Proof of concept (PoC) is confirmation that the therapeutic effect conceived in the research stage is effective in humans. Early PoC means that in addition to safety, signs of efficacy or pharmacological effect have been confirmed in a limited number of cases.

**Clinical trial**  
A study to verify the safety, efficacy and other characteristics of a drug in human subjects. Studies conducted for the purpose of filing an application for approval are called clinical trials.

Phase I: Performed on a small number of healthy volunteers (or, for certain disease areas and diseases, on patients) to assess the drug’s safety and the process by which it is absorbed, distributed, metabolized and eliminated by the body.

Phase II: Performed on a small number of consenting patients to determine the safest and most effective dosage and the dosing regimen.

Phase III: Performed on a large number of consenting patients to verify the efficacy and safety of the new drug in comparison with existing drugs or placebo.

Phase IV: Post-marketing clinical surveillance. Performed on a larger number of consenting patients than in phase III studies to verify the drug’s safety and efficacy for its approved indication(s).

**Application for approval**  
An application submitted by a pharmaceutical company to a regulatory agency to obtain approval for manufacturing and marketing of a new drug after its efficacy and safety have been verified in clinical trials. In Japan, the Minister of Health, Labour and Welfare (MHLW) grants manufacturing and marketing approval to substances deemed appropriate as pharmaceuticals based on reviews by the Pharmaceutical Affairs and Medical Devices Agency as well as academic and other experts in the Pharmaceutical Affairs and Food Sanitation Council.

**Additional indication**  
A new indication for a previously approved drug.

**Lifecycle management**  
The various measures taken to maximize the potential value of a drug, including shortening development time, expanding sales, extending the product’s life, and conducting appropriate cost control.

#### Terms Related to Drug Discovery

**Personalized Healthcare**  
Even when a particular disease is treated with the same drug, there may be differences in the efficacy and side effects of that drug depending on the patient. One of the causes is thought to be that the genetic information related to the disease is different in each patient. Personalized healthcare (PHC) is an approach that focuses on these genetic-level differences to provide treatment tailored to the characteristics of each patient’s disease. It therefore brings significant benefits in terms of efficiency, safety and cost effectiveness.

**Cancer Genomic Medicine**  
One example of personalized healthcare. Medical treatment that measures multiple cancer-related genes in a single operation using gene panel examination and performs optimal treatment according to each patient’s genomic profile.

**Biopharmaceuticals**  
Drugs created by applying biotechnology such as genetic recombination. In the 1980s, when rapid advances were made in genetic engineering, Chugai decided to shift to research and development of biopharmaceuticals and made related large-scale capital investments.

**Therapeutic antibody**  
A type of biopharmaceutical, it is an artificially created antibody used as a medicine to prevent or treat diseases. Therapeutic antibodies are designed to act only on the specific molecule (antigen) that causes the disease, and therefore can be expected to provide high therapeutic efficacy and reduce side effects. Chugai launched the first therapeutic antibody created in Japan in 2005, and is leading the world with its proprietary antibody engineering technologies.

**Modality**  
In the pharmaceutical industry, refers to the material classification of a medicine. Until the 1990s, small molecule drugs were virtually the only modality, but the options are now increasing. New modalities enable new approaches to diseases that have no effective treatment methods. Chugai is focusing on establishing middle molecules as a third modality, in addition to its biologics and small molecules.

**Open innovation**  
Generating innovative value by utilizing the technologies and development capabilities of external research networks such as with universities, research institutions and other organizations.

**Translational Research**  
Research that builds a bridge between the findings of basic research by academia and the development of new medicines by pharmaceutical companies.

#### Terms Related to Human Resources

**Work-life synergy (Work-life balance)**  
Chugai’s work-life synergy aims to generate a synergetic effect that brings forth motivation, vitality and innovation by enhancing both work and the lives of individuals. Work-life synergy, an advancement of the concept of work-life balance, is necessary for a fulfilling personal life, as well as for becoming the top innovator in the healthcare industry.

#### Diversity and Inclusion

At Chugai, diversity refers to a diversity of attributes such as gender, age and nationality, as well as ways of thinking, values and experience. Inclusion refers to the state of respecting each other’s differences and the ability of everyone to contribute and perform at his or her full potential. When people with various backgrounds work together, they become aware of diverse perspectives and ideas. Companies promote diversity to create new value, which leads to innovation. Using the true talents of all staff, business innovation, companies promote diversity to create better-quality products and services. Also called “diversity and inclusion (D&I),” which refers to receptivity to diversity and incorporating diverse opinions and ideas rather than the simple pursuit of variety, and also encompasses the concept of raising organizational value.

**Talent management**  
Talent management is the human resource strategy by which we identify and develop leaders and highly skilled specialists at an early stage. It is also the means by which we improve the skills and enhance the motivation of employees throughout the Company, with the aim of realizing our corporate strategy and catalyzing the creation of innovation. Each organization at Chugai has formulated a long-term human resource development plan and is building a talent pool of leaders.

#### Terms Related to the Roche Group

**Roche**  
A pharmaceutical company established in 1896 and headquartered in Basel, Switzerland. With business operations in more than 100 countries, the Roche Group contributes to medicine in a wide range of fields through its two business segments: pharmaceuticals and diagnostics. Central to the Roche Group’s strategy is personalized healthcare, the approach of selecting the most appropriate treatment by using biomarkers and diagnostic tests to identify patients most likely to show a significant response to a particular drug. The Roche Group’s sales in 2018 were 56.8 billion Swiss francs.

**Roche Diagnostics K.K.**  
The Japanese subsidiary of the Roche Group’s diagnostics division. Established in 1996. Roche Diagnostics K.K. provides a wide range of innovative diagnostic solutions, including in-vitro diagnostics and diagnostic equipment and research reagents and related equipment.

**Genentech Inc.**  
A leading biotechnology company headquartered in South San Francisco, California. Genentech has been a member of the Roche Group since 1990.

**Foundation Medicine Inc. (FMI)**  
FMI was established in Massachusetts, U.S.A. in 2010. In 2015, Roche took a majority stake, and then acquired the remaining outstanding shares in 2018 to make FMI a wholly-owned subsidiary. Chugai established the FMI business as a specialized unit in October 2018 to carry out commercialization and product value maximization of FMI’s “Comprehensive Genomic Profiling Service” in Japan.
**Network** (As of April 1, 2019)

**Chugai Pharmaceutical**

**Head Office**
Nihonbashi Mitsui Tower (Reception 15F)
2-1-1 Nihonbashi-Murumachi,
Chuo-ku, Tokyo 103-8324 Japan
Tel +81-(0)3-3281-6611 (main switchboard)
URL: https://www.chugai-pharm.co.jp/english/

**Research Laboratories**
Fuji Gotemba Research Laboratories
1-135 Komakado, Gotemba City,
Fuji Gotemba Research Laboratories
Research Laboratories
URL: https://www.chugai-pharm.co.jp/english/

**Plants (Chugai Pharma Manufacturing Co., Ltd.)**

**Ukima Plant**
5-5-1 Ukima, Kita-ku,
Tokyo 115-8543 Japan
Tel +81-(0)3-3968-6200

**Fujieda Plant**
2500 Takayanagi, Fujieda City,
Shizuoka Pref. 426-0041 Japan
Tel +81-(0)54-639-2311

**Iwate Branch**
(Iwate/Aomori/Akita)
Tel +81-(0)22-225-8551

**Kita-Ohoku Branch**
(Iwate/Aomori/Akita)
9F Hijagish Nihonfudosan Morikoa Ekima Bldg.,
15-20 Morikoa-eikima-dori, Morikoa City,
Iwate Pref. 020-0034 Japan
Tel +81-(0)19-625-2811

**Fukushima Branch**
17F Bigi-K^23^2, 2-1-1 Kouryuymashiki Ekima Bldg.,
Fukushima Pref. 963-8002 Japan
Tel +81-(0)24-933-6303

**Saitama Branch**
8F Omiya Center Bldg.,
1-9-6 Sakuragicho,
Omiya-ku, Saitama City,
Saitama Pref. 330-0854 Japan
Tel +81-(0)48-642-4771

**Ibaraki Branch**
8F Nissai Mito Bldg., 2-2-27 Izumi-cho,
Mito City, Ibaraki Pref. 310-0026 Japan
Tel +81-(0)29-227-1951

**Gunma and Tochigi Branch**
9F East Tower, 16-11 Sakae-cho,
Takasaki City, Gunma Pref. 370-0841 Japan
Tel +81-(0)27-321-6511

**Niigata Branch**
9F Nissai Ekima Bldg., 3-2-3 Benten,
Chuuo-ku, Niigata City,
Niigata Pref. 950-0001 Japan
Tel +81-(0)25-247-7331

**Nagano and Yamanashi Branch**
8F Kenshin Matsumoto Fukashi Bldg.,
2-5-2 Fukashi, Matsumoto City,
Nagano Pref. 390-0815 Japan
Tel +81-(0)263-34-1373

**Tokyo Branch 1**
Tokyo Branch 2
17F Osaki Bright Core Bldg.,
5-5-15 Kita-shinaragawa, Shinagawa-ku,
Tokyo 141-0011 Japan
Tel +81-(0)3-5449-1460

**Tokyo Tama Branch**
6F Tachikawa Nishiki-cho Bldg.,
1-8-7 Nishiki-cho, Tachikawa City,
Tokyo 190-0022 Japan
Tel +81-(0)42-523-6661

**Chiba Branch**
5F Fujimi Hanesu Bldg., 2-7-5 Fujimi-cho,
Chiba City, Chiba Pref. 260-0015 Japan
Tel +81-(0)43-224-1511

**Yokohama Branch**
3F Yokohama East Square, 1-4 Kinkou-cho,
Yokohama City, Kanagawa Pref. 220-0015 Japan
Tel +81-(0)45-464-7170

**Atsugi Branch**
8F Nihon Seimei Hon-atsugi Bldg.,
1-2-1 Asahi-cho, Atsugi-ku,
Chiba Pref. 250-0021 Japan
Tel +81-(0)467-47-2260

**Aichi Branch**
KDX Sakuradori Bldg., 3-20-7 Marunouchi,
Naka-ku, Nagoya City,
Aichi Pref. 460-0002 Japan
Tel +81-(0)52-961-8511

**Gifu and Mie Branch**
11F Nishi Nissei Bldg., 2-8 Shimohimoto-cho,
Gifu City, Gifu Pref. 500-8556 Japan
Tel +81-(0)58-282-2340

**Shizuoka Branch**
4F Nissai Shizuoka Ekima Bldg.,
59-7 Kurogane-cho, Aoi-ku,
Shizuoka City,
Shizuoka Pref. 420-0851 Japan
Tel +81-(0)54-252-5125

**Kyoto and Shiga Branch**
7F Karasuma Chuo Bldg., 659 Tearamizumi-cho,
Nishikyo-ku, Karasuma-ku, Kyoto City,
Kyoto Pref. 604-8152 Japan
Tel +81-(0)75-212-6090

**Hokuriku Branch**
(Ishikawa/Toyama/Fukui)
9F Visage, 19-1 Shovyo-cho, Kanazawa City,
Ishikawa Pref. 920-0856 Japan
Tel +81-(0)76-232-6766

**Osaka-Kita Branch**
13F Lermura Nisseli Bldg.,
3-3-11 Miyahara, Yodogawa-ku,
Osaka City, Osaka Pref. 532-0003 Japan
Tel +81-(0)6-6305-6355

**Osaka-Minami Branch**
14F Portas Center Bldg.,
4-4-1 Ebisujima-cho, Sakae-ku,
Kakogawa City, Osaka Pref. 550-0855 Japan
Tel +81-(0)72-223-1575

**Nara and Wakayama Branch**
5F Nara Center Bldg.,
7-1-31 Omiai-cho, Nara City,
Nara Pref. 630-8115 Japan
Tel +81-(0)74-33-6011

**Hyogo Branch**
9F Mei Yasuda Seimei Kobe Bldg.,
8-3-5 Isogami-dori, Chuo-ku, Kobe City,
Hyogo Pref. 651-0086 Japan
Tel +81-(0)79-241-6851

**Hiroshima Branch**
6F Nissei Hiroshima Bldg.,
7-32 Nakamachi, Naka-ku, Hiroshima City,
Hiroshima Pref. 730-0007 Japan
Tel +81-(0)82-347-0263

**Yamaguchi Branch**
10F Square Shin-yamaguchi, 2-21 Ogori-kogen-machi, Yamaguchi City,
Yamaguchi Pref. 751-0011 Japan
Tel +81-(0)83-972-1666

**Tottori and Shimane Branch**
16F Yanayama Bldg., 1-2-17 Tottori-cho,
Tottori City, Tottori Pref. 688-0823 Japan
Tel +81-(0)859-34-3521

**Okayama Branch**
4F Lit City Bldg., 5-1-1 Eikimoto-machi, Kita-ku,
Okayama City, Okayama Pref. 700-0024 Japan
Tel +81-(0)86-214-3760

**Kagawa and Tokushima Branch**
7F Ichigo Takamatsu Bldg.,
2-2-7 Kotobuki-cho, Takamatsu City,
Kagawa Pref. 760-0023 Japan
Tel +81-(0)87-811-6988

**Ehime and Kochi Branch**
8F Taiyu Seimei Matsuyama Bldg.,
1-1-24-1 Ichibanchi-machi, Matsuyama City,
Ehime Pref. 790-0001 Japan
Tel +81-(0)89-945-3600

**Fukuoka Branch**
8F Echo Bldg., 2-13-3 Hakataeki-higashi,
Hakata-ku, Fukuoka City,
Fukuoka Pref. 812-0113 Japan
Tel +81-(0)92-511-8181

**Nagasaki and Saga Branch**
Nagasaki Ekima Daichi Seimei Bldg.,
2-3 Nishizaka-machi, Nagasaki City,
Nagasaki Pref. 850-0051 Japan
Tel +81-(0)95-825-4772
Major Shareholders

<table>
<thead>
<tr>
<th>Name</th>
<th>Number of Shares Held (Thousands)</th>
<th>Percentage of Voting Rights (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche Holding Ltd</td>
<td>335,223</td>
<td>61.27</td>
</tr>
<tr>
<td>The Master Trust Bank of Japan, Ltd. (Trust Account)</td>
<td>29,342</td>
<td>5.36</td>
</tr>
<tr>
<td>Japan Trustee Services Bank, Ltd. (Trust Account)</td>
<td>16,320</td>
<td>2.98</td>
</tr>
<tr>
<td>STATE STREET BANK AND TRUST COMPANY 505001</td>
<td>15,614</td>
<td>2.85</td>
</tr>
<tr>
<td>JP MORGAN CHASE BANK 380055</td>
<td>13,924</td>
<td>2.54</td>
</tr>
<tr>
<td>STATE STREET BANK WEST CLIENT - TREATY 505234</td>
<td>4,231</td>
<td>0.77</td>
</tr>
<tr>
<td>Japan Trustee Services Bank, Ltd. (Trust Account 5)</td>
<td>4,091</td>
<td>0.74</td>
</tr>
<tr>
<td>Trust &amp; Custody Services Bank, Ltd. (Securities Investment Trust Account)</td>
<td>3,829</td>
<td>0.70</td>
</tr>
<tr>
<td>Japan Trustee Services Bank, Ltd. (Trust Account 7)</td>
<td>3,748</td>
<td>0.68</td>
</tr>
<tr>
<td>SSBTC CLIENT OMNIBUS ACCOUNT</td>
<td>3,651</td>
<td>0.66</td>
</tr>
</tbody>
</table>

Note: 12,459,413 shares of treasury stock held by the Company are not included in the above breakdown of major shareholders.

Classification of Shareholders

<table>
<thead>
<tr>
<th>Shareholder Type</th>
<th>Shares:</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Financial instruments firms</td>
<td>335,223,645</td>
<td>59.89%</td>
</tr>
<tr>
<td>Treasury stock</td>
<td>10,644,649</td>
<td>18.16%</td>
</tr>
<tr>
<td>Individuals and other</td>
<td>7,968,192</td>
<td>14.23%</td>
</tr>
<tr>
<td>Financial institutions</td>
<td>19,865,429</td>
<td>3.54%</td>
</tr>
<tr>
<td>Treasury stock</td>
<td>12,459,413</td>
<td>2.22%</td>
</tr>
<tr>
<td>Financial instruments firms</td>
<td>5,751,170</td>
<td>1.02%</td>
</tr>
<tr>
<td>Other corporations</td>
<td>5,054,391</td>
<td>0.90%</td>
</tr>
</tbody>
</table>

Classification of Shareholders

<table>
<thead>
<tr>
<th>Shareholder Type</th>
<th>Shares:</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche Holding Ltd</td>
<td>335,223,645</td>
<td>59.89%</td>
</tr>
<tr>
<td>Foreign corporations other than Roche</td>
<td>7,968,192</td>
<td>14.23%</td>
</tr>
<tr>
<td>Financial institutions</td>
<td>19,865,429</td>
<td>3.54%</td>
</tr>
<tr>
<td>Individuals and other</td>
<td>12,459,413</td>
<td>2.22%</td>
</tr>
<tr>
<td>Financial instruments firms</td>
<td>5,751,170</td>
<td>1.02%</td>
</tr>
<tr>
<td>Other corporations</td>
<td>5,054,391</td>
<td>0.90%</td>
</tr>
</tbody>
</table>

Stock Price Information (From January 1, 2018 to December 31, 2018)

<table>
<thead>
<tr>
<th>Stock Price</th>
<th>Low</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Quarter</td>
<td>¥5,080</td>
<td>¥6,080</td>
</tr>
<tr>
<td>Second Quarter</td>
<td>5,310</td>
<td>6,210</td>
</tr>
<tr>
<td>Third Quarter</td>
<td>5,430</td>
<td>7,370</td>
</tr>
<tr>
<td>Fourth Quarter</td>
<td>6,230</td>
<td>7,850</td>
</tr>
</tbody>
</table>

Note: 12,459,413 shares of treasury stock held by the Company are not included in the above breakdown of major shareholders.

Share Performance with Stock Indices

1. Closing price on December 30, 2013 = 100
2. A capitalization-weighted index that consists of pharmaceutical companies on the Tokyo Stock Exchange, First Section.

Share Price Indicators

<table>
<thead>
<tr>
<th>Price/Earnings Ratio</th>
<th>Year-end share price/Basic net income per share</th>
<th>Price/Book Ratio</th>
<th>Year-end share price/Equity per share attributable to Chugai shareholders</th>
<th>Dividend Yield</th>
<th>Dividends per share/Year-end share price</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Times)</td>
<td>50.00</td>
<td>(Times)</td>
<td>5.00</td>
<td>(%)</td>
<td>2.50</td>
</tr>
<tr>
<td>40.00</td>
<td>31.69</td>
<td>4.30</td>
<td>3.00</td>
<td>1.62</td>
<td></td>
</tr>
<tr>
<td>30.00</td>
<td>37.86</td>
<td>2.71</td>
<td>2.71</td>
<td>1.37</td>
<td></td>
</tr>
<tr>
<td>20.00</td>
<td>34.19</td>
<td>2.84</td>
<td>2.84</td>
<td>1.55</td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td>37.37</td>
<td>4.56</td>
<td>4.56</td>
<td>1.07</td>
<td></td>
</tr>
<tr>
<td>0.00</td>
<td>43.37</td>
<td>4.62</td>
<td>4.62</td>
<td>1.35</td>
<td></td>
</tr>
</tbody>
</table>

Note: 12,459,413 shares of treasury stock held by the Company are not included in the above breakdown of major shareholders.
Corporate Overview (As of December 31, 2018)

**Company Name**
Chugai Pharmaceutical Co., Ltd.

**Year of Foundation**
1925

**Year of Establishment**
1943

**Address**
2-1-1, Nihonbashi-Muromachi, Chuo-ku,
Tokyo 103-8324 Japan

**Stated Capital**
¥73,202 million

**Number of Employees**
7,432 (Consolidated)

**Number of Shares Issued of Common Stock**
559,685,889

**Number of Shareholders**
19,947

**Stock Listing**
Tokyo Stock Exchange, First Section

**Fiscal Year-End**
December 31

**General Meeting of Shareholders**
March

**Transfer Agent**
Mitsubishi UFJ Trust and Banking Corporation

**Public Notices**
Public notices are made electronically on the Chugai website (https://www.chugai-pharm.co.jp/ir/) in Japanese. In case electronic communications are unavailable, public notices will be made in the newspaper Nihon Keizai Shimbun.

For further information, please contact:
Corporate Communications Dept.
Tel: +81-(0)3-3273-3313
Fax: +81-(0)3-3281-6607
E-mail: ir@chugai-pharm.co.jp

IR website
https://www.chugai-pharm.co.jp/english/ir/

Sustainability website
https://www.chugai-pharm.co.jp/english/csr/